


**Please cite the Published Version**

Gumley, AI, Bradstreet, S, Ainsworth, J, Allan, S, Alvarez-Jimenez, M, Birchwood, M, Briggs, A, Bucci, S, Cotton, S, Engel, L, French, P , Lederman, R, Lewis, S, Machin, M, Maclennan, G, McLeod, H, McMeekin, N, Mihalopoulos, C, Morton, E, Norrie, J, Reilly, F, Schwannauer, M, Singh, SP, Sundram, S, Thompson, A, Williams, C, Yung, A, Aucott, L, Farhall, J and Gleeson, J (2022) Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT. Health Technology Assessment, 26 (27). ISSN 1366-5278

**DOI:** <https://doi.org/10.3310/HLZE0479>

**Publisher:** National Institute for Health and Care Research

**Version:** Published Version

**Downloaded from:** <https://e-space.mmu.ac.uk/634995/>

**Usage rights:**  [Creative Commons: Attribution 4.0](https://creativecommons.org/licenses/by/4.0/)

**Additional Information:** This is an open access publication, which was published in Health Technology Assessment

**Enquiries:**

If you have questions about this document, contact [openresearch@mmu.ac.uk](mailto:openresearch@mmu.ac.uk). Please include the URL of the record in e-space. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from <https://www.mmu.ac.uk/library/using-the-library/policies-and-guidelines>)

## Health Technology Assessment

Volume 26 • Issue 27 • May 2022

ISSN 1366-5278

# Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT

*Andrew I Gumley, Simon Bradstreet, John Ainsworth, Stephanie Allan, Mario Alvarez-Jimenez, Maximilian Birchwood, Andrew Briggs, Sandra Bucci, Sue Cotton, Lidia Engel, Paul French, Reeva Lederman, Shôn Lewis, Matthew Machin, Graeme MacLennan, Hamish McLeod, Nicola McMeekin, Cathy Mihalopoulos, Emma Morton, John Norrie, Frank Reilly, Matthias Schwannauer, Swaran P Singh, Suresh Sundram, Andrew Thompson, Chris Williams, Alison Yung, Lorna Aucott, John Farhall and John Gleeson*





# Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT

Andrew I Gumley<sup>1\*</sup>, Simon Bradstreet<sup>1</sup>,  
John Ainsworth<sup>2</sup>, Stephanie Allan<sup>1</sup>,  
Mario Alvarez-Jimenez<sup>3,4</sup>, Maximillian Birchwood<sup>5</sup>,  
Andrew Briggs<sup>6</sup>, Sandra Bucci<sup>2,7</sup>, Sue Cotton<sup>3</sup>,  
Lidia Engel<sup>8</sup>, Paul French<sup>9</sup>, Reeva Lederman<sup>10</sup>,  
Shôn Lewis<sup>2,7</sup>, Matthew Machin<sup>11</sup>,  
Graeme MacLennan<sup>12</sup>, Hamish McLeod<sup>1</sup>,  
Nicola McMeekin<sup>1</sup>, Cathy Mihalopoulos<sup>8</sup>,  
Emma Morton<sup>13</sup>, John Norrie<sup>14</sup>, Frank Reilly<sup>15</sup>,  
Matthias Schwannauer<sup>16</sup>, Swaran P Singh<sup>5</sup>,  
Suresh Sundram<sup>17</sup>, Andrew Thompson<sup>3,5</sup>,  
Chris Williams<sup>1</sup>, Alison Yung<sup>2</sup>, Lorna Aucott<sup>12</sup>,  
John Farhall<sup>18,19</sup> and John Gleeson<sup>20</sup>

<sup>1</sup>Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK

<sup>2</sup>Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

<sup>3</sup>Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, VIC, Australia

<sup>4</sup>Centre for Youth Mental Health, University of Melbourne, Melbourne, VIC, Australia

<sup>5</sup>Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK

<sup>6</sup>Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK

<sup>7</sup>Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK

<sup>8</sup>School of Health and Social Development, Deakin University, Melbourne, VIC, Australia

<sup>9</sup>Department of Nursing, Manchester Metropolitan University, Manchester, UK

<sup>10</sup>School of Computing and Information Systems, Melbourne School of Engineering, University of Melbourne, Melbourne, VIC, Australia

<sup>11</sup>Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

<sup>12</sup>Health Services Research Unit, University of Aberdeen, Aberdeen, UK

<sup>13</sup>Department of Psychiatry, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

<sup>14</sup>Usher Institute, University of Edinburgh, Edinburgh, UK

<sup>15</sup>Scottish Recovery Network, Glasgow, UK

<sup>16</sup>School of Health in Social Science, University of Edinburgh, Edinburgh, UK

<sup>17</sup>Department of Psychiatry, Monash University, Melbourne, VIC, Australia

<sup>18</sup>Department of Psychology and Counselling, La Trobe University, Melbourne, VIC, Australia

<sup>19</sup>NorthWestern Mental Health, Melbourne, VIC, Australia

<sup>20</sup>Healthy Brain and Mind Research Centre, Australian Catholic University, Melbourne, VIC, Australia

\*Corresponding author

**Declared competing interests of authors:** Andrew I Gumley reports personal fees from the University of Manchester, the University of Exeter and the British Association for Behavioural & Cognitive Psychotherapies (BABCP) (Accrington, UK), and other interests with NHS Education for Scotland outside the submitted work. John Ainsworth reports other interests with Affigo CIC (Manchester, UK) outside the submitted work. Sandra Bucci is a director of Affigo CIC, a not-for-profit social enterprise company spun out of the University of Manchester in December 2015 to enable access to social enterprise funding and to promote ClinTouch, a symptom-monitoring app, to the NHS and public sector. Andrew Briggs reports personal fees from Bayer (Leverkusen, Germany), Merck Sharp & Dohme (Kenilworth, NJ, USA), Janssen Pharmaceutica (Beerse, Belgium), Novartis (Basel, Switzerland), SWORD Health (Porto, Portugal), Amgen Inc. (Thousand Oaks, CA, USA) and Daiichi Sankyo (Tokyo, Japan) outside the submitted work. John Farhall reports grants from the National Health and Medical Research Council (Australia) during the conduct of the study and other interests with Melbourne Health (NorthWestern Mental Health, Parkville, VIC, Australia) outside the submitted work. Shôn Lewis reports grants from the Medical Research Council, non-financial support from Affigo CIC and personal fees from XenZone plc (Manchester, UK) outside the submitted work. Cathy Mihalopoulos reports grants from National Health and Medical Research Council (Australia) during the conduct of the study. John Norrie reports grants from the University of Aberdeen and the University of Edinburgh during the conduct of the study and declares membership of the following NIHR boards: CPR Decision Making Committee (2016), HTA Commissioning Board (2010–16), HTA Commissioning Sub-Board (EOI) (2012–16), HTA Funding Boards Policy Group (2016), HTA General Board (2016–19), HTA Post-Board funding teleconference (2016–19), NIHR CTU Standing Advisory Committee (2017–present), NIHR HTA and EME Editorial Board (2014–19) and Pre-exposure Prophylaxis Impact Review Panel (2017–present). Paul French is a member of the HTA Mental Health Prioritisation Panel (2017–present). Chris Williams reports grants from NIHR during the conduct of the study (HTA 10/104/34 BEAT-IT: a randomised controlled trial comparing a behavioural activation treatment for depression in adults with learning disabilities with attention control; NIHR multicentre RCT of a group psychological intervention for postnatal depression in British mothers of South Asian Origin: RP-PG-0514-20012: Integrated therapist and online CBT for depression in primary care); other from Five Areas Ltd (Clydebank, UK) outside the submitted work; and that he has twice been president of the British Association for Behavioural & Cognitive Psychotherapies, the lead body for cognitive–behavioural therapy in the UK. This body aims to advocate use of evidence-based delivery of cognitive–behavioural therapy.

**Disclaimer:** This report contains transcripts of interviews conducted in the course of the research and contains language that may offend some readers.

Published May 2022

DOI: 10.3310/HLZE0479

This report should be referenced as follows:

Gumley AI, Bradstreet S, Ainsworth J, Allan S, Alvarez-Jimenez M, Birchwood M, *et al.* Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT. *Health Technol Assess* 2022;**26**(27).

*Health Technology Assessment* is indexed and abstracted in *Index Medicus/MEDLINE*, *Excerpta Medica/EMBASE*, *Science Citation Index Expanded (SciSearch®)* and *Current Contents®/Clinical Medicine*.



# Health Technology Assessment

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.014

*Health Technology Assessment* is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) ([www.publicationethics.org/](http://www.publicationethics.org/)).

Editorial contact: [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

The full HTA archive is freely available to view online at [www.journalslibrary.nihr.ac.uk/hta](http://www.journalslibrary.nihr.ac.uk/hta). Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: [www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

## Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

## HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

## This report

The research reported in this issue of the journal was funded by the HTA programme as project number 13/154/04. The contractual start date was in April 2016. The draft report began editorial review in September 2019 and was accepted for publication in March 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health and Care Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, the HTA programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2022. This work was produced by Gumley *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health and Care Research, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library ([www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)), produced by Prepress Projects Ltd, Perth, Scotland ([www.prepress-projects.co.uk](http://www.prepress-projects.co.uk)).



## NIHR Journals Library Editor-in-Chief

---

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

## NIHR Journals Library Editors

---

**Professor John Powell** Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

**Professor Andrée Le May** Chair of NIHR Journals Library Editorial Group (HSDR, PGfAR, PHR journals) and Editor-in-Chief of HSDR, PGfAR, PHR journals

**Professor Matthias Beck** Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly** Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin** Consultant in Public Health, Delta Public Health Consulting Ltd, UK

**Dr Peter Davidson** Consultant Advisor, Wessex Institute, University of Southampton, UK

**Ms Tara Lamont** Senior Adviser, Wessex Institute, University of Southampton, UK

**Dr Catriona McDaid** Reader in Trials, Department of Health Sciences, University of York, UK

**Professor William McGuire** Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads** Emeritus Professor of Wellbeing Research, University of Winchester, UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma** Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts** Professor of Child Health Research, Child and Adolescent Mental Health, Palliative Care and Paediatrics Unit, Population Policy and Practice Programme, UCL Great Ormond Street Institute of Child Health, London, UK

**Professor Jonathan Ross** Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: [www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

# Abstract

## Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT

Andrew I Gumley<sup>1\*</sup>, Simon Bradstreet<sup>1</sup>, John Ainsworth<sup>2</sup>,  
Stephanie Allan<sup>1</sup>, Mario Alvarez-Jimenez<sup>3,4</sup>, Maximillian Birchwood<sup>5</sup>,  
Andrew Briggs<sup>6</sup>, Sandra Bucci<sup>2,7</sup>, Sue Cotton<sup>3</sup>, Lidia Engel<sup>8</sup>,  
Paul French<sup>9</sup>, Reeva Lederman<sup>10</sup>, Shôn Lewis<sup>2,7</sup>,  
Matthew Machin<sup>11</sup>, Graeme MacLennan<sup>12</sup>, Hamish McLeod<sup>1</sup>,  
Nicola McMeekin<sup>1</sup>, Cathy Mihalopoulos<sup>8</sup>, Emma Morton<sup>13</sup>,  
John Norrie<sup>14</sup>, Frank Reilly<sup>15</sup>, Matthias Schwannauer<sup>16</sup>,  
Swaran P Singh<sup>5</sup>, Suresh Sundram<sup>17</sup>, Andrew Thompson<sup>3,5</sup>,  
Chris Williams<sup>1</sup>, Alison Yung<sup>2</sup>, Lorna Aucott<sup>12</sup>, John Farhall<sup>18,19</sup>  
and John Gleeson<sup>20</sup>

<sup>1</sup>Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK

<sup>2</sup>Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

<sup>3</sup>Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, VIC, Australia

<sup>4</sup>Centre for Youth Mental Health, University of Melbourne, Melbourne, VIC, Australia

<sup>5</sup>Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK

<sup>6</sup>Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK

<sup>7</sup>Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK

<sup>8</sup>School of Health and Social Development, Deakin University, Melbourne, VIC, Australia

<sup>9</sup>Department of Nursing, Manchester Metropolitan University, Manchester, UK

<sup>10</sup>School of Computing and Information Systems, Melbourne School of Engineering, University of Melbourne, Melbourne, VIC, Australia

<sup>11</sup>Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

<sup>12</sup>Health Services Research Unit, University of Aberdeen, Aberdeen, UK

<sup>13</sup>Department of Psychiatry, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

<sup>14</sup>Usher Institute, University of Edinburgh, Edinburgh, UK

<sup>15</sup>Scottish Recovery Network, Glasgow, UK

<sup>16</sup>School of Health in Social Science, University of Edinburgh, Edinburgh, UK

<sup>17</sup>Department of Psychiatry, Monash University, Melbourne, VIC, Australia

<sup>18</sup>Department of Psychology and Counselling, La Trobe University, Melbourne, VIC, Australia

<sup>19</sup>NorthWestern Mental Health, Melbourne, VIC, Australia

<sup>20</sup>Healthy Brain and Mind Research Centre, Australian Catholic University, Melbourne, VIC, Australia

\*Corresponding author [andrew.gumley@glasgow.ac.uk](mailto:andrew.gumley@glasgow.ac.uk)

**Background:** Relapse is a major determinant of outcome for people with a diagnosis of schizophrenia. Early warning signs frequently precede relapse. A recent Cochrane Review found low-quality evidence to suggest a positive effect of early warning signs interventions on hospitalisation and relapse.

**Objective:** How feasible is a study to investigate the clinical effectiveness and cost-effectiveness of a digital intervention to recognise and promptly manage early warning signs of relapse in schizophrenia with the aim of preventing relapse?

**Design:** A multicentre, two-arm, parallel-group cluster randomised controlled trial involving eight community mental health services, with 12-month follow-up.

**Settings:** Glasgow, UK, and Melbourne, Australia.

**Participants:** Service users were aged > 16 years and had a schizophrenia spectrum disorder with evidence of a relapse within the previous 2 years. Carers were eligible for inclusion if they were nominated by an eligible service user.

**Interventions:** The Early signs Monitoring to Prevent relapse in psychosis and prOmote Wellbeing, Engagement, and Recovery (EMPOWER) intervention was designed to enable participants to monitor changes in their well-being daily using a mobile phone, blended with peer support. Clinical triage of changes in well-being that were suggestive of early signs of relapse was enabled through an algorithm that triggered a check-in prompt that informed a relapse prevention pathway, if warranted.

**Main outcome measures:** The main outcomes were feasibility of the trial and feasibility, acceptability and usability of the intervention, as well as safety and performance. Candidate co-primary outcomes were relapse and fear of relapse.

**Results:** We recruited 86 service users, of whom 73 were randomised (42 to EMPOWER and 31 to treatment as usual). Primary outcome data were collected for 84% of participants at 12 months. Feasibility data for people using the smartphone application (app) suggested that the app was easy to use and had a positive impact on motivations and intentions in relation to mental health. Actual app usage was high, with 91% of users who completed the baseline period meeting our a priori criterion of acceptable engagement (> 33%). The median time to discontinuation of > 33% app usage was 32 weeks (95% confidence interval 14 weeks to  $\infty$ ). There were 8 out of 33 (24%) relapses in the EMPOWER arm and 13 out of 28 (46%) in the treatment-as-usual arm. Fewer participants in the EMPOWER arm had a relapse (relative risk 0.50, 95% confidence interval 0.26 to 0.98), and time to first relapse (hazard ratio 0.32, 95% confidence interval 0.14 to 0.74) was longer in the EMPOWER arm than in the treatment-as-usual group. At 12 months, EMPOWER participants were less fearful of having a relapse than those in the treatment-as-usual arm (mean difference -4.29, 95% confidence interval -7.29 to -1.28). EMPOWER was more costly and more effective, resulting in an incremental cost-effectiveness ratio of £3041. This incremental cost-effectiveness ratio would be considered cost-effective when using the National Institute for Health and Care Excellence threshold of £20,000 per quality-adjusted life-year gained.

**Limitations:** This was a feasibility study and the outcomes detected cannot be taken as evidence of efficacy or effectiveness.

**Conclusions:** A trial of digital technology to monitor early warning signs that blended with peer support and clinical triage to detect and prevent relapse is feasible.

**Future work:** A main trial with a sample size of 500 (assuming 90% power and 20% dropout) would detect a clinically meaningful reduction in relapse (relative risk 0.7) and improvement in other variables (effect sizes 0.3–0.4).

**Trial registration:** This trial is registered as ISRCTN99559262.

**Funding:** This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 26, No. 27. See the NIHR Journals Library website for further project information. Funding in Australia was provided by the National Health and Medical Research Council (APP1095879).



# Contents

List of tables	xv
List of figures	xvii
List of supplementary material	xix
Glossary	xxi
List of abbreviations	xxiii
Plain English summary	xxv
Scientific summary	xxvii
<b>Chapter 1 Introduction</b>	<b>1</b>
Relapse in psychosis	1
Evidence for the prevention of relapse	2
<i>Early warning signs monitoring and interventions</i>	2
<i>Service user barriers to relapse detection and prevention</i>	4
<i>Service barriers to relapse detection and prevention</i>	4
<i>Conceptual framework for improving relapse detection and prevention</i>	5
Digital technology for early warning signs monitoring and intervention	5
Peer support working	7
Conclusion	7
<b>Chapter 2 Methods</b>	<b>9</b>
EMPOWER phase 1	9
<i>Objective</i>	9
<i>Settings</i>	9
<i>Methods</i>	9
<i>Study population</i>	10
<i>Eligibility criteria</i>	11
<i>Sample size</i>	12
<i>Analytic methods</i>	12
<i>Participant safety and withdrawal</i>	12
<i>Data security and management</i>	14
<i>Protocol amendments</i>	14
<i>Protocol breaches</i>	15
EMPOWER phase 2	15
<i>Objectives</i>	15
<i>Trial design</i>	16
<i>Ethics and governance</i>	16
<i>Preliminary work: patient and public involvement</i>	16
<i>Eligibility criteria</i>	16
<i>Interventions</i>	18
<i>Outcomes</i>	23
<i>Candidate outcomes</i>	25
<i>Process evaluation</i>	27

## CONTENTS

<i>Sample size</i>	27
<i>Recruitment and randomisation</i>	28
<i>Statistical analysis</i>	28
<i>Work package 6: widening stakeholder engagement</i>	29
<i>Protocol amendments</i>	29
<i>Protocol breaches</i>	29
<i>Study amendments</i>	29
<i>System safety and privacy protection</i>	30
<b>Chapter 3 Qualitative findings</b>	<b>31</b>
Background	31
<i>Theory</i>	32
Methods	32
Aims	32
<i>Sampling and recruitment</i>	34
Analysis	34
Results	36
<i>Task groups with service users (work package 1)</i>	36
<i>Task groups with carers (work package 1)</i>	37
<i>Task groups with staff (work package 2)</i>	38
<i>Beta testing (work package 3)</i>	41
<i>Interpretative phenomenological analysis (work package 3)</i>	42
Discussion	46
Coherence	46
Cognitive participation	46
Collective action	47
Translation to EMPOWER phase 2	48
Beta testing	48
<b>Chapter 4 Baseline, feasibility, acceptability and safety results</b>	<b>51</b>
Recruitment and participant flow	51
Baseline characteristics	52
<i>Service user baseline demographic characteristics</i>	52
<i>Clinical characteristics of service users at baseline</i>	52
<i>Carer and care co-ordinator baseline characteristics</i>	52
General feasibility	55
Feasibility and acceptability of the EMPOWER app	56
App engagement	57
Provision of study phones	58
Safety	58
Adverse events	58
Device deficiencies	59
<b>Chapter 5 Candidate outcomes of the main trial</b>	<b>61</b>
Candidate service user outcomes	61
Candidate primary outcomes	61
Candidate secondary outcomes	63
Clinical outcomes	63
Substance use outcomes	65
Emotional distress outcomes	65
Service engagement and adherence	65
Candidate mechanism outcomes	67

Carer and care co-ordinator outcomes	67
<i>Carers</i>	67
<i>Care co-ordinators</i>	67
Sensitivity analyses	70
<i>Small numbers of clusters</i>	70
<i>Impact of possible informative withdrawal</i>	70
<b>Chapter 6 Health economic analysis</b>	<b>71</b>
Introduction	71
Methods	71
<i>Overview</i>	71
<i>Study perspective</i>	71
<i>Identification, measurement and valuation of resource use</i>	71
<i>Identification, measurement and valuation of outcome measures</i>	75
<i>Missing data</i>	75
<i>Analysis</i>	75
<i>Sensitivity analysis</i>	76
Results	76
<i>Missing data</i>	76
<i>Outcome measures</i>	77
<i>Resource use</i>	80
<i>Mean costs and quality-adjusted life-years</i>	81
<i>Mean costs and relapse cases</i>	84
Carer costs and outcomes	86
<b>Chapter 7 Discussion</b>	<b>87</b>
Eligibility, consent and recruitment	87
Feasibility, acceptability and usability of the EMPOWER intervention	88
Performance and safety of the EMPOWER app	90
Assessment of candidate primary and secondary outcomes	91
<i>Candidate primary outcomes</i>	91
<i>Secondary and mechanism outcomes</i>	92
Health economics parameters	93
Enhance and tailor the EMPOWER mobile phone app	95
Considerations for a larger trial of EMPOWER	95
Strengths and limitations	96
<i>Strengths</i>	96
<i>Limitations</i>	97
Conclusions and recommendations	98
<b>Acknowledgements</b>	<b>99</b>
<b>References</b>	<b>103</b>
<b>Appendix 1 Novel or adapted measures</b>	<b>123</b>
<b>Appendix 2 Work package 3 semistructured interview</b>	<b>131</b>
<b>Appendix 3 Additional baseline tables</b>	<b>133</b>
<b>Appendix 4 General feasibility tables</b>	<b>135</b>
<b>Appendix 5 Describing engagement with the EMPOWER app</b>	<b>139</b>



## CONTENTS

<b>Appendix 6</b> Additional relapse outcome table	<b>143</b>
<b>Appendix 7</b> Clinical assessment calibration and reliability	<b>145</b>
<b>Appendix 8</b> Intervention costs	<b>147</b>
<b>Appendix 9</b> Unit costs	<b>153</b>
<b>Appendix 10</b> Resource use outcomes	<b>159</b>
<b>Appendix 11</b> Work package 6 public engagement	<b>169</b>

# List of tables

<b>TABLE 1</b> Phase 1 protocol amendments	<b>15</b>
<b>TABLE 2</b> Participant timeline	<b>17</b>
<b>TABLE 3</b> EMPOWER relapse criteria	<b>26</b>
<b>TABLE 4</b> Phase 2 protocol amendments	<b>30</b>
<b>TABLE 5</b> Work packages 1 and 2 sampling table	<b>35</b>
<b>TABLE 6</b> Service user characteristics and app usage	<b>41</b>
<b>TABLE 7</b> Service user demographic characteristics at baseline	<b>54</b>
<b>TABLE 8</b> Service user clinical characteristics at baseline	<b>54</b>
<b>TABLE 9</b> Feasibility and acceptability for app users	<b>56</b>
<b>TABLE 10</b> Adverse events	<b>58</b>
<b>TABLE 11</b> Primary outcome analysis	<b>61</b>
<b>TABLE 12</b> The FoRSe at all time points	<b>62</b>
<b>TABLE 13</b> Service user clinical outcomes at all time points	<b>63</b>
<b>TABLE 14</b> Service user substance use outcomes at all time points	<b>65</b>
<b>TABLE 15</b> Service user emotional distress outcomes at all time points	<b>66</b>
<b>TABLE 16</b> Service user service engagement and adherence at all time points	<b>67</b>
<b>TABLE 17</b> Candidate mechanism outcomes at all time points	<b>68</b>
<b>TABLE 18</b> Carer outcomes at all time points	<b>68</b>
<b>TABLE 19</b> Care co-ordinator outcomes at all time points	<b>69</b>
<b>TABLE 20</b> Economic measures completion at all time points	<b>77</b>
<b>TABLE 21</b> The EQ-5D-5L service user results at all time points	<b>77</b>
<b>TABLE 22</b> The AQoL-8D service user results at all time points	<b>78</b>
<b>TABLE 23</b> The EQ-5D-5L carer results at all time points	<b>79</b>
<b>TABLE 24</b> The CarerQoL-7D results at all time points	<b>79</b>
<b>TABLE 25</b> Mean costs and QALYs (base case)	<b>82</b>

## LIST OF TABLES

<b>TABLE 26</b>	Cost-utility analysis	<b>84</b>
<b>TABLE 27</b>	Base-case and sensitivity analyses (health-care payer perspective)	<b>85</b>
<b>TABLE 28</b>	Cost-effectiveness analysis	<b>85</b>
<b>TABLE 29</b>	Carer costs and outcomes	<b>86</b>
<b>TABLE 30</b>	Carer baseline characteristics	<b>133</b>
<b>TABLE 31</b>	Care co-ordinator baseline characteristics	<b>133</b>
<b>TABLE 32</b>	Service user general feasibility	<b>136</b>
<b>TABLE 33</b>	Carer general feasibility	<b>137</b>
<b>TABLE 34</b>	Care co-ordinator general feasibility	<b>137</b>
<b>TABLE 35</b>	Recovery to intended engagement level following an event	<b>140</b>
<b>TABLE 36</b>	App engagement of participants achieving a baseline	<b>141</b>
<b>TABLE 37</b>	Relapse characteristics at all time points	<b>143</b>
<b>TABLE 38</b>	Sequence of reliability co-ratings post calibration	<b>145</b>
<b>TABLE 39</b>	Post-calibration item-level rater reliability	<b>146</b>
<b>TABLE 40</b>	Breakdown of intervention costs	<b>148</b>
<b>TABLE 41</b>	UK unit costs	<b>153</b>
<b>TABLE 42</b>	Australian unit costs	<b>155</b>
<b>TABLE 43</b>	Service user resource use	<b>160</b>
<b>TABLE 44</b>	Carer resource use	<b>167</b>

# List of figures

<b>FIGURE 1</b> Cognitive–interpersonal framework for EWS	<b>5</b>
<b>FIGURE 2</b> The EMPOWER system	<b>21</b>
<b>FIGURE 3</b> EMPOWER algorithm responding	<b>21</b>
<b>FIGURE 4</b> Superordinate and subordinate themes	<b>42</b>
<b>FIGURE 5</b> Service user recruitment over time	<b>51</b>
<b>FIGURE 6</b> The CONSORT flow diagram	<b>53</b>
<b>FIGURE 7</b> Kaplan–Meier curve of time to 4 weeks’ app use < 33%	<b>57</b>
<b>FIGURE 8</b> Kaplan–Meier plot of time to first relapse	<b>62</b>
<b>FIGURE 9</b> The EQ-5D-5L service user results, with 95% CIs	<b>78</b>
<b>FIGURE 10</b> The AQoL-8D service user results, with 95% CIs	<b>78</b>
<b>FIGURE 11</b> The EQ-5D-5L carer results, with 95% CIs	<b>79</b>
<b>FIGURE 12</b> The CarerQoL-7D results, with 95% CIs	<b>80</b>
<b>FIGURE 13</b> Breakdown of the total costs of EMPOWER and TAU (societal perspective)	<b>84</b>
<b>FIGURE 14</b> Cost-effectiveness plane (health-care payer perspective)	<b>85</b>
<b>FIGURE 15</b> The ‘EMPOWER now?’ themes	<b>169</b>
<b>FIGURE 16</b> The ‘EMPOWER future?’ themes	<b>171</b>



# List of supplementary material

**Report Supplementary Material 1** Task group topic guides

**Report Supplementary Material 2** The EMPOWER app question set

Supplementary material can be found on the NIHR Journals Library report page (<https://doi.org/10.3310/HLZE0479>).

Supplementary material has been provided by the authors to support the report and any files provided at submission will have been seen by peer reviewers, but not extensively reviewed. Any supplementary material provided at a later stage in the process may not have been peer reviewed.



## Glossary

We use the term 'service user' to refer to people with direct personal experiences of schizophrenia and psychosis who were recruited to the study. We are aware that the preferred term in Australia is 'consumer' and also that the term 'service user' can be criticised for, among other things, collectively describing a group of people based on their receipt of mental health services, which is limiting. However, we agreed this as our preferred option given its widespread adoption in related mental health research and also to be consistent with the language used in our protocol.

While service user eligibility criteria for different study elements related to schizophrenia and related diagnoses, we more routinely refer to psychosis when describing participants' experiences and the intervention's purpose. In doing so we are recognising that relapse relates specifically to psychosis experiences. We do, however, acknowledge that people with other diagnoses who would not have been eligible for this study, for example those with bipolar disorder, may also experience psychosis.





## List of abbreviations

app	smartphone application	ITAREPS	Information Technology Aided Relapse Prevention Programme in Schizophrenia
AQoL-8D	Assessment of Quality of Life		
CBT	cognitive-behavioural therapy	JCP	joint crisis plan
CDSS	Calgary Depression Scale for Schizophrenia	MBS	Medicare Benefits Schedule
CHaRT	Centre for Healthcare Randomised Trials	MHRA	Medicines and Healthcare products Regulatory Agency
ChIP	check-in prompt	NIHR	National Institute for Health and Care Research
CI	confidence interval	NPT	normalisation process theory
CMHS	community mental health service	PANSS	Positive and Negative Syndrome Scale
CONSORT	Consolidated Standards of Reporting Trials	PBIQ-R	Personal Beliefs About Illness Questionnaire-Revised
cRCT	cluster randomised controlled trial	PSP	Personal and Social Performance
CTU	Clinical Trials Unit	QALY	quality-adjusted life-year
DMEC	Data Monitoring and Ethics Committee	R&D	research and development
EMA	ecological momentary assessment	RCT	randomised controlled trial
EMPOWER	Early signs Monitoring to Prevent relapse in psychosis and prOmote Wellbeing, Engagement, and Recovery	RR	relative risk
EQ-5D-5L	EuroQoL-5 Dimensions, five-level version	RUQ	resource use questionnaire
EWS	early warning signs	SD	standard deviation
GP	general practitioner	SSC	Study Steering Committee
HADS	Hospital Anxiety and Depression Scale	TAU	treatment as usual
ICER	incremental cost-effectiveness ratio	UX	user experience
		WP	work package



# Plain English summary

## What was the problem?

Relapse is a considerable problem for people with a diagnosis of schizophrenia. Relapse can be predicted by early warning signs that are unique to the person. They include withdrawal, fear and paranoia.

## What was the question?

Is it possible to investigate the effectiveness of an intervention to recognise and promptly manage early warning signs of relapse in schizophrenia with the aim of preventing relapse?

## What did we do?

We spoke with 88 mental health staff, 40 carers and 21 service users before we designed a system that used a mobile phone to help people monitor early warning signs. We included peer support to help people using the system reflect on their experiences. We hoped the overall system, called EMPOWER, would help people to be more in charge of their mental health.

After consenting 86 people to the study, we were able to randomly assign 73 people either to use the EMPOWER system (42 people) or to receive their normal treatment alone (31 people). We used research measures over 1 year to help us better understand people's experiences. We also involved carers (for example family or friends) and mental health service providers in the research.

## What did we find?

We found that it was possible to recruit people to the study and to gather research data. We also found that people used the EMPOWER system and found it acceptable. We found that those who used EMPOWER had a lower rate of relapse over 12 months than people who did not. They were also less likely to be fearful of relapse. We found that EMPOWER was likely to be cost-effective.

## What does this mean?

This means that a study to investigate the effectiveness of a system to recognise and respond to early warning signs of relapse in schizophrenia is possible.



# Scientific summary

## Background

Schizophrenia is a long-term and serious mental illness with a lifetime prevalence rate of 4.0 per 1000 people, and it is estimated to affect 21 million people worldwide. It is one of the top 15 leading global causes of disability, and estimates suggest that around 80% of people with a diagnosis experience a relapse after 5 years. Relapse and associated hospital admissions can be deeply distressing and traumatic for those affected, and the direct treatment costs for people who experience a relapse are three times higher than for those who do not. Additionally, relapse is associated with a lifetime risk of clinical and functional deterioration. There is, therefore, some urgency to develop interventions to identify and respond to valid predictors of relapse in psychosis.

Antipsychotic medication has the strongest evidence for relapse prevention but its benefits are limited by high levels of discontinuation, often associated with common and burdensome side effects. Although there is some evidence for the effectiveness of psychological approaches, their availability is limited and questions have been raised over the supporting evidence. A further approach, known as early warning signs monitoring, is generally achieved by comparing ongoing assessments of potential early signs of relapse against earlier assessments and, where necessary, responding with an appropriate plan for relapse prevention. Although significantly fewer people relapse as a result of early warning signs monitoring, the quality of the supporting evidence makes it impossible to recommend the approach in routine practice. Identifying and responding to early warning signs is constrained by a variety of factors, including the effect of previous negative experiences at times of crisis for service users, fear of relapse, the consequences of help-seeking and a prioritisation of risk within services.

Mobile health technology, and smartphone interventions specifically, offer potential solutions to some of the implementation barriers that have hindered early signs monitoring approaches. Emerging evidence suggests that people with experiences of psychosis are generally comfortable with the application of digital mobile technologies in this context, with studies suggesting good levels of acceptability. Blending peer support with digital interventions has the potential to improve engagement and user experience.

## Objectives

The objectives of phase 1 of the study were to conduct task group interviews to explore the acceptability and usability of mobile symptom reporting using smartphones among service users, carers and mental health staff and to identify the incentives and barriers to use by service users and carers and to implementation by mental health staff. We also sought to identify current pathways to relapse identification and prevention with mental health staff. These interviews informed modifications to the EMPOWER app (smartphone application), which then underwent a 5-week beta-testing period with a group of service users.

The purpose of phase 2 was to establish the feasibility of conducting a definitive cluster randomised controlled trial comparing the EMPOWER intervention with treatment as usual. We sought to establish the parameters of the feasibility, acceptability, usability, safety and outcome signals of a mobile and peer-supported intervention as an adjunct to usual care that would be deliverable in the NHS and Australian community mental health service settings.

## Methods

In phase 1, task group participants were approached via community mental health services and other groups in Glasgow and Melbourne, with analysis based on the framework approach. Beta testing was conducted with service users over a 5-week period, recruited via task groups and local networks, after which we conducted interviews exploring experiences of beta testing, applying interpretative phenomenological analysis. We utilised normalisation process theory as a framework to understand the work required to optimise the EMPOWER intervention ahead of conducting the feasibility trial.

In phase 2, we evaluated EMPOWER using a multicentre, two-arm, parallel-group cluster randomised controlled trial involving eight purposively selected community mental health services (two in Melbourne and six in Glasgow) with 12-month follow-up. The services were the unit of randomisation (the cluster), with the intervention delivered by the teams to people using services and with outcomes assessed within these clusters. We engaged services likely to have five or more care co-ordinators willing to participate and where potential care co-ordinators had eligible service users on their caseload. Service users were eligible if they were aged > 16 years and had a schizophrenia or related diagnosis, and for whom there was evidence of a relapse within the previous 2 years. Carers of people receiving support from participating services were eligible for inclusion if they were nominated by an eligible service user.

The EMPOWER intervention was designed to enable participants to monitor changes in their well-being on a daily basis using a mobile phone. Participants could use their own mobile phone; if preferred, they were provided with a mobile phone from the study team. A peer support worker was involved in setting up the app and following up people using the app every 2 weeks. Clinical triage of changes in well-being that were suggestive of early signs of relapse was enabled through an algorithm that triggered a check-in prompt that informed a relapse prevention pathway if warranted. The app included messaging, diary and charting functions intended to support self-management.

We used a variety of validated, novel and adapted measures to assess feasibility, acceptability and usability, safety and performance. Carers also completed measures of feasibility. We also assessed the candidate primary outcome of relapse by reviewing electronic patient records with ratings made independent of and blind to allocation to EMPOWER and treatment as usual. We assessed a series of candidate secondary and mechanistic outcomes and completed a health economic evaluation. These were rated independently but not blinded. All outcome measures were administered at baseline and then repeated at 3, 6 and 12 months. A statistical analysis plan and a health economic analysis plan were agreed prior to any analyses.

All analyses were carried out using the intention-to-treat principle with data from all participants included in the analysis, including those who did not complete the intervention.

## Results

Phase 1 task groups identified that the EMPOWER intervention made sense to our stakeholder groups and was relevant both to existing mental health services practice and to the concerns and values of service users and carers. We identified barriers to implementation in routine clinical practice, which included worries about additional workload for mental health services and the validity of data. Although service users and carers valued relapse prevention, they also raised concerns around fears of help-seeking and unhelpful service responses in the event of a crisis. We addressed these concerns by reviewing and adapting our approach to the triage of check-in prompts, by reviewing the language we used to describe the intervention and by refining the practices of the peer support workers. Through conducting beta testing, we identified a number of relevant and important technical issues, which were addressed prior to phase 2. Overall, the app was well received by beta testers and was considered to be a useful tool for self-monitoring and recovery.

In phase 2, we were able to recruit our target of 86 service users, of whom 73 were randomised (42 to EMPOWER and 31 to treatment as usual). At 12 months, primary outcome data were collected for 76% of service users in the EMPOWER arm and for 90% in the treatment as usual arm. During the study, seven people withdrew from the EMPOWER arm, two moved out of area and there was one death. There was a clear association between those who withdrew from the EMPOWER arm and low engagement with the app. One person withdrew from the treatment as usual arm. Feasibility data for people using the app suggested that the app was easy to use and had an impact on mental health, but the sharing of early warning signs with carers and care co-ordinators was less frequent. Actual app usage was high, with 91% of users who completed the baseline period meeting our a priori criterion of acceptable engagement (> 33%). The length of time at which 50% of participants no longer meet the intended adherence criterion is hard to predict in this sample (especially in terms of an upper limit) but is likely not to fall below 14 weeks (the lower end of a 95% confidence interval). We supplied 28 mobile phones to service users, six of which were lost or stolen. Across both arms there were 54 adverse events affecting 29 people. Around half were classified as serious adverse events, the vast majority of which were anticipated. There were 13 app-related adverse events affecting 11 people, one of which was serious.

Fewer participants in the EMPOWER arm had a relapse and time to first relapse was longer than in the treatment as usual arm. At 12 months EMPOWER participants were less fearful of having a relapse than those in the treatment as usual arm. These and other secondary and mechanism outcomes offer encouraging signals for a larger study and inform the selection of measures for a definitive trial. Additionally, our health economic analysis suggested that EMPOWER resulted in fewer costs and greater outcomes than treatment as usual in terms of both quality-adjusted life-years and relapses avoided.

## Conclusions

We demonstrated the feasibility of recruitment and retention of service user participants into the trial. In addition, the rates of data completeness for candidate primary, secondary and mechanistic outcomes were excellent over the 12 months. However, we did identify problems with the completeness of the health economic measures data. We demonstrated that we can deliver the EMPOWER intervention blending our mobile app with peer support and an algorithm that supports the delivery of tailored messaging and clinical triage of possible early warning signs of relapse. In addition, we learned how to integrate check-in prompts generated by the algorithm into peer support to promote increased awareness and motivation to engage in self-management. It is likely that EMPOWER may reduce relapse over 12 months and reduce fear of relapse. The intervention may improve other outcomes including negative symptoms, depression, personal recovery and self-efficacy. It is unlikely that EMPOWER improves medication adherence. It is likely that overall the costs for the EMPOWER arm are increased but the intervention also results in improved quality-adjusted life-years and reduced relapse. The incremental cost-effectiveness ratio of £3089 per quality-adjusted life-year gained is below the current £20,000 threshold recommended by the National Institute for Health and Care Excellence and there was a 70% probability that EMPOWER is cost-effective from the health-care payer perspective. A further main trial seems merited by these overall findings. We estimate that for a main trial (assuming 90% power and 20% dropout) we would require a sample size of 500 service users to detect a relative risk of 0.7 for reduction of relapse and for continuous variables effect sizes of between 0.3 and 0.4.

## Trial registration

This trial is registered as ISRCTN99559262.



## Funding

This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 26, No. 27. See the NIHR Journals Library website for further project information. Funding in Australia was provided by the National Health and Medical Research Council (APP1095879).

# Chapter 1 Introduction

Schizophrenia is a long-term and serious mental illness for which a wide variety of risk and protective factors have been evidenced.<sup>1</sup> It is a form of psychosis characterised by positive and negative symptoms. Positive symptoms relate to distortions of thinking, including fixed beliefs, delusions and paranoia, as well as auditory and visual hallucinations. Negative symptoms include deficits in cognitive functioning, low mood and blunted emotions. Schizophrenia has a lifetime prevalence rate of 4.0 (1.6–12.1) per 1000 people<sup>2</sup> and is estimated to affect 21 million people worldwide. Onset of symptoms typically occurs in early adulthood, with the majority of people continuing to experience persisting or fluctuating symptoms.<sup>2</sup> Schizophrenia contributes 13.4 (9.9–16.7) million years of life lived with disability to burden of disease<sup>3</sup> and is one of the top 15 leading global causes of disability.<sup>4</sup>

People with a schizophrenia diagnosis die 14.5 (11.2–17.8) years earlier than those in the general population, with a mean age at death for men of 59.9 (55.5–64.3) years and 67.6 (63.1–72.1) years for women,<sup>5</sup> meaning it is a major public health concern. In a recent longitudinal study,<sup>6</sup> 11.7% of 171 participants were deceased at follow-up 20 years after a first episode of psychosis, more than double the expected mortality. Worryingly, this differential mortality gap has widened over recent decades.<sup>7</sup> Although it is impossible to quantify the significant emotional distress and life disruption associated with schizophrenia and psychosis for people directly affected and for those closest to them, it is estimated that the overall costs to society are somewhere in the region of £11B in the UK<sup>8</sup> and AU\$4.9B annually in Australia.<sup>9</sup>

## Relapse in psychosis

Estimates suggest that around 80% of people with a schizophrenia diagnosis experience a relapse after 5 years.<sup>10,11</sup> A 2012 systematic review<sup>12</sup> found pooled prevalence rates of relapse in positive symptoms following a first episode of 28% (range 12–47%) at 1-year follow-up, 43% (range 35–54%) at 18 months and 54% (range 40–63%) at 3 years, with similar relapse rates identified in more recent longitudinal studies.<sup>13,14</sup> The second Australian national survey of psychosis<sup>15</sup> found that > 60% of respondents had experienced multiple episodes of psychosis symptoms interspersed with periods of full or partial remission, with 35% having experienced one or more hospital admissions in the previous year. Relapse and associated hospital admissions can be deeply distressing and traumatic experiences for people affected,<sup>16</sup> and fear of future relapse can be disabling for service users<sup>17</sup> and family members alike.<sup>18</sup>

Direct treatment costs for people who experience a relapse are three times higher than they are for people who do not, with the majority of additional costs associated with unplanned hospital admissions.<sup>19</sup> Health-care costs for people characterised as unstable (defined as having had one or more admissions in the previous 2 years) have been found to be four times higher than for people who are stable, again with the vast majority of additional costs associated with hospital admissions.<sup>20</sup> Almost half (46%) of health sector costs for psychosis are generated by inpatient care in Australia, accounting for 96% of the total (AU\$609M).<sup>9</sup> The greatest impact on these patterns of service use is relapsing psychosis.<sup>15</sup> Inpatient admissions are associated with suicidal ideation, younger age, poorer functioning and increased symptomology.<sup>21</sup>

Relapse in psychosis is associated with a lifetime risk of functional and clinical deterioration,<sup>14</sup> meaning that there is an urgency to identify and respond to valid predictors to inform personalised treatment responses.<sup>22,23</sup> A broad range of potential predictors of relapse have been investigated, with a small number consistently identified across the literature.<sup>12,22</sup> Non-adherence to treatment, including medication, increases the risk of relapse<sup>12,14</sup> by potentially up to five times.<sup>11</sup> Medication non-adherence is, in turn, predicted by poorer insight of illness, previous involuntary treatment, poorer premorbid

functioning, forensic service history and substance misuse, previous suicide attempts, embarrassment, wider issues with service engagement and poor working alliance.<sup>24-28</sup> Other predictors of relapse include substance misuse,<sup>12</sup> cannabis use,<sup>13</sup> younger age at onset of psychosis,<sup>14</sup> poorer premorbid functioning, increased family criticism<sup>12</sup> and fear of relapse itself.<sup>17</sup> Reduced social functioning, isolation<sup>11,12,29</sup> and negative interpersonal style, possibly linked to poorer use of social support,<sup>30</sup> may also predict relapse, with a potential dose-response effect noted between repeated relapses and poorer social functioning.<sup>31</sup>

### Evidence for the prevention of relapse

Recent review evidence suggests that it is possible to intervene to reduce the likelihood of psychosis relapses, with absolute risk reductions of between 13.6% and 37.0%.<sup>32</sup> At the same time, it has been argued that it is not possible to make specific recommendations about the predictors that should be included in a prognostic model, owing to a lack of high-quality evidence.<sup>23</sup> At present, oral antipsychotic medication in combination with psychological interventions is the recommended treatment for prevention of relapse in first-episode and recurrent psychosis.<sup>33</sup>

Reviews and meta-analyses suggest that although antipsychotics are consistently more effective than placebo<sup>34</sup> they tend to be of intermediate efficacy for relapse prevention, with limited differences noted between individual drugs.<sup>35</sup> Discontinuation of antipsychotics is common and, although discontinuation rates vary between drugs,<sup>36</sup> one trial found that almost three-quarters of participants had an unplanned end to their antipsychotic treatment before the end of the 18-month study period.<sup>37</sup> The odds ratios of discontinuation compared with those for placebo have been found to range from 0.43 for the best-performing drug to 0.80 for the worst.<sup>34</sup> Discontinuation often relates to the intolerability of adverse effects of antipsychotics and, although the type and frequency of adverse effects vary considerably between medications, they can include weight gain, extrapyramidal side effects, sedation and prolactin increase.<sup>34</sup>

Meta-analyses of cognitive-behavioural therapy (CBT) for psychosis have found small to moderate effect sizes in favour of CBT for psychosis for a variety of outcomes, including improvement in mental state,<sup>38</sup> reduction in positive<sup>39,40</sup> and negative symptoms,<sup>40</sup> reduced hospital admissions<sup>41,42</sup> and improved mood and functioning.<sup>40</sup> Some have urged caution in the interpretation of positive effects given an apparent inverse relationship between effect size and methodological rigour, particularly in relation to masking,<sup>40,43</sup> and effects in favour of CBT for psychosis may also be less clear when trials use other psychological therapies as the comparator.<sup>44</sup> Reviews of family interventions, which take different forms but tend to be underpinned by cognitive-behavioural principles,<sup>45</sup> have shown reductions in relapse and hospital admissions<sup>38,46</sup> as well as improvements in treatment compliance.<sup>46</sup> However, the availability of both CBT for psychosis and family therapies is limited by poor implementation in adult mental health services.<sup>8,47</sup>

In summary, the strongest evidence among treatment approaches for relapse prevention is to be found for antipsychotic medication, but its benefits are limited by high levels of discontinuation and it is often associated with prevalent and burdensome side effects. Evidence in support of psychological therapies for relapse prevention is limited, with questions over methodological rigour. Access to psychological therapies is also limited by poor implementation in services. This means that there is a pressing need to investigate alternative methods of relapse prevention.

### *Early warning signs monitoring and interventions*

A further well-established approach for relapse prevention in research and practice is early warning signs (EWS) monitoring, established by Birchwood, Herz and colleagues.<sup>48,49</sup> EWS monitoring is based on the assumption that it is possible to intervene to reduce the likelihood of a relapse of psychosis through its timely prediction. This is generally achieved by comparing ongoing assessments of EWS

indicators against an individual's 'baseline' score.<sup>50</sup> Relapse in psychosis is now understood to be the end point of a process of change associated with early signs including changes in affect and incipient psychotic experiences.<sup>50</sup> EWS may be identifiable for as long as 5–8 weeks prior to a relapse,<sup>51</sup> creating significant opportunity for early intervention. However, review evidence suggests considerable variation in the proportion of relapses correctly predicted by EWS (sensitivity 10–80%, median 60%) and non-relapses correctly predicted (specificity 38–100%, median 81%), with more frequent monitoring and the inclusion of both affective and psychosis symptoms found to improve prediction.<sup>52</sup>

Eisner *et al.*<sup>52</sup> identified 17 papers involving early signs interventions in their 2013 review. Early signs interventions involve responding to EWS changes with a plan designed to prevent or minimise relapse. Just one of these studies used a purely psychological approach, with two or three sessions of relapse prevention focused CBT administered in response to an assessed increase in EWS from baseline.<sup>53</sup> People in the CBT arm had significantly fewer relapses than people in a treatment-as-usual arm, but the findings may have been influenced by the lack of masked assessment of relapse. Four studies included interventions in response to EWS increases that Eisner *et al.* described as multicomponent relapse prevention techniques. These included stress management and problem-solving methods, increased practitioner contact and antipsychotic medication increases,<sup>54–57</sup> as well as three interventions that involved a relative or friend.<sup>54,55,57</sup> In two out of the three studies that assessed relapse, those in the intervention arm had significantly improved outcomes compared with those receiving treatment as usual,<sup>54,55</sup> and the other study was potentially underpowered to show an effect on relapse.<sup>57</sup>

The remaining studies in the Eisner *et al.*<sup>52</sup> review related to interventions in response to EWS that involved changes in medication alone. In one study, targeted medication or placebo was given in addition to maintenance medication on the emergence of EWS. However, no differences were observed between the arms in relation to time to symptom exacerbation at 2-year follow-up.<sup>58</sup> The remaining 11 studies temporarily used targeted medication on the emergence of EWS but in the absence of other 'maintenance' antipsychotic medication.<sup>59–70</sup> Although there were variations in the method of treatment and in comparators, in all but one<sup>65</sup> of the seven studies of targeted medication approaches where relapse was assessed the outcomes were better for people in receipt of a moderate dose of maintenance medication than for people receiving targeted medication alone.<sup>61,62,64,67–69</sup> Two studies<sup>59,60</sup> measured hospital admission alone, finding no significant differences in admission rates between people in receipt of maintenance medication regimes and those in receipt of targeted medication regimes.

Across all of the included studies, comparison was complicated by the heterogeneity of EWS assessment and the definition of relapse alongside a number of methodological weaknesses, including potential sampling bias and underpowered studies. Despite this, a number of conclusions were drawn about EWS-informed interventions. Targeted medication in response to EWS was found to be less effective than maintenance for relapse prevention, and replication with blinded assessment of relapse was recommended for the lone psychological intervention<sup>53</sup> before firm conclusions could be drawn about its seeming potential. Multicomponent responses to EWS were described as showing promise for relapse prevention, but methodological weaknesses were highlighted, suggesting the need for further research.

Additional evidence of the potential for EWS interventions was provided in a 2013 Cochrane review<sup>71</sup> that compared the effectiveness of EWS interventions with that of treatment as usual on time to relapse, hospitalisation, functioning and symptoms. The review found that significantly fewer people relapsed with EWS interventions than with usual care [23% vs. 43%; risk ratio 0.53, 95% confidence interval (CI) 0.36 to 0.79; 15 randomised controlled trials (RCTs),  $n = 1502$ ] and significantly fewer people were readmitted to hospital (19% vs. 39%; risk ratio 0.48, 95% CI 0.35 to 0.66; 15 RCTs,  $n = 1457$ ). There was, however, no effect on reducing time to relapse. However, the review found low overall quality of evidence, which limited generalisability to usual care, making it impossible to recommend the use of EWS interventions in routine practice until higher-quality evidence becomes available.

### ***Service user barriers to relapse detection and prevention***

Uncertainty about the prognostic validity of EWS<sup>52</sup> brings with it a risk of unnecessary interventions from services, which may, in turn, heighten the fear of relapse in people with experiences of psychosis and their carers.<sup>17</sup> Feelings of fear, helplessness and depression are commonly experienced prior to full relapse.<sup>72</sup> Fear of illness or relapse is also associated with poorer insight,<sup>25</sup> emotional dysfunction,<sup>73</sup> suicide risk,<sup>74</sup> more traumatic experiences of psychosis, and fear of psychosis symptoms and hospital.<sup>16</sup> It is also a barrier to coping and relapse prevention for family members.<sup>18</sup> Our 2015 RCT<sup>17</sup> of relapse detection showed that fear of recurrence contributed independently to the prediction of relapse (sensitivity 72%, 95% CI 52% to 86%) compared with EWS (sensitivity 79%, 95% CI 62% to 89%) and should, therefore, be included in EWS monitoring. Fear of recurrence was also associated with increased depression and feelings of entrapment, self-blame and shame and was a significant predictor of time to relapse. This suggests that fear of recurrence may be a risk factor for relapse and for increased distress arising from psychosis experiences and that it may play some role in accelerating the process of relapse. All in all, this suggests that fear of recurrence is a key barrier to, and potential target for, interventions to predict and prevent relapse.

Concurrently, people affected by psychosis are more likely than those in the general population to adopt avoidant coping styles,<sup>75,76</sup> which may be an attempt to prevent relapse and minimise the effects of public stigma.<sup>73</sup> Avoidant coping in psychosis has been associated with higher neuroticism and lower extraversion,<sup>77</sup> reduced insight,<sup>78</sup> negative early childhood experiences, insecure identity,<sup>79</sup> cognitive deficits<sup>80</sup> and a generally greater insecurity in relationships and reluctance to seek help in a crisis.<sup>81,82</sup> In the context of active psychosis symptoms, avoidance may represent a safety behaviour based on the perceived threat of other people.<sup>83</sup> Review evidence suggests that greater difficulties in forming relationships among people affected by psychosis is associated with poorer service engagement and poorer relationships with practitioners, as well as longer and more frequent inpatient admissions.<sup>81</sup> Reluctance to seek help may be an understandable response to fear generated through previous negative, and potentially traumatic, experiences of inpatient admission.<sup>16</sup> In totality, this suggests that identifying and responding to EWS may be constrained by a variety of factors. These include avoidant coping styles and an associated reluctance to seek help or disclose EWS, poor-quality relationships between people in receipt of services and those providing them, and a wider fear of relapse.

### ***Service barriers to relapse detection and prevention***

One potentially important means of improving the implementation of EWS approaches without necessarily increasing fear of relapse is using interventions to increase shared decision-making for relapse prevention and risk management. Joint crisis plans (JCPs), which allow for the expression of service user preferences in the event of a future relapse, are one such example in the UK. The CRIMSON study<sup>84</sup> compared the effectiveness of JCPs with that of treatment as usual for people with a diagnosis of schizophrenia but found no significant impact on the reduction of compulsory treatment, raising questions about the wider application of JCPs. An associated process evaluation<sup>85</sup> examined how stakeholders perceived JCPs and shared decision-making as well as the barriers to implementation. The main barriers identified related to practitioners and included a general ambivalence towards JCPs and the perception that shared decision-making was already happening, as well as concerns about service users' expressed wishes for JCPs. These barriers led to poor clinician engagement, which in turn undermined service users' contributions to the process. It was also noted that, in times of crisis, JCPs were largely ignored, with practitioners reverting to standard practice. As a result of feeling unable to influence practitioner views through JCPs, people using services felt that there was a lack of respect for their views and that they were not able to influence shared decisions. Clinicians themselves experienced their ongoing clinical interactions as ritualised, particularly in relation to risk, while wider evidence highlights the need to be conscious that EWS monitoring for relapse prevention is also contingent on the person receiving services initiating help-seeking from a position of vulnerability and perceived threat (linked, for example, to previous experiences of coercive treatment).<sup>86</sup>

People affected by psychosis may have had difficult or traumatic experiences of relapse,<sup>16</sup> and there can be many barriers to help-seeking,<sup>87</sup> which reduce the possibility of early intervention at times of crisis. This may in turn increase reliance on coercive practices, potentially building on already negative expectations in a vicious cycle. This means that there is some urgency to develop and evaluate an intervention that can facilitate safe and honest disclosure of possible EWS while also encouraging collaborative and non-coercive responses from mental health practitioners.

### Conceptual framework for improving relapse detection and prevention

Our conceptual framework for improving relapse detection and prevention aims to understand the awareness of and response to EWS in the context of relationships. *Figure 1* illustrates a cognitive–interpersonal model of EWS in which fear of recurrence drives negative emotions including fear, anxiety and shame. This distress may be regulated by coping strategies including avoidance and hypervigilance. Such responses may in turn influence practitioner responses at times of increased risk of relapse, for example interpreting avoidance (of appointments, telephone calls, etc.) as evidence of the need to focus more on risk management. For someone using services, such shifts in practice may in turn simply reaffirm existing negative expectations in a cyclical manner. Therefore, interventions that can enhance positive emotional awareness, choice and autonomy (through self-management promotion) and improved communication (through increased understanding) could provide a means to disrupt and change these negative interpersonal cycles. Given that the modal time window to intervene in the context of EWS is 2 weeks,<sup>52</sup> interventions that can enhance access to data to inform help-seeking and shared decision-making could contribute to relapse detection and prevention. Digital technology may offer such an opportunity for this kind of timely intervention.

### Digital technology for early warning signs monitoring and intervention

Mobile health technology, also known as mHealth, has the potential to make a variety of mental health interventions more widely available through a combination of computing power, portability and widespread ownership of mobile devices. There has been a rapid increase in internet-connected smartphone ownership with an estimated 3 billion smartphone users globally in 2019.<sup>88</sup> There are indications that a ‘digital divide’,




FIGURE 1 Cognitive–interpersonal framework for EWS.

restricting access to mobile technologies for people affected by psychosis in comparison with the general population, has diminished in recent years,<sup>89</sup> with estimated rates of ownership ranging from 66.4% (95% CI 54.1% to 77.6%) to 81.4% in more recent studies.<sup>90</sup>

The potential of mHealth to transform remote measurement of changes in health and well-being across health conditions has been recognised,<sup>91</sup> and in mental health this includes the identification of its potential to improve EWS monitoring and relapse prevention.<sup>92,93</sup> Emerging evidence suggests that people with experiences of psychosis are generally comfortable with the application of digital mobile technologies to support self-management and enhance service engagement.<sup>90,94</sup> Many studies of mHealth for psychosis also show high levels of acceptability,<sup>95</sup> although problems with inconsistent assessment and reporting of usability and acceptability in mHealth for psychosis studies need to be addressed.<sup>96</sup>

Mobile technologies, in particular smartphones, provide an opportunity to overcome some of the known barriers to EWS implementation potentially through both 'active' and 'passive' data collection. Active data collection invites people to respond to intermittent EWS self-report assessments on their mobile device.<sup>97</sup> Passive monitoring relates to the assessment of relevant data routinely gathered on a mobile device, for example in relation to phone usage or location.<sup>98</sup> Both approaches may also be combined.<sup>99</sup>

The mobile collection of data on repeated occasions in real-world circumstances represents a form of ecological momentary assessment (EMA). EMA, which is being applied increasingly in psychosis research,<sup>100</sup> brings with it the potential to reduce the type of recall bias often associated with retrospectively gathered data.<sup>101</sup> Such routine monitoring can generate rich data about people's experiences, which have the potential to support shared decision-making and to reduce the ambiguity within which practitioners may be required to reach clinical decisions, particularly at times of crisis. Bell *et al.*<sup>100</sup> reviewed nine EMA interventions for people with experiences of psychosis ( $n = 459$ ),<sup>97,102-109</sup> finding some evidence for improved clinical outcomes as well as reasonable feasibility and acceptability. Similarly, positive results have been reported in terms of feasibility, acceptability and adherence for a further 10 mHealth for psychosis studies that feature the prospective assessment of symptom course. Of particular relevance are studies of the Information Technology Aided Relapse Prevention Programme in Schizophrenia (ITAREPS)<sup>97,108,109</sup> and ExPRESS<sup>110</sup> early signs interventions.

The ITAREPS system, which was tested in Czech and Slovak mental health services, used text-based EWS data collection to notify clinicians when scores breached a specified threshold. Treating clinicians were expected to increase medication by 20% within 24 hours of an alert. Initial non-controlled mirror design testing suggested a 60% decrease in hospital admissions during ITAREPS participation over a mean of 283.3 days ( $\pm 111.9$ ) when compared with the same time period before entering the programme.<sup>108,109</sup> However, a more rigorous follow-up double-blind randomised trial found no statistically significant differences in hospitalisation rates between people in an ITAREPS group and people in a control group.<sup>97</sup> However, there were significant problems with clinicians' adherence to the treatment protocol, and a post hoc analysis suggested a ninefold reduction in the risk of hospitalisation for the subset of people among whom there was found to be high clinician adherence. A later study of the ITAREPS system, which removed the mHealth component, found that adherence to the protocol improved when mental health nurses were employed to triage EWS assessments.<sup>111</sup> More recently, Eisner *et al.*<sup>110</sup> tested the feasibility of combining conventional EWS monitoring with basic symptoms<sup>112</sup> monitoring in an app (smartphone application), with scores above a specified threshold prompting a phone-based assessment of relapse. Participants completed 65% of app assessments over 6 months. App ratings also showed high concurrent validity with researcher assessments and there was preliminary evidence of the predictive validity of app ratings.

Although the overall results of mHealth for psychosis studies are promising, it should be noted that the vast majority of research in the field relates to small pilot or feasibility studies. Questions have been

raised over the quality of reporting generally<sup>96</sup> and the assessment and reporting of safety outcomes<sup>113</sup> and also how end-user experience and engagement are measured<sup>114</sup> and encouraged.<sup>115</sup> There is, however, emerging evidence to suggest that engagement with mHealth for psychosis interventions can be enhanced by providing social support, including peer support, as part of the interventions.<sup>116,117</sup>

## Peer support working

The creation of formalised peer support roles in mental health systems, where peer workers are employed and trained to work with people in receipt of services, in part based on a shared lived experience of mental distress, is considered to be an important component of recovery-oriented mental health systems.<sup>118,119</sup> Peer workers are theoretically well placed to reduce the power imbalances inherent in mental health services, drawing on their own experiences to build relationships with people using services that are reciprocal and founded on mutuality.<sup>120</sup> Although limitations in the conduct and reporting of research on peer support<sup>121</sup> should be acknowledged, there is increasing evidence that peer supported interventions are at least as effective as non-peer-delivered equivalents<sup>122</sup> and that peer workers are particularly well placed to deliver on recovery-related outcomes, including hope and empowerment.<sup>119,121</sup> Recent trial evidence also suggested that a peer-supported self-management intervention with people in receipt of crisis services was effective in reducing hospital re-admissions.<sup>123</sup> Fortuna *et al.*<sup>124</sup> have proposed a theoretical model of the role of peer support specific to digital health behaviour interventions. Central to this model are reciprocal accountability processes shared between peer supporters and people using digital interventions, which the authors argue build engagement through various mechanisms, including the promotion of autonomy, goal-setting, a strong peer-to-end-user working alliance and therapeutic bonding.

## Conclusion

In summary, mHealth interventions, and smartphone interventions specifically, offer a significant opportunity to deliver EMA-based monitoring of changes in well-being that are ecologically valid and contextually sensitive. They also offer potential solutions to some of the implementation barriers that have hindered the routine application of EWS approaches. Although there is a need for more rigorous and consistent research, preliminary studies have shown encouraging levels of user acceptability and engagement, including those specific to EWS interventions, facilitating timely assessment and intervention to promote self-management and relapse prevention. However, there are important implementation challenges to ensure that these technologies can enhance relationships and shared decision-making, particularly during times of increased stress and crisis. Blending peer support with digital EWS interventions has the potential to improve engagement and user experience, contributing to the need to develop interventions that enhance positive emotional awareness, choice and autonomy.





# Chapter 2 Methods

## EMPOWER phase 1

### Objective

The objective of phase 1 was to conduct task group interviews to (1) evaluate the acceptability and usability of mobile symptom reporting using smartphones among service users, carers and mental health staff; (2) identify incentives and barriers to use by service users and carers and to implementation by mental health staff; and (3) identify pathways to relapse identification and prevention. These interviews informed modifications to the EMPOWER mobile app, which was then subjected to a 5-week beta-testing phase.

The aims of the work packages (WPs) that constituted phase 1 are as follows.

- WP 1: (1) evaluate the acceptability and usability of mobile symptom recording using smartphones among service users and their carers; and (2) identify incentives and barriers to use.  
Deliverables: software and protocol updates in response to feedback from service users and carers.
- WP 2: (1) evaluate the acceptability and usability of mobile symptom recording using smartphones among professional mental health care staff; (2) identify incentives and barriers to implementation by mental health staff; and (3) identify relapse prevention pathways and whole-team responses.  
Deliverables: (1) carry out software and team protocol updates in response to feedback from professional care staff; (2) develop care pathways and identify operational barriers and enablers; and (3) identify the training needs of teams participating in the phase 2 pilot cluster randomised controlled trial.
- WP 3: finalise the EMPOWER app for its implementation in phase 2.  
Deliverables: (1) carry out software and protocol updates in response to feedback from service users, carers and staff; (2) agree on final modifications to the EMPOWER app to enhance its usability; (3) and finalise measurement methods for the assessment of self-reported acceptability and usability.

### Settings

Parallel arms of data collection for phase 1 took place in NHS Greater Glasgow & Clyde, UK, and NorthWestern Adult Community Mental Health Services in Melbourne, Australia.

### Methods

#### Work package 1: task groups with service users and carers

A task group is a type of focus group designed to generate qualitative data and the principles for action, which are grounded in the experience of group members. Task groups were used to elicit views about experiences of relapse, incentives and barriers to help-seeking and optimal responses to relapse or the threat of relapse. Task groups explored:

1. the utility of early signs monitoring
2. views about using self-management messages and which self-management messages would have greatest salience
3. the design parameters of the system that could best sustain their involvement
4. views about help-seeking and activating a relapse prevention pathway
5. the best way to involve carer stakeholders
6. the best way to contact mental health staff
7. how they would like to use their data from EMPOWER.

A copy of the task group guide can be found in *Report Supplementary Material 1*. These data informed the final design and beta testing of the EMPOWER app to optimise the usability, salience, applicability and overall coherence of the intervention. We also recognised that some participants would be unable to attend task groups (e.g. owing to time constraints or difficulties engaging in groups). Therefore, to maximise engagement and diversity of views, we offered participants who were unable to attend task groups the opportunity to participate in individual interviews.

### **Work package 2: task groups with professional mental health care staff**

The aim of the task groups with mental health care staff was to clarify the existing support pathways and procedures, systems and policies in teams participating in usual care, and to clearly differentiate these from our experimental intervention. We focused on the following topic areas:

1. strengths and limitations of these existing pathways
2. relevant policies and procedures that guide treatment as usual
3. feasibility and risks of and incentives to incorporating mobile phone technology into the monitoring and detection of risk of relapse
4. best methods to deal with false positives
5. opportunities to optimise pathways to relapse prevention.

A copy of the task group guide can be found in *Report Supplementary Material 1*. We recognised that some staff members may have been unable attend task groups, for example because of the time required. Therefore, to maximise engagement and diversity of views, we offered participants who were unable to attend task groups the opportunity to participate in individual interviews.

### **Work package 3: software beta testing**

Beta testing was conducted with service users over a 5-week period. We utilised beta testing as a form of software user experience (UX) testing and investigation conducted to provide stakeholders with information about the quality of the tested software product.<sup>125</sup> Following the software beta testing, we conducted in-depth interviews exploring service user participants' experiences of using the app and their perspectives on its acceptability and utility.

## **Study population**

### **Recruitment procedure**

#### **Work package 1**

Potential service user participants were approached to participate via community mental health services (CMHS). We invited mental health care staff to identify potentially eligible participants and we also placed posters in local CMHS advertising the research. Potential participants were provided with a participant information sheet and a consent form. They were advised that participation was entirely voluntary and that refusal to participate would not affect the care provided by their local CMHS. Following the provision of written and informed consent, service user participants were invited to nominate a carer to participate. When insufficient carers were recruited via service users, task group participation was opened to any carer associated with, and made known through carer organisations at, each participating site. Following an amendment to the protocol (SA01-AM02: see *Table 1*) in Glasgow, we also engaged with the Mental Health Network (Greater Glasgow & Clyde) and ACUMEN to support the recruitment of potentially eligible participants. Both of these organisations work directly with NHS Greater Glasgow & Clyde to promote the wider involvement of service users and carers in shaping mental health services and facilitate collaboration through support and networking. In addition, we engaged with Support in Mind Scotland, which has strong engagement with carers of people diagnosed with schizophrenia. These organisations expressed a strong interest to engage with EMPOWER to highlight the study among members of their constituencies.

**Work package 2**

Professional mental health care staff were identified through service managers and through presentations at staff meetings. Staff members were invited to take part in a task group and provided with a participant information sheet and a consent form. They were advised that participation was entirely voluntary and that refusal to participate would not affect their employment.

**Work package 3**

In the first instance, service users who took part in WP 1 were invited to take part in the software beta testing. In addition, we recruited eligible participants from our local service user networks.

**Eligibility criteria****Service users**

Service users were eligible for participation in WP 1 if:

1. they were adults ( $\geq 16$  years of age)
2. they were in contact with a local community-based service
3. they had either:
  - i. been admitted to a psychiatric inpatient service at least once in the previous 2 years for a relapse of psychosis or
  - ii. received crisis intervention (e.g. via a crisis intervention service; re-engaged with a CMHS) in the previous 2 years for a relapse of psychosis
4. they had a diagnosis of a relevant DSM-5 schizophrenia-related disorder (i.e. schizophrenia, schizoaffective disorder or substance-/medication-induced psychotic disorder)
5. their current presentation did not include severe acute symptoms
6. they were able to provide informed consent as judged by their care co-ordinator/case manager or, if in doubt, the responsible consultant
7. they were able to manage the language requirement of participation.

Service users were eligible for participation in WP 3 if:

1. they were adults ( $\geq 16$  years of age)
2. they were in contact with a local community-based service
3. they had a diagnosis of a relevant DSM-5 schizophrenia-related disorder (i.e. schizophrenia, schizoaffective disorder or substance-/medication-induced psychotic disorder)
4. their current presentation did not include severe acute symptoms
5. they were able to provide informed consent as judged by their care co-ordinator/case manager or, if in doubt, the responsible consultant
6. they were able to manage the language requirement of participation.

**Carers**

Carers were family members who were in regular (i.e. at least weekly) contact with an individual using services who had a diagnosis of a relevant DSM-5 schizophrenia-related disorder (i.e. schizophrenia, schizoaffective disorder or substance-/medication-induced psychotic disorder). The frequency of contact was the only eligibility criterion for carer participation. Carers nominated by eligible service users who provided informed consent were also approached for inclusion in the study.

**Professional mental health care staff**

Professional mental health care staff were eligible for participation if they had been working for the service for longer than 2 months, to ensure that they had an orientation to and were familiar with the local service system.

### **Sample size**

The numbers projected for WPs 1 and 2 (i.e. 30 service users, 30 carers and 20–30 professional mental health care staff) and WP 3 (i.e. 10 service users) were to provide sufficient data to create the framework of analysis. No formal sample size calculation (e.g. power analysis) was considered appropriate for these WPs, as their aim was not to evaluate treatment effects.

### **Analytic methods**

Task groups (WPs 1 and 2) and follow-up interviews (WP 3) were digitally recorded, transcribed and anonymised before being entered into NVivo version 12 (a computer-assisted qualitative software package; QSR International, Warrington, UK) to organise the data and enable progression to analysis. Analysis drew on framework analysis, which is a qualitative approach specialising in pragmatic, generalisable qualitative methods designed for real-world implementation.<sup>126,127</sup> This approach has been developed specifically for applied or policy-relevant qualitative research in which the objectives of the investigation are typically set in advance and shaped by the information requirements of the funding body. The time scales of applied research tend to be short and there is often a need to link the analysis with quantitative findings.

### **Participant safety and withdrawal**

#### **Risk identification**

##### ***Risks associated with work packages 1 and 2***

The potential risks of harm or discomfort to service users, carers and professional mental health care staff who participated in the task groups (i.e. WPs 1 and 2) included:

- risks to personal privacy associated with the dissemination of personal information by other participants
- distress from inappropriate, abusive or offensive interaction(s) with other participants
- increased paranoia resulting from participation, especially in the event of deterioration of the mental well-being of service user participants
- potential distress from talking about experiences of relapse.

The likelihood of these risks eventuating was considered low based on the past experiences of the investigators.

##### ***Risks associated with work package 3***

The potential risks of harm or discomfort to service users who participated in the software beta testing (i.e. WP 3) included:

- risk to personal privacy associated with the unlawful dissemination of personal information by hackers
- risks to the clinical safety of service user participants (i.e. true- and false-positive detections of relapse).

The likelihood that personal privacy would be breached by the unlawful dissemination of personal information by hackers was considered low given the past experiences of the investigators. Specifically, this related to experiences developing and implementing the ClinTouch system that was the platform for EMPOWER.

The likelihood that clinical safety would be compromised (i.e. service user participants' well-being deteriorating and the system flagging a true-positive detection of relapse, or the system flagging a false-positive detection of relapse) was also considered low given the short duration of the software beta testing.

### **Risk management**

The potential risks of harm or discomfort to service users, carers and professional mental health care staff who participated in the task groups (i.e. WPs 1 and 2) as outlined above were negated, minimised or managed through the following processes:

- All task groups were co-facilitated by two individuals. Key facilitator responsibilities included advising participants of rules of engagement with the group (e.g. confidentiality, respectful communication), and upholding the same.
- Facilitators also monitored participants' degree of distress and took action accordingly. Participants who displayed or reported distress were offered a debriefing session.

The potential risks to system and personal privacy and clinical safety associated with WP 3 were negated/minimised/managed via a rigorous safety protocol developed by the research team and experts from the information systems discipline. The safety protocol comprised two levels of security: system and privacy protection and clinical safety.

### **Clinical safety**

A range of measures were also in place to ensure participants' clinical safety. Changes in EWS were observable by the researchers, and responses were manual rather than automated. Information related to clinical safety (i.e. EWS, idiosyncratic signs, etc.) was screened three times per week on the clinician interface, and specific attention was paid to the deterioration of EWS. Any detected increase meant that the study research assistant advised the clinical team of any significant change to the participant's mental health.

In the case that a participant contacted the study research assistant, or another member of the research team, communicating distress, the study research assistant or member of the research team provided immediate support, and then contacted the participant's treating team.

If a participant stopped using the system (i.e. they missed more than two scheduled prompts), the following protocol was adopted: (1) after two missed prompts, a SMS would be sent reminding the service user to use the app, and (2) after subsequent instances/missed prompts, the research team would follow up with a supportive telephone call encouraging participation. Information was to be passed on to the service user's treating team if the service user stopped responding to the prompts to monitor their EWS, and if they missed the follow-up interview with the study research assistant.

### **Risk monitoring**

Risks were monitored by the study research assistant. As part of their role as interviewer and group facilitator of the various work packages, the study research assistant monitored participants' degree of distress and took action accordingly. All interviewees were invited to discuss any feelings of distress associated with participating in the interview, and task group participants were also invited to speak privately with the study research assistant and/or co-facilitator at the conclusion of the task group if they felt distressed. The study research assistant monitored the risks associated with the software beta testing; information about clinical safety was screened three times per week.

### **Risk reporting**

The study research assistant reported all instances of distress that came to their attention and any potential clinical deterioration in participants' mental health to the chief investigator and to the participant's treating team. The study research assistant also recorded all instances in a database, and the chief investigator reported any serious adverse events that were related and unexpected according to the International Conference on Harmonisation Guidelines on reporting Serious Adverse Events (Section II B) to the sponsor and the Research Ethics Committee.

## Handling of withdrawals

### **Procedures**

Participants were free to withdraw from the study at any time. As a part of the informed consent procedure, participants were instructed to let a member of the research team know of their withdrawal ahead of time. Participants who chose to withdraw were offered debriefing as a matter of course. The treating team overseeing the care of service user participants was also advised of any withdrawals. Information collected from participants up to the point of withdrawal was stored in the databank.

### **Data security and management**

The confidentiality of all study data was ensured using the security mechanisms outlined below.

### **The EMPOWER app**

A range of measures were in place to ensure the security of the EMPOWER app and the data generated by its users. The app was hosted on the University of Manchester web server, which had standard measures in place to prevent unauthorised access. All data transmitted to and from EMPOWER servers were encrypted over https with strong ciphers as detailed in *Approved Cryptographic Algorithms: Good Practice Guideline*.<sup>128</sup> Cipher suites were implemented in compliance with section 6 ('Preferred uses of cryptographic algorithms in security protocols') of the Good Practice Guidelines.<sup>128</sup> In cases where participant data were downloaded from the EMPOWER site, these data were securely encrypted with a pass phrase of appropriate length and complexity. Data transfers were secured using standard web security protocols. Uploading study data to a central server in real time enabled them to be captured and so this protected against data loss, such as if a phone was lost or stolen. This removed the need for personal data to be stored on the device. The purpose of the server in this case was secure data storage. We also incorporated ISO 25010,<sup>129</sup> which provides for safety-in-use and measures satisfaction with security. These security measures correspond closely to the NHS standards.

A number of technical measures were also employed to protect personally identifiable data. Any data stored on the phone by the participant were encrypted. We also recommended that service users set a passcode to access their smartphone. All service users recruited to the study gave their informed consent, and this included acknowledging risks to the security of their data.

### **Other study data**

Each study participant was assigned a unique trial identification number at the start of the assessment process. This number was written on all clinical assessment forms/datasheets and databases used to record data on study participants. A securely stored and encrypted electronic copy of a record sheet linking patient identity, contact details and trial identification numbers for all participants was kept at each site.

The local study research assistant entered the data on to an electronic database, and all of these data were checked for errors before being transferred to the appropriate statistical package. All data were kept secure at all times and maintained in accordance with General Data Protection Regulation (GDPR)<sup>130</sup> requirements.

Audio recordings of the task groups and participant interviews were also stored securely on a server at the University of Glasgow and were destroyed following transcription and analysis of the data. Digital recordings from Melbourne were sent by secure transfer and stored on secure servers at the University of Glasgow.

### **Protocol amendments**

Protocol amendments are described in *Table 1*.

TABLE 1 Phase 1 protocol amendments

Amendment number	Date	Protocol number	Main change summary
SA01	3 August 2016	1.2	<ul style="list-style-type: none"> <li>• In recognition of challenges attending task groups, we made provision for individual interviews with service users</li> <li>• In recognition of challenges attending task groups, we made provision for individual interviews with staff</li> <li>• Provision to make leaflets and posters available in CMHS for task group recruitment</li> <li>• Facility to engage Mental Health Network, ACUMEN and Support in Mind Scotland in task group recruitment</li> </ul>
SA02	2 November 2016	1.3	<ul style="list-style-type: none"> <li>• Broadened service users inclusion criteria from who had been admitted to a psychiatric inpatient service at least once in the previous 2 years for a relapse of psychosis to also include service users who had received crisis intervention (e.g. via a crisis intervention service; re-engaged with a CMHS) in the previous 2 years for a relapse of psychosis</li> </ul>
SA03	15 December 2016	1.4	<ul style="list-style-type: none"> <li>• Addition of in-depth IPA-based interview on completion of beta testing</li> <li>• Altered inclusion criteria for beta-testing eligibility to remove need for evidence of relapse within the previous 2 years</li> <li>• Extended beta-testing period from 7 days to 5 weeks to allow for more complete testing of the EMPOWER algorithm</li> </ul>

IPA, interpretative phenomenological analysis.

### Protocol breaches

The Post-Study System Usability Questionnaire was omitted from WP 3 follow-up interviews.

## EMPOWER phase 2

### Objectives

Our phase 2 protocol is published elsewhere.<sup>131</sup> The overall purpose of this study was to establish the feasibility of conducting a definitive cluster randomised controlled trial (cRCT) comparing EMPOWER with treatment as usual (TAU). We sought to establish the parameters of the feasibility, acceptability, usability, safety and outcome signals of an intervention as an adjunct to usual care that would be deliverable in the NHS and Australian CMHS settings. The EMPOWER intervention aimed to:

1. enhance the recognition of EWS among people using services and their carers
2. provide a stepped-care pathway that was either self-activated or in liaison with a carer and/or a community health-care professional, which then
3. triggered a relapse prevention strategy that could be stepped up to a whole-team response to reduce the likelihood of a psychotic relapse.

Specifically, we aimed to:

1. determine the rates of eligibility, consent and recruitment of potentially eligible participants (people using services, carers and care co-ordinators) to the study
2. assess the performance and safety of the EMPOWER class 1 medical device (CI/2017/0039)
3. assess the feasibility, acceptability and usability of the intervention, including feedback on suggested enhancements from people receiving the intervention, peer support workers and clinicians



4. assess primary and secondary outcomes to determine the preliminary signals of efficacy of the EMPOWER intervention as a basis for assessing the feasibility of collecting follow-up measures, determining primary and secondary outcomes, and determining probable sample size requirements for a future main trial
5. undertake a qualitative analysis of relapses to refine the intervention in the main trial
6. establish the study parameters and data-gathering frameworks required for a co-ordinated health economic evaluation of a full trial across the UK and Australia
7. enhance and tailor our mobile phone software app to deliver EWS monitoring, self-management interventions and access to a relapse prevention pathway that was embedded in whole-team protocols and action.

### **Trial design**

We evaluated EMPOWER using a multicentre, two-arm, parallel-group cRCT involving eight purposively selected CMHS (two in Melbourne, Australia, and six in Glasgow, UK) with 12-month follow-up. The CMHS were the unit of randomisation (the cluster), with the intervention delivered by the teams to people using services and with the outcomes assessed within these clusters. The study was planned and implemented in concordance with the Consolidated Standards of Reporting Trials (CONSORT) cluster trial extension<sup>132</sup> and the extension to randomised pilot and feasibility trials.<sup>133</sup> We chose a cluster design as the EMPOWER intervention aimed to enable a team-based response to people in receipt of services whose real-time EWS monitoring activates a relapse prevention pathway.

### **Ethics and governance**

The study received approvals from the West of Scotland Research Ethics Service (GN16MH271 reference 16/WS/0225) and Melbourne Health Human Research Ethics Committee (HREC/15/MH/344). The study sponsors were NHS Greater Glasgow & Clyde in the UK and the Australian Catholic University in Australia. The trial also received approvals from the NHS Health Research Authority and a notice of no objection for a trial of a medical device (CI/2017/0039) from the UK Medicines and Healthcare products Regulatory Agency (MHRA), and was prospectively registered (ISRCTN99559262). The trial methods of enrolment, interventions and assessments are summarised in *Table 2*.

A trial Study Steering Committee (SSC) and a Data Monitoring and Ethics Committee (DMEC) were constituted in accordance with National Institute for Health and Care Research (NIHR) guidance. The DMEC reported to the SSC and the SSC reported to NIHR. Protocol amendments were reviewed by the DMEC and SSC before being submitted to the relevant Research Ethics Committee (see *Table 4*). The study was conducted in accordance with the recommendations for physicians involved in research on human participants adopted by the 18th World Medical Assembly, Helsinki 1964,<sup>134</sup> and later revisions.

### **Preliminary work: patient and public involvement**

Phase 1, as described above, was included to ensure extensive consultation with key stakeholders, namely mental health care staff, people with lived experience and carers, in a series of task groups across Glasgow and Melbourne. Stakeholder consultation directly shaped the development of the EMPOWER intervention. The Scottish Recovery Network also played a key role in shaping further consultation with people with lived experience to further refine intervention development and planning.

### **Eligibility criteria**

Participation was sought from CMHS in NHS Greater Glasgow & Clyde in the UK and NorthWestern Mental Health services in Melbourne, Australia. All participants (mental health care staff, service users and carers) were approached for their informed and written consent prior to assessment and randomisation. Research assistants were responsible for recruitment and taking informed consent. Written informed consent was obtained from all trial participants.

TABLE 2 Participant timeline

Assessment	Enrolment: baseline	Allocation: 0 months	Post allocation		Close-out: 12 months
			3 months	6 months	
<b>Enrolment</b>					
Eligibility screen	X <sup>a</sup>	— <sup>b</sup>	—	—	—
Informed consent	X	—	—	—	—
Allocation	—	X	—	—	—
<b>Intervention</b>					
EMPOWER	—	—	X	X	X
<b>Service user assessments</b>					
Feasibility	X	—	X	X	X
Acceptability and usability		—	X	X	X
Remission status	X	—	X	X	X
Relapse		—	X	X	X
PANSS	X	—	X	X	X
Personal and Social Performance Scale	X	—	X	X	X
CDSS	X	—	X	X	X
Timeline Followback	X	—	X	X	X
HADS	X	—	X	X	X
PBIQ-R	X	—	X	X	X
Service Attachment Questionnaire	X	—	X	X	X
Medication Adherence Rating Scale	X	—	X	X	X
EuroQol-5 Dimensions	X	—	X	X	X
Assessment of quality of life	X	—	X	X	X
Resource Use Questionnaire	X	—	X	X	X
Questionnaire about the Process of Recovery	X	—	X	X	X
General Self-Efficacy Scale	X	—	X	X	X
Psychosis Attachment Measure	X	—	X	X	X
Perceived Criticism and Warmth Measure	X	—	X	X	X
<b>Carer assessments</b>					
Feasibility	X	—	X	X	X
Carer Quality of Life-7 Dimensions	X	—	X	X	X
EuroQol-5 Dimensions, five-level version	X	—	X	X	X
Resource use questionnaire	X	—	X	X	X
Perceived Criticism and Warmth Measure	X	—	X	X	X
Involvement Evaluation Questionnaire	X	—	X	X	X
<b>Care co-ordinator</b>					
Feasibility	X	—	X	X	X
Service Engagement Scale	X	—	X	X	X
CDSS, Calgary Depression Scale for Schizophrenia; HADS, Hospital Anxiety and Depression Scale; PANSS, Positive and Negative Syndrome Scale; PBIQ-R, Personal Beliefs About Illness Questionnaire-Revised.					
a Item was applicable at the relevant study time point.					
b Item was not applicable at the relevant study time point.					

### Community mental health services

We engaged CMHS that were likely to have five or more care co-ordinators willing to participate for a period of 12 months and had potential care co-ordinators with eligible service users on their caseload who were likely to consider participating.

### Service users

Service users from participating CMHS were eligible for inclusion if they:

- were adults (aged  $\geq 16$  years)
- were in contact with a local CMHS
- had either:
  - been admitted to a psychiatric inpatient service at least once in the previous 2 years for a relapse of psychosis or
  - received crisis intervention (e.g. via a crisis intervention service; re-engaged with a CMHS) in the previous 2 years for a relapse of psychosis.
- had received a diagnosis of a schizophrenia-related disorder, specifically:
  - 295.40 schizophreniform disorder [*International Statistical Classification of Diseases and Related Health Problems*, Tenth Revision (ICD-10), F20.81]
  - 295.70 schizoaffective disorder (ICD-10 F25)
  - 295.90 schizophrenia (ICD-10 F20.9)
  - 297.10 delusional disorder (ICD-10 F22).
- were able to provide informed consent as judged by the care co-ordinator or, if in doubt, the responsible consultant.

### Carers

Carers of people receiving support from participating CMHS were eligible for inclusion if they:

- had been nominated by eligible participants
- were in regular contact (weekly) with the person receiving services
- provided informed consent to participate in the study.

### Exclusion criteria

Individuals were ineligible for participation if they did not meet the inclusion criteria outlined above. In addition, participants were excluded if they had experienced a recent relapse, operationally defined as having been discharged from the care of a crisis team or psychiatric inpatient service within the previous 4 weeks.

### Interventions

In describing the EMPOWER intervention we utilise the Template for Intervention Description and Replication (TIDieR) checklist.<sup>135</sup>

### EMPOWER intervention

#### Rationale

The rationale for the EMPOWER intervention was informed by the cognitive–interpersonal model outlined in *Chapter 1* and was designed to enable participants to monitor changes in their well-being on a daily basis. In EMPOWER, we referred to changes in well-being as ‘ebb and flow’ as a means of moving away from risk-orientated monitoring that can sensitise individuals to increased fear of relapse. The terminology also attempted to convey a normalising framework for understanding changes in emotions and psychotic

experiences in daily life. Clinical triage of changes in well-being that were suggestive of EWS was enabled through an EMPOWER algorithm that triggered a check-in prompt (ChIP). This enabled the prompt identification of any EWS and triggered a relapse prevention pathway if warranted.

The EMPOWER app was developed in part through consultation with people using services, their carers and mental health care professionals. Service user participants had access to the EMPOWER app for up to 12 months of the intervention period. EMPOWER was developed as a flexible tool for users to:

1. monitor daily the 'ebb and flow' of changes in well-being
2. incorporate personalised EWS items
3. receive automated EMPOWER (self-management) messages directly
4. review their own data and keep a diary of their experiences via a smartphone user interface.

### **Materials**

Daily monitoring of well-being was initiated by pseudo-random mobile phone notifications to complete the EMPOWER questionnaire (see *Report Supplementary Material 2*). Notification reminders were sent after 5 minutes (when there had been no response), after which app users were allowed a 5-hour time window within which they could respond to questions. The questionnaire contains 22 items reflecting 13 domains (e.g. mood, anxiety, coping, psychotic experiences, self-esteem, connectedness to others, fear of relapse and personalised EWS). Items included both positive (e.g. 'I've been feeling close to others') and negative (e.g. 'I've been worrying about relapse') content. Each item was completed using a simple screen swipe, which enabled quick and efficient completion by users. Each item was automatically scored on a scale of 1–7. Where particular items scored > 3, users were invited to complete supplementary questions to enable a more fine-grained assessment of that domain. This provided up to a maximum of 56 questionnaire items.

### **Peer support working in EMPOWER**

The EMPOWER intervention was blended with peer support. Peer support workers are people who bring lived experience of mental health problems and recovery to their work in mental health services, with practices underpinned by a set of values and principles.<sup>120,136</sup> The role is increasingly well established in mental health policy and practice in many countries, including the UK and Australia.<sup>137</sup> Peer support is also being increasingly integrated with digital mental health interventions.<sup>124</sup> Two peer support workers were employed in Glasgow and one was employed in Melbourne, all on a part-time basis, to work with people in the intervention arm of the study. Their work was underpinned by a values framework developed by the Scottish Recovery Network,<sup>138</sup> with supervision available at both sites and also across sites.

Peer support worker roles initially focused on introducing participants to the ethos and principles of the EMPOWER stepped-care approach and setting up and personalising the app on provided or personal handsets. Following this set-up and familiarisation period, peer support workers maintained regular contact with app users, at least weekly in the baseline period and approximately fortnightly following the baseline. Contact was maintained primarily through telephone calls, although text messaging and in-person meetings also took place, with the type and amount of contact determined by personal preference and need. Peer support worker roles included:

1. Supporting engagement with the intervention. This included checking in with people to assess whether or not there were any blocks to their successful use of the app and to advise on how usage might be adapted to individual needs, for example encouraging people to take breaks from self-monitoring as required.
2. Offering technical advice and support in relation to participants' use of the phone. This included supporting people in becoming familiar with mobile phone functions and ensuring that they had mobile phone data connectivity and adequate credit for data.

3. Encouraging the general exploration of well-being and of how data generated through the app reflected life experience and aided self-management.
4. Reviewing and supporting participants' use of different app functions. This included supporting participants to access and make use of chart and diary functions. In particular, peer support workers encouraged participants to review charts and sought to prompt curiosity about chart data and the implications of these for self-management and well-being.
5. Aiding the interpretation of messages generated by the app. This included giving app users additional information on message content, as required, for example providing further information on how to access support to develop an advance statement.
6. Sharing personal experiences of app use. Peer support workers had personal experience of using the EMPOWER app and were able to reflect with research participants on their own experiences and, if required, offer practical advice and share aspects of their experience that they felt might support participants.
7. Monitoring and reporting performance and safety issues. This included making routine enquiries in relation to any possible adverse events and the extent to which these were associated with the intervention.

### **Procedures**

A peer support worker met with participants on an individual basis to introduce the rationale for using the app, to collaboratively set up the app on their participant's mobile phone or a study phone, and to support the individual's familiarisation with the handset and app functions. Participants were invited to choose up to three personalised EWS items to be included in the EMPOWER questionnaire and further personalisation of delusion-specific items could also be made. Where possible, an individual's care co-ordinator and nominated carer were invited to contribute to this meeting. Participants were asked to undertake daily monitoring for an initial 4-week baseline period to help establish their personal baseline of the 'ebb and flow' of their well-being. During this period, additional support was provided by peer support workers through weekly telephone follow-up. This provided an opportunity to encourage use of the app, solve any technical problems and identify any adverse effects. At the end of the 4 weeks, a further meeting was arranged with the peer support worker or mental health nurse to review monitoring, encourage engagement with EMPOWER messages, agree participants' preferences for actions in response to changes in well-being that were suggestive of EWS and encourage participants to continue utilising local CMHS for clinical care. All participants were offered ongoing fortnightly peer support worker support to encourage them to use the app, to support their reflection on changes in well-being and their broader context including, for example, stressful life events, and to encourage them to use self-management strategies prompted by EMPOWER messages.

### **Digital procedures**

The analysis and handling of questionnaire data was governed by the EMPOWER algorithm. The EMPOWER algorithm is a class 1 medical device (CI/2017/0039) that forms one part of a broader system that was designed to identify and respond to changes in well-being that were suggestive of EWS. *Figure 2* provides a graphical representation of the system's high-level components and data flow.

Participants used a mobile phone app that prompted them to answer a daily questionnaire about the potential EWS of psychosis. The data were then submitted to the EMPOWER server and analysed by the ChIP algorithm. The algorithm, which is summarised in *Figure 3*, compared a participant's latest data entry against their personal baseline. If changes exceeded predefined thresholds, a ChIP was generated for the participant. The consequences of the ChIP were that the research team, which included a registered mental health nurse (in the UK), clinical psychologists (in the UK and Australia) and a general psychologist (in Australia only), were e-mailed about the participant and that participant's status was set to 'alert' and was highly visible on a secure web-based researcher interface. In addition to viewing and handling ChIPs, researchers could view longitudinal graphs of their participants' well-being and possible EWS, filtered by question or by domain (group of questions). ChIPs were initially screened by a member of the research team, followed by (1), in Australia, sharing a summary of




FIGURE 2 The EMPOWER system. Google and the Google logo are registered trademarks of Google LLC, used with permission.




FIGURE 3 EMPOWER algorithm responding.

relevant ChIP data with the clinical team, and (2), in the UK, a member of the research team checking in with the participant. Based on the outcome of this triage assessment the researcher could share an update with the participant’s care co-ordinator, who could, if indicated, escalate increased support to the participant from their local CMHS to reduce risk of relapse. We aimed to respond to ChIPs in some way within 24 hours or the next working day.

The alert algorithm also ran a separate process scanning for EWS changes against the baseline. Based on these changes, the logic selected a message from the most appropriate of several content-based message pools (i.e. one message pool contained helpful messages about ‘mood’, another had messages

about 'anxiety and coping', etc.). This message was delivered back to, and displayed on, the participant's EMPOWER app. Messages were intended to help people have a greater sense of control over their mental health and well-being and to support self-management. We set up a specific patient and public involvement group to assist us in the co-design of the message function in the app. The group advised on the curation, content and delivery of messages. This group met on four occasions and had public representation from four people with direct lived experience of psychosis.

### ***Training and support to community mental health service staff***

After CMHS had been randomised to EMPOWER, we aimed to provide training to those mental health care staff in teams based on our model of relapse prevention, which emphasised:

- therapeutic alliance
- barriers to help-seeking
- familiarisation with the app
- developing an individualised formulation of risk of relapse
- developing a collaborative relapse prevention plan.

Following this, we aimed to meet with care co-ordinators on a fortnightly basis to provide support in the implementation of EMPOWER. These meetings aimed to clarify and encourage formulation of any changes and participant responses within the model, and support clinicians to consider EMPOWER-consistent intervention options.

### ***Background intellectual property***

The background intellectual property and functionality was the pre-existing ClinTouch app developed in 2010 and funded by two grants from the UK Medical Research Council. The aims of the app were to help people with serious mental illnesses to manage their own symptoms and to prevent relapse. Software development and beta testing used an experience-driven design process in which service users with psychosis were involved in the design and development of the app, its functionality and its standard operating procedures. Health professionals were included in system design where it related to routine practice, and in the design of new, digitally enabled workflows. Randomised feasibility trials showed this method of active symptom monitoring to be safe, feasible and acceptable.<sup>139-141</sup> This personalised smartphone application triggers the collection of symptom self-ratings several times daily and wirelessly uploads these in real time to a secure central server. A semi-random beep (two to four times daily) alerts the user to complete a set of 12-14 branching items about current symptom severity using a touchscreen slider. A graphical summary of how symptoms fluctuate over time is assembled and displayed on the handset. A validation study compared face-to-face ratings on the gold-standard Positive and Negative Syndrome Scale (PANSS) with four-times-daily ClinTouch assessments over 1 week. This confirmed the validity of the self-reported items, with core psychotic symptom and mood items showing moderate to strong ( $r > 0.6$ ) correlations between the two methods.<sup>139</sup> Non-core, behaviourally assessed items, such as negative symptoms, showed weaker correlations.

Based on this proof of concept, the standalone smartphone system was integrated via an application programming interface into NHS trust ICT (information and communication technology) platforms to allow the streaming of summary information into electronic health records, and to enable health professionals to track current symptoms on desktops at the team base and receive alerts when symptoms exceeded a pre-agreed personalised threshold. An open, randomised trial of ClinTouch active symptom monitoring compared with management as usual was conducted in NHS mental health trusts in Manchester and South London.<sup>142</sup> Recruitment to the trial took place between February 2014 and May 2015. The aims were to assess (1) the acceptability and safety of continuous monitoring over 3 months, (2) the impact of active self-monitoring on positive psychotic symptoms assessed at 6 and 12 weeks, (3) the feasibility of detecting EWS of relapse communicated to health-care staff via an application programming interface allowing data to be streamed into the electronic health record and (4) the impact of active self-monitoring on positive psychotic symptoms assessed at 6 and 12 weeks.

Eligible participants with a DSM-IV (*Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition) diagnosis of schizophrenia and related disorders and a history of relapse within the previous 2 years were enrolled from an early intervention team and a community mental health team.

The findings were that, of 181 eligible patients, 81 (45%) consented and were randomised to either active symptom monitoring or management as usual. Of those in the active symptom monitoring group, 90% continued to use the system at 12-week follow-up. In this group, adherence, defined as responding to > 33% of alerts, was 84%. At 12 weeks, active symptom monitoring compared with usual management was associated with no difference on the empowerment scale. The pre-planned intention-to-treat analysis of the primary outcome (i.e. positive symptom score on the PANSS scale) showed a significant reduction in the active symptom monitoring group over 12 weeks in the early intervention centre. Alerts for personalised EWS of relapse were able to be built into the workflows of the two NHS trusts, and 100% of health professional staff used the system in a new digital workflow. Qualitative analyses supported the acceptability of the system to participants and staff.

### Treatment-as-usual control

Treatment as usual (TAU) was chosen as a control condition in both the Glasgow and Melbourne centres as this provided a fair comparison with routine clinical practice. In Glasgow and Melbourne, secondary care is delivered by adult CMHS, which largely involves regular (fortnightly or monthly) follow-up with a care co-ordinator and regular review by a psychiatrist.

### Outcomes

All outcome measures were administered at baseline and subsequently at 3, 6 and 12 months by research assistants who were trained in the use of all of the instruments and scales and had achieved a satisfactory level of inter-rater reliability (see *Appendix 7*). Research assistants had, as a minimum, a strong honours degree in psychology or a related discipline. Regular inter-rater reliability assessments were conducted during the trial. Research assistants entered anonymised participant data from paper records onto an electronic case record form hosted by the University of Aberdeen, with the exception of relapse data, which were entered by the trial manager. In Glasgow, data were collected in participants' homes or in health service facilities. In Melbourne, all data were collected on health service premises. Data quality and error checking were conducted at each time point, namely baseline and 3, 6 and 12 months post randomisation.

### Primary outcomes

#### **Feasibility: service users**

For all participants, outcome assessment included:

- proportion of eligible and willing service users who then consented and the proportion continuing for 3, 6 and 12 months to the end of the study
- frequency of service user seeking help in relation to EWS
- frequency of family member/carer seeking help in response to EWS
- frequency of clinical care changes in response to EWS at 3, 6 and 12 months.

#### **Feasibility: mental health care staff**

We assessed:

- self-reported frequency of discussing EWS with care co-ordinator
- frequency of person seeking help in relation to EWS
- frequency of care co-ordinator seeking help in response to EWS
- frequency of clinical care changes in response to EWS at 3, 6 and 12 months (e.g. appointment brought forward, medication changed).



### **Feasibility: carers**

We assessed:

- self-reported frequency of discussing EWS with family member/carer
- frequency of person seeking help in relation to EWS
- frequency of family member/carer seeking help in response to EWS
- frequency of clinical care changes in response to EWS at 3, 6 and 12 months (e.g. appointment brought forward, medication changed).

### **Acceptability and usability**

For those randomised to EMPOWER, we assessed:

- the length of time participants were willing to use the app
- the number who completed > 33% EWS data sets
- self-reported frequency of app use
- frequency of sharing data with the key worker
- frequency of sharing data with family member/carer
- frequency of accessing charts at 3, 6 and 12 months
- self-reported acceptability and usability using an adapted version of the Mobile App Rating Scale user version (uMARS;<sup>143</sup> see *Appendix 1*).

### **Safety: adverse events**

Details of recording and reporting of all adverse events complied with the Medical Devices Regulations 2002 (MEDDEV 2.1/6),<sup>144</sup> ISO/FDIS 14155:2011<sup>145</sup> and Standards for Good Clinical Practice.<sup>146</sup> An adverse event was defined as serious if it:

- resulted in death
- was a life-threatening illness or injury
- required (voluntary or involuntary) hospitalisation or prolongation of existing hospitalisation
- resulted in persistent or significant disability or incapacity, or medical or surgical intervention was required to prevent any of the above
- led to fetal distress or fetal death or consists of a congenital anomaly or birth defect, or
- was otherwise considered medically significant by the investigator.

Our adverse event procedures involved recording all untoward medical occurrences or clinical indications, their relatedness to the investigational medical device, their seriousness and intensity and whether or not the event was anticipated. We separately monitored and reported device deficiencies that were inadequacies of the medical device (the algorithm) with respect to its identity, quality, reliability, safety or performance. In addition, we measured all adverse effects arising from study procedures including the use of the EMPOWER app. We prespecified (but did not limit) these as:

1. Increased fear of relapse or paranoia associated with responding to questions in the EMPOWER app.
2. Increased worries about surveillance by psychiatric services. We also assessed changes in fear of relapse using the Fear of Recurrence Scale.<sup>17</sup>

The relationship between the investigational medical device and the occurrence of each adverse event was assessed and categorised. The chief investigator used clinical judgement to determine the relationship. Alternative causes, such as natural history of the participant's underlying condition, concomitant therapy and other risk factors, were considered.

All serious adverse events were reported to the chairperson of the DMEC, the MHRA and the manufacturer (the University of Manchester) via the Glasgow study sponsor. Summaries of all adverse events were reported to and discussed by the DMEC and the SSC on a 6-monthly basis.

### Performance

The following performance end points were identified:

- Each participant had the app successfully uploaded on a smartphone.
- Each participant had personalised EWS included in the EMPOWER questionnaire.
- Each participant received a daily prompt to complete their questionnaire.
- Participants received an EMPOWER message each time they completed the questionnaire.
- Following 4 weeks of app use, the EMPOWER algorithm calculated each of the participant's individualised baseline or variance of symptoms and experiences.
- Participants could access charts of their symptoms and experiences covering 1-week and 1-month time intervals.
- Following completion of the questionnaire, participants' data were transferred to the secure server.
- Researchers accessed participants' questionnaire responses and generated charts to observe changes over time.
- Researchers received a record of alerts for each participant and could record actions in relation to these alerts.

### Candidate outcomes

Across measures, a lower score generally represents a positive or more desirable rating. Exceptions to this are the Service Attachment Questionnaire<sup>147</sup> and the Medication Adherence Rating Scale,<sup>148</sup> on which a lower score represents poorer engagement and poorer adherence, respectively.

### Candidate primary outcome

Research assistants extracted data on symptom changes and possible relapse from electronic case notes. Relapse was defined as:

- a return of or an exacerbation in psychotic symptoms of at least moderate degree
- symptoms of at least 1 week in duration
- evidence of a decline in functioning or an increase in risk to self or others
- evidence of a clinical response from services.

The relapse criteria are summarised in *Table 3*.

Our assessment of relapse was blinded. Research assistants screened electronic case records to identify potential episodes of relapse and exacerbation. These episodes provided the basis for individual anonymised case vignettes that were submitted to our independent adjudication panel. All vignettes were fully anonymised, and any information relating to the EMPOWER intervention was concealed. This panel contained expert clinicians/researchers who had the necessary knowledge, experience and skills to make independent blinded judgements regarding relapse/exacerbation. We planned to report the number (%) of relapses and time to relapse between groups, and number (%) with (1) return or exacerbation of psychotic symptoms, (2) duration of at least 1 week, (3) reduction in functioning, (4) increase in risk, (5) change in clinical management, (6) admission to hospital and (7) use of the Mental Health Act.<sup>149</sup> For each relapse we determined a severity score by allocating a point for each of these criteria (score = 0–7). All participants were assessed at each follow-up point for the presence of any of the criteria described below, enabling calculation of a mean severity score across participants and allocated groups at each follow-up point.

TABLE 3 EMPOWER relapse criteria

Criterion	Notes and definitions
A return of or exacerbation in psychotic symptoms of at least moderate severity (if present, score 1)	<ul style="list-style-type: none"> <li>• These are defined as first-rank psychotic symptoms, including hallucinations, delusions, thought disorder and persecutory paranoia</li> <li>• In line with PANSS assessments, moderate severity means that these occur at least occasionally or intrude on daily life to a moderate extent</li> </ul>
AND Where symptoms have lasted at least 1 week (if present, score 1)	
AND Where there is evidence of a decline in functioning (if present, score 1)	<p>Includes a decline in one or more of the role performance areas identified from the PSP scale:</p> <ul style="list-style-type: none"> <li>• Socially useful activities, including work and study (this should include co-operation with household tasks, voluntary work and 'useful' hobbies such as gardening)</li> <li>• Personal and social relationships (this includes relationships with a partner or relatives and broader social relationships)</li> <li>• Self-care (personal hygiene, personal appearance, dressing)</li> <li>• General domains to consider are physical and psychological health care; lodging (area of residence and living space care); contribution to household activities; participation in family life or residential/day-centre life; intimate and sexual relationships; child care; social network, friends and helpers; general interests; financial management; use of transport; coping skills in crisis; and keeping social rules</li> </ul>
OR An increase in risk to self or others (if present, score 1)	<ul style="list-style-type: none"> <li>• Increase in risk to self includes deliberate self-injury and/or suicidal ideation that in the investigator's judgement was clinically significant. Evidence is required of an increase in thoughts and/or an intent to act on such thoughts. These must occur in the context of the episode and be accompanied by a service response. The service response can be reflected in a statement of increased risk, a note of discussing safety plans, or staff ensuring that the participant has access to crisis contacts</li> <li>• Increase in risk to others includes significant violent and aggressive behaviour. This also includes homicidal ideation, with evidence of intent to act on this. Violent and aggressive behaviour should be recorded as an increase in risk only where there is evidence of a service response to manage this behaviour</li> </ul>
AND There is evidence of a clinical response from services (if present, score 1 for each of these criteria; maximum score 3)	<ul style="list-style-type: none"> <li>• An increase or change in medication, increased home visits or referral to crisis services</li> <li>• Any hospital admission or imposition of a community treatment order in response to psychosis</li> <li>• Use of the Mental Health Act<sup>149</sup> to enforce an involuntary hospital admission</li> </ul>

PSP, Personal and Social Performance.

### Candidate secondary outcomes

We assessed changes in symptoms, substance use, emotional distress, carer burden, service engagement and adherence and health-related quality of life.

- Mental health status: the PANSS,<sup>150</sup> the Personal and Social Performance Scale,<sup>151</sup> and the Calgary Depression Scale for Schizophrenia (CDSS)<sup>152</sup> were completed with service user participants.
- Substance use measures: the Timeline Followback for drugs and alcohol (over 28 days) was completed.<sup>153</sup>
- Emotional distress: the Hospital Anxiety and Depression Scale (HADS)<sup>154</sup> and the Personal Beliefs About Illness Questionnaire-Revised (PBIQ-R) were completed.<sup>155</sup>
- Service engagement: the Service Attachment Questionnaire<sup>147</sup> and the Medication Adherence Rating Scale<sup>148</sup> were completed by service user participants.
- Health economics: the EuroQol-5 Dimensions,<sup>156</sup> the Assessment of Quality of Life–Eight Dimensions,<sup>157</sup> the CarerQoL-7D<sup>158</sup> and a resource use questionnaire (RUQ) were completed.

### Candidate mechanisms

Measures were selected that map directly on to hypothesised mechanisms of change as well as known predictors of relapse. Mechanisms of service user benefit were operationalised as improvements in personal recovery, efficacy and utilisation of social supports.

- Recovery and self-efficacy: the Questionnaire about the Process of Recovery<sup>159</sup> and the General Self-Efficacy Scale<sup>160</sup> were completed by service user participants.
- Social and interpersonal context: the Psychosis Attachment Measure<sup>161</sup> and the Perceived Criticism and Warmth Measure adapted from the Perceived Criticism Measure<sup>162</sup> were completed by service user participants.

### Carer outcomes

The Involvement Evaluation Questionnaire<sup>163</sup> was completed as a measure of carers' worrying, tension, urging and supervision. A carer-perceived criticism measure, adapted from the Perceived Criticism Measure, was used as a measure of carers' perspectives on relationship quality.

We also assessed carer health economic outcomes using a purposively designed RUQ, the EuroQol-5 Dimensions, five-level version (EQ-5D-5L) and the CarerQol-7D.

### Care co-ordinator outcomes

Participants' care co-ordinators completed the Service Engagement Scale.<sup>164</sup>

### Process evaluation

In line with Medical Research Council guidance on the process evaluation of complex interventions,<sup>165</sup> we produced a logic model for the EMPOWER intervention and conducted a process evaluation. The process evaluation will be used to explore the ways in which EMPOWER may operate to produce outcomes. Specifically, it will focus on intervention fidelity, exposure, reach, context, recruitment, retention and contamination, as well as the acceptability of study procedures. We will interview service users, carers, mental health care staff and research staff to ensure a multiperspective understanding of the intervention. The process evaluation has been published elsewhere.<sup>166</sup>

### Sample size

No formal sample size calculation was appropriate for this pilot phase. The proposed sample size of up to 120 service users across 40 care co-ordinators in eight CMHS was deemed to be sufficient to establish feasibility and obtain parameters, including the relevant intracluster correlation coefficients for the cluster design, to inform the design and size of a future definitive, pragmatic, multicentre and multinational cRCT.

### **Recruitment and randomisation**

The unit of randomisation was the CMHS (the cluster). Participating CMHS were randomised within stratified pairs to the EMPOWER relapse prevention intervention or to continue their usual approach to care.

Researchers approached each eligible care co-ordinator and sought their consent to participate in the trial. Prior to randomisation, consenting care co-ordinators provided an anonymised list of their current potentially eligible caseload of people using services. This list was then randomly ordered by the Centre for Healthcare Randomised Trials (CHaRT). Researchers then approached identified people sequentially in blocks of up to five potentially eligible participants and sought informed consent to participate in the study. If there were further participants eligible for inclusion at the end of this block, the researcher moved onto the next block of five (if applicable). Care co-ordinators provided participants with an easy-to-read information leaflet about the study to enable potential participants to express interest in finding out more information. In Australia, information posters were displayed in the staff areas of participating sites to inform care co-ordinators about the study and the contact details of research assistants were provided for those who wanted to participate.

We aimed to approach and consent, on average, three participants per care co-ordinator (giving a total of up to 120 potential participants). Following delays resulting from Medical Device Registration procedures and consultation with the independent DMEC and SSC, this recruitment target was amended to 86 participants. After completing baseline assessments on all consenting service users in care co-ordinators' and CMHS' caseloads, the clinical trials unit (CTU) at CHaRT conducted randomisation of the CMHS. For Australia, with just two clusters, this was by simple randomisation by the CTU. For Glasgow, with six clusters, the CTU created three pairs of teams based on similarity of the catchment area in terms of social deprivation (Carstairs) score or CMHS type (e.g. early intervention service). The CTU randomly allocated one member of the pair to the intervention and the remaining member to control.

In this pilot phase we explored the best method of randomly allocating the clusters in the full trial, specifically to establish what matching factors (if any, and/or if matching at all is appropriate, methodologically) were suitable. Any violations of the study protocol were recorded and reported to the Research Ethics Committee, the SSC and the independent DMEC.

### **Statistical analysis**

A full statistical analysis plan was written (and published on the CHaRT website<sup>167</sup>) prior to any analysis being undertaken. All analyses were carried out using the intention-to-treat principle with data from all participants included in the analysis including those who did not complete the intervention. Every effort was made to follow up all participants in both arms for research assessments. The analysis followed the guidelines of the CONSORT statement for cluster randomised trials and recommendations for the analysis of cluster randomised trials when presenting and analysing the data. Here, we had potentially repeated measures on individual patients nested within care co-ordinators who were nested within teams (the unit of randomisation) who were nested within region (Australia and Scotland).

A full trial analysis may consider adjusting for these factors using appropriate random (service user, if relevant; care co-ordinator; and team) and fixed (region) effects. However, for this feasibility study, analysis models for all outcomes used a simplified approach whereby we analysed the unmatched data.

Baseline characteristics were also examined for dropouts and completers in each treatment arm. Treatment arms were described at baseline and follow-up using means [with standard deviations (SDs)], medians (with interquartile ranges) and numbers (with percentages), where relevant, for demographics and outcome measures. We analysed the main primary outcome, one or more relapses within the previous 12 months, using a generalised linear model, as a modified random-effects multilevel Poisson regression with a log-link function and robust error variance.<sup>168</sup> This facilitates the estimation of covariate adjusted relative risks (RRs) and the derivation of the absolute risk difference. This model

was adjusted for a fixed country effect and accounted for possible CMHS clustering using a random-effects robust variance for centres. As relapse was not assessed formally at baseline, this could not be incorporated into the model. Time to the first relapse was assessed using Cox regression.

The repeated measures aspects of the secondary outcomes meant that we used mixed random-effects generalised linear models with appropriate distributional forms depending on the outcome being analysed. These allowed the estimation of the treatment effects over time by including a time-by-treatment interaction for fixed (nominal) time points of 3, 6 and 12 months from randomisation. These were adjusted for the baseline measures for the outcome being assessed as well as having a fixed country effect and random centre effect. Owing to the large number of secondary outcome measures and the feasibility nature of the study, although we examined *p*-values (but only those with < 1% significance) and effect size (using Cohen's *d*), this was not to judge the treatment impact but rather to assess the worth of each scale for inclusion in any potential full trial. The trial statistician remained blind to the primary outcome until the final data cut.

A full health economic statistical analysis plan was written prior to analysis being undertaken. As part of the within-trial economic evaluation, we tested two health-related quality of life measures that can be used to assess quality-adjusted life-years (QALYs), the EQ-5D-5L, and the Assessment of Quality of Life (AQoL-8D), in the feasibility trial. Although the EQ-5D-5L is very commonly used in the UK and Australian contexts, its sensitivity in and appropriateness for people with schizophrenia has been seriously questioned.<sup>169</sup> The AQoL-8D is a newer health-related quality-of-life measure that was developed to be sensitive to the quality-of-life domains that are important to people with mental health problems. A RUQ to capture the costs incurred was also tested. This questionnaire needed to be appropriate to both the UK and the Australian contexts but would possibly require some system-specific modules for services that differ between the two.

### **Work package 6: widening stakeholder engagement**

Following the cRCT, we aimed to engage with mental health services and local service user and carer organisations in the potential centres for a main trial (Edinburgh, Manchester and Birmingham). Our plan was to host three knowledge exchange events in Edinburgh, Manchester and Birmingham and invite key representatives of NHS services, professional staff and local service user and carer organisations. At these events we aimed to identify the key learning outcomes from the EMPOWER project and work with stakeholders to develop plans for the main study phase. We aimed to follow up these knowledge exchange events with active engagement with local NHS services, CMHS and management, local research and development (R&D) and information governance departments. We aimed to identify potential changes to services that would threaten cluster randomisation in a future trial. The outcomes of WP 6 are summarised in *Appendix 11*.

### **Protocol amendments**

The protocol amendments are described in *Table 4*.

### **Protocol breaches**

There were no protocol breaches.

### **Study amendments**

In September 2018 we were granted a 6-month extension to the study by the Health Technology Assessment programme team on the basis of delays incurred as a result of medical device registration. Within the extension request we made the case, with the backing of our SSC and DMEC, for a reduction in the target sample from 120 service user participants to 86. This revised target was based on our recruitment progress and justified with reference to sample sizes of similar feasibility studies of mHealth for psychosis.<sup>117,170</sup>

TABLE 4 Phase 2 protocol amendments

Amendment number	Date	Protocol number	Main change summary
1.0	7 August 2017	1.1	<ul style="list-style-type: none"> <li>• Reformatting of existing assessments and questionnaires into new booklets</li> <li>• Removal of the following measures: Empowerment Scale – Making Decisions, Internalised Stigma of Mental Illness–10, Alcohol Use Disorders Identification Test, Drug Abuse Screening Test, Cannabis Use Disorder Identification Test, Working Alliance Inventory-Short Form, Psychosis Attachment Measure (Observer)</li> <li>• New measures added of feasibility, acceptability, health economic analysis and carers' relationships</li> <li>• Changes to patient information sheets</li> <li>• Changes to protocol and addition of adverse events standard operating procedure resulting from EMPOWER's registration as a clinical investigation of a class 1 medical device by the MHRA</li> </ul>
2.0	4 December 2017	1.2	<ul style="list-style-type: none"> <li>• Alteration to recruitment to approach participants in blocks of five</li> <li>• Providing participants with a leaflet if they express interest in the study</li> <li>• Provision to share data reports from app monitoring with participants</li> <li>• Proposition to update participants regularly on their monitoring via the app</li> <li>• Agreement for new method of relapse assessment</li> <li>• Updates to participant information sheets</li> </ul>
3.0	4 June 2018	1.3	<ul style="list-style-type: none"> <li>• New documents and protocol amendment in relation to the delivery of a process evaluation</li> <li>• Protocol changes to harmonise between sites</li> <li>• EMPOWER arm leaflet amendments</li> <li>• Protocol change in relation to continued use of the intervention in the event a participant moved between teams</li> </ul>

### ***System safety and privacy protection***

Three general principles of information security (confidentiality, integrity and availability) were followed in the design and implementation of EMPOWER, which applied to phases 1 and 2 (WPs 3 and 4). All data transmitted to and from EMPOWER servers were encrypted over https with strong ciphers as detailed in *Approved Cryptographic Algorithms: Good Practice Guideline*.<sup>128</sup> Cipher suites were implemented in compliance with section 6 ('Preferred uses of cryptographic algorithms in security protocols') of the Good Practice Guidelines. In cases where participant data were downloaded from the EMPOWER site, these data were securely encrypted with a pass phrase of appropriate length and complexity. Data transfers were secured using standard web security protocols. Uploading study data to a central server in real time enabled them to be captured and so this protected against data loss, such as if a phone was lost or stolen. This removed the need for personal data to be stored on the device. The purpose of the server in this case was secure data storage.

## Chapter 3 Qualitative findings

### Background

Digital interventions for psychosis have shown promising preliminary acceptability and efficacy in feasibility studies.<sup>171</sup> However, many digital interventions that report effectiveness have failed to generalise from clinical trials into clinical practice.<sup>115,172</sup> Given concerns about generalisation beyond trials, the UK Department of Health and Social Care<sup>173</sup> now encourages systematic implementation research to increase understanding of how interventions become implemented or rejected. Embedding implementation research from the earliest stages of a trial appears key to understanding the emerging implementation process. Beyond psychosis research, there is evidence of the value of user involvement in implementation. For example, the early involvement of key stakeholders was noted to be important in developing implementable digital interventions to support caregivers of people with dementia.<sup>174</sup> Key implementation issues identified for digital interventions for psychosis that require further research include developing an understanding of the logistics of how a digital intervention might fit into clinical practice.<sup>175</sup> Additionally, developing knowledge of what factors are important in understanding and optimising user engagement is important,<sup>114</sup> especially because user engagement with digital interventions for psychosis can be low.<sup>115,176</sup> Understanding implementation from the point of view of intended end-users may present a way forward in anticipating implementation logistics and user engagement.

However, understanding implementation from the point of view of end-users has not always been valued. Historically, mental health service users' personal perspectives about interventions are rated low in the evidence hierarchy,<sup>177</sup> with RCT evidence (especially in systematic reviews) rated highest.<sup>178</sup> However, even with strong RCT evidence, no relapse prediction system for schizophrenia will be useful if it is not able to be integrated into clinical care and actually used by clinicians and patients,<sup>175</sup> making implementation key. Implementation research differs from most clinical research because it aims to understand why (historically) clinicians come to use interventions in routine care<sup>179</sup> rather than to test for clinical efficacy. However, the range of interventions on offer continues to expand, and digital interventions in particular<sup>91</sup> can be used outside clinical settings. The implementation (or implementation failure) of interventions emerges out of many decision-making processes that occur over a period of time. Therefore, it is important to conceptualise service users (and carers) as potential intervention implementers as well as end-users.

Decisions to use interventions are shaped by numerous factors, including individual preferences, professional roles and the environment in which decisions are made.<sup>180</sup> The inherent complexity of decisions to use interventions has been described as being a socially constructed process.<sup>181</sup> It is understood that the health-care system comprises dynamically interacting factors that are enmeshed in longstanding social practices, with which an intervention will come to interact.<sup>182</sup> As highlighted by Moore and Evans,<sup>183</sup> adding something new to a complex system, such as adding a new part to a car, should be completed only once there is a clear understanding of the complex system (in their example, the car). Therefore, it makes sense to try to understand the clinical health-care system and its dynamically interacting factors, and longstanding social practices, before attempting to implement an intervention.

The Medical Research Council framework for evaluating complex interventions recommends that implementation research proactively include stakeholders because people who are expected to engage with an intervention are likely to have relevant experiential knowledge that is useful for understanding the implementation process during a trial.<sup>165</sup> Despite the value of mapping out complex systems prior to testing an intervention, the majority of implementation research on engagement with interventions has been retrospective<sup>184</sup> and, therefore, not conducted in the early stages of feasibility or pilot trials, when researchers generally engage potential stakeholders for later trial activities, such as recruitment.



However, there are notable exceptions.<sup>185-187</sup> Qualitative research carried out during a trial can aid understanding of why an intervention might work and how context affects implementation.<sup>188</sup> However, stakeholders may have pre-existing expectations about implementation that may be important for researchers to be aware of. To capture these, we incorporated qualitative research methods to understand the expectations held by mental health care staff, carers and service users in advance of intervention testing.

### Theory

In understanding a problem in health care, it is important to be pragmatic and use methodologies that create interpretive insights for researchers to theorise about how a problem is sustained.<sup>189</sup> Moore and Evans<sup>183</sup> state that implementation theories are useful because they help to explain what happens during clinical trials.<sup>190</sup> Incorporating theory can also enhance understandings of barriers to research translation and how these barriers might operate. The Medical Research Council guidelines on evaluating complex interventions<sup>165</sup> recommend using theory to understand implementation processes. In line with this, questions asked of participants during phase 1 were designed using normalisation process theory (NPT),<sup>191</sup> which is concerned with the work that groups and individuals do when interacting with an intervention and how they make sense of it within their everyday practices. To differentiate EMPOWER from current relapse prevention practice, we also used NPT to characterise stakeholder discussions about both current practice and the proposed intervention. In particular, we evaluated expectations of the EMPOWER intervention using the following NPT constructs: coherence (e.g. did EMPOWER make sense to service users, clinicians and carers?), cognitive participation (e.g. did stakeholders think it was a good idea?) and collective action (operational work that people expect they would need to do to implement EMPOWER). Our rationale for using theory to analyse the data was the pragmatic goal of explaining stakeholder views as discussed during the preliminary qualitative phase, rather than building or testing theories.<sup>192</sup> Therefore, the results will be reported in line with whether or not the EMPOWER approach made sense to participants and how the intervention was expected to 'fit' in terms of relationships and the everyday work of relapse prevention.

## Methods

### Aims

The aims have been detailed in *Chapter 2*. To summarise, there were three WPs.

#### Work package 1

The aims of WP 1 were to:

- evaluate the acceptability and usability of mobile symptom recording using smartphones among service users and their carers
- identify incentives and barriers to use.

Deliverables were software and protocol updates in response to feedback from service users and carers.

#### Work package 2

The aims of WP 2 were to:

- evaluate the acceptability and usability of mobile symptom recording using smartphones among professional mental health care staff
- identify incentives and barriers to implementation by mental health staff
- identify relapse prevention pathways and whole-team responses.

Deliverables were:

- Software and team protocol updates in response to feedback from professional care staff. We will operationalise protocols for dealing with false positives and activation of relapse prevention pathways.
- The development of care pathways, identification of operational barriers and enablers.
- Identification of training needs of teams participating in our future pilot cRCT.

### **Work package 3**

The aim of WP 3 was to:

- finalise the EMPOWER app for implementation in a pilot cRCT that will compare EMPOWER with treatment as usual.

Deliverables were:

- software and protocol updates in response to feedback from service users, carers and staff
- agreement of final modifications to the EMPOWER app to enhance usability
- finalisation of measurement methods for assessment of self-reporting of acceptability and usability to be administered in our future pilot cRCT.

### **Work packages 1 and 2**

The methods are reported in line with COREQ (Consolidated Criteria for Reporting Qualitative Research).<sup>193</sup> For WPs 1 and 2 we utilised a task group design to gain insight into participants' perspectives, experiences and expectations.<sup>194</sup> Using task groups enabled respondents to interact with and respond to the ideas and comments of other participants.<sup>195</sup> Following best practice guidelines,<sup>165</sup> we used a theoretical framework to guide our task group schedule. An interview schedule informed by NPT<sup>191</sup> was developed to explore stakeholders' expectations. A copy of the topic guide for each stakeholder task group is provided in *Report Supplementary Material 1*. We planned to use NPT to explore how mental health care staff, carers and service users made sense of EWS, how they responded to EWS, the actions they took in relation to EWS and how useful they thought EWS were in detecting and preventing relapse. We also explored with stakeholders their expectations for the implementation of the EMPOWER intervention in their context.

### **Work package 3**

A range of different testing techniques were applied during the development of EMPOWER, including automated testing, manual testing, validation of the alert algorithm and beta testing. Automated testing consisted of unit testing to verify the functionality of specific sections of code and integration testing to test how parts of the system worked together. Manual testing included running through a full set of system tests and formally recording the results. The alert algorithm was validated by having an external validator produce an entirely separate implementation of the algorithm. Both implementations of the algorithm were then given the same input data and the outputs checked to ensure that they matched. For WP 3, we utilised beta testing as a form of software UX testing and an investigation conducted to provide stakeholders with information about the quality of the tested software product.<sup>125</sup> According to Bertolino,<sup>196</sup> testing software involves its validation in order to assess the extent to which it behaves as predicted. This enables the systematic and independent identification of errors to understand the risks involved in subsequent implementation.<sup>125</sup> Test techniques include the process of executing a program or application with the intent of finding software bugs (errors and other defects) and verifying that a product is viable.<sup>125</sup>

For WP 3, we utilised individual qualitative interviews to explore any software problems or defects, and to explore broader UX. First, the participants' general experiences with using the app were reviewed.

Thereafter, during the course of the interview the conversation moved towards more specific aspects such as experiences with the questions and generated messages. The final interview stage aimed for a more in-depth exploration of the EMPOWER app use in relation to recovery. In the course of that, participants were asked to consider if and how the app would enhance their well-being or could serve as a tool for self-management in their personal recovery journeys. Details of the interview are in *Appendix 2*.

### *Sampling and recruitment*

#### **Work packages 1 and 2**

Staff who support people with psychosis were recruited from CMHS in Glasgow, UK, and Melbourne, Australia. Staff were invited to take part through the research team making contact with clinical team leads in all eligible CMHS in both health boards. Service users were recruited to take part in task groups through being directly approached by mental health staff and via posters placed in relevant support organisations. Service user participants were eligible if they were in contact with a local CMHS, had experienced a psychotic relapse in the previous 2 years, had a diagnosis of a schizophrenia spectrum condition and were able to provide informed consent. Self-identified carers of people with psychosis were recruited by the research team advertising on posters and by word of mouth in mental health services and support groups. Participants included 86 mental health care staff working either in the NHS in the UK ( $n = 54$ ; 9 focus groups) or in NorthWestern Mental Health services in Australia ( $n = 32$ ; 5 focus groups). Twenty-one service users were recruited from local mental health services in the UK ( $n = 5$ ; 3 focus groups) and Australia ( $n = 16$ ; 4 focus groups) and 40 carers were recruited in the UK ( $n = 20$ ; 2 focus groups) and Australia ( $n = 20$ ; 3 focus groups). To maximise participant anonymity, we did not collect any demographic data beyond whether the participant was a carer, a service user or a mental health clinician. Following a short presentation about EMPOWER, which covered the trial rationale and design and the key aspects of the intervention, researchers trained in qualitative methods conducted 25 task groups locally, following the topic guide, between 20 July 2016 and 6 September 2017. Task group length ranged from 57 minutes to 2 hours and 9 minutes (*Table 5*).

#### **Work package 3**

Participants were eligible irrespective of whether they owned a smartphone. Smartphones were made available to participants if they did not own an Android device or if they expressed a preference for using a study smartphone. Seven service users participated in a 5-week beta-testing phase. This time scale was chosen to adequately assess users' experiences of the mobile app and to provide enough time to test the EMPOWER algorithm, which required a 4-week baseline phase to allow subsequent changes in well-being to be calculated in week 5. Interviews were conducted between 29 March 2017 and 19 April 2017. The interviews lasted between 15 and 40 minutes.

### *Analysis*

#### **Work package 1 and 2**

All data from recorded task groups were transcribed, largely verbatim. As the focus of this research was establishing actions and expectations, it was decided that language features such as 'uhms' and 'erms' would not be transcribed.<sup>197</sup> Following transcription, the transcripts were read and inductive thematic coding<sup>198</sup> was performed. Following the inductive coding stage, the data were deductively coded utilising key concepts from NPT as a framework for analysis.<sup>127</sup> The themes presented in this report were constructed as being the most salient in terms of establishing existing clinical practice around EWS-based monitoring and implementation expectations for the EMPOWER intervention. Strategies to improve rigour such as member-checking<sup>199</sup> (i.e. presenting analysis to participants to check if it makes sense to them) were not used.

TABLE 5 Work packages 1 and 2 sampling table

Group	Location	Participants (n)
Carer 1	UK	11
Carer 2	UK	9
Carer 3	Australia	4
Carer 4	Australia	9
Carer 5	Australia	7
Service user 1	UK	2
Service user 2	UK	1
Service user 3	UK	2
Service user 4	Australia	5
Service user 5	Australia	2
Service user 6	Australia	8
Service user 7	Australia	1
Staff 1	UK	4
Staff 2	UK	8
Staff 3	UK	10
Staff 4	UK	7
Staff 5	UK	5
Staff 6	UK	5
Staff 7	UK	3
Staff 8	UK	6
Staff 9	UK	6
Staff 10	Australia	7
Staff 11	Australia	9
Staff 12	Australia	10
Staff 13	Australia	6

### Work package 3

All interviews were digitally recorded, transcribed verbatim and anonymised. Data were analysed in line with interpretative phenomenological analysis<sup>200,201</sup> because we wanted to specifically focus on participants' experiences of using the app and how they made sense of these in terms of their experience of recovery and staying well. The process of analysis comprised the following stages:

- multiple reading of each transcript
- initial note-taking
- development of emerging themes through close line-by-line analysis and identification of descriptive, linguistic and conceptual codes
- establishment of inter-relationships across emerging themes
- search for patterns across cases and clustering of emergent themes into superordinate and subordinate themes and creation of a coherent table.<sup>201,202</sup>

## Results

### *Task groups with service users (work package 1)*

#### Coherence

Early signs monitoring-based approaches to relapse prevention seemed to make sense to service users. Service users reported that being aware of changes in their well-being was generally helpful and could help make them aware of potential signs of relapse:

*Researcher 2: And how helpful would you say it is to kind of monitor early warning signs?*

*Participant 2: It's important. It's important for your well-being. See how you feel the next morning. See how your health is, your mindset. It's very important.*

*Service user group 6, Australia*

*Researcher 1: Do you think it's helpful to monitor early warning signs, or?*

*Participant 3: Yeah.*

*Participant 2: I think it helps to be aware of them.*

*Service user group 3, UK*

However, there were barriers to the use of EWS monitoring-based approaches among service users in the task groups. For example, service users were concerned about potential over-reaction from mental health services, which could act as a block to their reporting of EWS:

*I get a bit scared to tell people about the early signs. Because you don't want people to blow it out of proportion and then they're staring at you and watching your every move. I don't like that; I like my privacy. And so, I like ... I don't know.*

*Participant 1, service user group 1, UK*

#### Cognitive participation

EMPOWER as it was described to participants during task groups seemed to make sense to service user participants. Having access to data was perceived as potentially helpful, and service users remarked that the technology associated with the intervention and having easy access to a record could make self-monitoring of experiences easier, as evidenced by the following quotation:

*I love the idea of being able to log, during the bad time, what exactly is bad about the day and my mood and the symptoms and seeing it in black and white, not just the graph but the questions that you are asked, to know that you don't have to text in a couple of sentences or a paragraph, you just slide a slider up and down on the bar.*

*Participant 1, service user group 2, UK*

Service users seemed aware that EWS monitoring-based approaches to relapse prevention were part of a social practice in a system that included actions by the whole mental health team. Relating this to the EMPOWER intervention, some service users were concerned about staff receiving their personal EWS-based data. It appeared that service users expected the relational work of EWS monitoring that exists in current practice to possibly act as a barrier to using EMPOWER because there was uncertainty about how staff may respond to the data if these were shared:

*Participant 3: We know that nothing is essentially private, well I happen to know that nothing that you tell any counsellor or social worker, nurse, therapist, anything, everything you tell them can be transferred even if it's just in the lounge in the kitchen during lunchtime 'oh blah de blah de blah'. We know they share information about us. We know they ... um there is no privacy. Well I know it.*

Participant 1: *Uh what was the question again?*

Researcher 1: *It's really about the security arrangements and confidentiality with app as we have explained it, if there is any concerns or comments about that?*

Participant 3: *Totally, it's going to be sending information to the treating team.*

*Service user group 7, Australia*

The well-being messages approach seemed to generally make sense to participants as an intervention component. For example, the message that generated information tailored to service users' input appeared coherent as the first step of a stepped-care pathway:

*I'm sure EMPOWER could step before . . . you're not sick enough to go to the hospital, you're having a setback but maybe just need a little bit of encouragement.*

*Participant 2, service user group 7, Australia*

However, as can be seen in the following exchange, some participants raised caution that message content could have the potential to be perceived negatively, for example if a message seemed to downplay or minimise distress or to be inappropriate to the context of that distress. Therefore, message content would need to be portrayed in an appropriate manner that did not seem dismissive of people's struggles:

Participant 1: *Yeah. There's a risk that it might be a wee bit patronising. Just a risk, I don't know. I know that me personally if I was feeling down in the dumps and I got a message saying 'go for a walk' . . . [laughs].*

Researcher 1: *Pull your socks up.*

Participant 1: *Yeah. It may infuriate me. But maybe if I had the option to read the message, I was choosing to read the message, it wouldn't be so annoying.*

*Service user group 1, UK*

### Collective action

Although concerns about staff having access to the data in terms of privacy and personal service user autonomy were common, these were set among discussions that support from a human being was always going to be important in relapse management and that an app on its own would not be considered helpful:

*Seems a poor substitute for seeing a person that knows you.*

*Participant 2, service user group 1, UK*

### Task groups with carers (work package 1)

#### Coherence

Throughout carer task groups, EWS monitoring approaches were described as having utility in relapse prevention. Moreover, monitoring EWS made sense to participants because being aware of EWS provided an opportunity to intervene early in relapse prevention:

*You can stop it from escalating and into a full-blown episode. You can see when it's coming on. They can increase the medication or encourage them to see the doctor or something like that. There's lots of things you can do. But, you know, once they get too sick, then it gets more difficult, they get more suspicious.*

*Participant 6, carer group 4, Australia*

One key issue highlighted by carers in both Australia and the UK was the perception that mental health staff did not always agree with carers' own assessment of whether or not a service user was exhibiting EWS. Carers seemed to feel that they were on the outside in this process and were unable to influence clinician decision making:

*Well I don't like the fact that I get told 'your son is doing really really well, really really really' and I phone up and say 'I'm really concerned'.*

*Participant 2, carer group 2, UK*

### Cognitive participation

The EMPOWER approach to EWS monitoring was described as making sense because it could help to identify patterns in well-being changes and highlight when additional support might be needed. In terms of cognitive participation, the EMPOWER data were expected to signal when help-seeking might need to be initiated:

*If the chart was, you notice yourself it's is [sic] negative, they are definitely going down the tube, you will encourage them, if they don't see their doctor on a regular basis, that we should go and visit a doctor.*

*Participant 2, carer group 3, Australia*

### Collective action

Despite largely positioning themselves as on the outside of the mental health staff–service user relationship that forms current EWS monitoring approaches, carers did situate themselves as potentially in a position to encourage use of the app. Carers stated that they would require some basic knowledge of how EMPOWER works to be able to do this optimally. However, carers were acutely aware of the importance of their loved ones seeking their involvement in and support with using the app, something that could not be taken for granted:

*If we [as carers] had a good working understanding of it [EMPOWER] I'd find it easier to say to her 'oh how are you getting on with the app?' and just encouraging her with it if she was happy to be encouraged, yeah. So, I think that'd be really good.*

*Participant 5, carer group 1, UK*

### Task groups with staff (work package 2)

#### Coherence

Mental health care staff reported that an EWS monitoring approach made sense as a standard clinical approach to relapse prevention. Mental health care staff appeared to value their clinical ability to identify, recognise and then act on changes in well-being suggestive of EWS:

*I think it's their behaviours; you know, if there's a sudden change or you know, that if you've done your relapse prevention and they have identified relapse triggers, then the person's starting to do them.*

*Participant 1, staff group 7, UK*

In mapping out current relapse prevention in both the UK and Australia, staff responses to EWS depended on a triage-like process. If EWS were perceived to be lower risk, staff typically responded by getting in touch with the participant. However, if EWS appeared to be signalling a more imminent relapse, then escalation to input from the medical team and, potentially, coercive measures such as community treatment orders could be employed:

*There will be steps to take to ensure the consumer isn't getting to the point where they are really unwell – being able to prevent that pretty much – most of it, all of it, getting in contact, you know. Getting input from the medical team – even using legal measures such as a temporary community treatment order or a*

*system those things . . . yeah. It's different for everybody, but there are ways where we can really try and manage someone.*

*Participant 3, staff group 12, Australia*

However, mental health care staff across the task groups said that they were not always aware of EWS because there were numerous barriers to the implementation of standard EWS-based approaches in current clinical practice. For example, identifying EWS was challenging as the signs were not necessarily clear-cut; common EWS are not always specific to relapse and may reflect other issues, such as reactions to life events and adverse circumstances. In addition, service users may downplay experiences or avoid appointments, further reducing the staff's ability to detect EWS:

*I think sometimes for ourselves, well partly how people might present, or like the content of what they're maybe wanting to discuss in their sessions. But also people started to DNA [did not attend], or just not turning up to sessions. So something it's that they're not presenting at all, and you think, 'Oh my goodness, what's going on here?'*

*Participant 2, staff group 7, UK*

Staff spoke about encountering barriers when trying to undertake relapse prevention work, even when they had identified EWS successfully:

*You can only do what you can do as a key clinician in terms of you know those policy procedures we've just discussed and there's a whole other gamut of influences that might impact on a consumer that are out of our scope to influence.*

*Participant 1, staff group 12, Australia*

Examples of barriers to successfully using EWS monitoring approaches that staff identified as out of their control were typically factors in a service user's life (often structural) that had the potential to impact on their well-being. Staff appeared to feel powerless in the face of these challenges. Highlighting these barriers was important because it revealed the context in which the work of EWS-based monitoring is carried out in current practice. In the following quotation, a staff member reflects on the fact that participants can be socially isolated and may take either alcohol or drugs:

*Isolation. Out bevvyng that night and the next morning they felt awful. Whatever . . .*

*Participant 2, staff group 6, UK*

In addition to sociodemographic factors, barriers to the implementation of EWS monitoring approaches could be systemic. For example, when discussing current EWS monitoring-based practice, it was very common for mental health staff (in both the UK and Australia) to refer to the fact that staff are under enormous time pressure. In the following quotation, a participant alludes to needing to almost ration their clinical time, with the result that not every patient receives what is perceived to be best practice. Therefore, it is important to note that staff are likely to interact with the EMPOWER intervention in a context of significant time constraints:

*What we find difficult as nurses is massive caseloads and trying to maintain quality of care trying to make sure things like that are all up to date so it's hard it's nice in theory to say 'oh this is what happens and this always happens' but we'd love it to always happen but sometimes we don't have time to do that and it's there chasing you every day and you're thinking oh my god. Best practice. Core standard. Every patient would have that, but reality is we don't often get the time to do it for everybody.*

*Participant 1, staff group 1, UK*



### Cognitive participation

Associated with significant time constraints, staff reported that they may not have adequate time to allocate to using the EMPOWER intervention:

*It definitely makes sense, in that my only worry about it is that thinking about my caseload at the moment and I just don't know where we'd have the capacity to be working with it. [Sounds of agreement from other participants.] Particularly because it's psychosis and schizophrenia illness and how disabling that is . . . erm, to people.*

*Participant 1, staff group 2, UK*

Among the staff groups, the EMPOWER intervention was described as making sense and was generally expected to result in data that could be useful for staff to identify EWS and offer an opportunity for relapse prevention. Therefore, the EMPOWER intervention seemed to staff to be a coherent approach:

*You see where the stressors are, what times, what the patterns are, the patterns would be so clear.*

*Participant 1, staff group 2, UK*

Although the EMPOWER approach to EWS-based monitoring seemed coherent to staff, concerns were raised about how the intervention would interact with current practice. For example, staff expressed concern that, based on the data they had inputted to the app, patients might expect a response from staff that staff may not be able to provide:

*Patients might have a higher expectation of seeing somebody if they pressed these buttons then that somebody's going to come and see them a lot quicker.*

*Participant 4, staff group 8, UK*

Beyond concerns that intervention would increase service users' expectations of support, staff were concerned about the accuracy of data input and the subsequent clinical value of the data in decision-making. One barrier staff anticipated was if they perceived that the data entered by patients did not provide an accurate reflection of well-being; this was a common concern throughout the task groups:

*Researcher 1: What would possibly make you lose that confidence in its potential?*

*Participant 2: If it was you know people misusing the app for not the correct purpose - maybe if some of the data didn't appear to be correct.*

*Staff group 10, Australia*

### Collective action

Although staff generally anticipated that EMPOWER data would add value to current EWS monitoring-based relapse prevention, they expected barriers to both mental health staff and service users using the app as intended. For example, the intervention was expected to be too burdensome for at least some service users. Therefore, although staff perceived the EMPOWER approach as coherent, they also expected that they would not choose to use EMPOWER with every patient:

*It sounds like there'd be quite a specific group of patients that would benefit from this in terms of the people who are able to kind of reflect, who are you know, their lives aren't so chaotic that they can't keep hold of a mobile phone, you know, it doesn't end up somewhere else or in someone else's hands or whatever, and it's - I think it will be really useful for people who are functioning at that level and are able to reflect on things like that, but I guess it's - I suppose I'm just thinking it's a shame because it's often the people I suppose who I wonder might be at more risk of more kind of relapsing or being lost in the system somehow and becoming very unwell, are maybe already a bit too chaotic or functioning at too poor a level supposed to be able to make use of something as helpful potentially as this.*

*Participant 1, staff group 7, UK*

Another potential barrier staff identified was that EMPOWER data, even if considered an accurate reflection of a service user's mental state, lacked important contextual information. There was concern that it could become overwhelming for staff if EMPOWER data were presented in their 'raw' form. To reduce this risk, the task groups suggested that humans be involved in interpreting the clinical significance of the EMPOWER data:

*Participant 3: A bit of an overload of information perhaps if we're getting like you know three or whatever plus messages from the app a day and we'd need to do a management plan around ... at presentation and a big limitation in that sort of context is that you don't ... it's difficult to get a feel from the person about what is happening for the person ...*

*Participant 4: Missing out on the interpersonal context.*

*Staff group 12, Australia*

### Beta testing (work package 3)

Participants had access to the app for an average of 36.7 days (range 32–49 days) and completed the app questionnaire on an average of 25.4 days (range 16–35 days), giving an overall rate of engagement of 68.9%. These data are summarised in *Table 6*. All service users described the app as easy to use, including three participants who were not familiar with smartphones. Participants' experiences were generally positive, and the majority of participants felt that the EMPOWER app was an accessible and useful tool to enhance self-management.

### Questionnaire

The questions were generally considered relevant to participants. One service user described the questionnaire as more 'in depth' when she was not so well and 'shallow' when she was doing OK. Another service user described the questions as being pertinent to indication of relapse. The personalised questions were appreciated, although it was suggested that the questions could be personalised further (e.g. not all participants hear voices).

### Charts

One service user described the charts as transferring a sense of ownership of their data to them. A few participants found that the charts did not work (as they were using an earlier version) or that when the charts did work they were not as clear as they could be, indicating that some improvements could be made in this area. One participant suggested the app was useful because it gathered a lot of data that could be used in appointments with mental health professionals (e.g. being able to share charts would provide a useful memory aid).

TABLE 6 Service user characteristics and app usage

Participants (pseudonyms)	Gender	Age (years)	App beta-testing duration (days)	Number of completed days	Number of days with missed alert	Percentage responding days
(1) Robyn	Female	35	36	32	4	88.9
(2) Emma	Female	25	34	26	8	76.5
(3) Nancy	Female	31	34	20	14	58.8
(4) Paul	Male	53	32	16	16	50.0
(5) Susan	Female	30	35	26	9	74.3
(6) David	Male	36	49	35	14	71.4
(7) Kevin	Male	53	37	23	14	62.2

### Diary

The use of the diary varied; it was not used by all participants, and when it was used it was used occasionally rather than every day. One participant mentioned that he would like to be able to share his diary (as well as the other data) with the EMPOWER research nurse and mental health care professionals.

### EMPOWER messages

Not all participants were able to receive the EMPOWER messages. However, participants who did receive the messages described them as helpful and, in some cases, empowering. After reading messages about getting back into work, two service users began considering returning to work for themselves. One service user described how he had not previously given much consideration to returning to work, but reading about how other people with severe mental health problems were getting back to work had sparked his curiosity and hope. Another participant found that messages gave him perspective to think about himself beyond his mental health issues.

### *Interpretative phenomenological analysis (work package 3)*

As part of the analysis of the transcribed interviews with seven participants, three inter-related superordinate themes were constructed: (1) generating evidence, (2) awareness and learning and (3) acceptability and feasibility. *Figure 4* illustrates these three superordinate themes and their subordinate themes.

### Generating evidence

The first superordinate theme, 'generating evidence', was closely linked to 'awareness and learning'. However, this superordinate theme focused on the meaning of using the app as a tool for self-monitoring.




FIGURE 4 Superordinate and subordinate themes.

The vast majority of participants recognised the ability to track their well-being and link responses to experiences as one of the most beneficial elements of the EMPOWER app:

*[Most beneficial element for recovery] Being able to track it on an app, (. . .) having a record on your phone which is easily accessed; that would be the best thing for me.*

Emma

The creation of evidence also led to significant opportunities for relapse prevention and early intervention. Most of the informants felt that being able to access their data enhanced self-reflection as it enabled them to explore their own judgement of their well-being and to use the graphs as visible proof of their improvement or deterioration. EMPOWER was therefore considered a useful tool for self-monitoring and could heighten the chances of receiving support in the early stages of a possible recurrence, as well as reinforcing well-being:

*You can see – well I am actually recovering, I am doing quite well.*

Emma

*Red flags if you scored high at a certain question; are a warning sign. Something you need to deal with; reach out and get help from your team, your family.*

David

The consistency among participants' data-sharing preferences was striking. All of the participants stated that to varying degrees they were willing to share data with professionals such as their general practitioner (GP) or psychiatrist, but not with family or friends:

*I probably wouldn't share it with friends or family but I might use it as evidence for myself or evidence for professionals.*

Nancy

*[Long-term monitoring] Might be very useful for if I am seeing my psychiatrist cause I don't see her very often and sometimes I forget how I am over the longer term.*

Susan

### Awareness and learning

The second superordinate theme encompassed what was described as 'awareness and learning'. Participants saw the questions in the app as a tool for self-reflection. The following quotations illustrate how the questions enhanced the reflexivity of two participants, Robyn and Paul:

*It made me think of things which I hadn't really considered but which had been in the background.*

Robyn

*Got my feelings out and you know, getting that therapy type thing.*

Paul

Moreover, several of the participants noted the benefits of the personalised questions as these were tailored specifically to users' own experiences:

*I liked that they could be personalised 'cause of course psychosis is such a broad construct and means lots of different things to different people.*

Susan

## QUALITATIVE FINDINGS

After the questionnaire was completed, the app generated a message that aimed to prompt users to explore and reflect on different approaches to recovery and self-management. Several participants described how the messages gave them access to relevant and useful information:

*I do feel the utility of the messages is – it's giving people access to information and self-management they might not typically get from the NHS.*

Susan

*Took me to some interesting links – like a newspaper with a mental health newsletter; they had quite interesting articles.*

Kevin

The subordinate theme of self-reflection and self-management also included discussions of how participants incorporated new learning strategies through their use of the app:

*The app was a bit of a revolution in how to deal with you – how to manage your health.*

David

*[Most useful element for future usage] Facing up to reality. Realising your problems and that.*

Paul

Two of the participants described the usefulness of the app in the social context, suggesting that awareness of one's own emotions and coping strategies could influence interpersonal relationships:

*It's a good gauge of how I am gonna respond for a day – how I am gonna respond to other people.*

Robyn

*If it's hard to talk about something you could just show them.*

Emma

It appeared that self-awareness increased through the recognition of subjective triggers through the questions and charts facility. Ease of access to evidence in the graphs could promote reflection on and recognition of individuals' own triggers. This was particularly evident in relation to hospitalisation, which had a strong negative association. Therefore, fear of relapse and subsequent hospitalisation was an element that some participants brought up. One participant recognised the benefits of early intervention opportunities fostered by ongoing mood-tracking:

*Having something to kind of track moods and also have someone at the end of the phone if I needed it is a good idea as well – rather than going at a full-blown relapse before I get help (. . .) That's what happens a lot – you have to be really, really ill in order to get help and then it's too late basically and you are back to square one.*

Emma

### Acceptability and feasibility

The final superordinate theme, 'acceptability and feasibility', encapsulated the participants' experiences and assessment of the app with regard to simplicity of use, relevance of questions, randomisation and issues of disclosure, timing of use and, finally, aspects of commitment, trust and honesty. All participants, including one who had no previous experience with smartphones, felt that the app was straightforward and easy to use. Moreover, the majority of participants viewed the questions as relevant:

*I can't really put my finger on anything which wasn't useful. Everything that was there was relevant.*

Robyn

There were some contrary opinions about disclosing mental illness as a result of using the app. One participant valued the app more than innovations that relied on paper, such as psychosis diaries, because it increased their feelings of privacy and anonymity. Another informant was interested in changing the app diary function into a journal with unrestricted access given to the treating team; that, in turn, could offer professionals some context for the given data. One participant was critical about the randomised timing of alerts to complete the questionnaire at different times of the day:

*If you are not open about mental health anyway; I think it would be very difficult to use the app in public.*  
Nancy

Participants reflected about the most favourable time to use the app. Some felt that they would gain most benefits from using it in the recovery period after a relapse:

*I probably wouldn't want to do it if I was very unwell but if I was recovering from coming unwell I might want to do it again.*  
Nancy

Several participants who considered themselves recovered felt that the app would have greater utility at times when they were less well:

*I have recovered you know, but it has only been a few years ago when I was still in the hospital. It would have been more useful you know – when I wasn't quite recovered fully, you know. So when I came out of the hospital for the last time; it would have been very useful then I think.*  
Kevin

Most of the participants were unsure about the benefits of the randomised timing of alerts to complete the questionnaire and its feasibility in day-to-day life, for example the alarm going off while they were at work. The beta-testing version had a reduced response window, and one participant was disappointed that they had 'just one chance' to complete the questionnaire. Based on this, giving users the chance to respond to the questions over a longer period of time might improve acceptability and feasibility:

*I would have preferred if you could just – if there was a flexible time; you can just, you know, just tap one and go into it at any time.*  
Kevin

Moreover, participants reflected on important issues of commitment, trust and honesty. For example, commitment was identified as an important basis for longer-term app use:

*You have to be quite on the ball to use that thing by the way (. . .) You know what I mean, you got to be with it.*  
Paul

*It really takes for you to embrace it for it to work for you. You know it can't just be a casual thing, it is a lifestyle thing.*  
David

The aspects of trust and honesty were closely related. Previous negative experiences with services could decrease participants' trust in the app and reduce the likelihood of their disclosing EWS because of fear of rehospitalisation:

*Not everybody in my shoes will be trusting enough to pour their heart out into this app and it just really – the success of it just depends upon being honest.*  
David

Altogether, the data gathered in this study indicate that the EMPOWER app contributed to participants' enhanced self-reflection on the 'ebb and flow' of emotions and experiences in daily life. The app also promoted participants' access to new channels of learning. Overall acceptability was high, and suggestions for improvements were focused primarily on technical aspects of the app. Even though these results cannot be generalised to the broader population of potentially eligible service users, a closer look at the data suggests that most participants regarded the app as a useful tool for exploring aspects of recovery and self-management:

*I was quite happy to use it - quite happy to be part of its trial.*

*Robyn*

## Discussion

The objective of this study was to conduct task groups to:

1. evaluate the acceptability and usability of mobile symptom reporting using smartphones among service users, carers and mental health care staff
2. identify the incentives and barriers to use by service users and carers and to implementation by mental health care staff
3. identify pathways to relapse identification and prevention.

Our further aim was to finalise the EMPOWER app for implementation in the phase 2 feasibility cRCT comparing EMPOWER with treatment as usual. This was assessed over a 5-week beta-testing phase plus follow-up interviews with service user participants to identify technical issues that needed to be resolved prior to phase 2, and to explore participants' experiences of using the app. This phase was an important precursor to establishing the key parameters of the EMPOWER intervention, that is to enable the recognition of EWS by service users and their carers and to support a care pathway towards relapse prevention. We utilised NPT as a framework to understand the work required to optimise the EMPOWER intervention ahead of conducting the feasibility trial.<sup>203</sup>

### Coherence

In WPs 1 and 2, it was important to understand if the EMPOWER app made sense, had a clear purpose, was distinct from existing practices, would bring benefits that stakeholders would value, and would fit with the goals and activities of stakeholders. In NPT, this is referred to as coherence: the extent to which participants make sense of an intervention. During WPs 1 and 2, all participants described relapse as a negative event leading to significant distress and/or disruption in their spheres and contexts. There was a clear and shared understanding of the function of monitoring EWS to identify changes in well-being suggestive of relapse. The EMPOWER app seemed to offer something distinctive from routine care and was valued by participants. Anticipated benefits included being able learn from the data and develop a better understanding of well-being, providing a memory aid to support personal decision-making or shared decision-making, providing a tool to enable carers to encourage learning, monitoring and help-seeking, and offering a means of developing greater self-reflection.

### Cognitive participation

It was also important to understand if stakeholders thought that the app was a good idea, the extent to which they saw the app as having utility, and whether or not they would be prepared to invest time and effort in the EMPOWER app. In NPT this is referred to as cognitive participation, or the extent of necessary commitment and engagement by participants. Although the app was distinctive and made sense to mental health care staff, they also raised important and distinctive concerns, especially in relation to high caseloads and time pressures that already had an impact on their ability to spend time working with service users. Staff perceived that if the app increased their workload then they would

not have capacity to work with it. Staff also were concerned that many of their service users would not use the intervention because of the severity of illness, cognitive impairments, the impacts of digital exclusion or other stresses arising from poverty and deprivation. These are common concerns that have resulted in digital triallists conducting research focusing on digital exclusion in the context of psychosis.<sup>204</sup> Staff reflected that often it was these same service users who were at highest risk of relapse, and therefore those most in need of relapse prevention would be least likely to utilise the intervention. Berry *et al.*<sup>205</sup> previously reported that mental health care staff have conflicting views about the use of the internet and mobile phones for self-management by people with psychosis. The authors found that mental health care staff were cautiously optimistic about using mobile phone apps for monitoring. However, they also found that staff had concerns about their responsibility when receiving symptom reports from service users as they were worried about missing important risk information. Therefore, staff expressed a preference for receiving reports on monitoring during sessions with service users. In other research,<sup>170</sup> staff have found the number of data from digital interventions overwhelming. These findings resonate with our own finding that concerns about lack of staff time and capacity are key logistical barriers to the implementation of digital technologies in psychosis care<sup>175</sup> and should be considered when designing interventions. By contrast, both service users and carers felt that the app provided an important opportunity to keep track of and identify changes in well-being as a way of improving self-management and control. In addition, service users saw messages as a potential means of additional support and encouragement to access the knowledge and skills to stay well, as long as those messages were salient and meaningful.

### Collective action

In NPT, collective action relates to the work that participants need to engage in to make an intervention function in its context. This includes questions regarding how the intervention may promote or impede existing practices, and what impact the intervention might have on the division of resources or allocations of responsibilities among stakeholders.<sup>206</sup> Mental health care staff spoke about the importance of data from the EMPOWER app being reliable and valid in order to be useful for incorporation into routine practice and clinical decision-making. This included reflections on threats to the reliability and validity of data. Staff were concerned that service users may use the app to increase access to support and crisis care by exaggerating the severity of their experiences and that service users might lack the insight to reliably enter data that would be helpful to clinical decision-making. Staff were also concerned about data being viewed without broader awareness of the context of either the person (e.g. their access to sources of support, coping) or the service (e.g. its knowledge and expertise in delivering care to that individual). All of these factors were seen as potentially having an impact on existing practice in unhelpful ways, such as by increasing workload. Service users expressed concerns about help-seeking in the context of early signs of relapse, in particular about their data being shared and utilised to initiate unwanted interventions, including changes to medication and rehospitalisation. At the same time, service users said that the app should not be seen as a replacement for routine support from mental health services (a concern also expressed by mental health care staff and carers). In mapping out standard EWS-based monitoring from the task groups, it appeared that carers felt they were on the outside of the service user–clinician relationship, and many reported that clinicians could fail to take their concerns about their loved one’s well-being on board. These concerns manifested in relation to the app, and carers expressed a desire to be involved, where agreed with their loved one, in encouraging use of the app. In summary, different stakeholder groups had unique perspectives and concerns about current relapse management that appeared to act as a barrier to shared decision-making, echoing the qualitative work conducted following the CRIMSON study.<sup>207</sup> In terms of collective action, predictions about EMPOWER implementation barriers appeared to be clustered around whether or not the intervention was expected to have an impact on existing issues and concerns. For example, if the intervention increased workload, staff would be likely to resist using it, a phenomenon sometimes observed when novel digital interventions are implemented in clinical settings.<sup>172</sup>



### **Translation to EMPOWER phase 2**

Task groups identified that the proposed EMPOWER intervention (including the app) made sense to all of our stakeholder groups and was relevant to either existing mental health services practice or the concerns and values of service users and carers. We identified and theoretically framed important barriers to implementation in routine clinical practice. These barriers included the current context of practice, as staff reported carrying large and busy caseloads and were concerned that the app might create additional and unnecessary work as a result of the lack of reliability and validity of service users' self-reported data. In addition, staff saw themselves as having strengths in their knowledge about and expertise in managing relapse and in their ability to tailor their approach to relapse detection and prevention to individual service users based on their knowledge of that person. Therefore, based on the NPT framework,<sup>190</sup> there exists in current clinical practice potential structural barriers (e.g. lack of staff time) but also cognitive barriers (e.g. how staff think about their own role and skills in relation to relapse prevention). In response, we were careful to consider the role of triage in the design of the broader EMPOWER intervention. That is, rather than alerts triggered by changes in well-being going directly to mental health care staff, these alerts would be triaged by members of the research team and shared with staff members as part of a broader discussion incorporating relevant changes having an impact on the service user and relevant staff interactions with the service user. Sekhon *et al.*<sup>208</sup> stated that decisions about whether or not an intervention is appropriate for end-users are made through anticipated or actual cognitive and emotional responses to that intervention. Although service users and carers in this study valued relapse prevention as an important goal, they also raised important concerns around fears of help-seeking in the event of a crisis and the risk of exposure to unwanted interventions, particularly rehospitalisation. Mapping out the extent to which emotional responses such as fear may factor into hypothetical intervention acceptability was a key part of this research. The triage by research team members of changes in well-being was an important component of the EMPOWER intervention as a means of making sense of changes in well-being over time, linking changes to broader contextual factors and identifying patterns of change over time, all of which it was hoped would create an enriched understanding of changes in well-being. Therefore, the aim of the triage role was to reduce the fear and uncertainty of using a novel self-monitoring approach situated within existing fears about help-seeking that are inherent in current EWS-based monitoring approaches to relapse prevention. In addition, an important part of the EMPOWER intervention was the role of peer support. The results from task groups and beta testing also enabled the research team to carefully consider and refine the role of peer support workers in the intervention. We further emphasised the peer support workers' role in helping service users (and, where relevant, carers) learn about the mobile app and its functions, providing support with using the app and reflecting on app-generated messages, prompting engagement and curiosity in these messages as a basis for developing greater autonomy and self-management. As part of this, peer support workers were also app users, enabling them to share their own experiences of mental health more broadly or their experiences of using the app more specifically.

### **Beta testing**

User experience research in digital interventions for psychosis has been important in understanding and anticipating potential implementation barriers for interventions addressing smoking,<sup>209</sup> paranoia<sup>185</sup> and symptom management.<sup>210</sup> Conducting UX testing directly with end-users in advance of the trial was a further important step in anticipating specific implementation issues with the EMPOWER intervention. Through conducting beta testing, we identified a number of relevant and important technical issues. Fixes for these technical issues were included in software updates successfully delivered before phase 2. Technical problems resulting in poor UX, such as apps crashing, have been identified as key implementation barriers in clinical trials of digital interventions for psychosis,<sup>211</sup> highlighting the importance of conducting short-scale UX testing to identify technical issues. There were a number of important findings in relation to participants' experience of the app, including learning from the experiences of those who had never used a smartphone previously, themselves an under-researched subgroup.<sup>204</sup> Participants noted that the app was simple to use and that the questions were relevant to their well-being. Participants felt that the app was a useful tool that they

would be able to use to self-monitor their own well-being, and this was viewed as an important basis for staying well. Having used the app, all participants in the beta-testing phase expressed a preference for being able to share data with others, particularly mental health care professionals. In this regard, the app was seen as a tool for generating evidence to support personal awareness and learning or, indeed, for sharing evidence with mental health care professionals. The well-being messages generated in response to user data were understood as credible and a helpful prompt for self-management, providing access to broader information about experiences relevant to staying well.

Although the hypothetical acceptability of the well-being messages appeared reasonable in both the task groups and the UX testing phase, service user participants nonetheless expressed that if they perceived the messages to be patronising they would not be likely to engage with them. Furthermore, previous research has demonstrated framing effects (e.g. a willingness to even continue to read messages) of the words that are used in well-being messages.<sup>212</sup> To ensure that the messages were most relevant and salient to service users, we set up a patient and public involvement group to steer the development of principles for the curation and refinement of messages, to provide advice and good sources of user-friendly information and also to review the content and delivery of messages for EMPOWER. In recognition of how participants spoke about how current relapse prevention practice operates within an overarching structure of fear and uncertainty, we also changed the language around EWS monitoring. The language of EWS monitoring used by the researchers during task groups suggested that all stakeholders identified strong associations with risk. By using the app as a way to monitor the 'ebb and flow' of well-being, the language took on a more normalising and engaging tone. This was reflected in changes to the 'clinician interface' (where app user data were monitored by the research team), where changes identified by the algorithm generated 'alerts' that also continued to evoke the language of risk. We modified this to the term 'check-in prompts' to reflect the shift towards triage as a basis for learning and recognising that there was significant uncertainty about the clinical relevance of changes detected by the algorithm and the extent to which these may reflect true or false positives.



## Chapter 4 Baseline, feasibility, acceptability and safety results

### Recruitment and participant flow

Eight CMHS were recruited to the study, six from NHS Greater Glasgow & Clyde and two from NorthWestern Mental Health in Melbourne. In each team we drew from a reservoir of potentially eligible participants who were approached for consent prior to the allocation of treatment condition. After initially screening caseloads for diagnosis and the presence of a designated care co-ordinator, we fully screened 1140 potentially eligible service users across all teams. From these, we excluded a further 66 people on diagnostic grounds, 187 people who were being transferred or discharged and nine people who were deceased. Among the remaining 878 potentially eligible service users, we excluded 491 for whom there was no evidence of a relapse in the previous 2 years, 31 who were currently experiencing a relapse and 93 for other reasons including lack of capacity, communication needs and being in a first episode of psychosis. From the remaining group of 263 service users, we were able to approach 129 people between January and August 2018 in order to seek their informed consent. Of this group, 86 service users initially provided informed consent across the two sites: 56 in Glasgow and 30 in Melbourne. *Figure 5* describes the recruitment of these 86 service users to the study over time.

Thirteen service user participants withdrew before the treatment allocation was revealed to them or to their service. Reasons for withdrawal at this stage were available for six people. Three people cited a change in life circumstances after consent that meant that they were no longer able to commit to the study. Two people described being worried after providing consent about the implications of their involvement and one participant withdrew because they did not want to use the app (despite assurances that they might be allocated to the TAU arm). This left 73 service user participants who




FIGURE 5 Service user recruitment over time.

took part in the trial. Among this group, 27 (37%) participants had a nominated carer: 10 (24%) in EMPOWER and 17 (55%) in TAU. Of these 27 carers, 17 (63%) gave their informed consent to participate: seven (70%) in EMPOWER and 10 (59%) in TAU.

The flow of participants through the study is summarised in a CONSORT flow diagram (*Figure 6*). Four teams were randomised to each arm of the study: three in Glasgow and one in Melbourne. Within those teams, 42 service users were allocated to the EMPOWER arm and 31 were allocated to TAU. The small imbalance in the allocated number of participants in each arm was due to randomising a small number of clusters of varying size. In the EMPOWER arm all but one service user participant had the EMPOWER app installed. The remaining service user participant received part of the intervention (peer support). Participant follow-up took place between March 2018 and July 2019. At 12 months, primary outcome data were collected for 32 service user participants in the EMPOWER arm (76%) and for 28 (90%) in the TAU arm. During the study seven people withdrew from the EMPOWER arm, two moved out of the area and there was one death. There was a clear association between withdrawing from the EMPOWER arm and low engagement with the app. Four out of the seven participants who withdrew had the app installed but failed to complete an adequate number of baseline observations. The other three participants did not use the app at all. Additional information on withdrawals is as follows. In two instances people withdrew from the EMPOWER arm of the study directly after an app-related adverse event (see *Table 10*). Another person withdrew for reasons that were less clear but may have been influenced by a technical issue with their phone that had caused some distress at that time. One person described the reason as being related to stress and their general mental health. One participant was withdrawn as a result of their behaviour towards a member of the research team. In two instances the reasons for withdrawal were not clear. In the TAU arm, one service user participant withdrew but it was not clear why. Of those who withdrew from the EMPOWER arm, four were male and three were female. The mean age of those who withdrew appeared to be slightly higher, at 50 years (SD 12 years), than the mean age of the sample as a whole, at 43 years (SD 12 years).

## Baseline characteristics

### *Service user baseline demographic characteristics*

Baseline characteristics are summarised in *Table 7*. Men and women were similarly represented in the sample, and the mean age of service user participants was 43 years. Thirty-seven per cent of participants described themselves as having an informal carer. We noted a higher proportion of service users in the TAU arm stating that they had a carer ( $n = 17$ , 55%) than in the EMPOWER arm ( $n = 10$ , 24%). On average, service users had been in contact with mental health services for around 12 years.

### *Clinical characteristics of service users at baseline*

Clinical characteristics of service users at baseline are described in *Table 8*. Ninety-five per cent of service users were assessed as being in full or partial remission at baseline. The total scores on the PANSS indicate that this group of individuals had a moderate level of illness severity,<sup>213</sup> and Personal and Social Performance (PSP) scale scores suggest a marked impairment of functioning across the group.<sup>151</sup> Levels of depression were also high, with 56% of the sample scoring  $\geq 6$  on the CDSS, suggesting the presence of major depression.<sup>214</sup> Levels of alcohol and other drug use were low at baseline.

### *Carer and care co-ordinator baseline characteristics*

Carer and care co-ordinator baseline characteristics are summarised in *Tables 30* and *31* (see *Appendix 3*). Carers were predominantly female (71%) and had a mean age of 49 years. Care co-ordinators were also predominantly female (74%) and had been qualified for 11 years on average.




FIGURE 6 The CONSORT flow diagram. Values for those lost or withdrawn are cumulative.

TABLE 7 Service user demographic characteristics at baseline

Characteristic	EMPOWER (n = 42)	TAU (n = 31)	Total (N = 73)
Gender, n (%)			
Male	21 (50)	16 (52)	37 (51)
Female	21 (50)	15 (48)	36 (49)
Age (years), n: mean (SD)	42: 42 (13)	31: 43 (12)	73: 43 (12)
Years of education, n: mean (SD)	35: 12 (3)	30: 13 (3)	65: 12 (3)
First contact with mental health services (months), n: mean (SD)	38: 154 (121)	30: 134 (92)	68: 145 (109)
Have a career: yes, n (%)	10 (24)	17 (55)	27 (37)
UK ethnicity, n (%)	30 (71)	19 (61)	49 (67)
Scottish	21 (70)	16 (84)	37 (76)
Other British	1 (3)	1 (5)	2 (4)
Other white ethnic group	1 (3)	-	1 (2)
Mixed or multiple ethnic group	1 (3)	1 (5)	2 (4)
Pakistani	2 (7)	-	2 (4)
Indian	1 (3)	-	1 (2)
African	3 (10)	-	3 (6)
Unknown	-	1 (5)	1 (2)
Australian ethnicity, n (%)	12 (29)	12 (39)	24 (33)
Born in Australia	7 (58)	12 (100)	19 (79)
Born elsewhere	5 (42)	-	5 (21)
Aboriginal/Torres Strait Islander	-	1 (8)	1 (4)

TABLE 8 Service user clinical characteristics at baseline

Assessment	EMPOWER (N = 42)	TAU (N = 31)	Total (N = 73)
<b>Remission at baseline, n (%)</b>			
Full remission	20 (48)	12 (39)	32 (44)
Partial remission	19 (45)	18 (58)	37 (51)
Inadequate evidence	2 (5)	1 (3)	3 (4)
Missing	1 (2)		1 (1)
<b>PANSS, n: mean (SD)</b>			
Positive	42: 14.83 (5.92)	30: 15.43 (6.68)	72: 15.08 (6.21)
Negative	42: 13.90 (5.45)	30: 12.47 (4.08)	72: 13.31 (4.95)
Disorganisation	42: 15.86 (7.17)	30: 14.63 (4.67)	72: 15.35 (6.24)
Excitement	42: 4.95 (1.65)	30: 4.33 (0.55)	72: 4.69 (1.34)
Emotional distress	42: 11.95 (4.40)	30: 12.07 (3.24)	72: 12.00 (3.93)
Total	42: 61.50 (18.14)	30: 58.93 (13.73)	72: 60.43 (16.39)

TABLE 8 Service user clinical characteristics at baseline (continued)

Assessment	EMPOWER (N = 42)	TAU (N = 31)	Total (N = 73)
<b>PSP scale, n: mean (SD)</b>			
PSP total	42: 56.86 (16.02)	30: 59.37 (19.29)	72: 57.90 (17.37)
<b>CDSS, n: mean (SD)</b>			
CDSS total	42: 6.93 (5.34)	30: 6.97 (4.15)	72: 6.94 (4.85)
<b>Timeline Followback for drugs and alcohol, n (%)</b>			
In last 28 days, n (%)			
Alcohol	15 (36)	12 (39)	27 (37)
Not used	26 (62)	18 (58)	44 (60)
Missing	1 (2)	1 (3)	2 (3)
Cannabis	7 (17)	5 (16)	12 (16)
Not used	34 (81)	25 (81)	59 (81)
Missing	1 (2)	1 (3)	2 (3)
Other main drug	4 (10)	5 (16)	9 (12)
Not used	37 (88)	25 (81)	62 (85)
Missing	1 (2)	1 (3)	2 (3)
<b>HADS, n: mean (SD)</b>			
Anxiety	41: 9.76 (5.11)	30: 10.70 (4.88)	71: 10.15 (5.00)
Depression	40: 7.38 (4.98)	29: 8.03 (4.66)	69: 7.65 (4.83)
<b>PBIQ-R, n: mean (SD)</b>			
Control	41: 10.29 (2.52)	30: 9.83 (2.61)	71: 10.10 (2.55)
Shame	41: 10.10 (2.96)	30: 10.67 (3.07)	71: 10.34 (2.99)
Entrapment	41: 10.73 (2.88)	30: 10.80 (3.38)	71: 10.76 (3.08)
Loss	41: 9.84 (2.82)	30: 10.20 (2.54)	71: 9.99 (2.69)
Socially marginalised	41: 11.64 (2.89)	30: 11.87 (2.75)	71: 11.74 (2.82)
PSP, Personal and Social Performance.			

## General feasibility

Service users, carers and care co-ordinators in both arms of the trial were asked questions at all time points about general feasibility. Novel measures were developed that assessed their use of health and well-being apps and help-seeking related to EWS and their consequent changes in clinical management. Measures are available in *Appendix 1. Table 32* (see *Appendix 4*) shows that, among those randomised to the EMPOWER arm, we observed greater self-reported use of well-being apps (rated as 'sometimes') over 12 months than among those randomised to TAU (rated as between 'not at all' and 'rarely'). In both groups, help-seeking for EWS, carer help-seeking for EWS and changes in clinical management were rated as between 'not at all' and 'sometimes'. *Tables 33 and 34* (see *Appendix 4*) show these ratings from the perspective of carers and care co-ordinators, respectively. These show a similar pattern of results as observed in relation to help-seeking and changes in clinical management for service users. We asked carers and care co-ordinators to rate how often service users discussed EWS with them. We found that, in both arms of the trial, carers and care co-ordinators rated these discussions as happening between 'rarely' and 'sometimes'.



## Feasibility and acceptability of the EMPOWER app

The feasibility and acceptability results relate to the 41 service users in the EMPOWER intervention arm who had the EMPOWER app installed, and these are summarised in *Table 9*. Self-reported app usage was consistently reported as high at all time points, but the self-reported sharing of information from the app in the form of charts was more limited, both with care co-ordinators and with carers. At all time points, people were more likely to share information with a care co-ordinator than with

TABLE 9 Feasibility and acceptability for app users

Assessment	3 months	6 months	12 months
<b>App feasibility</b>			
Roughly how often use app? <sup>a</sup>			
Not at all, <sup>b</sup> <i>n</i> (%)	1 (3)		
<i>n</i> : mean (SD)	30: 4.63 (0.96)	26: 4.65 (0.75)	23: 4.65 (0.57)
Roughly how often share with key worker? <sup>c</sup>			
Not sure, <i>n</i> (%)	3 (10)	1 (4)	1 (4)
<i>n</i> : mean (SD)	26: 2.04 (1.00)	25: 2.24 (1.16)	22: 2.45 (1.30)
Roughly how often share with family? <sup>c</sup>			
Not sure, <i>n</i> (%)	1 (3)		1 (4)
<i>n</i> : mean (SD)	28: 1.71 (0.98)	26: 1.96 (1.15)	22: 1.91 (1.19)
Roughly how often access charts? <sup>c</sup>			
Not sure, <i>n</i> (%)	1 (3)		
<i>n</i> : mean (SD)	28: 3.04 (0.74)	26: 2.54 (1.14)	23: 3.00 (1.04)
<b>uMARS<sup>d</sup></b>			
Is the app interesting to use?, <i>n</i> : mean (SD)	29: 3.93 (0.88)	26: 3.92 (0.98)	23: 3.52 (0.99)
Is it easy to learn?, <i>n</i> : mean (SD)	29: 4.14 (0.64)	26: 4.12 (0.91)	23: 4.17 (0.78)
Moving/links between screens work?, <i>n</i> : mean (SD)	29: 3.97 (0.87)	26: 4.12 (0.71)	23: 4.17 (0.78)
Is app content correct/well written/relevant?, <i>n</i> : mean (SD)	29: 4.07 (0.70)	26: 4.04 (0.77)	23: 4.13 (0.69)
Is app information from a credible source?, <i>n</i> : mean (SD)	29: 4.45 (0.78)	26: 4.58 (0.58)	23: 4.57 (0.66)
Would you recommend the EMPOWER app?, <i>n</i> : mean (SD)	29: 3.83 (1.07)	26: 3.85 (1.12)	23: 3.83 (1.34)
How do you rate the app?			
NA, <i>n</i> (%)	10 (33)	10 (38)	6 (26)
<i>n</i> : mean (SD)	19: 4.26 (0.81)	16: 4.31 (0.79)	17: 4.06 (0.75)
App has increased awareness, <i>n</i> : mean (SD)	29: 3.97 (0.98)	26: 4.46 (0.71)	23: 4.22 (1.04)
App has increased knowledge/understanding, <i>n</i> : mean (SD)	29: 3.76 (1.09)	26: 4.19 (0.80)	23: 3.96 (1.02)
App changed attitudes towards improvement, <i>n</i> : mean (SD)	29: 3.72 (0.88)	26: 4.04 (0.96)	23: 3.83 (1.03)
App increased my intentions/motivation, <i>n</i> : mean (SD)	29: 3.97 (0.87)	26: 4.35 (0.75)	23: 3.87 (0.97)
App encourages me to seek help, <i>n</i> : mean (SD)	29: 4.14 (0.88)	26: 4.42 (0.70)	23: 4.09 (1.04)
NA, not applicable.			
a Scale of 1–5 (since last assessment), where 1 is 'not at all', 2 is 'once a month', 3 is 'a few times a month', 4 is 'weekly' and 5 is 'daily'.			
b 'Not at all' was included in summaries for 'how often used' but was not relevant to remaining questions.			
c Scale of 1–4 (since last assessment), where 1 is 'not at all', 2 is 'rarely', 3 is 'sometimes' and 4 is 'often'.			

a carer, but this may in part reflect that not all app users were identified as having a carer. However, people reported accessing the charts for their own use on a regular basis.

Acceptability ratings from the adapted uMARS measure suggested that the app was interesting to use and was consistently rated as easy to learn. Content was rated as being well written and the credibility of information was rated particularly positively throughout, peaking at 4.58 out of a possible 5 at 6 months. There was also a consistently positive overall rating for the app, ranging between 3.83 and 3.85 out of 5.

In terms of perceived mental health impact, positive ratings were given for awareness, attitudes, motivation and help-seeking (with a range of between 3.72 and 4.46 out of 5 across these indicators at all time points).

### App engagement

Of the 41 participants who had the app set up, 33 (80.5%) completed the 4-week baseline. These participants used the app for a mean of 31.5 weeks (SD 14.5 weeks; range 44 weeks). During that period, participants used the app for a mean of 64.1% (SD 22.5%; range 76.3%) of days. Therefore, according to our a priori criterion for acceptable engagement of 33% daily use, 30 (91%) participants met our criterion for adherence. Among those randomised to the EMPOWER arm, this represents 71% meeting the criterion. This range of 71–91% provides a broader estimate of overall engagement.

Fourteen participants (42.4%) were still using the app at their final follow-up assessment. Survival analysis methods are recommended for understanding attrition in digital interventions.<sup>215</sup> Attrition represents the amount of time to a relevant event occurring; in this case, the criterion was 4 sequential weeks of not meeting the intended adherence criterion of 33%. The analysis was completed using the `survfit` function in the survival package in R, with bootstrapping performed using the `bootkm` function from the `hmisc` package in R. Overall, the median survival for not missing 4 sequential weeks of 33% use was 32 weeks (bootstrapped 95% CI 14 weeks to  $\infty$ ). We noted that the upper limit returned an infinite value, likely to be a result of the skewed data. In other words, for 50% of participants who had completed a baseline it took 33 weeks before missing 4 sequential weeks of intended intervention usage. The width of the CIs suggest that some level of uncertainty is appropriate when interpreting the result of this test (Figure 7). To summarise, the length of time at which 50% of participants no longer meet the intended adherence criterion is hard to predict within this sample (especially in terms of an upper limit) but it is likely not to fall below 14 weeks. Supplementary information on our approach to describing engagement with the EMPOWER app is provided in Appendix 5.




FIGURE 7 Kaplan-Meier curve of time to 4 weeks' app use < 33%.

We explored the number of peer support worker sessions delivered over the course of the study. A total of 522 peer support worker sessions were offered to 42 participants in the EMPOWER arm (mean 12.4, SD 6.8; median 11.0, interquartile range 10.0). We also explored the number of ChIPs triggered by the algorithm during the study. There were 558 ChIPs during the study across 37 participants (mean 15.1 per participant, SD 10.5 per participant; median 13.0, interquartile range 15).

### Provision of study phones

A total of 28 mobile phones were provided to and used by participants: 22 in Glasgow and six in Melbourne. Six provided phones were either lost or stolen, four in Glasgow and two in Melbourne, and handsets were replaced on three of those occasions. The remaining participants in the EMPOWER arm chose to have the app installed on a personal handset. We did not ask for provided phones to be returned.

## Safety

### Adverse events

Adverse events monitoring and reporting included serious and non-serious adverse events, in line with the registration of the study as the Investigation of a Class 1 Medical Device. The medical device was specifically the algorithm that reviewed app data and determined responses. Across both arms there was a total of 54 adverse events, affecting 29 people, during the study. Around half of all events across arms were classified as serious adverse events, and the vast majority of these were anticipated. There was one death during the study. In terms of relatedness of adverse events, six events were assessed as being related to a study procedure, one of which was serious. This involved a threat made to a member of research staff in Melbourne in relation to the use of a study phone.

Adverse events are summarised in *Table 10*. There were no adverse events of any type related to the EMPOWER Class 1 Medical Device. However, to ascertain a fuller picture of possible harms than would have been available from focusing solely on medical device-related events, we additionally

TABLE 10 Adverse events

Event characteristics	EMPOWER (N = 42)		TAU (N = 31)		Total (N = 73)	
Adverse events	29		25		54	
People affected	19		10		29	
Adverse event type, n (%)						
Serious adverse event	Yes, 11 (38)	No, 18 (62)	Yes, 15 (60)	No, 10 (40)	Yes, 26 (48)	No, 28 (52)
Anticipated	7 (64)	-	14 (93)	-	21 (81)	-
Death	1 (9)				1 (4)	
Event relatedness, n (%)						
Study procedure <sup>a</sup>	1 (9)	3 (17)		2 (20)	1 (4)	5 (18)
App	1 (9)	12 (67)			1 (4)	12 (43)
Medical device	-	-				
Event intensity, n (%)						
Mild	1 (9)	3 (17)		4 (40)	1 (4)	7 (25)
Moderate	1 (9)	12 (67)		3 (30)	1 (4)	15 (54)
Severe	9 (82)	3 (17)	15 (100)	3 (30)	24 (92)	6 (21)

a Adverse events related to any aspect of study procedures (e.g. research assessments) but did not include the use of the app.

monitored adverse events related to people's experience of the EMPOWER app more generally. There were 13 app-related adverse events, affecting 11 people, one of which was serious. This involved a brief hospital admission for a physical health complaint, which the service user described as being in part related to feeling overwhelmed by the recent installation of the app. The service user, who had not yet used the app, appeared to be experiencing depression based on their contemporaneous CDSS assessment, and subsequently withdrew from the study. Examples of non-serious app-related adverse events included four instances in which the app caused unhelpful rumination. In one of these instances, where the self-monitoring approach was described as counter to the service user's usual coping strategy of 'burying things', the participant withdrew from the study. Other participants described feeling forced to think about being unwell because of questions in the app, with one person suggesting less frequent monitoring in future iterations. Unhelpful rumination of this type was identified by one participant as an issue when they were well, whereas a second person was affected when they felt more depressed. Two participants specifically cited increased paranoia as a result of the app. On one occasion this related to the timing of question alarms and on another it related to the specific content of personalised questions. A further participant identified that personalised question content unhelpfully triggered traumatic memories of psychosis. One participant reported experiencing increased anxiety after being asked a question that was new to them as a result of branching rules in the question set. In one case a participant reported increased worry as a result of losing their provided mobile phone, and, in a further event, a participant experienced distress as a result of a technical fault arising from a conflict between the app's software and their personal phone. App-related adverse events and our responses to them are described in more detail elsewhere.<sup>113</sup>

### **Device deficiencies**

Two device deficiencies of the investigational medical device were identified during the study. The first was categorised as a manufacturing defect and was related to the following performance end point:

- Following 4 weeks of usage, the EMPOWER algorithm calculates participants' individualised baseline of symptoms and experiences.

One participant's initial baseline observations showed no variation. That is, they scored the same for each item on each day of the baseline period. As the result of an anomaly in the algorithm's calculation of standard deviation, every time the participant responded to questions following the baseline period, a ChIP was automatically generated regardless of any relevant change in scores.

A second device deficiency, which was categorised as a device malfunction, involved an unexpected server shutdown at the University of Manchester. This lasted for around 5 hours, affecting the following performance end points during that time:

- Researcher accesses participants' questionnaire responses and generates charts to observe changes over time.
- Researcher receives a record of alerts for each participant and is able to record actions in relation to these alerts.



# Chapter 5 Candidate outcomes of the main trial

## Candidate service user outcomes

### Candidate primary outcomes

We collected complete relapse data on 67 (92%) participants at 3 months and on 61 (84%) participants at every follow-up time point. Research assistants screened electronic case records to identify potential episodes of relapse and exacerbation at 3, 6 and 12 months post randomisation. These episodes provided the basis for individual anonymised case vignettes that were reviewed by an independent and blinded adjudication panel, who determined what, if any, criteria for relapse were met, the date of relapse and the type of relapse. Following calibration on four relapse assessments, inter-rater reliability testing was undertaken on a further 12 assessments for which we noted substantial agreement ( $k = 0.80$ ). These findings demonstrate the feasibility of collecting data relating to relapses and exacerbations from routine clinical data.

During the study, we identified 27 relapses over 12 months, with a larger number in the TAU arm ( $n = 19$ ) than in the EMPOWER arm ( $n = 8$ ). Among these relapses were 11 hospital admissions, nine in the TAU arm and two in the EMPOWER arm. Five relapses involved the use of mental health legislation, all of which were in the TAU arm. Details of the relapse characteristics collected at each follow-up time point are in *Appendix 6, Table 37*.

Our main approach was to include participants with complete 12-month follow-up data; there were 8 out of 33 (24%) relapses in EMPOWER and 13 out of 28 (46%) in TAU (*Table 11*). Using all available follow-up data in a time-to-first relapse analysis showed that relapse was less likely in the EMPOWER arm (hazard ratio 0.32, 95% CI 0.14 to 0.74). This is also illustrated in the Kaplan–Meier plot in *Figure 8*.

*Table 11* also shows the time to first relapse, with indications that this was longer for those in the EMPOWER arm (median 4.8 months) than for those in the TAU arm (median 1.4 months).

A key concern was that the EMPOWER intervention would lead to an increased fear of relapse because of the potential that monitoring possible early signs of relapse would lead to increased anxiety and hypervigilance. *Table 12* summarises the outcomes of all subscales and the total scale of the Fear of Recurrence Scale (FoRSe) at all time points, including baseline. At 12 months, FoRSe data were

TABLE 11 Primary outcome analysis

Outcome <sup>a</sup>	Summary	EMPOWER	TAU	Risk rate estimate (95% CI)
Relapse over 12 months <sup>b</sup>	$n/N$ (%)	8/33 (24)	13/28 (46)	ARD -0.24 (-0.43 to -0.04) RR 0.50 (0.26 to 0.98)
Time to first relapse (months) <sup>c</sup>	$n$ : mean (SD)	8: 5.20 (2.99)	13: 3.63 (3.88)	HR 0.32 (0.14 to 0.74)
	Median (IQR)	4.8 (2.7, 7.6)	1.4 (0.7, 7.1)	
	Minimum, maximum	2, 10	0, 10	

ARD, adjusted risk difference; HR, hazard ratio; IQR, interquartile range.

a Model adjusted for country fixed effects and centre clustering random effects.

b Random-effects multilevel modified Poisson regression model using log-link and robust variance.<sup>168</sup>

c Cox survival model: censored at time of first event, at withdrawal or at study end (whichever is first).

CANDIDATE OUTCOMES OF THE MAIN TRIAL




FIGURE 8 Kaplan-Meier plot of time to first relapse.

TABLE 12 The FoRSe at all time points

Time point	EMPOWER		TAU		Effect <sup>a</sup> (95% CI)	Cohen's <i>d</i>
	N	n: mean (SD)	N	n: mean (SD)		
<b>Intrusiveness</b>						
Baseline	42	42: 16.93 (6.01)	31	30: 16.60 (6.87)		
3 months	38	32: 14.41 (5.84)	31	28: 16.82 (6.93)	-2.57 (-5.22 to 0.09)	-0.41
6 months	33	30: 15.60 (4.95)	30	25: 15.24 (7.61)	-0.10 (-2.82 to 2.62)	-0.02
12 months	32	30: 14.96 (6.02)	30	28: 15.82 (6.08)	-1.16 (-3.84 to 1.52)	-0.18
<b>Awareness</b>						
Baseline	42	42: 22.63 (6.33)	31	30: 19.73 (5.06)		
3 months	38	32: 20.66 (4.81)	31	28: 20.36 (5.66)	-1.17 (-3.44 to 1.09)	-0.20
6 months	33	30: 22.00 (5.44)	30	25: 19.58 (6.50)	0.83 (-1.52 to 3.18)	0.14
12 months	32	30: 19.31 (5.47)	30	28: 20.02 (6.47)	-2.17 (-4.47 to 0.12)	-0.36
<b>Fear of relapse</b>						
Baseline	42	42: 16.25 (5.39)	31	30: 16.12 (6.16)		
3 months	38	32: 13.63 (4.53)	31	28: 16.23 (6.12)	-2.89 (-5.88 to 0.09)	-0.51
6 months	33	30: 13.97 (4.55)	30	25: 15.88 (6.11)	-2.68 (-5.71 to 0.35)	-0.47
12 months	32	30: 13.24 (4.73)	30	28: 16.93 (5.99)	-4.29 (-7.29 to -1.28)	-0.76
<b>Total</b>						
Baseline	42	42: 55.81 (12.89)	31	30: 52.45 (15.69)		
3 months	38	32: 48.69 (11.05)	31	28: 53.40 (16.42)	-6.50 (-13.36 to 0.36)	-0.46
6 months	33	30: 51.57 (10.49)	30	25: 50.70 (18.78)	-1.86 (-8.87 to 5.14)	-0.13
12 months	32	30: 47.51 (12.90)	30	28: 52.77 (16.09)	-7.53 (-14.45 to -0.60)	-0.53

<sup>a</sup> Effect is estimated mean difference at each time point from multilevel mixed-effects generalised linear model, adjusted for FoRSe at baseline, country and centre.

available for 58 (79.5%) randomised participants. We did not observe any increase in the FoRSe subscale fear of relapse over time in the EMPOWER group. However, we did observe that fear of relapse appeared to be lower in the EMPOWER arm than in the TAU arm at 12 months (mean difference  $-4.29$ , 95% CI  $-7.29$  to  $-1.28$ ; Cohen's  $d = -0.76$ ). For intrusiveness the mean difference was  $-1.16$  (95% CI  $-3.84$  to  $1.52$ ; Cohen's  $d = -0.18$ ) and for awareness the mean difference was  $-2.17$  (95% CI  $-4.47$  to  $0.12$ ; Cohen's  $d = -0.36$ ); the FoRSe total mean difference was  $-7.53$  (95% CI  $-14.45$  to  $0.60$ ; Cohen's  $d = -0.53$ ).

We undertook an analysis of the eight relapses in the EMPOWER arm. Of these, seven occurred during exposure to the EMPOWER intervention, and six of these were associated with a CHIP. Among the seven relapses, help-seeking was initiated by a service user on four occasions and by a carer on one occasion. In the remaining two events, the relapse was identified by a care co-ordinator during a routine follow-up appointment.

In summary, fewer participants in the EMPOWER arm had a relapse and time to first relapse was longer, and at 12 months the EMPOWER participants were less fearful of having a relapse than participants receiving TAU. For a feasibility study, these are encouraging results.

## Candidate secondary outcomes

### Clinical outcomes

Mental health outcomes were assessed using the PANSS, the PSP scale and the CDSS at baseline and at 3, 6 and 12 months. Our approach to establishing and monitoring rater reliability is detailed in Appendix 7. Overall rater agreement was as follows: PANSS (84%), CDSS (96%) and PSP scale (86%). Table 13 shows that, at 12 months, PANSS data were available for 55 (75%), PSP scale for 55 (75%) and CDSS for 53 (73%) of randomised participants. Outcomes at 12 months on the PANSS scales were as follows: PANSS positive (mean difference  $0.67$ , 95% CI  $-1.56$  to  $2.91$ ; Cohen's  $d = 0.11$ ), PANSS negative (mean difference  $-2.82$ , 95% CI  $-4.75$  to  $-0.89$ ; Cohen's  $d = -0.57$ ), PANSS disorganisation (mean difference  $-0.48$ , 95% CI  $-2.01$  to  $1.06$ ; Cohen's  $d = -0.08$ ), PANSS excitement (mean difference  $-0.04$ , 95% CI  $-0.45$  to  $0.37$ ; Cohen's  $d = -0.03$ ), PANSS emotional distress (mean difference  $-0.65$ , 95% CI  $-2.26$  to  $0.95$ ; Cohen's  $d = -0.17$ ), and PANSS total (mean difference  $-3.75$ , 95% CI  $-8.31$  to  $0.81$ ; Cohen's  $d = -0.23$ ). The mean difference was  $-6.09$  for the PSP scale (95% CI  $-0.23$  to  $12.41$ ; Cohen's  $d = 0.35$ ) and  $-1.20$  for the CDSS (95% CI  $-2.83$  to  $0.44$ ; Cohen's  $d = -0.25$ ).

TABLE 13 Service user clinical outcomes at all time points

Time point	EMPOWER		TAU		Effect <sup>a</sup> (95% CI)	Cohen's <i>d</i>
	N	n: mean (SD)	N	n: mean (SD)		
<b>PANSS positive</b>						
Baseline	42	42: 14.83 (5.92)	31	30: 15.43 (6.68)		
3 months	38	35: 13.80 (5.76)	31	28: 14.46 (6.61)	0.33 (-1.80 to 2.46)	0.053
6 months	33	30: 13.47 (6.55)	30	25: 13.56 (7.03)	0.84 (-1.39 to 3.07)	0.136
12 months	32	30: 13.27 (6.41)	30	25: 13.32 (5.80)	0.67 (-1.56 to 2.91)	0.109

continued



TABLE 13 Service user clinical outcomes at all time points (continued)

Time point	EMPOWER		TAU		Effect <sup>a</sup> (95% CI)	Cohen's <i>d</i>
	N	n: mean (SD)	N	n: mean (SD)		
<b>PANSS negative</b>						
Baseline	42	42: 13.90 (5.45)	31	30: 12.47 (4.08)		
3 months	38	35: 10.51 (3.50)	31	28: 12.64 (5.03)	-2.82 (-4.68 to -0.95)	-0.57
6 months	33	30: 11.27 (4.21)	30	25: 12.40 (4.90)	-1.71 (-3.63 to 0.21)	-0.35
12 months	32	30: 10.57 (3.95)	30	25: 12.64 (5.07)	-2.82 (-4.75 to -0.89)	-0.57
<b>PANSS disorganisation</b>						
Baseline	42	42: 15.86 (7.17)	31	30: 14.63 (4.67)		
3 months	38	35: 14.20 (5.87)	31	28: 14.25 (3.96)	-0.38 (-1.85 to 1.09)	-0.06
6 months	33	30: 13.60 (6.62)	30	25: 13.56 (4.74)	0.24 (-1.29 to 1.77)	0.04
12 months	32	30: 13.20 (5.18)	30	25: 13.44 (4.23)	-0.48 (-2.01 to 1.06)	-0.08
<b>PANSS excitement</b>						
Baseline	42	42: 4.95 (1.65)	31	30: 4.33 (0.55)		
3 months	38	35: 4.26 (0.44)	31	28: 4.50 (1.07)	-0.36 (-0.75 to 0.02)	-0.27
6 months	33	30: 4.30 (0.84)	30	25: 4.64 (0.99)	-0.42 (-0.83 to -0.01)	-0.31
12 months	32	30: 4.37 (0.96)	30	25: 4.32 (0.63)	-0.04 (-0.45 to 0.37)	-0.03
<b>PANSS emotional distress</b>						
Baseline	42	42: 11.95 (4.40)	31	30: 12.07 (3.24)		
3 months	38	35: 10.60 (3.84)	31	28: 11.57 (3.62)	-0.68 (-2.21 to 0.85)	-0.17
6 months	33	30: 10.47 (3.69)	30	25: 10.20 (3.04)	0.14 (-1.46 to 1.75)	0.04
12 months	32	30: 10.17 (3.97)	30	25: 10.48 (3.79)	-0.65 (-2.26 to 0.95)	-0.17
<b>PANSS total</b>						
Baseline	42	42: 61.50 (18.14)	31	30: 58.93 (13.73)		
3 months	38	35: 53.37 (11.72)	31	28: 57.43 (13.43)	-4.45 (-8.78 to -0.12)	-0.27
6 months	33	30: 53.10 (15.78)	30	25: 54.36 (12.60)	-1.34 (-5.89 to 3.22)	-0.08
12 months	32	30: 51.57 (12.87)	30	25: 54.20 (11.13)	-3.75 (-8.31 to 0.81)	-0.23
<b>PSP scale score</b>						
Baseline	42	42: 56.86 (16.02)	31	30: 59.37 (19.29)		
3 months	38	33: 55.70 (14.82)	31	28: 55.32 (16.74)	1.89 (-4.16 to 7.94)	0.11
6 months	33	30: 60.97 (14.44)	30	25: 57.08 (18.13)	3.42 (-2.89 to 9.72)	0.20
12 months	32	30: 62.07 (15.15)	30	25: 58.48 (20.14)	6.09 (-0.23 to 12.41)	0.35
<b>CDSS total</b>						
Baseline	42	42: 6.93 (5.34)	31	30: 6.97 (4.15)		
3 months	38	33: 5.67 (4.30)	31	28: 5.93 (3.76)	0.01 (-1.55 to 1.57)	0.00
6 months	33	30: 4.70 (3.30)	30	25: 5.52 (4.02)	-0.87 (-2.49 to 0.75)	-0.18
12 months	32	28: 5.75 (4.53)	30	25: 6.60 (5.05)	-1.20 (-2.83 to 0.44)	-0.25

<sup>a</sup> Effect is estimated mean difference at each time point from multilevel mixed-effects generalised linear model, adjusted for measure at baseline, country and centre.

### Substance use outcomes

Substance use outcomes were assessed using the Timeline Followback measure at baseline and at 3-, 6- and 12-month follow-up (Table 14). At 12 months, data on substance use were available for 62 (85%) randomised participants. At 12 months, the RR indices were as follows: alcohol (RR 1.09, 95% CI 0.94 to 1.16), cannabis (RR 0.96, 95% CI 0.91 to 1.02) and other drugs (RR 0.97, 95% CI 0.93 to 1.02).

### Emotional distress outcomes

Emotional distress outcomes were assessed using the HADS and the PBIQ-R at baseline and at the 3-, 6- and 12-month follow-ups (Table 15). At 12 months, data were available for 58 (80%) randomised participants. At 12 months, the mean differences were -1.40 for HADS anxiety (95% CI -3.53 to -0.47; Cohen's  $d = -0.28$ ) and -2.00 for HADS depression (95% CI -3.05 to 0.26; Cohen's  $d = -0.41$ ). For PBIQ-R, mean difference was -1.07 for control (95% CI -2.12 to -0.02; Cohen's  $d = -0.42$ ), -0.60 for shame (95% CI -1.85 to 0.50; Cohen's  $d = -0.23$ ), -1.06 for entrapment (95% CI -2.28 to 0.16; Cohen's  $d = -0.34$ ), -0.45 for loss (95% CI -1.45 to 0.55; Cohen's  $d = -0.17$ ) and 0.00 for social marginalisation (95% CI -1.41 to 1.42; Cohen's  $d = -0.00$ ).

### Service engagement and adherence

Service engagement outcomes were measured using the Service Attachment Questionnaire. Medication adherence was measured using the Medication Adherence Rating Scale. Both measures were administered at baseline and at the 3-, 6- and 12-month follow-ups (Table 16). At 12 months, data were available for 58 (80%) randomised participants. The outcomes at 12 months were mean difference of 0.04 on the Service Attachment Questionnaire (95% CI -0.09 to 0.16; Cohen's  $d = 0.15$ ) and mean difference of -0.84 on the Medication Adherence Rating Scale (95% CI -1.66 to -0.01; Cohen's  $d = 0.50$ ).

TABLE 14 Service user substance use outcomes at all time points

Time point	EMPOWER, n/N (%)	TAU, n/N (%)	RR <sup>a</sup> (95% CI)
<b>Timeline Followback for drugs and alcohol: alcohol in last 28 days</b>			
Baseline	15/42 (36)	12/31 (39)	
3 months	15/38 (36)	13/31 (42)	0.98 (0.88 to 1.10)
6 months	13/33 (31)	12/30 (39)	1.04 (0.82 to 1.32)
12 months	12/32 (29)	15/30 (48)	1.09 (0.94 to 1.26)
<b>Timeline Followback for drugs and alcohol: cannabis in last 28 days</b>			
Baseline	7/42 (17)	5/31 (16)	
3 months	6/38 (14)	4/31 (13)	0.98 (0.92 to 1.04)
6 months	4/33 (10)	2/30 (6)	0.98 (0.90 to 1.06)
12 months	4/32 (10)	3/30 (10)	0.96 (0.91 to 1.02)
<b>Timeline Followback for drugs and alcohol: other main drug in last 28 days</b>			
Baseline	4/42 (10)	5/31 (16)	
3 months	3/38 (7)	3/31 (10)	0.98 (0.93 to 1.03)
6 months	1/33 (2)	2/30 (6)	1.00 (0.98 to 1.02)
12 months	2/32 (5)	2/30 (6)	0.97 (0.93 to 1.02)

a Multilevel mixed-effects generalised linear model as a modified Poisson regression with log-link and robust variance,<sup>168</sup> also accounting for time. Adjusted for country fixed effects, with centre clustering and individuals nested within centres as random effects.

TABLE 15 Service user emotional distress outcomes at all time points

Time point	EMPOWER		TAU		Effect <sup>a</sup> (95% CI)	Cohen's <i>d</i>
	N	n: mean (SD)	N	n: mean (SD)		
<b>HADS anxiety</b>						
Baseline	42	41: 9.76 (5.11)	31	30: 10.70 (4.88)		
3 months	38	32: 9.34 (5.42)	31	27: 11.19 (4.70)	-1.00 (-2.64 to 0.65)	-0.20
6 months	33	30: 9.30 (4.70)	30	25: 9.48 (4.70)	0.44 (-1.25 to 2.14)	0.09
12 months	32	30: 8.80 (4.75)	30	28: 10.64 (4.13)	-1.40 (-3.05 to 0.26)	-0.28
<b>HADS depression</b>						
Baseline	42	40: 7.38 (4.98)	31	29: 8.03 (4.66)		
3 months	38	32: 6.22 (4.59)	31	27: 8.85 (4.27)	-1.81 (-3.33 to -0.29)	-0.38
6 months	33	29: 7.07 (4.92)	30	25: 8.68 (3.58)	-1.07 (-2.64 to 0.49)	-0.22
12 months	32	30: 7.13 (4.75)	30	28: 9.54 (3.87)	-2.00 (-3.53 to -0.47)	-0.41
<b>PBIQ-R control</b>						
Baseline	42	41: 10.29 (2.52)	31	30: 9.83 (2.61)		
3 months	38	32: 9.66 (2.46)	31	28: 9.43 (2.77)	-0.08 (-1.11 to 0.96)	-0.03
6 months	33	30: 9.37 (2.24)	30	26: 9.62 (2.59)	-0.55 (-1.62 to 0.52)	-0.22
12 months	32	30: 9.08 (3.01)	30	28: 9.79 (1.93)	-1.07 (-2.12 to -0.02)	-0.42
<b>PBIQ-R shame</b>						
Baseline	42	41: 10.10 (2.96)	31	30: 10.67 (3.07)		
3 months	38	32: 9.97 (2.97)	31	28: 10.42 (3.11)	-0.14 (-1.30 to 1.03)	-0.05
6 months	33	30: 10.06 (2.76)	30	25: 10.32 (2.56)	0.02 (-1.18 to 1.22)	0.01
12 months	32	30: 9.57 (3.21)	30	28: 10.36 (2.33)	-0.68 (-1.85 to 0.50)	-0.26
<b>PBIQ-R entrapment</b>						
Baseline	42	41: 10.73 (2.88)	31	30: 10.80 (3.38)		
3 months	38	32: 10.00 (3.10)	31	28: 10.00 (3.37)	-0.07 (-1.28 to 1.13)	-0.024
6 months	33	30: 9.47 (2.73)	30	26: 10.46 (2.32)	-1.05 (-2.28 to 0.19)	-0.341
12 months	32	30: 9.70 (3.15)	30	28: 10.62 (2.48)	-1.06 (-2.28 to 0.16)	-0.344
<b>PBIQ-R loss</b>						
Baseline	42	41: 9.84 (2.82)	31	30: 10.20 (2.54)		
3 months	38	32: 9.46 (3.14)	31	28: 10.32 (2.99)	-0.64 (-1.62 to 0.35)	-0.24
6 months	33	30: 9.93 (2.74)	30	26: 10.67 (2.26)	-0.47 (-1.48 to 0.54)	-0.17
12 months	32	30: 9.91 (2.76)	30	28: 10.54 (2.56)	-0.45 (-1.45 to 0.55)	-0.17
<b>PBIQ-R socially marginalised</b>						
Baseline	42	41: 11.64 (2.89)	31	30: 11.87 (2.75)		
3 months	38	32: 11.13 (3.63)	31	28: 11.79 (3.61)	-0.50 (-1.90 to 0.90)	-0.18
6 months	33	30: 11.13 (2.75)	30	26: 11.46 (2.10)	-0.09 (-1.53 to 1.35)	-0.03
12 months	32	30: 11.33 (3.46)	30	28: 11.61 (2.25)	0.00 (-1.41 to 1.42)	0.00

<sup>a</sup> Effect is estimated mean difference at each time point from multilevel mixed-effects generalised linear model, adjusted for measure at baseline, country and centre.

TABLE 16 Service user service engagement and adherence at all time points

Time point	EMPOWER		TAU		Effect <sup>a</sup> (95% CI)	Cohen's <i>d</i>
	<i>N</i>	<i>n</i> : mean (SD)	<i>N</i>	<i>n</i> : mean (SD)		
<b>Service Attachment Questionnaire</b>						
Baseline	42	41: 2.36 (0.24)	31	30: 2.35 (0.25)		
3 months	38	32: 2.29 (0.30)	31	28: 2.30 (0.31)	-0.05 (-0.17 to 0.07)	-0.21
6 months	33	30: 2.29 (0.27)	30	26: 2.31 (0.30)	-0.11 (-0.23 to 0.02)	-0.44
12 months	32	30: 2.37 (0.28)	30	28: 2.27 (0.37)	0.04 (-0.09 to 0.16)	0.15
<b>Medication Adherence Rating Scale</b>						
Baseline	42	42: 3.83 (1.69)	31	30: 4.04 (1.64)		
3 months	38	32: 3.77 (1.52)	31	27: 4.44 (1.78)	-0.50 (-1.31 to 0.32)	-0.30
6 months	33	30: 4.23 (1.92)	30	26: 4.35 (1.69)	-0.08 (-0.92 to 0.75)	-0.05
12 months	32	30: 3.47 (1.56)	30	28: 4.43 (1.89)	-0.84 (-1.66 to -0.01)	-0.50

a Effect is estimated mean difference at each time point from multilevel mixed-effects generalised linear model, adjusted for measure at baseline, country and centre.

## Candidate mechanism outcomes

Table 17 summarises the outcomes for the Questionnaire for Personal Recovery, the General Self Efficacy Scale and the Psychosis Attachment Measure at baseline and at 3, 6 and 12 months. At 12 months, data were available for 62 (85%) randomised participants. The outcomes at 12 months were mean difference of 3.41 for the Questionnaire for Personal Recovery (95% CI -0.51 to 7.32; Cohen's *d* = 0.32), 1.91 for the General Self Efficacy Scale (95% CI -0.40 to 4.21, Cohen's *d* = 0.33), -0.13 for the Psychosis Attachment Measure Avoidance (95% CI -0.36 to 0.09; Cohen's *d* = -0.22) and -0.05 for the Psychosis Attachment Measure Anxiety (95% CI -0.31 to 0.20; Cohen's *d* = -0.07).

## Carer and care co-ordinator outcomes

### Carers

Descriptions of carer outcomes using the Involvement Evaluation Questionnaire at baseline and at 3, 6 and 12 months are presented in Table 18. At 12 months, data were available for eight (47%) consented carers. Only descriptive data are provided for information and transparency purposes.

### Care co-ordinators

Data for care co-ordinators' assessment of service user engagement with services using the Service Engagement Scale at baseline and at 3, 6 and 12 months are summarised in Table 19. At 12 months, data were available for 31 (42%) randomised service user participants. Lower scores on this scale are indicative of better service engagement. The outcomes at 12 months were mean difference of -0.16 for availability (95% CI -1.20 to 0.88; Cohen's *d* = 0.59), 0.54 for collaboration (95% CI -0.77 to 1.85; Cohen's *d* = 0.26), 1.03 for help-seeking (95% CI -0.49 to 2.55; Cohen's *d* = 0.33), 1.15 for treatment adherence (95% CI -0.21 to 2.09; Cohen's *d* = 0.58) and 2.50 for treatment total (95% CI -0.79 to 5.79; Cohen's *d* = 0.37).

TABLE 17 Candidate mechanism outcomes at all time points

Time point	EMPOWER		TAU		Effect <sup>a</sup> (95% CI)	Cohen's <i>d</i>
	<i>N</i>	<i>n</i> : mean (SD)	<i>N</i>	<i>n</i> : mean (SD)		
<b>Questionnaire for Personal Recovery score</b>						
Baseline	42	41: 37.66 (11.09)	31	30: 36.67 (10.31)		
3 months	38	32: 39.81 (10.10)	31	28: 37.39 (10.66)	2.45 (-1.42 to 6.32)	0.23
6 months	33	30: 40.12 (11.12)	30	26: 37.35 (7.62)	2.29 (-1.69 to 6.26)	0.21
12 months	32	30: 38.35 (12.01)	30	28: 35.34 (9.70)	3.41 (-0.51 to 7.32)	0.33
<b>General Self Efficacy Scale</b>						
Baseline	42	42: 27.12 (6.20)	31	30: 26.10 (5.44)		
3 months	38	32: 27.09 (7.28)	31	28: 26.68 (5.33)	-0.20 (-2.48 to 2.09)	-0.03
6 months	33	30: 28.23 (7.30)	30	25: 26.45 (5.17)	1.08 (-1.28 to 3.43)	0.18
12 months	32	30: 27.40 (6.77)	30	28: 25.05 (5.75)	1.91 (-0.40 to 4.21)	0.33
<b>Psychosis Attachment Measure avoidance</b>						
Baseline	42	41: 1.52 (0.59)	31	30: 1.44 (0.60)		
3 months	38	32: 1.40 (0.73)	31	28: 1.60 (0.56)	-0.31 (-0.53 to -0.09)	-0.52
6 months	33	30: 1.37 (0.62)	30	26: 1.46 (0.56)	-0.18 (-0.41 to 0.05)	-0.31
12 months	32	30: 1.48 (0.67)	30	28: 1.50 (0.50)	-0.13 (-0.36 to 0.09)	-0.22
<b>Psychosis Attachment Measure anxiety</b>						
Baseline	42	41: 1.26 (0.74)	31	30: 1.27 (0.73)		
3 months	38	32: 1.28 (0.81)	31	28: 1.32 (0.73)	0.01 (-0.25 to 0.26)	0.01
6 months	33	30: 1.09 (0.68)	30	26: 1.18 (0.75)	-0.08 (-0.34 to 0.18)	-0.11
12 months	32	30: 1.24 (0.87)	30	28: 1.26 (0.83)	-0.05 (-0.31 to 0.20)	-0.07

a Effect is estimated mean difference at each time point, from multilevel mixed-effects generalised linear model, adjusted for measure at baseline, country and centre.

TABLE 18 Carer outcomes at all time points

Time point	EMPOWER		TAU	
	<i>N</i>	<i>n</i> : mean (SD)	<i>N</i>	<i>n</i> : mean (SD)
<b>Involvement Evaluation Questionnaire tension</b>				
Baseline	7	7: 7.32 (4.30)	10	10: 5.24 (3.62)
3 months	6	5: 8.95 (5.72)	10	6: 4.83 (3.60)
6 months	6	5: 5.00 (1.87)	10	6: 6.00 (4.15)
12 months	6	4: 7.69 (2.22)	10	4: 5.00 (2.16)
<b>Involvement Evaluation Questionnaire supervision</b>				
Baseline	7	7: 4.07 (2.86)	10	10: 4.60 (4.55)
3 months	6	5: 7.80 (6.30)	10	6: 4.33 (5.09)
6 months	6	5: 3.80 (3.27)	10	6: 6.50 (7.23)
12 months	6	4: 5.75 (3.86)	10	4: 4.25 (2.50)

TABLE 18 Carer outcomes at all time points (continued)

Time point	EMPOWER		TAU	
	N	n: mean (SD)	N	n: mean (SD)
<b>Involvement Evaluation Questionnaire worrying</b>				
Baseline	7	7: 11.29 (7.06)	10	10: 7.30 (3.43)
3 months	6	5: 12.60 (6.27)	10	6: 6.83 (3.37)
6 months	6	5: 8.60 (5.50)	10	6: 7.00 (2.45)
12 months	6	4: 10.95 (7.20)	10	4: 6.25 (2.06)
<b>Involvement Evaluation Questionnaire urging</b>				
Baseline	7	7: 13.43 (9.40)	10	10: 10.30 (3.30)
3 months	6	5: 14.20 (6.10)	10	6: 9.17 (3.87)
6 months	6	5: 10.80 (6.22)	10	6: 10.00 (5.18)
12 months	6	3: 8.67 (1.41)	10	4: 8.75 (2.22)
<b>Involvement Evaluation Questionnaire total</b>				
Baseline	7	7: 34.88 (19.35)	10	10: 26.39 (9.53)
3 months	6	5: 41.98 (22.10)	10	6: 24.08 (12.18)
6 months	6	5: 27.50 (13.66)	10	6: 28.33 (15.76)
12 months	6	4: 32.67 (12.05)	10	4: 23.13 (6.47)

TABLE 19 Care co-ordinator outcomes at all time points

Time point	EMPOWER		TAU		Effect <sup>a</sup> (95% CI)	Cohen's <i>d</i>
	N	n: mean (SD)	N	n: mean (SD)		
<b>Service Engagement Scale availability<sup>b</sup></b>						
Baseline	42	39: 0.74 (1.37)	31	25: 1.52 (2.14)		
3 months	38	30: 0.83 (1.72)	31	23: 0.87 (1.46)	0.41 (-0.45 to 1.28)	0.24
6 months	33	23: 0.83 (1.87)	30	13: 0.46 (0.66)	0.28 (-0.71 to 1.27)	0.16
12 months	32	19: 0.74 (1.66)	30	12: 1.00 (1.28)	-0.16 (-1.20 to 0.88)	0.09
<b>Service Engagement Scale collaboration<sup>b</sup></b>						
Baseline	42	39: 2.62 (2.07)	31	25: 2.72 (2.15)		
3 months	38	30: 1.77 (1.87)	31	23: 2.26 (2.07)	-0.58 (-1.63 to 0.48)	0.28
6 months	33	23: 1.65 (1.67)	30	13: 2.00 (1.91)	-0.64 (-1.88 to 0.61)	-0.31
12 months	32	19: 3.00 (1.83)	30	12: 2.67 (2.71)	0.54 (-0.77 to 1.85)	0.26
<b>Service Engagement Scale help-seeking<sup>b</sup></b>						
Baseline	42	39: 3.68 (3.11)	31	25: 3.89 (3.22)		
3 months	38	29: 3.45 (3.16)	31	23: 2.70 (2.57)	0.61 (-0.58 to 1.79)	0.19
6 months	33	23: 2.57 (2.11)	30	13: 2.26 (2.97)	0.19 (-1.23 to 1.62)	0.06
12 months	32	19: 2.95 (2.86)	30	12: 2.42 (3.00)	1.03 (-0.49 to 2.55)	0.33

continued

TABLE 19 Care co-ordinator outcomes at all time points (continued)

Time point	EMPOWER		TAU		Effect <sup>a</sup> (95% CI)	Cohen's <i>d</i>
	N	n: mean (SD)	N	n: mean (SD)		
<b>Service Engagement Scale treatment adherence<sup>b</sup></b>						
Baseline	42	39: 1.44 (1.74)	31	25: 1.52 (2.35)		
3 months	38	29: 0.90 (1.59)	31	23: 1.00 (1.83)	-0.16 (-0.96 to 0.65)	-0.08
6 months	33	23: 0.83 (1.34)	30	13: 0.69 (0.75)	0.09 (-0.81 to 1.00)	0.05
12 months	32	19: 1.42 (1.80)	30	12: 0.67 (1.23)	1.15 (0.21 to 2.09)	0.58
<b>Service Engagement Scale treatment total<sup>b</sup></b>						
Baseline	42	39: 8.47 (6.13)	31	25: 9.65 (7.76)		
3 months	38	29: 7.03 (6.28)	31	23: 6.83 (6.09)	0.56 (-2.08 to 3.20)	0.08
6 months	33	23: 5.87 (5.04)	30	13: 5.41 (4.69)	-0.17 (-3.28 to 2.95)	-0.03
12 months	32	19: 8.11 (5.94)	30	12: 6.75 (6.28)	2.50 (-0.79 to 5.79)	0.37
a Effect is estimated mean difference at each time point from multilevel mixed-effects generalised linear model, adjusted for measure at baseline, country and centre.						
b Lower score is indicative of better service engagement.						

## Sensitivity analyses

### Small numbers of clusters

Despite the use of random-effects models, the estimates from these models may not be robust because of the small number of clusters. To investigate the impact of this, the models presented above for continuous (or pseudo-continuous) outcomes were compared with those using the Kenward–Roger correction<sup>216</sup> in Stata<sup>®</sup> version 15 (Stata Corp LP, College Station, TX, USA). The point estimates were similar to the original analyses, as were the Cohen's *d* estimates. These were the measures used to assess the outcomes. Therefore, the interpretation of the original models remains unchanged, although this should be done with caution given that the models are based on a feasibility study.

### Impact of possible informative withdrawal

The possibility of informative withdrawal was also investigated, with several scenarios considered. There are too few data points to conduct the usual type of pattern mixture with multiple imputed data sets using the full model. To get an initial feel of the impact, a simple pattern mixture investigation using a basic logistic model was used. This indicated that the point estimates were stable if around 50% of those who withdrew were set to 'relapse'. Next, we examined several different scenarios using the more complex full model. This included (1) the best outcome – all who withdrew (without primary outcome data) were set as 'no relapse'; (2) the worst outcome – all who withdrew were set as 'relapse'; and (3) all points in between.

A conservative rate of 'relapse' for these withdrawals would be the rate observed in the TAU arm (46%) implying that no more than three might have been expected to 'relapse' had they remained in the study. However, a RR of 0.70 is a clinically significant effect for relapse reduction. Using the pattern mixture scenarios and the full models indicated that while standard errors increased there had to be 6 or more of these withdrawals set to 'relapse' for the RR to increase beyond 0.70. The original intention-to-treat (ITT) estimate was 0.50. Using the scenarios if 5 withdrawals were set to 'relapse' this still only increased the estimate to 0.69.

# Chapter 6 Health economic analysis

## Introduction

The aim of the health economic analysis was to test the feasibility, acceptability and usability of collecting economic measures in the EMPOWER trial for service users and carers, and to inform the design of an economic evaluation alongside a full trial of the EMPOWER intervention. The objectives of the health economic analysis included the development and testing of an economic resource use questionnaire (one each for service users and carers), collecting quality-of-life data using the EQ-5D-5L<sup>217</sup> and AQoL-8D<sup>157</sup> for service users and the EQ-5D-5L<sup>217</sup> and CarerQoL-7D<sup>218</sup> for carers. We planned to report missingness for all measures, test the data for usability in carrying out an economic evaluation, make recommendations for economic data collection in a full trial, identify key cost drivers and establish the cost of the EMPOWER intervention.

## Methods

### Overview

The report of this health economic evaluation followed the Consolidated Health Economics Evaluation Reporting Standards (CHEERS) guidance.<sup>219</sup> The economic evaluation was conducted using individual participant cost and effect data collected alongside the EMPOWER trial. The time horizon of the analysis was 12 months with four assessment points: baseline and 3-, 6- and 12-month follow-up.

### Study perspective

Different perspectives were adopted for the economic analysis, reflecting the national health technology assessment guidelines in Australia and the UK.<sup>220,221</sup> The base-case scenario adopted three perspectives. First, a health-care payer perspective was adopted; this perspective was limited to costs borne directly by the UK NHS or Australian government (e.g. primary, secondary and community services) and outcomes related to service users (EQ-5D-5L<sup>217</sup> and AQoL-8D<sup>157</sup>). Second, a health-care sector perspective was adopted; this perspective extended the health-care payer perspective to include medical costs paid for by patient out-of-pocket expenses and third-party payers. These additional costs are of particular relevance to the Australia health-care system. The final perspective adopted was societal; this includes all of the costs considered in the health-care sector perspective plus additional relevant costs outside the health-care sector. These additional costs include service user time for using the app, informal care, productivity loss, costs of online self-help services and contacts with the legal, criminal and justice departments. The societal perspective also includes additional outcomes; in the case of EMPOWER, this included outcomes for carers (EQ-5D-5L<sup>217</sup> and CarerQoL-7D<sup>218</sup>).

### Identification, measurement and valuation of resource use

Guided by the different perspectives adopted in this study, different cost components were identified: costs related to the intervention, health service use costs, costs outside the health-care sector and costs directly incurred by service users and their carers. All costs were collected based on the 2017 reference year and were expressed as Great British pounds. Australian unit costs were converted to pounds using the CCEMG-EPPI-Centre Cost Converter.<sup>222</sup> As the costs were collected over a 1-year period, discounting was not applied.

### Intervention cost

A micro-costing approach was undertaken that allowed for a precise assessment of the economic costs of the EMPOWER app. Costing consisted of two parts: collecting detailed data on resources utilised (i.e. measuring quantities of resource use) and assigning unit costs or prices. Unlike the gross-costing



approach that uses aggregate-level estimates, micro-costing is particularly useful for estimating the costs of new interventions when there is no established estimate of their aggregate costs. In the calculations of the costs of the EMPOWER app, detailed cost information was provided by the principal investigators.

The cost of the intervention included initial R&D costs, ongoing maintenance costs and costs of delivering the intervention. Costs can be categorised into direct costs, such as costs incurred in implementing and running the intervention (e.g. labour, consumable, capital), and indirect costs, which refer to productivity loss in paid and unpaid economic activity as a result of premature death or disability. Direct costs can be incurred in the health sector or outside the health-care sectors. A further distinction can be made between fixed costs, which do not change with an increase in additional users of the intervention, and variable costs, which do vary with the quantity of users. It is important to separate fixed costs from variable costs, as variable costs are the important drivers of scaling up the intervention. The intervention costs are summarised in *Appendix 8, Table 40*, and further discussed in the following paragraphs.

Research and development costs comprised the costs associated with the development of the EMPOWER content, the actual app development and the registration of the app as a medical device. Although R&D costs are generally considered as a 'sunk cost' in economics, which would not need to be repeated if the intervention were adopted on a broader scale,<sup>223</sup> these still constitute important opportunity costs, as the resources could have been spent on other health interventions and services. These costs, generally, are an important component of the overall costs<sup>224</sup> and previous economic evaluations have included development costs in their analyses.<sup>225</sup> However, allocating these costs to study service users in the intervention arm is inappropriate and does not accurately reflect the true cost per service user once the intervention has been disseminated to a wider audience. Therefore, the R&D costs were attributed to all potential users of EMPOWER. Thereby, we estimated the number of people likely to receive the intervention when it is implemented in the Australian and UK contexts using assumptions based on the published literature.

The intervention pathway starts with adults aged  $\geq 16$  years living in Australia ( $n = 20,290,033$ )<sup>226</sup> and the UK ( $n = 53,257,957$ ).<sup>227</sup> Published evidence has found a 0.4% prevalence among the population for schizophrenia-related disorder,<sup>228</sup> which was estimated to be 294,192 for the combined population across Australia and the UK. The rate of relapse was based on a previous review of relapse rates among people with a diagnosis of schizophrenia in receipt of maintenance antipsychotic medication, which was estimated to be 27%.<sup>229</sup> This reduces the number of potential users to 79,432 individuals. For this cohort, a conservative assumption was made that approximately half of those would be interested in using EMPOWER. This leads to an average R&D cost per person of £3.27.

Ongoing maintenance costs included app hosting and labour costs for app maintenance. Both cost categories can be considered fixed costs that do not change if additional service users are enrolled in the intervention. Similar to R&D costs, these costs need to be allocated to all potential users of EMPOWER. The average ongoing maintenance costs per person was estimated to be £0.37.

The costs of the intervention delivery were the most relevant component that can be broken down into capital costs, consumables and labour costs.

Capital costs are costs associated with the purchase of the major capital assets required that represent investments at a single point in time. This comprises the costs of smartphone devices for using the EMPOWER app. An Android operating system is required to use the EMPOWER app. Some study service users owned their own smartphone and only for some service users was the purchase of a new smartphone required. In costing the intervention, these costs that occurred for some service users were distributed to all service users in the intervention arm, with an average price of £109.52 per service user. Data connection, which represents consumable costs, was costed at £69.30 per service user for the 12-month study period.

Labour costs were associated with:

- the training of care co-ordinators
  - the training of research assistants (Australia) and research nurses (UK) for monitoring EWS
  - peer support workers' engagement with service users
  - the time spent using the app intervention by service users
  - the routine monitoring of EWS
  - the ongoing supervision of CMHS staff.
1. Despite some variations between countries, the training of care co-ordinators generally consisted of a half-day workshop (lasting around 3 hours) provided by a consultant clinical psychologist. Each workshop consisted, usually, of six care co-ordinators, a peer support worker and a research assistant (in Australia) or a research mental health nurse (in the UK) who was responsible for monitoring EWS. The training cost of EMPOWER was determined based on 28 care co-ordinators recruited for the EMPOWER study.
  2. Monitoring training consisted of approximately 4 hours of training provided by a consultant clinical psychologist to a research mental health nurse in Glasgow and a research assistant in Melbourne.
  3. The role of the peer support worker in EMPOWER involved introducing the rationale for using the app to the service user, setting up the app on the phone and supporting the individual's familiarisation with the handset and app functions. During the initial 4-week period, the peer support worker provided additional support through weekly telephone follow-up. After this period, the peer support worker provided ongoing fortnightly support by encouraging the service user to use the app and by checking on the service user's well-being.
  4. The time spent using the EMPOWER app is an important opportunity cost from the service user perspective and needs to be considered as part of the societal perspective.<sup>223</sup> As it was not possible to track the actual time service users spent on the app, the minimum amount of 2 minutes per day was estimated that was necessary to answer a daily questionnaire about potential EWS of psychosis. The time cost was estimated based on the opportunity cost method, using 25% of the average national income that reflected the value of the leisure activity forgone.
  5. The routine monitoring of potential EWS of psychosis was undertaken by a research mental health nurse in Glasgow and a research assistant in Melbourne.
  6. The final component was the ongoing supervision of CMHS staff. The supervision was provided by a consultant clinical psychologist from the study team. The peer support worker and the research co-ordinator also attended those sessions. During the 12-month study period, there were nine 1-hour supervision sessions, with an average of three CMHS staff attending each session. Importantly, these supervision sessions were conducted in Australia only, as in the UK the research nurse liaised with CMHS staff.

Depending on the different perspective adopted, the final intervention costs were £2202 from a health-care payer perspective, £2380 from a health-care sector perspective and £2447 from a societal perspective. These intervention costs were assigned to everyone in the intervention arm according to the perspective under consideration.

### Health service use costs

We worked with different health service systems in the UK and Australia to produce resource use questionnaires applicable to both contexts for service users and carers (available on request from the corresponding author). We used the feasibility study to refine the capture and measurement of economic data.

Payers and services in the two countries are different and some services have different names. Health services included publicly funded services and voluntary sector services in both countries, as well as private services in Australia (specialised mental health clinical services). Data on service user and carer resource use were collected at baseline and at 3, 6 and 12 months for the period prior to the last data collection (except the baseline questionnaire, which collected information for the previous 3 months).

Health service use costs in the service user resource use questionnaire included primary health-care services (e.g. GP and mental health nurse), hospital services, non-hospital mental health care (e.g. respite and residential care), diagnostic tests, mental health-related medication and non-mental health-related medication. A carer-specific resource use questionnaire was also developed, which covered health professional visits, hospital services, diagnostic tests, medication and informal care (available on request from the corresponding author).

There is little guidance on how to value resource use in multicountry trials.<sup>230,231</sup> Given the size of this feasibility study, no attempt was made to quantitatively adjust for differences in each country's resource use. Country-specific results are presented by pooling all resource use and applying jurisdiction-specific unit cost estimates. Therefore, this study employed a multicountry costing approach, whereby unit cost estimates were applied from individual countries.<sup>232</sup>

The UK context unit costs were taken from *NHS Reference Costs*<sup>233</sup> and Personal Social Services Research Unit<sup>234</sup> for health-care costs, from the *British National Formulary*<sup>235</sup> for medication costs and from the literature for other costs. A detailed listing of UK unit costs is provided in *Appendix 9, Table 41*. For Australia, the unit costs (see *Table 42*) for different resources used were obtained from the Medicare Benefits Schedule (MBS) book,<sup>236</sup> the Pharmaceutical Benefits Scheme,<sup>237</sup> the National Hospital Cost Data Collection Cost Report (Round 21),<sup>238</sup> the Australian Institute of Health and Welfare Health Expenditure Report,<sup>239</sup> and the Victoria Mental Health Services Annual Report 2016/17.<sup>240</sup>

### **Costs directly incurred by service users and their carers**

Costs directly incurred by service users consisted of out-of-pocket costs for health-care services as well as out-of-pocket costs for (online) self-help services that included formal online therapy, smartphone self-help apps, other self-help materials such as books or DVDs, gym memberships and other services used for mental health. Costs directly incurred by carers included out-of-pocket costs for health-care services. Costs directly incurred by service users and their carers were considered only when adopting a health-care sector or societal perspective (i.e. not when adopting a health-care payer perspective).

### **Costs outside the health-care sector**

Costs outside the health-care sector included criminal justice, productivity (absenteeism and presenteeism) and informal care, and were considered only when adopting a societal perspective. In terms of criminal justice, this included the number of contacts with the police, the number of nights spent in a police cell or prison, psychiatric assessment while in custody and the number of court appearances. Costs of contact with police and criminal court were sourced from the *Bedfordshire/Cambridgeshire/Hertfordshire Fees & Charges Handbook* (in the UK)<sup>241</sup> and the Australian Government Productivity Commission (in Australia),<sup>242</sup> and *Costs of the Criminal Justice System in Scotland Dataset 2018* (in the UK)<sup>243</sup> and the Australian Bureau of Statistics (in Australia).<sup>244</sup> Productivity costs included both absenteeism and presenteeism. Absenteeism for paid work was valued at the national average hourly rate in Australia and the UK, plus 25% on-costs. Presenteeism was measured using a modified version of the Work Productivity and Activity Impairment Questionnaire.<sup>245</sup> The costs of productivity loss as a result of presenteeism were calculated by multiplying the national average hourly rate (+25% on-costs) by the formula  $[(1 - X/10) \times \text{lost hours}]$ , where X denotes the score on the Likert scale included in the Work Productivity and Activity Impairment Questionnaire. The Likert scale ranges from 0 to 10, with higher scores indicating better work capacity. Informal care was measured from the perspective of service users who reported the number of hours of extra help they received from friends or relatives (unpaid help) with different tasks (hours spent on childcare, household activities, help outside the home, personal care and other help). Informal care hours were valued using the opportunity cost method, by multiplying the hours of informal care by the national minimum wage in Australia and the UK. While the resource use questionnaire completed by carers also contained questions related to informal care, the informal care cost for the base-case analysis was based on service users' self-report of informal care. Finally, service users were asked to report the number

of hours of work their friends or relatives took off because of their mental or physical health. Carers' productivity loss was valued at the national average hourly rate, plus 25% on-costs.

### **Identification, measurement and valuation of outcome measures**

For service users, we tested two health-related quality-of-life measures, both of which can be used to estimate QALYs: the EQ-5D-5L<sup>217</sup> and the AQoL-8D.<sup>157</sup>

The EQ-5D-5L is used frequently in the UK and Australian contexts. It is a generic questionnaire with five questions covering mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of these questions has a possible five levels of response. However, a previous review has indicated mixed findings in terms of the measure's responsiveness to change and convergent validity.<sup>169</sup> Therefore, the EQ-5D-5L was complemented with the newer AQoL-8D, which was designed to be sensitive to the aspects of quality of life important to people with mental health problems. The AQoL-8D contains 35 items, each of which has between four and six possible responses. It has eight dimensions, which are further summarised as super-dimension physical and super-dimension psychosocial.

The outcome measures were valued using preference-based value sets. Although a value set has been published for the EQ-5D-5L for England,<sup>156</sup> currently the National Institute for Health and Care Excellence (NICE) does not recommend the use of this measure.<sup>246</sup> Therefore, the EQ-5D-5L utility scores were mapped on to the EQ-5D-3L using the EQ5Dmap command in Stata.<sup>247</sup> As there is currently no Australian value set available for the EQ-5D-5L, the UK value set was used and then also mapped on to the EQ-5D-3L, reflecting the preferences of members of the public in the UK. Finally, the AQoL-8D responses were converted to utilities using the scoring algorithm developed by Richardson *et al.*<sup>157</sup>

With regard to carer outcomes, two outcome measures were included in the carer survey to capture the impact of EMPOWER on carers' health-related quality of life, using the EQ-5D-5L, and informal care, using the CarerQoL-7D.<sup>218</sup> Carers' EQ-5D-5L responses were also mapped on to the EQ-5D-3L, whereas the UK utility weights were used for the CarerQoL-7D.<sup>248</sup>

All outcome measures were administered at baseline and at 3, 6 and 12 months by trained research assistants.

### **Missing data**

The extent of missing data was examined and assessed to establish the completion rates of the RUQ and outcome measures. Missing data are a well-known issue in cost-effectiveness analyses alongside clinical trials. Instead of conducting a complete-case analysis that is likely to result in bias in economic evaluation, multiple imputation by chained equations was applied to impute missing values for cost and effects. The analysis was performed in Stata using the 'ice' package and Stata codes developed by Faria *et al.*<sup>249</sup> In total, 34 data sets were imputed that reflected the percentage of cumulative missing values. The costs and outcome analysis models were then run across the 34 imputed data sets and combined using Rubin's rules<sup>250</sup> to produce a single set of results.

### **Analysis**

The analysis carried out was according to the ITT principle, which implies that service users will be analysed in accordance with their allocated treatment arm, irrespective of the treatment they received. The differences in resource use between the groups is presented without costs attached to exclude any issues with valuing resource use. The results are unadjusted and include available cases to make use of all data. 'Available cases' include all complete data collected during the trial, irrespective of whether, for a particular participant, this included all follow-up points. All outcome measures were assessed for their suitability for collection during the definitive trial. The utility scores derived from the outcome measures are presented for available cases for each arm without adjustment to make use of all data.

Resource use and unit costs were then combined to give a total cost for each participant. The primary type of analysis was a cost-utility analysis, using QALYs as a measure of outcome derived from the EQ-5D-5L measure. For both arms, the mean values of costs and outcomes are reported, as well as the mean differences between the groups. Generalised linear models were used to assess the mean difference in costs and outcomes between the arms, adjusted for baseline characteristics (i.e. baseline utility, baseline costs, country, age and gender). For mean differences in total costs, a gamma distribution and an identity link were applied, whereas for the incremental effect in QALYs, a Gaussian distribution and identity link were used. The Glass's Delta effect size was calculated (i.e. the difference between the mean scores of the EMPOWER and TAU arms divided by the standard deviation of the TAU arm) for all costs and outcomes, with the recommended minimum effect size defined as  $\Delta = 0.41$ , moderate  $\Delta = 1.15$ , and strong  $\Delta = 2.70$ .<sup>251</sup>

Once the difference in cost and QALYs had been estimated, a joint assessment of the two was reported using an incremental approach, with differences in mean costs and mean outcome scores expressed using a ratio of incremental cost per QALY [i.e. an incremental cost-effectiveness ratio (ICER)]:

$$\text{ICER} = (\text{cost A} - \text{cost B}) / (\text{effect A} - \text{effect B}) = \Delta C / \Delta E. \quad (1)$$

The non-parametric 'bootstrapping' technique was then used with 1000 iterations of incremental cost and incremental effect so that sampling uncertainty could be graphically plotted on a cost-effectiveness plane. Cost-effectiveness planes are graphical displays of cost-effectiveness results plotted on a two-by-two-dimension graph where the horizontal axis represents the differences in outcomes (in this case QALYs) and the vertical axis represent the differences in costs. Results in the north-east quadrant show that the intervention costs more but also has greater benefits than the comparator, whereas results in the south-east quadrant show that the intervention costs less but has greater benefits than the comparator (this is referred to as the intervention being 'dominant'). Results in the south-west quadrant show that the intervention costs less but also has fewer health benefits than the comparator and results in the north-west quadrant show that the intervention costs more but also has fewer health benefits than the comparator (this is referred to as the intervention being 'dominated'). The proportions of ICERs falling in each quadrant of the cost-effectiveness plane were calculated, as were the proportions falling underneath the threshold of £20,000 per QALY (for results falling in the top right-hand quadrant and the bottom right-hand quadrant).

An additional cost-effectiveness analysis was carried out that combined the costs with within-trial relapse data (primary outcome) to present a cost per relapse case avoided.

Owing to the small number of carers recruited, carer costs and effects are presented descriptively and not as a formal incremental analysis or combined with service user costs and effects.

### **Sensitivity analysis**

To explore the robustness of the results, sensitivity analyses were carried out. First, owing to the use of multiple imputation, we conducted a complete-case analysis. Secondly, the AQoL-8D questionnaire results were used as the outcome, rather than the results from the EQ-5D-5L.

## **Results**

### **Missing data**

The number (and percentages) of completed economic measures are presented in *Table 20* for both randomised service users and carers. For the resource use questionnaire at baseline, 97% ( $n = 71$ ) of service users and 100% ( $n = 17$ ) of carers had completed measures. At 3 months post randomisation, this fell to 81% ( $n = 59$ ) and 65% ( $n = 11$ ). At 6 months, the percentage of completed measures for service users reduced to 77% ( $n = 56$ ), but for carers it remained at 65% ( $n = 11$ ). At the final follow-up at 12 months, 75% ( $n = 55$ ) of service users and 47% ( $n = 8$ ) of carers completed measures.

TABLE 20 Economic measures completion at all time points

Economic measure	Time point, n (%)				Complete case, n (%)
	Baseline	3 months	6 months	12 months	
Service users					
RUQ	71 (97.3)	59 (80.8)	56 (76.7)	55 (75.3)	46 (63.0)
EQ-5D-5L	70 (95.9)	56 (76.7)	56 (76.7)	54 (74.0)	45 (61.6)
AQoL-8D	69 (94.5)	57 (78.1)	56 (76.7)	55 (75.3)	45 (61.6)
Carers					
RUQ	17 (100.0)	11 (64.7)	11 (64.7)	8 (47.1)	7 (41.2)
EQ-5D-5L	16 (94.1)	11 (64.7)	11 (64.7)	8 (47.1)	7 (41.2)
CarerQoL-7D	17 (100.0)	11 (64.7)	11 (64.7)	8 (47.1)	7 (41.2)

## Outcome measures

### Service users

Outcome measure results for service user available cases are presented in *Tables 21* and *22*. In the EMPOWER arm, EQ-5D-5L-derived utilities increased at each follow-up point; the utility score was 0.644 at baseline (SD 0.258) and 0.732 at the 12-month follow-up (SD 0.231). In the TAU arm, EQ-5D-5L utilities decreased slightly over the follow-up period; at baseline they were 0.620 (0.268), at 3-month follow-up they decreased to 0.593 (0.285), but at 6-month follow-up they increased to 0.657 (0.209) and they finally decreased to 0.607 (0.254) at 12-month follow-up. These trends are illustrated in *Figure 9*.

Total AQoL-8D utilities show a similar trend to EQ-5D-5L utilities; in the EMPOWER arm AQoL-8D utilities increased at each follow-up point from 0.522 (SD 0.228) at baseline to 0.609 (SD 0.210) at 12-month follow-up. In the treatment-as-usual arm, the utilities decreased at each follow-up point, from 0.500 (0.190) at baseline to 0.485 (SD 0.200) at the 12-month follow-up point. These trends are illustrated in *Figure 10*.

The AQoL-8D psychosocial dimension scores increased over the follow-up period, from 0.234 at baseline (SD 0.162) to 0.299 at the 12-month follow-up (SD 0.176), but decreased between the 3- and 6-month follow-up points. In the TAU arm, the psychosocial dimension decreased at each follow-up point, from 0.221 (0.160) at baseline to 0.201 (SD 0.132) at the 12-month follow-up. In terms of the physical dimension, scores in the EMPOWER arm increased during the follow-up period, from 0.595 at baseline (SD 0.250) to 0.649 (SD 0.266) at the 12-month follow-up, with a decrease between baseline and 3-month follow-up points. In the treatment-as-usual arm the physical dimension score also increased between baseline and 12 months follow-up; 0.553 (SD 0.190) to 0.569 (SD 0.226), with decreases between baseline and 3 months and 6 and 12 months, and an increase between 6- and 12-month follow-up. Again, overall AQoL-8D completion was higher in the TAU arm (93.5–83.9%,  $n = 29$ – $26$ ) than in the EMPOWER arm (95.2–66.7%,  $n = 40$ – $28$ ).

TABLE 21 The EQ-5D-5L service user results at all time points

Time point	EMPOWER		TAU	
	Mean (SD)	n (%)	Mean (SD)	n (%)
Baseline	0.644 (0.258)	40 (95.2)	0.620 (0.268)	30 (96.8)
3 months	0.666 (0.234)	30 (71.4)	0.593 (0.285)	26 (83.9)
6 months	0.694 (0.197)	30 (71.4)	0.657 (0.209)	26 (83.9)
12 months	0.732 (0.231)	28 (66.7)	0.607 (0.254)	26 (83.9)

TABLE 22 The AQoL-8D service user results at all time points

Time point	EMPOWER		TAU	
	Mean (SD)	n (%)	Mean (SD)	n (%)
<b>Psychosocial</b>				
Baseline	0.234 (0.162)	40 (95.2)	0.221 (0.160)	29 (93.5)
3 months	0.271 (0.207)	30 (71.4)	0.216 (0.149)	27 (87.1)
6 months	0.269 (0.179)	30 (71.4)	0.207 (0.156)	26 (83.9)
12 months	0.299 (0.176)	28 (66.7)	0.201 (0.132)	27 (87.1)
<b>Physical</b>				
Baseline	0.595 (0.250)	40 (95.2)	0.553 (0.190)	29 (93.5)
3 months	0.576 (0.226)	30 (71.4)	0.551 (0.216)	27 (87.1)
6 months	0.600 (0.227)	30 (71.4)	0.582 (0.245)	26 (83.9)
12 months	0.649 (0.226)	28 (66.7)	0.569 (0.226)	27 (87.1)
<b>Total</b>				
Baseline	0.522 (0.228)	40 (95.2)	0.500 (0.190)	29 (93.5)
3 months	0.545 (0.233)	30 (71.4)	0.491 (0.200)	27 (87.1)
6 months	0.557 (0.220)	30 (71.4)	0.489 (0.212)	26 (83.9)
12 months	0.609 (0.210)	28 (66.7)	0.485 (0.200)	27 (87.1)




FIGURE 9 The EQ-5D-5L service user results, with 95% CIs.




FIGURE 10 The AQoL-8D service user results, with 95% CIs.

## Carers

Outcome measures for carer available cases are presented in *Tables 23* and *24*. In the EMPOWER arm, EQ-5D-5L utilities decreased over the follow-up period from 0.815 (SD 0.107) at baseline to 0.798 (SD 0.099) at 12-month follow-up, with an increase between 3 and 6 months and 6 and 12 months. In the TAU arm, EQ-5D-5L utilities decreased over the follow-up period, from 0.748 (SD 0.195) at baseline to 0.695 (SD 0.156) at 12-month follow-up. These trends are illustrated in *Figure 11*.

For the CarerQoL-7D results, scores in the EMPOWER arm increased over the 12 months' follow-up from 85.9 (SD 15.8) at baseline to 91.8 (SD 5.24) at 12 months, with a decrease between 6 and 12 months. This overall increase is mirrored in the TAU arm: 78.7 (SD 14.3) at baseline compared with 91.5 (SD 2.67) at 12 months, with a decrease between 3- and 6-month follow-up. These trends are illustrated in *Figure 12*. Similar to the EQ-5D-5L completion, numbers were greater in the EMPOWER arm (100–57.1%,  $n = 7$ –5) than in the TAU arm (100–40%,  $n = 9$ –6).

TABLE 23 The EQ-5D-5L carer results at all time points

Time point	EMPOWER		TAU	
	Mean (SD)	$n$ (%)	Mean (SD)	$n$ (%)
Baseline	0.815 (0.107)	7 (100)	0.748 (0.195)	9 (90.0)
3 months	0.775 (0.184)	5 (71.4)	0.678 (0.283)	6 (60.0)
6 months	0.797 (0.169)	5 (71.4)	0.686 (0.233)	6 (60.0)
12 months	0.798 (0.099)	4 (57.1)	0.695 (0.156)	4 (40.0)

TABLE 24 The CarerQoL-7D results at all time points

Time point	EMPOWER		TAU	
	Mean (SD)	$n$ (%)	Mean (SD)	$n$ (%)
Baseline	85.9 (15.8)	7 (100)	78.7 (14.3)	10 (100)
3 months	86.1 (12.9)	5 (71.4)	79.5 (21.4)	6 (60.0)
6 months	86.0 (5.08)	5 (71.4)	77.8 (19.0)	6 (60.0)
12 months	91.8 (5.24)	4 (57.1)	91.5 (2.67)	4 (40.0)




FIGURE 11 The EQ-5D-5L carer results, with 95% CIs.






FIGURE 12 The CarerQoL-7D results, with 95% CIs.

## Resource use

### Service users

The mean frequency of resource use and the numbers (and percentages) of service users reporting resource use are presented in *Appendix 10, Table 43*. Direct health-care resources reported as used by the greatest number of service users included GP visits, psychiatrist, mental health nurse and mental health medication, with a general trend for more people in the TAU arm to use these. Nobody reported using formal online therapy, and small numbers reported using counsellors, alcohol workers and speech therapists, and having had mental health inpatient stays or using other mental health resources such as Facebook groups and leaflets. The largest number of contacts with direct health care reported (a mean of  $\geq 4$ ) at any time point in either arm was for GP visit, psychologist, counsellor, mental health nurse, alcohol worker, case manager, speech therapist and occupational therapist. However, as mentioned above, small numbers of service users reported contact with these resources, suggesting that the larger mean number of visits were skewed by a small number of service users. A small number of service users reported having contact with the criminal justice system and with the police and making court appearances. Nobody reported spending nights in a police cell, having psychiatric assessments in custody or making civil court appearances.

The largest number of service users reporting receiving a specific benefit at a given time point was 17 for sickness/disability benefits [although a larger number of service users reported receiving 'other benefits' (33 at 3 months)]. The high use of the 'other' category was because researchers in the UK felt that it was a better fit for the large numbers of people in receipt of the new Employment Support Allowance and Personal Independence Payments benefits.

The most frequently reported employment status was unemployed, followed by employed, retired/unpaid work and school/studying. No service users reported being self-employed, a housewife/househusband or 'other'. Of those service users reporting employed status, none reported being a manager or professional; the largest number reported 'other' as their occupation. Service users reported working between 16.4 and 26.3 hours per week on average, and between 2.04 and 4.33 days per week, with no trend towards differences between the arms. In terms of presenteeism, between two and six service users reported working when they felt bothered by physical or mental health problems over all time points; on average, the number of days worked while feeling bothered ranged from 5.0 (over 3 months) to 84.0 (over 6 months). On a Likert scale of 0–10, where 10 is worked at full capacity, the mean score was between 6.0 and 9.3, suggesting that, although the service user was bothered by physical or mental health problems, they were still able to work at a high capacity.

Small numbers of service users reported reducing their number of days and hours of unpaid work because of physical or mental health reasons; a large number of missing data for these variables means that the results for reducing unpaid work should be interpreted with caution.

In terms of receiving extra informal care for health reasons, a small number of service users reported needing extra help with child care, the greatest number of service users reporting receiving informal care was for help with household tasks (18 to 23) with no trend in differences between arms, and help outside the home (13 to 24) where there was a trend for more service users receiving help in the EMPOWER arm. A small number of service users (two to four) reported friends or relatives taking time off work because of the service user's mental or physical health across all time points; the mean number of hours taken off by the friend or relative, reported across all time points and both arms, was between 18 and 268.3 hours.

A small number of participants in Glasgow reported feeling distress as a result of questions in the RUQ being similar to those asked during Department of Work and Pensions benefits assessments.

### Carers

The mean frequency of resource use and the numbers (and percentages) of carers reporting resource use are presented in *Appendix 10, Table 44*. No carers reported using a speech therapist, occupational therapist, physiotherapist or inpatient for mental health. GP visits, care nurse and medication were reported at each time point.

### Mean costs and quality-adjusted life-years

The multiple imputation base-case mean costs and QALYs are presented in *Table 25*. From the health-care sector and the health-care payer perspectives, the mean total costs for the EMPOWER arm were lower than those for the TAU arm, whereas the mean total societal costs for the EMPOWER arm were marginally higher than those for the TAU arm: £12,991 (SD £2622) compared with £12,820 (SD £2892), a difference of £170 (95% CI -£7783 to £8124). Key cost drivers include the intervention cost, health professional visits (mean of £2419 for EMPOWER and £2824 for TAU), hospital admission (mean of £2286 for EMPOWER and £3388 for TAU), stays at on-site accommodation (non-acute specialist residential mental health care in Melbourne only: mean of £2734 for EMPOWER and £3300 for TAU) and mental health medication (£836 for EMPOWER and £1106 for TAU). These cost drivers are illustrated in *Figure 13*, with a complete breakdown of total mean costs per arm. References to hospital admission costs and to 'on-site' costs reflect the differences in reporting of costs according to jurisdiction.

As discussed in *Results, Outcome measures*, there is a trend for the QALYs to be higher in the EMPOWER arm; this result is reflected in the multiple imputation results, with higher QALYs in the EMPOWER arm.

The results of the base-case cost-utility analysis are in *Table 26*. From both the health-care payer and the health-care sector perspectives, EMPOWER is dominant; it is both less costly and more effective than TAU. From the societal perspective, EMPOWER is more costly and more effective, resulting in an ICER of £3041. This ICER would be considered cost-effective using the NICE threshold of £20,000 per QALY gained.<sup>220</sup>

A cost-effectiveness plane for the health-care payer perspective is presented in *Figure 14*. It shows that the majority of cost and effect pairs fall beneath the £20,000 threshold. A minority of pairs fall into the north-west and south-west quadrants, which would indicate that EMPOWER would be considered less effective than TAU. However, the majority of pairs fall into the north-east and south-east quadrants, where EMPOWER is more effective than TAU. Although the cost-effectiveness plane shows uncertainty around whether EMPOWER is more or less costly than TAU, there is less certainty around whether EMPOWER is more effective in terms of QALYs calculated using the EQ-5D-5L. At a willingness-to-pay threshold of £20,000 per QALY gain, there is around a 70% probability that EMPOWER is cost-effective. The probability that EMPOWER dominates TAU is 58%.

TABLE 25 Mean costs and QALYs (base case)

Cost	EMPOWER (n = 42)		TAU (n = 31)		Treatment effect coefficient <sup>b</sup>	SE	95% CI	Effect size <sup>c</sup>
	Mean	SD	Mean	SD				
Intervention cost <sup>a</sup>	2202.00	0	0.00	0	NA	NA	NA	NA
	2380.00							
	2447.00							
Health professionals' visits	2419.12	224.59	2824.18	406.79	-405.06	440.39	-1270.41 to 460.29	-1.00
Ambulance	94.00	72.82	70.93	51.54	23.07	97.65	-175.13 to 221.28	0.45
Emergency department	89.88	50.04	158.42	62.90	-68.54	97.17	-259.49 to 122.41	-1.09
Day treatment at hospital	50.09	21.65	117.10	37.59	-67.01	50.82	-166.90 to 32.89	-1.78
Hospital admission	2285.98	1667.44	3388.42	1597.31	-1102.43	2919.98	-6837.78 to 4632.92	-0.69
Accommodation	2734.09	1642.28	3299.65	2281.12	-565.56	2808.36	-6077.17 to 4946.05	-0.25
Diagnostic tests	70.23	19.30	115.17	27.70	-44.96	36.28	-116.22 to 26.34	-1.62
Medication (mental health)	835.82	194.59	1105.54	267.65	-269.73	352.93	-964.15 to 424.70	-1.01
Medication (non-mental health)	108.11	38.62	61.02	31.73	47.09	52.52	-56.17 to 150.35	1.48
Total health-care payer costs	10,899.30	2609.83	11,140.40	2802.01	-1587.11	2593.92	-6688.38 to 3514.17	-0.09
Online self-help	10.81	4.38	10.07	4.91	0.74	6.92	-12.89 to 14.34	0.15
Out of pocket	544.99	189.71	854.22	294.10	-309.23	365.15	-1026.98 to 408.52	-1.05
Total health-care sector costs	11,623.10	2622.91	12,004.70	2903.02	-1275.84	2612.94	-6418.38 to 3866.71	-0.13
Criminal justice	168.16	74.15	40.74	51.97	127.43	111.80	-92.36 to 347.21	2.45
Absenteeism (paid)	37.17	37.32	117.12	65.76	-79.96	87.73	-252.25 to 92.33	-1.22
Presenteeism	7.00	7.72	26.33	16.26	-19.33	20.61	-59.84 to 21.18	-1.19

Cost	EMPOWER (n = 42)		TAU (n = 31)		Treatment effect coefficient <sup>b</sup>	SE	95% CI	Effect size <sup>c</sup>
	Mean	SD	Mean	SD				
Carer productivity loss	430.67	342.03	126.35	202.06	304.32	434.61	-551.11 to 1159.75	1.51
Informal care	657.48	182.29	505.01	160.50	152.46	252.93	-345.51 to 650.44	0.95
Total societal costs	12,990.60	2622.58	12,820.30	2891.64	-1625.09	262,679.26	-6893.12 to 3642.95	0.06
QALYs	0.684	0.027	0.628	0.035	0.056	0.044	-0.014 to 0.118	1.60
EQ-5D-5L baseline	0.642	0.041	0.618	0.049	0.024	0.063	-0.100 to 0.147	0.49
EQ-5D-5L 3 months	0.662	0.041	0.600	0.054	0.062	0.066	-0.050 to 0.192	1.15
EQ-5D-5L 6 months	0.694	0.033	0.659	0.040	0.353	0.053	-0.065 to 0.140	0.87
EQ-5D-5L 12 months	0.711	0.040	0.613	0.049	0.098	0.061	-0.014 to 0.220	2.00

NA, not applicable; SE, standard error.

a Intervention costs varied depending on perspective.

b Generalised linear models were used to assess mean difference in costs and outcomes in two arms. For mean differences in costs, a gamma distribution and an identity link were applied, whereas for the incremental effect in QALYs and EQ-5D-5L utilities, a Gaussian distribution and identity link were used. Total costs were adjusted for baseline costs, country, age and gender. Total QALYs were adjusted for baseline utility, country, age and gender.

c Glass's Delta effect size.




FIGURE 13 Breakdown of the total costs of EMPOWER and TAU (societal perspective).

TABLE 26 Cost-utility analysis

Arm	Cost (£)	QALY	Incremental costs (£) (95% CI)	Incremental QALYs (95% CI)	ICER (£)
<b>Health-care payer perspective</b>					
EMPOWER	10,889.30	0.684	-251.10 (-8073.34 to 7571.15)	0.056 (-0.031 to 0.143)	Dominant
TAU	11,140.40	0.628			
<b>Health-care sector perspective</b>					
EMPOWER	11,623.10	0.684	-381.60 (-8346.56 to 7583.39)	0.056 (-0.031 to 0.143)	Dominant
TAU	12,004.70	0.628			
<b>Societal perspective</b>					
EMPOWER	12,990.60	0.684	170.34 (-7783.36 to 8124.03)	0.056 (-0.031 to 0.143)	3089.29
TAU	12,820.30	0.628			

Table 27 shows the results for the two sensitivity analyses for the health-care payer perspective. When including complete-case costs and QALYs only, the ICER is £2817, indicating cost-effectiveness. Including QALYs from the AQoL-8D instead of the EQ-5D-5L results in EMPOWER dominating TAU.

### Mean costs and relapse cases

The results of the cost-effectiveness analysis are presented in Table 28. The number of relapse cases avoided is greater in the EMPOWER arm than in the TAU arm. The cost-effectiveness analysis results show that when using relapse cases avoided as the outcome, both the health-care payer and the societal perspective are dominant and when using the health-care sector perspective the ICER is £12 per relapse case avoided.




FIGURE 14 Cost-effectiveness plane (health-care payer perspective).

TABLE 27 Base-case and sensitivity analyses (health-care payer perspective)

Arm	Cost (£)	QALY	Incremental costs (£) (95% CI)	Incremental QALYs (95% CI)	ICER (£)
<b>Base-case analysis</b>					
EMPOWER (n = 42)	10,889.30	0.684	-251.10 (-8073.34 to 7571.15)	0.056 (-0.031 to 0.143)	Dominant
TAU (n = 31)	11,140.40	0.628			
<b>Sensitivity analysis 1: complete case</b>					
EMPOWER (n = 23)	12,305.53	0.722	236.63 (-10,278.12 to 10,751.38)	0.084 (-0.028 to 0.197)	2817.02
TAU (n = 24)	12,068.90	0.638			
<b>Sensitivity analysis 2: AQoL-8D-QALYs</b>					
EMPOWER (n = 42)	10,889.30	0.554	-251.10 (-8073.34 to 7571.15)	0.059 (-0.028 to 0.146)	Dominant
TAU (n = 31)	11,140.40	0.495			

TABLE 28 Cost-effectiveness analysis

Arm	Cost (£)	Relapse cases avoided	Incremental costs (£)	Incremental relapse cases avoided	ICER (£)
<b>Health-care payer perspective</b>					
EMPOWER	10,889.30	32.35	-251.10	14.76	Dominant
TAU	11,140.40	17.59			
<b>Health-care sector perspective</b>					
EMPOWER	11,623.10	32.35	-381.60	14.76	Dominant
TAU	12,004.70	17.59			
<b>Societal perspective</b>					
EMPOWER	12,990.60	32.35	170.00	14.76	11.53
TAU	12,820.30	17.59			

## Carer costs and outcomes

Table 29 presents the complete-case costs and outcomes for carers. Owing to the small number of carers it was not possible to carry out a formal analysis and so the results should be interpreted with caution. There is a trend for the total societal costs to be higher in the TAU arm. However, the SDs are wide, indicating a lot of variation in the resources reported for carers.

TABLE 29 Carer costs and outcomes

Cost	EMPOWER			TAU		
	<i>n</i>	Mean	SD	<i>n</i>	Mean	SD
Health professionals	4	194.95	121.97	4	312.83	206.78
Hospital admission	0	NA	NA	4	842.50	842.50
Medication	4	42.75	42.75	4	35.63	13.93
Out of pocket	4	190.00	113.36	4	95.75	94.75
Informal care	4	43,168.13	15,008.21	4	37,074.38	16,454.42
Total societal costs	3	36,049.83	18,412.3	4	38,361.08	17,036.62
QALYs	4	0.797	0.078	3	0.631	0.159
EQ-5D-5L baseline	7	0.815	0.040	9	0.748	0.05
EQ-5D-5L 3 months	5	0.775	0.082	6	0.678	0.116
EQ-5D-5L 6 months	5	0.797	0.076	6	0.686	0.095
EQ-5D-5L 12 months	4	0.798	0.049	4	0.695	0.078
CarerQoL-7D baseline	7	85.871	5.987	10	78.680	4.518
CarerQoL-7D 3 months	5	86.100	5.751	6	79.500	8.724
CarerQoL-7D 6 months	5	85.980	2.274	6	77.767	7.756
CarerQoL-7D 12 months	4	91.825	2.621	4	91.475	1.333
NA, not applicable.						

## Chapter 7 Discussion

In this study we sought to establish the feasibility of conducting a definitive cRCT comparing the EMPOWER intervention with treatment as usual. Specifically, the EMPOWER intervention aimed to (1) enhance the recognition of EWS by people using services and their carers and (2) provide a stepped-care pathway that was either self-activated or in liaison with a carer and/or a care co-ordinator, which, if indicated, (3) triggered a relapse prevention strategy that could be stepped up to a whole-team response to reduce the likelihood of relapse. Each of the specific aims detailed in *Chapter 2* is now considered in turn.

### Eligibility, consent and recruitment

We aimed to determine the rates of eligibility, consent and recruitment of potential participants, including people using services, carers and care co-ordinators. During the study we successfully recruited and retained eight CMHS: six in Glasgow and two in Melbourne. We approached and screened the caseloads of care co-ordinators across these CMHS and identified 1140 potentially eligible service user participants. Following the screening of care co-ordinators' caseloads, we found that 263 (23%) service users met our eligibility criteria. Of these potentially eligible participants, we were able to approach 129 (49%) and over an 8-month period then recruit 86 (67%), giving a recruitment rate of just under 11 participants per month from across the eight CMHS. We also successfully recruited 47 care co-ordinators to participate in the study. We found that service user participants identified a small number of carers, which meant that there was a small pool of carers to potentially participate in the study.

A challenge that we had not anticipated was the loss of eligible participants between informed consent and randomisation. Of the 86 participants who gave their informed consent, we randomised 73. This finding is worthy of further discussion. Prior to conducting the trial we noted that a key criticism of cRCTs is the chronology of allocation concealment, where initially clusters are recruited and randomised and then participants are recruited. This can then induce differential recruitment and so imbalances between groups can occur as a consequence of clusters knowing the outcome of randomisation before recruitment.<sup>252-254</sup> In this study we sought to avoid this problem by identifying and consenting eligible participants from each CMHS before the clinical trials unit revealed the allocation. We learned in phase 1 (see *Chapter 3*) that staff were concerned that many of their eligible service users would not use a digital intervention. Perceived barriers included older age, greater severity of symptoms, more cognitive impairments, digital exclusion, lack of insight, social problems and stresses related to poverty and deprivation. Maintaining allocation concealment during recruitment was an important means of reducing the potential bias from these staff expectations. In addition, research staff stressed the feasibility nature of the study to overcome these negative expectations, highlighting that a key aim of the study was to examine service user engagement with the trial and the intervention. Before randomisation and team allocation were revealed, 13 of the participants who had given their informed consent decided to withdraw. Of these participants, six received services from teams subsequently allocated to EMPOWER and seven received services from teams allocated to TAU. Reasons for withdrawal were available for six people, with most citing changes in their personal circumstances. We were unable to get reasons for withdrawal from the remaining seven participants. However, the extended period between informed consent and the start of the study, which had been designed to reduce the potential for bias, may well have increased the likelihood of participant withdrawal. In a future trial using these methods, retention might be improved by providing participants with clearer information about the anticipated gap between consent and the start of research procedures and by increasing efforts to maintain contact with consented participants and provide them with regular updates on progress. Alternatively, individual randomisation, as opposed to cluster randomisation, would minimise the early loss of consented participants.



## Feasibility, acceptability and usability of the EMPOWER intervention

After being introduced to the app, 80% of participants completed the 4-week baseline self-monitoring period. This baseline period was necessary to enable the algorithm to calculate changes in well-being over time to both tailor self-management messages to changes in participants' well-being and also to deliver ChIPs to research clinicians to triage and assess EWS. We found that these participants used the app for an average of 32 weeks (SD 14.5 weeks) and that, during this period, the app was used on 64% of days. Prior to conducting the study, we determined that the intended usage would be the period during which users complete at least 33% of daily prompts because this would result in data that are of maximum benefit in being reliable for detecting clinical changes.<sup>255</sup> We found that 91% of those who completed baseline met this criterion. If we include those who did not complete baseline, this estimate falls to 71%. Based on these figures, we could estimate that between 71% and 91% of participants would produce sufficient data to be considered reliable for the intervention in a main trial.

Trying to develop an accurate estimation of intended usage over time is challenging in a feasibility trial. We explored when participants stopped inputting data at least 3 days per week (meeting 33% intended usage criteria) for 4 sequential weeks. Overall, the median survival for not missing 4 sequential weeks of intended usage was 32 weeks (bootstrapped 95% CI -14 weeks to  $\infty$ ). In other words, for 50% of participants who had completed a baseline, it took 33 weeks before they missed 4 sequential weeks of intended intervention usage. The width of the CI suggests that it is difficult to predict when participants stop adhering to use of the app (especially in terms of an upper limit), but it is probable that this time does not fall below 14 weeks.

Engagement with digital interventions can be conceptualised in multiple ways, including subjective experiences of how using an intervention makes a participant feel alongside purely behavioural measures of actual intervention usage.<sup>256</sup> Consistent with the behavioural data, participants reported using the app between 'weekly' to 'daily' during the 12-month follow-up. Participants themselves reported accessing their own data (using the charts function) 'sometimes'. They reported sharing their data with carers and care co-ordinators 'rarely'. We also observed signals of high levels of acceptability. Participants found the app interesting to use and easy to learn and navigate, and felt that the app content was well written, relevant and credible. They also said that they would recommend the app, and, overall, they rated the app very highly. Participants reported that the app increased their awareness, knowledge and understanding, improved their attitudes and intentions around staying well and encouraged help-seeking.

When we compared the use of well-being apps (more generally) between groups, we observed, as expected, higher levels of well-being app use in the EMPOWER arm than in the TAU arm. In terms of frequency, participants in EMPOWER reported using well-being apps 'sometimes' to 'often', compared with those in TAU, who reported using them either 'not at all' or 'rarely'. Interestingly, we did not observe differences between the two groups in terms of frequency of help-seeking for EWS, frequency of carer help-seeking for EWS, or frequency of changes in clinical management being initiated following help-seeking for EWS. In the main these were reported as occurring 'rarely' in both arms of the trial. We observed a similar pattern of reporting among carers and care co-ordinators. These findings ran counter to our expectations. In our cognitive-interpersonal model of EWS, help-seeking and relapse described in *Chapter 1* (see *Figure 1*), we expected that self-monitoring using the app would increase the availability of data to enhance shared decision-making. Consequently, we expected to observe an increase in reporting EWS in the EMPOWER arm (by service users and carers) and an increase in changes in clinical management in response to EWS. We did not observe this. There are a number of plausible reasons for these observations. It is possible that this lack of difference between groups was because EWS events were relatively infrequent and there were insufficient EWS events (at least from the perspectives of service users, carers and care co-ordinators) to generate a signal

from the data. It is also possible that the response categories from 'not at all' to 'often' were insensitive to relatively infrequent events. Alternatively, the behavioural and self-reported acceptability data do suggest that people were using the app regularly, reporting increased awareness and knowledge and improved attitudes and intentions around staying well and help-seeking. These findings may therefore suggest that the app increased users' self-management and autonomy in relation to staying well. Our findings in phase 1 (see *Figure 4*) suggested that users experienced the app as a tool to enhance self-awareness and reflection, enabling them to recognise changes in well-being that would trigger self-management and self-care. Previous qualitative studies that have explored experiences of mobile app monitoring have tended to focus on usability and acceptability.<sup>140,257,258</sup> They have shown that service users express a preference for utilising their data to enhance access to mental health care and for sharing with mental health staff<sup>257,258</sup> or in relation to help-seeking.<sup>259</sup> These studies did not explore how participants themselves made sense of their data in relation to personal well-being and staying well, and the extent to which they experienced or utilised an increased sense of self-awareness as a result of self-monitoring.

In our study, self-monitoring was implemented differently from in these earlier studies.<sup>140,257,258</sup> In EMPOWER, self-monitoring was linked to the delivery of tailored messages that were designed to promote curiosity about changes in well-being and to encourage greater autonomy and self-management. Self-monitoring was also integrated with peer support, which aimed to enable service users to engage with the app. Peer support workers also provided technical support and encouraged service users to make sense of changes in their well-being in the broader context of other changes in their life and circumstances. We also observed sharing of experiences between peer workers and app users in relation to their experiences of self-monitoring but also more widely in relation to coping, self-management and recovery. Over the course of the study, participants were offered an average of 12.4 sessions of peer support, and the vast majority of these sessions were delivered over the telephone. We also established clinical triage in response to ChIPs generated by the algorithm. Over the course of the study, the algorithm generated 558 ChIPs across 37 app users, with each person having, on average, 15 ChIPs. Thus, it is possible that the increase in shared decision-making that we expected to see (and was predicted by our theoretical model) happened at the point of triage, rather than with the care co-ordinator. That is, when the research clinician made contact with a participant to check in about changes observed on the clinical interface, these discussions involved coming to a shared decision about whether or not to escalate these changes to the care co-ordinator. At the outset of the study we expected ChIPs to generate risk information that would require routine clinical triage to escalate changes detected by the algorithm to the relapse pathway. Thus, we did not expect that peer support workers would be involved in responding to ChIPs. We also felt that there was some risk in peer support workers assuming what might be construed as a clinical, and, therefore, a non-peer, role. However, we learned that the majority of these ChIPs were not specific to EWS or relapse but did frequently relate to changes that were of personal significance to service users. We learned that it was indeed possible for peer support workers to integrate information about ChIPs into their routine contacts with service users. Our experience was that this enabled more focused conversations around changes in well-being and often encouraged the mutual sharing of experiences, while not diminishing the distinctiveness of the peer support role.

To summarise, we demonstrated the feasibility, acceptability and usability of the EMPOWER intervention. The feasibility trial enabled us to develop the intervention to combine a number of key components: (1) digital self-monitoring of well-being, (2) an algorithm that tailored self-management messages to changes in well-being and triggered clinical triage of changes in well-being to assess for EWS and (3) regular follow-up with peer support. We did not find evidence that using the app increased reporting of EWS based on the perspectives of participants, carers or mental health professionals. Nor did use of the app increase help-seeking in relation to relapse. Therefore, the intervention has two key points of human interaction: first, a clinician who monitored changes in

the service user's well-being during the course of the study and responded to ChIPs generated by the algorithm; and, second, a peer support worker who delivered technical support to help service users use the app but also provided a context for the interpretation of the 'ebb and flow' of well-being in daily life. We noted the overall high rates of usage during the trial that were well above our a priori expectations. It has been shown that participant use of digital interventions for psychosis is higher when there is an increased level of human contact.<sup>117</sup> In this study it is likely that the high rates of use were linked to the blending of human contact with app use, not least because we did not offer financial incentives for engagement, as has been used in other digital psychosis studies.<sup>170</sup> In our preliminary work this blending was an important priority for service users, who expressed concerns that a mobile app should not be a replacement for clinical contact but rather should enhance or augment mental health support.<sup>257,260</sup>

## Performance and safety of the EMPOWER app

Very few studies of digital interventions for psychosis utilising EMA methods have reported methods and protocols for monitoring adverse events,<sup>113</sup> and where this has been explicitly referenced it has been in relation to serious adverse events, such as hospitalisation or death.<sup>170</sup> Thus, adverse events or unwanted experiences have been a neglected area of study. Prior to starting the study we anticipated that fear of relapse was an important potential risk of introducing self-monitoring by digital technology. Relapse itself is associated with a range of distressing experiences including the return or exacerbation of distressing symptoms of psychosis, experiences of rehospitalisation and experiences of coercion into treatment.<sup>16</sup> Therefore, we expected that it was plausible that monitoring EWS may increase fear of relapse, especially given that early signs and fear of relapse are highly correlated.<sup>17</sup> Prior to undertaking the trial, we were required to register the EMPOWER app as a class 1 medical device with the UK MHRA (CI/2017/0039). It is our understanding that the EMPOWER app was the first mental health app to be regulated by the MHRA in this way. Medical device regulation requires detailed monitoring and reporting of performance and safety. In relation to performance, two device deficiencies were identified, which can be addressed in future versions of the app. Both events were identified quickly and did not result in any adverse effects on the participants or on the trial more broadly. No adverse events were related to the EMPOWER class 1 medical device (i.e. the EMPOWER algorithm). However, we identified 13 app-related adverse events (one serious adverse event) affecting 11 participants. For some people the app triggered unhelpful rumination by increasing their awareness of symptoms or anxiety or prompting distressing memories of previous relapses. Many of these adverse events occurred early in the course of using the app, and in two instances these led the participant to withdraw from the study. These findings have important implications for optimising the EMPOWER intervention. Before monitoring is initiated, it would be helpful to have a preliminary engagement phase for service users with the peer support worker to discuss and clarify the rationale for self-monitoring using the EMPOWER app, explore the advantages and disadvantages of self-monitoring, and identifying valued goals linked to self-monitoring and the broader EMPOWER intervention. Based on our experiences of adverse events, this phase would help address the triggers for adverse events and reduce the likelihood of their occurrence. In addition, this could possibly contribute to the informed and proactive withdrawal from the intervention of participants who express this preference (potentially without withdrawing more broadly from the main trial).

To summarise, a key learning point from this trial was that carefully monitoring adverse experiences of interacting with a digital intervention represents an important opportunity for learning and optimising digital interventions. Broader uptake of adverse event monitoring in digital health trials has clear potential to improve the experiences of end-users and reduce the risk of adverse events, while improving the overall design and acceptability of interventions. Our safety findings suggest that the design of the EMPOWER intervention could be improved to include an engagement phase prior to initiating self-monitoring, which would include sharing our cognitive-interpersonal model of relapse, exploring advantages and disadvantages of self-monitoring, and normalising monitoring 'ebb and flow' of well-being as a rationale for strengthening self-management, self-efficacy and empowerment.

## Assessment of candidate primary and secondary outcomes

### Candidate primary outcomes

A further aim of the feasibility trial was to assess primary and secondary outcomes to determine the preliminary signals of efficacy of the EMPOWER intervention as a basis for assessing the feasibility of collecting follow-up measures, determining primary and secondary outcomes, and determining probable sample size requirements for a future main trial. Our candidate co-primary outcomes were relapse and fear of relapse. Overall, the findings indicated that over 12 months, compared with TAU, EMPOWER appeared to reduce the number of relapses, increase the time to first relapse, and reduce fear of relapse. We successfully collected relapse data for 84% of participants at every follow-up point during the trial. We theorised that relapse events involve factors related to the service user (change in positive symptoms, duration of more than 1 week and reduction in functioning and/or increase in risk) and factors related to service responses (change in clinical management, hospitalisation and coercion into treatment). We successfully operationalised these criteria and measured relapse from routinely collected electronic patient record data. We subjected these data to blinded reliability assessments, finding substantial agreement between raters. Finally, all of these data were subject to a blinded outcome assessment.

In studies of interventions for relapse prevention in schizophrenia, there has been a lack of clear consensus about the definitions of relapse. For example, in a meta-analysis of antipsychotic drugs compared with placebo,<sup>229</sup> the trial definitions of relapse varied and included clinical judgement ( $n = 26$ ), need for medication ( $n = 17$ ), rating scale-based definitions ( $n = 15$ ), admission to hospital ( $n = 3$ ) and dropout because symptoms worsened ( $n = 2$ ). This lack of consensus is present in other meta-analyses.<sup>261,262</sup> In the Kishimoto *et al.* meta-analysis<sup>262</sup> of first- compared with second-generation antipsychotics, nine of the authors' included studies did not define relapse. A key strength of our study was that our definition was theoretically informed by our intervention model, was defined a priori, was capable of being extracted from routine health service data and was assessed blind with reliability data reported.

Relapse was less likely among participants in the EMPOWER arm, and we identified a RR of 0.50 (95% CI 0.14 to 0.74) over 12 months. This result, although encouraging, needs some cautionary interpretation given that the feasibility study had a small number of clusters, each with small numbers of participants, and that there were more withdrawals from the EMPOWER arm. The impact of the small numbers of clusters was examined and deemed not to be a major concern, although the overall small numbers prevent certainty about this. In terms of the potential impact of the withdrawals on the primary outcome, the number needed to change the benefit of the EMPOWER intervention would have to be set at six or more, a level felt to be unrealistically high. Sim<sup>263</sup> and Eldridge *et al.*<sup>264</sup> have cautioned against the use of effect sizes derived from feasibility and pilot trials to be used as the basis for sample size estimation for a main trial. The imprecision arising from the smaller sample sizes in feasibility or pilot studies can increase uncertainty. Although our sample size ( $n = 73$ ) is relatively good for a feasibility/pilot study,<sup>265</sup> we note the wide 95% CI around our estimate for reduced relapse. Sim<sup>263</sup> has recommended that effect size estimates for main trials be based on clinical judgement rather than on statistics. Our RR is comparable with meta-analytic evidence for early signs monitoring for relapse prevention<sup>71</sup> (RR 0.53, 95% CI 0.36 to 0.79), family interventions for schizophrenia<sup>46</sup> (RR 0.55, 95% CI 0.48 to 0.62: 12 months) and antipsychotic drugs compared with placebo over 12 months<sup>229</sup> (RR 0.40, 95% CI 0.33 to 0.49: 12 months). Recently, Johnson *et al.*<sup>123</sup> has shown that peer-supported self-management reduced readmissions to acute care (odds ratio 0.66, 95% CI 0.43 to 0.99).

In a future main trial we envisage randomising between 300 and 500 participants. With a trial of this size, we would have 90% power to detect a range of important but potentially more realistic effects across a range of outcomes. In terms of our candidate primary outcome, if we assume a relapse at 1 year of 50% in the control group, we would have 90% power to detect a RR of 0.7 (i.e. 35% in the EMPOWER arm) and if we make allowance for a 20% dropout rate with a sample size of 500.

For continuous outcomes we would have 90% power to detect effect sizes in the range of 0.3–0.4 SDs, or 80% power for 0.25 SD, which are worthwhile differences and are conservative in comparison with published data,<sup>46,71,229</sup> reflecting high-quality findings on self-management interventions for schizophrenia.<sup>123</sup> Our choice of a RR of 0.7 also takes into account our analysis of the impact of the seven withdrawals in TAU and allows for the scenario in which five out of these seven withdrawals experienced a relapse. This is a conservative estimate given that if we allowed for the number of relapses in the withdrawal group to resemble our findings in TAU this number would be set at 3.

Our finding that fear of relapse was reduced more in the EMPOWER arm than in the TAU arm is consistent with our earlier empirical work in relation to fear of recurrence.<sup>17</sup> In that study we found that, controlling for baseline psychiatric symptoms and EWS, fear of relapse was the only predictor of time to relapse, in that greater fear of relapse was linked to shorter time to relapse. We also found that fear of relapse increased in the weeks preceding relapse and had the same sensitivity and specificity to relapse prediction as traditional measures of EWS.<sup>17</sup> In our theory, fear of relapse drives avoidance of help-seeking and potentially unhelpful coping strategies, thereby increasing vulnerability to relapse (see *Figure 1*). The finding that fear of relapse was reduced in those in the EMPOWER arm signals that this variable is likely to be an important co-primary outcome of a main trial.

### **Secondary and mechanism outcomes**

Across our candidate secondary outcomes the rates of data completion among service user participants ranged from 73% to 85% (median 80%), demonstrating that collecting these outcomes is feasible. Again, although the impact of the small numbers of clusters was deemed not to be of major concern, as this was a feasibility study all of the results require cautionary interpretation. The profile of clinical and emotional distress outcomes was generally in favour of the EMPOWER arm, with some notable signals in relation to negative symptoms at 12 months (Cohen's  $d = -0.57$ ), self-rated depression (Cohen's  $d = -0.41$ ) and PBIQ-R control over illness (Cohen's  $d = -0.42$ ). We also noted that medication adherence was lower in the EMPOWER arm at 12 months (Cohen's  $d = -0.50$ ), signalling that the lower rate of relapse observed in the study may not be due to increased medication adherence. Although we would not rely on these outcome signals to infer efficacy, the measures provide important data that are relevant to the intervention and are feasible to collect in a main trial. We did note that rates of substance misuse were low and similar to those reported by Bucci *et al.*<sup>170</sup> We were successful in achieving good rates of follow-up using the Timeline Followback measure (85%) but, given the time-consuming nature of this measure, the low rates of substance misuse in the sample and the absence of any signals, we will carefully consider its inclusion in a main trial.

Across our candidate mechanism outcomes, rates of data completion were 85%. The profile of outcomes were generally in favour of the EMPOWER arm. We observed notable signals in relation to personal recovery at 12 months (Cohen's  $d = 0.33$ ) and general self-efficacy at 12 months (Cohen's  $d = 0.33$ ). These data indicate that these measures not only are feasible to collect but may provide important signals in a main trial in terms of mechanisms of action. In a future main trial we would also include fear of relapse as a mechanism of change, as discussed above.

As has been already noted, a minority of service users had a nominated carer and, overall, a small number of carers participated in the study. At 12-month follow-up, data were available for 47% of carer participants. Twelve-month data on care co-ordinators' ratings of service user engagement with services were available for 42% of service user participants. During the trial we observed high rates of staff turnover and absence and changes to care co-ordinators. We also observed that care co-ordinators would often be unavailable when we were arranging appointments to collect data from them. In *Chapter 3*, care co-ordinators raised a number of important service-related factors including high caseloads and time pressures that had an impact on their ability to spend time with service users. These observations regarding the small number of nominated carers and the high attrition of carers and care co-ordinators have important implications for a main trial.

In terms of carers, this group expressed clear needs in relation to wanting to support family members with a diagnosis of schizophrenia and experiencing both satisfaction and stress in relation to their caring responsibilities. The EMPOWER intervention did not address the needs of carers directly, only through providing a resource to service users that they could choose (or not) to share with carers or friends and family. A recent systematic review of digital interventions for people with psychosis or bipolar disorder<sup>115</sup> found that none of the 26 included studies targeted family or friends whereas the vast majority of digital interventions utilised support from staff or peers in delivery. There is clearly a need to develop interventions that focus on the needs of carers, families and friends. There are a number of emerging studies showing that online interventions that specifically target needs of carers are feasible, and future research aimed at involving relatives and friends should target their needs specifically.<sup>266-268</sup>

In terms of staff, we have noted (see *Chapters 1 and 3*) the demands of routine practice, constraints of high caseloads and a focus on risk as constraints on joint crisis care plans and shared decision-making approaches.<sup>84,85</sup> In phase 1 of this trial (see *Chapter 3*), staff reported that the proposed EMPOWER intervention made sense but that if the app increased workload then they would not have the capacity to work with it. Based on our findings, and to scale up the intervention for a main trial, triage of EWS could be better placed within CMHS, rather than within the research team, thereby facilitating team-wide implementation in local services and better accommodating staff turnover and absences.

## Health economics parameters

We aimed to establish the study parameters and data-gathering frameworks required for a co-ordinated health economic evaluation of a full trial across the UK and Australia. Overall, the findings indicated that, from a health-care payer and a health-care sector perspective, EMPOWER resulted in fewer costs and greater outcomes than TAU in terms of both QALYs gained and relapses avoided. When adopting a societal perspective, the EMPOWER arm resulted in higher costs but also in greater QALYs and more relapses avoided. Although there is no established willingness-to-pay threshold for a 'relapse case avoided', the resulting ICER of £3089 per QALY gained is below the current threshold of £20,000 recommended by NICE. The uncertainty analysis indicated that at a willingness-to-pay threshold of £20,000 per QALY gained there is around a 70% probability that EMPOWER is cost-effective from the health-care payer perspective. The results remained consistent after undertaking sensitivity analyses, using the AQL-8D as a measure to derive QALYs and re-running the analyses using complete cases. In terms of carer costs and outcomes, the results indicate that carers in the EMPOWER arm had lower costs and greater outcomes than those in the TAU arm. However, the small number of carers included in the study mean that the results need to be interpreted with significant caution.

One economic element of the feasibility study explored developing a RUQ and the feasibility, acceptability and usability of the resulting measure. The RUQ for service users and carers was developed to include potential resource use in both the UK and Australian contexts. Some questions in the RUQ resulted in participant distress, which was associated with current approaches to benefits assessments in the UK. This suggests that questions on resource use should be carefully considered in any full trial and that people with lived experience should be involved in refining the RUQ to improve service users' understanding of the importance of health economic evaluations in clinical trials and the acceptability of measures. Completion rates varied from 97% ( $n = 71$ ) and 100% ( $n = 17$ ) for service users and carers, respectively, at baseline, to 75% ( $n = 55$ ) and 41% ( $n = 7$ ), respectively, at 12-month follow-up.

The economic component also explored the feasibility, acceptability and usability of the chosen quality-of-life questionnaires. There were similar levels of completeness for the quality-of-life data collection as for the RUQ. No issues were reported with the acceptability of these measures and there were few partially completed questionnaires. The inclusion of two preference-based health-related quality-of-life measures also enabled the further exploration of the measures in terms of acceptance and suitability.

The AQoL-8D has a greater focus on psychosocial aspects of quality of life and, as a result, it was assumed that this measure would be more sensitive to changes. However, both the EQ-5D-5L and the AQoL-8D scores improved over the 12-month trial period, highlighting the need for further validation work. In addition to this, the ReQoL-10 or ReQoL-20<sup>269</sup> (a new recovery-focused outcome measure that can also be used to calculate QALYs) could be tested and considered in a final trial.

The economic component also estimated the costs of intervention and cost-effectiveness, and identified key cost drivers. The cost of the intervention was challenging to calculate as it comprised different elements between the UK and Australian settings; however, the micro-costing approach taken to the intervention produced an accurate cost of the EMPOWER intervention. Although previous studies have excluded the R&D costs of mobile apps, we have included these, although these costs were attributed to all future potential users of EMPOWER. The cost-effectiveness results presented indicate that EMPOWER would be cost-effective; while there is some uncertainty in the results, the two sensitivity analyses and the cost-effectiveness analysis indicate either that EMPOWER would be dominant or that the corresponding ICER would be considered well below the current NICE cost-effectiveness threshold.<sup>220</sup>

The key cost drivers identified in the feasibility study included hospital admissions, health professional visits, medication for mental health and staying on site at an organisation. It should be noted that the question 'staying on site at an organisation' was completed only by service users in Australia, and this included adult prevention and recovery care services and community care units. The adoption of a broader societal perspective has also enabled us to examine other costs outside the health care sector. Although these were relatively low in comparison with costs in the health-care sector, criminal justice costs and the cost of informal care as well as carer productivity losses were notable and, therefore, should remain in a definitive trial. Costs of online self-help and absenteeism (paid) were low. Limitations include the number of missing data and the fact that, owing to an error in the RUQ, we were not able to investigate absenteeism from unpaid work. Most of the trial service users were unemployed, highlighting the importance of assessing absenteeism from unpaid work in a definitive trial.

From a societal perspective, ideally all costs and benefits should be taken into account regardless of who experiences these. However, although we collected costs and outcomes from service users and their carers, owing to the small number of carers we were not able to combine carers' data with service users' data. Combining outcome data from carers and service users poses another challenge, as QALYs need to be established that combine the utility of both carers and the service user.

Strengths of the feasibility study include collecting data on carers' resource use and quality of life. Having these data enhanced the analysis and is best practice from a societal perspective. The analysis was further enhanced by the inclusion of sensitivity analyses, different perspectives and two different outcomes, one each for service users and carers. The inclusion of different outcome measures allowed the calculation of QALYs using the EQ-5D-5L as well as the AQoL-8D for service users. It is reassuring that, regardless of which measure was used, the EMPOWER intervention remained cost-effective.

A further strength of this economic analysis was the comprehensive design of the RUQ that enabled us to investigate which services were most commonly used to inform the design of the RUQ for the definitive trial.

Recommendations for data collection in a full trial include working with participants to include resource use that is not distressing or a burden to complete. Some work should also be completed to obtain the experiences of the researchers who filled in the questionnaires with the service users and carers, in order to understand why some variables were completed and others were not. Efforts should be made to minimise the number of missing data and to focus on obtaining good-quality data on resource use, particularly on the key cost drivers. Further involvement of people with lived experience of psychosis in developing methods to convey the rationale for the health economic evaluation, the

collection of such detailed data and the refinement of the RUQ may be an important step towards improving the uptake of health economic measures and reducing missingness. Some resources were not reported as being used during this study and these could be omitted from the RUQ in a full trial. In our analysis we estimated the time service users spent on the EMPOWER app; in a full trial it would be preferable to also collect this information through the software.

This study has shown that it is feasible to collect data for an economic evaluation for a trial of the EMPOWER app. However, attempts should be made to reduce the number of missing data, particularly as the trial progresses. If the main causes of missing data can be addressed, a robust economic evaluation could be included as part of a full trial.

## Enhance and tailor the EMPOWER mobile phone app

We aimed to enhance and tailor our mobile phone app to deliver EWS monitoring and self-management interventions and provide access to a relapse prevention pathway. We have already highlighted further opportunities for blending the app with peer support. We encountered a number of technical challenges. Installation would greatly be improved by making the app available from the Google Play store (Google Inc., Mountain View, CA, USA) or a similar online facility. We found for a number of individuals that the 4-week baseline used to enable the algorithm to function was not representative of the users' usual 'ebb and flow' of well-being. This meant that there were a number of occasions where baseline monitoring had to be restarted and this meant having to uninstall and reinstall the app. Usability and scalability would be greatly improved by having the flexibility to restart or recalibrate baselines based on app user feedback. For some app users there were individual items that were not relevant to their experiences, however we did not have the flexibility to modify item content, beyond a limited number of personalised items. Future versions of the technology would benefit from greater flexibility of item content over time. Service users were prompted daily on a pseudo-random basis to complete questionnaires within a 5-hour window. User experience could be substantially improved by increased flexibility to modify the frequency and time of day of self-monitoring. Finally, the ChIP algorithm conveyed information to research clinicians and later to peer support workers via the clinician interface (see *Figure 2*). Exploring ways of enabling app users to engage with ChIP data could increase access to changes in their 'ebb and flow' of well-being, increase the sense of ownership and encourage them to reflect on changes. However, the direct delivery of ChIPs to app users would also need to be carefully considered given its potential to generate fear of relapse or hypervigilance. Finally, use of passively collected data could enhance the development of a broader range of social, behavioural, smartphone and geolocation-sensing data to inform changes in well-being using digital phenotyping.<sup>270-272</sup>

## Considerations for a larger trial of EMPOWER

Based on our learning from this feasibility study and on learning derived from our associated process evaluation,<sup>166</sup> the findings of which will be published separately from this report, a number of considerations are needed in designing a larger multisite trial.

We designed the feasibility study as a cluster trial because we anticipated that potential intervention effects would, in part, be contingent on changes in clinical teams' responses as a result of information generated through app usage. We anticipated that clinicians would be able to improve clinical decision-making based on app-generated data and that more collaborative and shared decision-making with app users would be encouraged as a result of the intervention. However, in practice we observed that, although most practitioners were interested in service users' participation in the study and, to varying degrees, their use of the app, evidence of changes in practice as a result of app usage or improved access to data to inform decision-making was very limited. Consistent with our observations, our feasibility data showed us that participants, carers and mental health care staff did not report an



increase in reporting EWS or help-seeking in relation to relapse. Rather, we observed that using the app-based monitoring and peer support led to increased self-management and autonomy.

The logic of using cluster randomisation was that we anticipated that the intervention would have a greater impact on the care team environment. However, our experience was that custom and practice prevailed in most cases and that participants did not increase their reporting of EWS to care teams or increase help-seeking for relapse. Our findings highlight a lack of 'contamination' within the care team environment, negating the need to use cluster randomisation in a future evaluation. In addition to reducing the required sample size, individual randomisation could bring other advantages over cluster randomisation. We believe that individual randomisation will lead to fewer withdrawals between consent and allocation. As a result of needing to wait until target recruitment levels were reached in each paired cluster before randomisation, some people faced a considerable gap between consenting to the study and being allocated a treatment. We believe that this may have contributed to the relatively large number of withdrawals between consent and allocation ( $n = 13$ ). Individual randomisation would allow us to start people more promptly in either arm of the study, potentially reducing the general feelings of uncertainty that seemed to contribute to a number of pre-randomisation withdrawals in the feasibility study.

The peer support worker role in the intervention developed and changed over the course of the feasibility study, and we would like to enhance and more fully embed the role in a larger trial. Initially, peer workers were primarily concerned with setting up and providing technical support for the app, but over time they became more involved in encouraging service users to reflect on app data and in supporting self-management and recovery. Peer workers also assumed more of a role in discussing CHIPs with app users, given that they had the most regular contact with app users. Initially the research team felt that playing a role in reviewing and responding to app-generated data might negatively influence the peer relationship but, counter to this, we found that access to data actually created the foundation for richer discussions about wellness management and opportunities for reflection with app users. We would anticipate developing this practice in a main trial in tandem with a greater focus on self-management in app users.

We would also anticipate continuing to develop our practice in relation to adverse event monitoring, which we believe was a strength of the feasibility study. We would like to improve our monitoring and reporting of general deteriorations in mental health as adverse events and their relatedness to the intervention. As a result of data collected in the feasibility study, we will also be more able to anticipate the type, frequency and temporal likelihood of certain intervention-related adverse responses and to prepare participants and the research team accordingly. For example, we are aware that the start of app usage is a risk period and that better support may be needed for people who are adjusting to routine self-monitoring, particularly when it is an entirely new concept. There are clear indications to include an initial engagement phase to support people in developing an understanding of the rationale for monitoring their well-being, anticipating the costs and benefits of this approach, having a less fearful response to changes in early signs, and developing greater self-management in response to changes in well-being.

## Strengths and limitations

### Strengths

The trial had a number of important strengths. We established a priori our theory of EWS and relapse; we clearly defined our outcome variable of relapse and established the feasibility of utilising routine clinical data to inform classification of relapse; and we demonstrated reliability in the blind rating of these data to classify relapse events. Linked to our theory of EWS, we established clear mechanisms of relapse detection and prevention, including fear of relapse, personal recovery and self-efficacy.

Across these outcomes we demonstrated signals to suggest that improved outcomes were associated with the EMPOWER arm compared to TAU.

Our study also adds to the growing literature on digital technology for people with psychosis. We demonstrated the feasibility, acceptability and usability of a blended intervention combining digital technology with peer support and clinical triage to assess changes in well-being indicative of EWS, which then activated a relapse prevention pathway to local CMHS.

We delivered a feasibility trial of a digital intervention across two distinct health-care systems, in Scotland and Australia, demonstrating the potential scalability of the EMPOWER intervention across health-care systems internationally.

We overcame important limitations in relation to selection bias in cluster randomised trials by identifying, approaching, consenting and assessing participants prior to revealing allocation. Although this led to some participants dropping out prior to allocation, we learned important lessons for retaining participants in future studies.

This was the first digital technology mental health trial to be regulated by the MHRA. The trial developed significant strengths in the monitoring and detection of adverse events in digital technology trials. In addition, these adverse events have been important in helping shape the future development of the intervention.

### **Limitations**

The study had a number of important limitations. This was a feasibility trial and the outcome signals detected during the study cannot be taken as evidence of efficacy or effectiveness. We require a larger-scale definitive trial to determine effectiveness.

There appeared to be a differential rate of attrition from the EMPOWER arm of the study. This appeared to be related to the initial burden and effects of the intervention in terms of the daily monitoring. In addition, installation of the app could have been improved. More time could also have been spent at the outset supporting engagement with peer support, exploring the benefits and difficulties of self-monitoring and the model underpinning the intervention and linking this to the valued goals of participants. This might have reduced the rate of withdrawal or, at the very least, facilitated planned withdrawal and improved opportunities for participants to consider remaining in the study to complete follow-up assessments or to provide explicit consent for their routine data to be collected from case notes to allow relapse assessment. In retrospect, we do not feel that our participant information sheet was clearly worded in a way that made continued collection of these data possible following withdrawal.

The psychometric properties of the EMPOWER questionnaire require investigation, particularly the sensitivity and specificity to relapse. Our finding was that ChIPs were not specific to relapse, and while this was helpful to enable blending of the monitoring with peer support, we cannot use the measure to reliably predict relapse. In addition, the questionnaire would benefit from further patient and public involvement to help shape the content and range of questions in order to improve its salience for service users.

A further limitation of the study is that we did not measure participants' engagement with self-management interventions. Although we have an ongoing process evaluation, which included in-depth interviews with a purposive sample of just over 40% of participants in the EMPOWER arm, the lack of a quantitative measure of self-management limits how confidently we can understand how the EMPOWER intervention might work. Such a measure would be valuable to include in a main trial.

## Conclusions and recommendations

We demonstrated the feasibility of recruiting and retaining service user participants into the trial. In addition, the rates of data completeness for candidate primary, secondary and mechanistic outcomes over the 12 months were excellent. However, we did identify problems with the completeness of health economic measures data. We demonstrated that we can deliver the EMPOWER intervention blending our mobile app with peer support and an algorithm that supports the delivery of tailored messaging and clinical triage of possible EWS of relapse. In addition, we learned how to integrate CHIPs generated by the algorithm into peer support to promote increased awareness and motivation to engage in self-management. It is likely that EMPOWER may reduce relapse over 12 months and reduce fear of relapse. The intervention may improve other outcomes including negative symptoms, depression, personal recovery and self-efficacy. It is unlikely that EMPOWER improves medication adherence. It is likely that overall the costs of EMPOWER are higher than those of TAU, but the intervention also results in improved QALYs and reduced relapse. The ICER of £3089 per QALY gained is below the current £20,000 threshold recommended by NICE, and there is a 70% probability that EMPOWER is cost-effective from the health-care payer perspective. A further main trial seems merited by these overall findings. We estimate that in a main trial (assuming 90% power and 20% dropout) we would require a sample size of 500 service users to detect a RR of 0.7 for reduction of relapse and for continuous variables effect sizes of between 0.3 and 0.4.

More broadly, this trial has raised a number of important findings for research in digital interventions for psychosis and, potentially, for other conditions. The monitoring of adverse events tends to be poor, and future trials should establish transparent and robust frameworks for the monitoring of adverse events linked to digital interventions. Researchers and clinicians should utilise learning from these events to improve intervention delivery and user experience. Programme theory is critical to driving intervention development and evaluation. This trial raises important issues about the lack of theory underpinning relapse definition and the need to develop better measurements of relapse. Further research is required to incorporate the views of people with lived experience about the definitions of relapse, their preferences for intervention development to support staying well and the development of international consensus on relapse outcomes. More research is needed on peer support to facilitate personal recovery for people with a diagnosis of schizophrenia and in particular the opportunities provided by the integration of digital technology to support and optimise these interventions.

# Acknowledgements

We are grateful to all of the service users, carers and mental health staff and community mental health services who gave their time and resources to contribute to the development of this study during the consultation phase. This was critical in shaping the refinement of the EMPOWER intervention and outcomes. We are grateful to all of the service users, carers and mental health staff and community mental health services who gave their time and resources to contribute to the cluster randomised controlled trial. We would like to acknowledge and recognise the contribution of members of the research team not listed as authors. These include Jayne Artis, Imogen Bell, Emily Castagnini, Andrea Clark, Amy Hood, Maria Lambrou, Casey Lynch, Casey McCrae, Ishani Majmudar, Claire Matrunola, Giada Micolucci, Sophie Norman, Lesley Smith, Suzy Syrett, David Thomson, Helen Whitehill and Alison Wilson Kay. We also express our gratitude to our Study Steering Committee members: Professor David Kingdon (chairperson), Professor Daniel Freeman (independent member), Professor Fiona Lobban (independent member), David Kavanagh (independent member), Frances Simpson (independent public and patient involvement representative) and Graham Morgan (independent public and patient involvement representative). We also express our gratitude to our DMEC members: Professor Emmanuelle Peters (chairperson), Dr Alison Brabban (independent clinician), Professor Rod Taylor (independent statistician) and Professor Greg Murray (independent statistician).

## Contributions of authors

**Professor Andrew I Gumley** (<https://orcid.org/0000-0002-8888-938X>) (Professor of Psychological Therapy) was the chief investigator, with responsibility for all aspects of the study. He was extensively involved in preparing results for, and writing, the monograph.

**Dr Simon Bradstreet** (<https://orcid.org/0000-0002-0339-1882>) (Lecturer in Digital Health Interventions) was the trial manager, with managerial responsibilities across the study. He was extensively involved in preparing the results for, and writing, the monograph.

**Professor John Ainsworth** (<https://orcid.org/0000-0002-2187-9195>) (Professor of Health Informatics) was a principal investigator on the study. He was involved in the design of the study, software development and validation, and final approval of the monograph.

**Stephanie Allan** (<https://orcid.org/0000-0002-1016-0708>) (PhD Candidate) was involved in the analysis of phase 1 and app usage data and contributed to the preparation of the monograph.

**Professor Mario Alvarez-Jimenez** (<https://orcid.org/0000-0002-3535-9086>) (Director, eOrygen) was a principal investigator on the study. He contributed to the design and oversight of the study, and approved the monograph.

**Professor Maximillian Birchwood** (<https://orcid.org/0000-0002-7476-0171>) (Professor of Youth Mental Health) was a principal investigator on the study. He contributed to the design and oversight of the study, and approved the monograph.

**Professor Andrew Briggs** (<https://orcid.org/0000-0002-0777-1997>) (Professor of Health Economics) was a principal investigator on the study. He contributed to the design and oversight of the study, designed and oversaw the health economic analysis plan and approved the monograph.

**Professor Sandra Bucci** (<https://orcid.org/0000-0002-6197-5333>) (Professor of Clinical Psychology) was a principal investigator on the study. She contributed to the design and oversight of the study, was a member of the independent blind panel for relapse assessments, and approved the monograph.

## ACKNOWLEDGEMENTS

**Professor Sue Cotton** (<https://orcid.org/0000-0002-9386-8348>) (Head of Health Services and Outcomes Research, Orygen) was a principal investigator on the study. She contributed to the design and oversight of the study and approved the monograph.

**Dr Lidia Engel** (<https://orcid.org/0000-0002-7959-3149>) (Research Fellow) was a principal investigator on the study. She was involved in the design, analysis and write-up of health economic data for the monograph.

**Professor Paul French** (<https://orcid.org/0000-0003-4300-387X>) (Associate Director for Early Intervention Service) was a principal investigator on the study. He contributed to the design and oversight of the study and approved the monograph.

**Associate Professor Reeva Lederman** (<https://orcid.org/0000-0003-4005-329X>) was a principal investigator on the study. She contributed to the design and oversight of the study and approved the monograph.

**Professor Shôn Lewis** (<https://orcid.org/0000-0003-1861-4652>) (Clinical Professor in Adult Psychiatry) was a principal investigator on the study. He contributed to the design and oversight of the study and approved the monograph.

**Matthew Machin** (<https://orcid.org/0000-0001-6600-9508>) was a principal investigator on the study. He was involved in the design of the study and software development and validation and approved the monograph.

**Professor Graeme MacLennan** (<https://orcid.org/0000-0002-1039-5646>) (Director, CHaRT) was a principal investigator on the study. He was involved in the design of the study, offering expert methodological input. He was involved in the preparation of trial results for publication in the final monograph. He approved the monograph.

**Professor Hamish McLeod** (<https://orcid.org/0000-0002-4225-1815>) (Professor of Clinical Psychology) was a principal investigator on the study. He was involved in the design of the study, oversaw researcher calibration and inter-rater reliability procedures and approved the monograph.

**Nicola McMeekin** (<https://orcid.org/0000-0003-2918-8820>) (Research Assistant) was a health economist on the study. She was involved in the design, analysis and write-up of health economic data for the monograph. She approved the monograph.

**Professor Cathy Mihalopoulos** (<https://orcid.org/0000-0002-7127-9462>) (Chairperson and Head, Deakin Health Economics) was a principal investigator on the study. She contributed to the design and oversight of the study, designed and oversaw the health economic analysis plan and approved the monograph.

**Dr Emma Morton** (<https://orcid.org/0000-0001-6179-1983>) was a research co-ordinator on the study, with managerial responsibilities for the study in Melbourne. She was extensively involved in assessments and other research procedures and approved the monograph.

**Professor John Norrie** (<https://orcid.org/0000-0001-9823-9252>) (Director, Chairperson of Medical Statistics and Trial Methodology, University of Edinburgh) was a principal investigator on the study. He was involved in the design of the study, offering expert methodological input, and approved the monograph.

**Frank Reilly** (<https://orcid.org/0000-0002-3742-6668>) (Director, Scottish Recovery Network) was a principal investigator on the study. He employed the research assistant in Glasgow and approved the monograph.

**Professor Matthias Schwannauer** (<https://orcid.org/0000-0002-4683-2596>) (Professor of Clinical Psychology) was a principal investigator on the study. He was involved in the design and oversight of the study, was a member of the independent blind panel for relapse assessments and approved the monograph.

**Professor Swaran P Singh** (<https://orcid.org/0000-0003-3454-2089>) (Professor of Social and Community Psychiatry) was a principal investigator on the study. He was involved in the design and oversight of the study and approved the monograph.

**Professor Suresh Sundrum** (<https://orcid.org/0000-0002-9674-0227>) (Head, Department of Psychiatry, Monash University) was a principal investigator on the study. He was involved in the design and oversight of the study and approved the monograph.

**Associate Professor Andrew Thompson** (<https://orcid.org/0000-0002-0567-6013>) (Associate Clinical Professor in Psychiatry) was a principal investigator on the study. He was involved in the design and oversight of the study and approved the monograph.

**Professor Chris Williams** (<https://orcid.org/0000-0001-5387-2863>) (Honorary Senior Research Fellow) was a principal investigator on the study. He was involved in the design of the study and approved the monograph.

**Professor Alison Yung** (<https://orcid.org/0000-0002-0401-9791>) (Professor of Psychiatry) was a principal investigator on the study. She was involved in the design and oversight of the study and approved the monograph.

**Dr Lorna Aucott** (<https://orcid.org/0000-0001-6277-7972>) (Statistician) was a statistician on the study. She was involved in the analysis and preparation of trial results for publication in the final monograph.

**Associate Professor John Farhall** (<https://orcid.org/0000-0003-2439-2830>) (Psychology and Counselling) was co-chief investigator for the study in Australia, with responsibility for all aspects of the study there. He was involved in preparing results for, and writing, the monograph.

**Professor John Gleeson** (<https://orcid.org/0000-0001-7969-492X>) (Professor of Psychology) was co-chief investigator for the study in Australia, with responsibility for all aspects of the study there. He was involved in preparing results for, and writing, the monograph.

## Publications

Allan S, Bradstreet S, McLeod H, Gleeson J, Farhall J, Lambrou M, *et al*. Service Users, Carers and Mental Health Staff understandings of early warning signs of relapse in psychosis: a qualitative investigation. *BJPsych Open* 2019;**6**:1–7.

Allan S, McLeod H, Bradstreet S, Beedie S, Moir B, Gleeson J, *et al*. Understanding implementation of a digital self-monitoring intervention for relapse prevention in psychosis: protocol for a mixed-methods process evaluation. *JMIR Res Protoc* 2019;**8**:e15634.

Allan S, Bradstreet S, McLeod H, Farhall J, Lambrou M, Gleeson J, *et al*. Monitoring early signs of psychosis relapse using a mobile app: developing a hypothetical implementation framework of expectations for staff, carers and service users using qualitative methods. *J Med Internet Res* 2019;**21**:e14366.

Bradstreet S, Allan S, Gumley A. Adverse event monitoring in mHealth for psychosis interventions provides an important opportunity for learning. *J Ment Health* 2019;**28**:461–6.

## ACKNOWLEDGEMENTS

Gumley A, Bradstreet S, Ainsworth J, Allan S, Alvarez-Jinenez M, Beattie L, *et al.* Early signs Monitoring to Prevent relapse in psychosis and prOmote Wellbeing, Engagement and Recovery (EMPOWER): protocol for a feasibility cluster randomized controlled trial harnessing mobile phone technology blended with peer support. *JMIR Res Protoc* 2020;**9**:e15058.

Allan S, McLeod H, Bradstreet S, Bell I, Whitehall H, Wilson-Kay A, *et al.* Perspectives of trial staff on the barriers recruitment in a digital intervention for psychosis and how to work around them: qualitative study within a trial. *JMIR Hum Factors* 2021;**8**:e24055.

Gumley AI, Bradstreet S, Ainsworth J, Allan S, Alvarez-Jimenez M, Aucott L, *et al.* The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia. *Lancet Psychiatry* 2022;**9**:477–86.

## Data-sharing statement

We shall make data available to the scientific community with as few restrictions as feasible, while retaining exclusive use until the publication of major outputs. The data will be made available via the corresponding author.

## Patient data

This work uses data provided by patients and collected by the NHS as part of their care and support. Using patient data is vital to improve health and care for everyone. There is huge potential to make better use of information from people's patient records, to understand more about disease, develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone's privacy, and it's important that there are safeguards to make sure that it is stored and used responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives You can find out more about the background to this citation here: <https://understandingpatientdata.org.uk/data-citation>.

## References

1. Radua J, Ramella-Cravaro V, Ioannidis JPA, Reichenberg A, Phiphophathsanee N, Amir T, *et al.* What causes psychosis? An umbrella review of risk and protective factors. *World Psychiatry* 2018;**17**:49–66. <https://doi.org/10.1002/wps.20490>
2. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. *PLOS Med* 2005;**2**:e141. <https://doi.org/10.1371/journal.pmed.0020141>
3. Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, *et al.* Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016. *Schizophr Bull* 2018;**44**:1195–203. <https://doi.org/10.1093/schbul/sby058>
4. Vos T, Abajobir AA, Abbafati C, Abbas KM, Abate KH, Abd-Allah F, *et al.* Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;**390**:1211–59. [https://doi.org/10.1016/S0140-6736\(17\)32154-2](https://doi.org/10.1016/S0140-6736(17)32154-2)
5. Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. *Lancet Psychiatry* 2017;**4**:295–301. [https://doi.org/10.1016/S2215-0366\(17\)30078-0](https://doi.org/10.1016/S2215-0366(17)30078-0)
6. Doyle R, O’Keeffe D, Hannigan A, Kinsella A, Behan C, Kelly A, *et al.* The iHOPE-20 study: mortality in first episode psychosis—a 20-year follow-up of the Dublin first episode cohort. *Soc Psychiatry Psychiatr Epidemiol* 2019;**54**:1337–42. <https://doi.org/10.1007/s00127-019-01721-x>
7. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. *Arch Gen Psychiatry* 2007;**64**:1123. <https://doi.org/10.1001/archpsyc.64.10.1123>
8. Rethink. *The Abandoned Illness: A Report by the Schizophrenia Commission*. London: Rethink; 2012.
9. Neil AL, Carr VJ, Mihalopoulos C, Mackinnon A, Morgan VA. Costs of psychosis in 2010: findings from the second Australian National Survey of Psychosis. *Aust N Z J Psychiatry* 2014;**48**:169–82. <https://doi.org/10.1177/0004867413500352>
10. Hui CLM, Honer WG, Lee EHM, Chang WC, Chan SKW, Chen ESM, *et al.* Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. *Lancet Psychiatry* 2018;**5**:432–42. [https://doi.org/10.1016/S2215-0366\(18\)30090-7](https://doi.org/10.1016/S2215-0366(18)30090-7)
11. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, *et al.* Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. *Arch Gen Psychiatry* 1999;**56**:241–7. <https://doi.org/10.1001/archpsyc.56.3.241>
12. Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, *et al.* Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. *Schizophr Res* 2012;**139**:116–28. <https://doi.org/10.1016/j.schres.2012.05.007>
13. Bergé D, Mané A, Salgado P, Cortizo R, Garnier C, Gomez L, *et al.* Predictors of relapse and functioning in first-episode psychosis: a two-year follow-up study. *Psychiatr Serv* 2016;**67**:227–33. <https://doi.org/10.1176/appi.ps.201400316>



14. Pelayo-Terán JM, Gajardo Galán VG, de la Ortiz-García de la Foz V, Martínez-García O, Tabarés-Seisdedos R, Crespo-Facorro B, Ayesa-Arriola R. Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP). *Eur Arch Psychiatry Clin Neurosci* 2017;**267**:315–23. <https://doi.org/10.1007/s00406-016-0740-3>
15. Morgan VA, Waterreus A, Jablensky A, Mackinnon A, McGrath JJ, Carr V, *et al.* People living with psychotic illness in 2010: the second Australian national survey of psychosis. *Aust N Z J Psychiatry* 2012;**46**:735–52. <https://doi.org/10.1177/0004867412449877>
16. White RG, Gumley AI. Postpsychotic posttraumatic stress disorder. *J Nerv Ment Dis* 2009;**197**:841–9. <https://doi.org/10.1097/NMD.0b013e3181bea625>
17. Gumley AI, MacBeth A, Reilly JD, O'Grady M, White RG, McLeod H, *et al.* Fear of recurrence: results of a randomized trial of relapse detection in schizophrenia. *Br J Clin Psychol* 2015;**54**:49–62. <https://doi.org/10.1111/bjc.12060>
18. Lal S, Malla A, Marandola G, Thériault J, Tibbo P, Manchanda R, *et al.* 'Worried about relapse': family members' experiences and perspectives of relapse in first-episode psychosis. *Early Interv Psychiatry* 2019;**13**:24–9. <https://doi.org/10.1111/eip.12440>
19. Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. *BMC Psychiatry* 2010;**10**:2. <https://doi.org/10.1186/1471-244X-10-2>
20. Zeidler J, Slawik L, Fleischmann J, Greiner W. The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective. *Health Econ Rev* 2012;**2**:9. <https://doi.org/10.1186/2191-1991-2-9>
21. Raudino A, Carr VJ, Bush R, Saw S, Burgess P, Morgan VA. Patterns of service utilisation in psychosis: findings of the 2010 Australian national survey of psychosis. *Aust N Z J Psychiatry* 2014;**48**:341–51. <https://doi.org/10.1177/0004867413511996>
22. Gaebel W, Riesbeck M. Are there clinically useful predictors and early warning signs for pending relapse? *Schizophr Res* 2014;**152**:469–77. <https://doi.org/10.1016/j.schres.2013.08.003>
23. Sullivan S, Northstone K, Gadd C, Walker J, Margelyte R, Richards A, Whiting P. Models to predict relapse in psychosis: a systematic review. *PLOS ONE* 2017;**12**:e0183998. <https://doi.org/10.1371/journal.pone.0183998>
24. Subotnik KL, Nuechterlein KH, Ventura J, Gitlin MJ, Marder S, Mintz J, *et al.* Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. *Am J Psychiatry* 2011;**168**:286–92. <https://doi.org/10.1176/appi.ajp.2010.09010087>
25. Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, *et al.* Attitudes toward antipsychotic medication. *Arch Gen Psychiatry* 2005;**62**:717. <https://doi.org/10.1001/archpsyc.62.7.717>
26. Lambert M, Conus P, Cotton S, Robinson J, McGorry PD, Schimmelmann BG. Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosis. *J Clin Psychopharmacol* 2010;**30**:565–72. <https://doi.org/10.1097/JCP.0b013e3181f058a0>
27. Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. *Psychiatry Res* 2010;**176**:109–13. <https://doi.org/10.1016/j.psychres.2009.05.004>
28. Rummel-Kluge C, Schuster T, Peters S, Kissling W. Partial compliance with antipsychotic medication is common in patients with schizophrenia. *Aust N Z J Psychiatry* 2008;**42**:382–8. <https://doi.org/10.1080/00048670801961107>

29. Rooke O, Birchwood M. Loss, humiliation and entrapment as appraisals of schizophrenic illness: a prospective study of depressed and non-depressed patients. *Br J Clin Psychol* 1998;**37**:259–68. <https://doi.org/10.1111/j.2044-8260.1998.tb01384.x>
30. Gleeson JF, Rawlings D, Jackson HJ, McGorry PD. Agreeableness and neuroticism as predictors of relapse after first-episode psychosis: a prospective follow-up study. *J Nerv Ment Dis* 2005;**193**:160–9. <https://doi.org/10.1097/01.nmd.0000154841.99550.d3>
31. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. *Schizophr Bull* 1998;**24**:75–85. <https://doi.org/10.1093/oxfordjournals.schbul.a033315>
32. Vigod SN, Kurdyak PA, Dennis CL, Leszcz T, Taylor VH, Blumberger DM, Seitz DP. Transitional interventions to reduce early psychiatric readmissions in adults: systematic review. *Br J Psychiatry* 2013;**202**:187–94. <https://doi.org/10.1192/bjp.bp.112.115030>
33. National Institute for Health and Care Excellence. *Psychosis and Schizophrenia in Adults: Prevention and Management*. Clinical Guideline 178. London: NICE; 2014.
34. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet* 2013;**382**:951–62. [https://doi.org/10.1016/S0140-6736\(13\)60733-3](https://doi.org/10.1016/S0140-6736(13)60733-3)
35. Zhao YJ, Lin L, Teng M, Khoo AL, Soh LB, Furukawa TA, et al. Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials. *BJPsych Open* 2016;**2**:59–66. <https://doi.org/10.1192/bjpo.bp.115.002576>
36. Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. *World Psychiatry* 2019;**18**:208–24. <https://doi.org/10.1002/wps.20632>
37. Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, et al. What CATIE found: results from the schizophrenia trial. *Psychiatr Serv* 2008;**59**:500–6. <https://doi.org/10.1176/ps.2008.59.5.500>
38. Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Orbach G, Morgan C. Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. *Psychol Med* 2002;**32**:763–82. <https://doi.org/10.1017/s0033291702005895>
39. Zimmermann G, Favrod J, Trieu VH, Pomini V. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis. *Schizophr Res* 2005;**77**:1–9. <https://doi.org/10.1016/j.schres.2005.02.018>
40. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. *Schizophr Bull* 2008;**34**:523–37. <https://doi.org/10.1093/schbul/sbm114>
41. Lincoln TM, Suttner C, Nestoriuc Y. [Effects of cognitive interventions for schizophrenia: a meta-analysis.] *Psychol Rundschau* 2008;**59**:217–32. <https://doi.org/10.1026/0033-3042.59.4.217>
42. Jones C, Cormac I, Silveira daMota Neto J, Campbell C. Cognitive-behaviour therapy for schizophrenia. *Cochrane Database Syst Rev* 2004;**4**:159–63. <https://doi.org/10.1002/14651858.CD000524.pub2>
43. Jauhar S, McKenna PJ, Radua J, Fung E, Salvador R, Laws KR. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. *Br J Psychiatry* 2014;**204**:20–9. <https://doi.org/10.1192/bjp.bp.112.116285>

44. Jones C, Hacker D, Cormac I, Meaden A, Irving CB. Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. *Cochrane Database Syst Rev* 2012;**4**:CD008712. <https://doi.org/10.1002/14651858.CD008712.pub2>
45. Haddock G, Spaulding W. Family interventions for psychosis. *Prog Neurol Psychiatry* 2013;**17**:18–9. <https://doi.org/10.1002/pnp.273>
46. Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. *Cochrane Database Syst Rev* 2010;**12**:CD000088. <https://doi.org/10.1002/14651858.CD000088.pub2>
47. Harvey C, Lewis J, Farhall J. Receipt and targeting of evidence-based psychosocial interventions for people living with psychoses: findings from the second Australian national survey of psychosis. *Epidemiol Psychiatr Sci* 2019;**28**:613–29. <https://doi.org/10.1017/S2045796018000288>
48. Birchwood M, Smith J, Macmillan F, Hogg B, Prasad R, Harvey C, Bering S. Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. *Psychol Med* 1989;**19**:649–56. <https://doi.org/10.1017/s0033291700024247>
49. Herz MI. Prodromal symptoms and prevention of relapse in schizophrenia. *J Clin Psychiatry* 1985;**46**:22–5.
50. Birchwood M, Spencer E, McGovern D. Schizophrenia: early warning signs. *Adv Psychiatr Treat* 2000;**6**:93–101. <https://doi.org/10.1192/apt.6.2.93>
51. Spaniel F, Bakstein E, Anyz J, Hlinka J, Sieger T, Hrdlicka J, et al. Relapse in schizophrenia: definitively not a bolt from the blue. *Neurosci Lett* 2018;**669**:68–74. <https://doi.org/10.1016/j.neulet.2016.04.044>
52. Eisner E, Drake R, Barrowclough C. Assessing early signs of relapse in psychosis: review and future directions. *Clin Psychol Rev* 2013;**33**:637–53. <https://doi.org/10.1016/j.cpr.2013.04.001>
53. Gumley A, O'Grady M, McNay L, Reilly J, Power K, Norrie J. Early intervention for relapse in schizophrenia: results of a 12-month randomized controlled trial of cognitive behavioural therapy. *Psychol Med* 2003;**33**:419–31. <https://doi.org/10.1017/s0033291703007323>
54. Herz MI, Lamberti JS, Mintz J, Scott R, O'Dell SP, McCartan L, Nix G. A program for relapse prevention in schizophrenia: a controlled study. *Arch Gen Psychiatry* 2000;**57**:277–83. <https://doi.org/10.1001/archpsyc.57.3.277>
55. Lee SH, Choi TK, Suh S, Kim YW, Kim B, Lee E, Yook KH. Effectiveness of a psychosocial intervention for relapse prevention in patients with schizophrenia receiving risperidone via long-acting injection. *Psychiatry Res* 2010;**175**:195–9. <https://doi.org/10.1016/j.psychres.2008.06.043>
56. Stenberg JH, Jääskeläinen IP, Røyks R. The effect of symptom self-management training on rehospitalization for chronic schizophrenia in Finland. *Int Rev Psychiatry* 1998;**10**:58–61. <https://doi.org/10.1080/09540269875113>
57. van Meijel B, van der Gaag M, Kahn RS, Grypdonck M. The practice of early recognition and early intervention to prevent psychotic relapse in patients with schizophrenia: an exploratory study. Part 1. *J Psychiatr Ment Health Nurs* 2002;**9**:347–55. <https://doi.org/10.1046/j.1365-2850.2002.00500.x>
58. Marder SR, Wirshing WC, Van Putten T, Mintz J, McKenzie J, Johnston-Cronk K, et al. Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia. *Arch Gen Psychiatry* 1994;**51**:280–7. <https://doi.org/10.1001/archpsyc.1994.03950040024003>

59. Carpenter WT, Heinrichs DW. Early intervention, time-limited, targeted pharmacotherapy of schizophrenia. *Schizophr Bull* 1983;**9**:533–42. <https://doi.org/10.1093/schbul/9.4.533>
60. Carpenter WT, Heinrichs DW, Hanlon TE. A comparative trial of pharmacologic strategies in schizophrenia. *Am J Psychiatry* 1987;**144**:1466–70. <https://doi.org/10.1176/ajp.144.11.1466>
61. Wiedemann G, Hahlweg K, Müller U, Feinstein E, Hank G, Dose M. Effectiveness of targeted intervention and maintenance pharmacotherapy in conjunction with family intervention in schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 2001;**251**:72–84. <https://doi.org/10.1007/s004060170056>
62. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. *J Clin Psychiatry* 2007;**68**:654–61. <https://doi.org/10.4088/jcp.v68n0502>
63. Carpenter WT, Hanlon TE, Heinrichs DW, Summerfelt AT, Kirkpatrick B, Levine J, Buchanan RW. Continuous versus targeted medication in schizophrenic outpatients: outcome results. *Am J Psychiatry* 1990;**147**:1138–48. <https://doi.org/10.1176/ajp.147.9.1138>
64. Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, *et al.* Relapse prevention in first-episode schizophrenia – maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. *J Clin Psychiatry* 2011;**72**:205–18. <https://doi.org/10.4088/JCP.09m05459yel>
65. Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV, Hafez H, *et al.* Intermittent vs. maintenance medication in schizophrenia. Two-year results. *Arch Gen Psychiatry* 1991;**48**:333–9. <https://doi.org/10.1001/archpsyc.1991.01810280049007>
66. Prytys M, Garety PA, Jolley S, Onwumere J, Craig T. Implementing the NICE guideline for schizophrenia recommendations for psychological therapies: a qualitative analysis of the attitudes of CMHT staff. *Clin Psychol Psychother* 2011;**18**:48–59. <https://doi.org/10.1002/cpp.691>
67. Jolley AG, Hirsch SR, McRink A, Manchanda R. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. *BMJ* 1989;**298**:985–90. <https://doi.org/10.1136/bmj.298.6679.985>
68. Pietzcker A, Gaebel W, Köpcke W, Linden M, Müller P, Müller-Spahn F, *et al.* Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia-2-year results of a German multicenter study. *J Psychiatr Res* 1993;**27**:321–39. [https://doi.org/10.1016/0022-3956\(93\)90059-B](https://doi.org/10.1016/0022-3956(93)90059-B)
69. Ruskin PE, Bland W, Feldman S. Continuous vs. targeted medication in older schizophrenic outpatients. *Am J Geriatr Psychiatry* 1994;**2**:134–43. <https://doi.org/10.1097/00019442-199405000-00007>
70. Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, *et al.* Relapse rehospitalization schizophrenia. *Arch Gen Psychiatry* 1997;**54**:453–63. <https://doi.org/10.1001/archpsyc.1997.01830170079011>
71. Morriss R, Vinjamuri I, Faizal MA, Bolton CA, McCarthy JP. Training to recognise the early signs of recurrence in schizophrenia. *Cochrane Database Syst Rev* 2013;**2**:CD005147. <https://doi.org/10.1002/14651858.CD005147.pub2>
72. van Os J, Kapur S. Schizophrenia. *Lancet* 2009;**374**:635–45. [https://doi.org/10.1016/S0140-6736\(09\)60995-8](https://doi.org/10.1016/S0140-6736(09)60995-8)

73. Birchwood M. Pathways to emotional dysfunction in first-episode psychosis. *Br J Psychiatry* 2003;**182**:373–5. <https://doi.org/10.1192/bjp.182.5.373>
74. Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: systematic review of risk factors. *Br J Psychiatry* 2005;**187**:9–20. <https://doi.org/10.1192/bjp.187.1.9>
75. Phillips LJ, Francey SM, Edwards J, McMurray N. Strategies used by psychotic individuals to cope with life stress and symptoms of illness: a systematic review. *Anxiety Stress Coping* 2009;**22**:371–410. <https://doi.org/10.1080/10615800902811065>
76. Horan WP, Ventura J, Mintz J, Kopelowicz A, Wirshing D, Christian-Herman J, et al. Stress and coping responses to a natural disaster in people with schizophrenia. *Psychiatry Res* 2007;**151**:77–86. <https://doi.org/10.1016/j.psychres.2006.10.009>
77. Lysaker PH, Taylor AC. Personality dimensions in schizophrenia: associations with symptoms and coping concurrently and 12 months later. *Psychopathology* 2007;**40**:338–44. <https://doi.org/10.1159/000105532>
78. Lysaker PH, Wilt MA, Plascak-Hallberg CD, Brenner CA, Clements CA. Personality dimensions in schizophrenia: associations with symptoms and coping. *J Nerv Ment Dis* 2003;**191**:80–6. <https://doi.org/10.1097/01.NMD.0000050936.81128.5B>
79. Tait L, Birchwood M, Trower P. Adapting to the challenge of psychosis: personal resilience and the use of sealing-over (avoidant) coping strategies. *Br J Psychiatry* 2004;**185**:410–15. <https://doi.org/10.1192/bjp.185.5.410>
80. Lysaker PH, Bryson GJ, Marks K, Greig TC, Bell MD. Coping style in schizophrenia: associations with neurocognitive deficits and personality. *Schizophr Bull* 2004;**30**:113–21. <https://doi.org/10.1093/oxfordjournals.schbul.a007056>
81. Gumley AI, Taylor HE, Schwannauer M, MacBeth A. A systematic review of attachment and psychosis: measurement, construct validity and outcomes. *Acta Psychiatr Scand* 2014;**129**:257–74. <https://doi.org/10.1111/acps.12172>
82. Bucci S, Roberts NH, Danquah AN, Berry K. Using attachment theory to inform the design and delivery of mental health services: a systematic review of the literature. *Psychol Psychother* 2015;**88**:1–20. <https://doi.org/10.1111/papt.12029>
83. Freeman D, Garety PA, Kuipers E. Persecutory delusions: developing the understanding of belief maintenance and emotional distress. *Psychol Med* 2001;**31**:1293–306. <https://doi.org/10.1017/s003329170100455x>
84. Thornicroft G, Farrelly S, Szmukler G, Birchwood M, Waheed W, Flach C, et al. Clinical outcomes of joint crisis plans to reduce compulsory treatment for people with psychosis: a randomised controlled trial. *Lancet* 2013;**381**:1634–41. [https://doi.org/10.1016/S0140-6736\(13\)60105-1](https://doi.org/10.1016/S0140-6736(13)60105-1)
85. Farrelly S, Brown G, Rose D, Doherty E, Henderson RC, Birchwood M, et al. What service users with psychotic disorders want in a mental health crisis or relapse: thematic analysis of joint crisis plans. *Soc Psychiatry Psychiatr Epidemiol* 2014;**49**:1609–17. <https://doi.org/10.1007/s00127-014-0869-1>
86. Gumley AI, Park C. Relapse Prevention in Early Psychosis. In French P, Reed M, Rayne M, Shiers D, Smith J, editors. *Promoting Recovery in Early Psychosis: A Practice Manual*. Chichester: Wiley-Blackwell; 2010. pp. 157–65. <https://doi.org/10.1002/9781444318814.ch18>
87. Eisner E, Barrowclough C, Lobban F, Drake R. Qualitative investigation of targets for and barriers to interventions to prevent psychosis relapse. *BMC Psychiatry* 2014;**14**:201. <https://doi.org/10.1186/1471-244X-14-201>

88. Takahashi D. *Newzoo: Smartphone Users will Top 3 Billion in 2018, Hit 3.8 Billion by 2021*. 2018. URL: <https://venturebeat.com/2018/09/11/newzoo-smartphone-users-will-top-3-billion-in-2018-hit-3-8-billion-by-2021/> (accessed 26 June 2019).
89. Robotham D, Satkunanathan S, Doughty L, Wykes T. Do we still have a digital divide in mental health? A five-year survey follow-up. *J Med Internet Res* 2016;**18**:e309. <https://doi.org/10.2196/jmir.6511>
90. Firth J, Cotter J, Torous J, Bucci S, Firth JA, Yung AR. Mobile phone ownership and endorsement of 'mHealth' among people with psychosis: a meta-analysis of cross-sectional studies. *Schizophr Bull* 2016;**42**:448–55. <https://doi.org/10.1093/schbul/sbv132>
91. Simblett S, Greer B, Matcham F, Curtis H, Polhemus A, Ferrão J, *et al*. Barriers to and facilitators of engagement with remote measurement technology for managing health: systematic review and content analysis of findings. *J Med Internet Res* 2018;**20**:e10480. <https://doi.org/10.2196/10480>
92. Gleeson JF, Alvarez-Jimenez M, Lederman R. Moderated online social therapy for recovery from early psychosis. *Psychiatr Serv* 2012;**63**:719. <https://doi.org/10.1176/appi.ps.20120p719>
93. O'Hanlon P, Aref-Adib G, Fonseca A, Lloyd-Evans B, Osborn D, Johnson S. Tomorrows world: current developments in the therapeutic use of technology for psychosis. *BJPsych Adv* 2016;**22**:301–10. <https://doi.org/10.1192/apt.bp.115.014654>
94. Ben-Zeev D, Davis KE, Kaiser S, Krzsos I, Drake RE. Mobile technologies among people with serious mental illness: opportunities for future services. *Adm Policy Ment Health* 2013;**40**:340–3. <https://doi.org/10.1007/s10488-012-0424-x>
95. Naslund JA, Marsch LA, McHugo GJ, Bartels SJ. Emerging mHealth and eHealth interventions for serious mental illness: a review of the literature. *J Ment Health* 2015;**24**:321–32. <https://doi.org/10.3109/09638237.2015.1019054>
96. Torous J, Firth J, Mueller N, Onnela JP, Baker JT. Methodology and reporting of mobile health and smartphone application studies for schizophrenia. *Harv Rev Psychiatry* 2017;**25**:146–54. <https://doi.org/10.1097/HRP.000000000000133>
97. Španiel F, Hrdlička J, Novák T, Kožený J, Höschl C, Mohr P, Motlová LB. Effectiveness of the information technology-aided program of relapse prevention in schizophrenia (ITAREPS): a randomized, controlled, double-blind study. *J Psychiatr Pract* 2012;**18**:269–80. <https://doi.org/10.1097/01.pra.0000416017.45591.c1>
98. Barnett I, Torous J, Staples P, Sandoval L, Keshavan M, Onnela JP. Relapse prediction in schizophrenia through digital phenotyping: a pilot study. *Neuropsychopharmacology* 2018;**43**:1660–6. <https://doi.org/10.1038/s41386-018-0030-z>
99. Cella M, He Z, Killikelly C, Okruszek Ł, Lewis S, Wykes T. Blending active and passive digital technology methods to improve symptom monitoring in early psychosis. *Early Interv Psychiatry* 2019;**13**:1271–5. <https://doi.org/10.1111/eip.12796>
100. Bell IH, Lim MH, Rossell SL, Thomas N. Ecological momentary assessment and intervention in the treatment of psychotic disorders: a systematic review. *Psychiatr Serv* 2017;**68**:1172–81. <https://doi.org/10.1176/appi.ps.201600523>
101. Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. *Annu Rev Clin Psychol* 2008;**4**:1–32. <https://doi.org/10.1146/annurev.clinpsy.3.022806.091415>
102. Ben-Zeev D, Brenner CJ, Begale M, Duffecy J, Mohr DC, Mueser KT. Feasibility, acceptability, and preliminary efficacy of a smartphone intervention for schizophrenia. *Schizophr Bull* 2014;**40**:1244–53. <https://doi.org/10.1093/schbul/sbu033>

103. Ben-Zeev D, Wang R, Abdullah S, Brian R, Scherer EA, Mistler LA, *et al.* Mobile behavioral sensing for outpatients and inpatients with schizophrenia. *Psychiatr Serv* 2016;**67**:558–61. <https://doi.org/10.1176/appi.ps.201500130>
104. Depp CA, Mausbach B, Granholm E, Cardenas V, Ben-Zeev D, Patterson TL, *et al.* Mobile interventions for severe mental illness: design and preliminary data from three approaches. *J Nerv Ment Dis* 2010;**198**:715–21. <https://doi.org/10.1097/NMD.0b013e3181f49ea3>
105. Granholm E, Ben-Zeev D, Link PC, Bradshaw KR, Holden JL. Mobile Assessment and Treatment for Schizophrenia (MATS): a pilot trial of an interactive text-messaging intervention for medication adherence, socialization, and auditory hallucinations. *Schizophr Bull* 2012;**38**:414–25. <https://doi.org/10.1093/schbul/sbr155>
106. Pijnenborg GHM, Withaar FK, Brouwer WH, Timmerman ME, Van Den Bosch RJ, Evans JJ. The efficacy of SMS text messages to compensate for the effects of cognitive impairments in schizophrenia. *Br J Clin Psychol* 2010;**49**:259–74. <https://doi.org/10.1348/014466509X467828>
107. Sablier J, Stip E, Jacquet P, Giroux S, Pigot H, Franck N, Mobus Group. Ecological assessments of activities of daily living and personal experiences with Mobus, an assistive technology for cognition: a pilot study in schizophrenia. *Assist Technol* 2012;**24**:67–77. <https://doi.org/10.1080/10400435.2012.659324>
108. Spaniel F, Vohlídka P, Hrdlicka J, Kozený J, Novák T, Motlová L, *et al.* ITAREPS: information technology aided relapse prevention programme in schizophrenia. *Schizophr Res* 2008;**98**:312–17. <https://doi.org/10.1016/j.schres.2007.09.005>
109. Spaniel F, Vohlídka P, Kozený J, Novák T, Hrdlicka J, Motlová L, *et al.* The Information Technology Aided Relapse Prevention Programme in Schizophrenia: an extension of a mirror-design follow-up. *Int J Clin Pract* 2008;**62**:1943–6. <https://doi.org/10.1111/j.1742-1241.2008.01903.x>
110. Eisner E, Bucci S, Berry N, Emsley R, Barrowclough C, Drake RJ. Feasibility of using a smartphone app to assess early signs, basic symptoms and psychotic symptoms over six months: a preliminary report. *Schizophr Res* 2019;**208**:105–13. <https://doi.org/10.1016/j.schres.2019.04.003>
111. Komatsu H, Sekine Y, Okamura N, Kanahara N, Okita K, Matsubara S, *et al.* Effectiveness of Information Technology Aided Relapse Prevention Programme in Schizophrenia excluding the effect of user adherence: a randomized controlled trial. *Schizophr Res* 2013;**150**:240–4. <https://doi.org/10.1016/j.schres.2013.08.007>
112. Schultze-Lutter F, Klosterkötter J, Picker H, Steinmeyer EM, Ruhrmann S. Predicting first-episode psychosis by basic symptom criteria. *Clin Neuropsychiatry* 2007;**4**:11–22.
113. Bradstreet S, Allan S, Gumley A. Adverse event monitoring in mHealth for psychosis interventions provides an important opportunity for learning. *J Ment Health* 2019;**28**:461–6. <https://doi.org/10.1080/09638237.2019.1630727>
114. Ng MM, Firth J, Minen M, Torous J. User engagement in mental health apps: a review of measurement, reporting, and validity. *Psychiatr Serv* 2019;**70**:538–44. <https://doi.org/10.1176/appi.ps.201800519>
115. Aref-Adib G, McCloud T, Ross J, O'Hanlon P, Appleton V, Rowe S, *et al.* Factors affecting implementation of digital health interventions for people with psychosis or bipolar disorder, and their family and friends: a systematic review. *Lancet Psychiatry* 2019;**6**:257–66. [https://doi.org/10.1016/S2215-0366\(18\)30302-X](https://doi.org/10.1016/S2215-0366(18)30302-X)
116. Biagianni B, Hidalgo-Mazzei D, Meyer N. Developing digital interventions for people living with serious mental illness: perspectives from three mHealth studies. *Evid Based Ment Health* 2017;**20**:98–101. <https://doi.org/10.1136/eb-2017-102765>

117. Killikelly C, He Z, Reeder C, Wykes T. Improving adherence to web-based and mobile technologies for people with psychosis: systematic review of new potential predictors of adherence. *JMIR Mhealth Uhealth* 2017;**5**:e94. <https://doi.org/10.2196/mhealth.7088>
118. Chinman M, McInnes DK, Eisen S, Ellison M, Farkas M, Armstrong M, Resnick SG. Establishing a research agenda for understanding the role and impact of mental health peer specialists. *Psychiatr Serv* 2017;**68**:955–7. <https://doi.org/10.1176/appi.ps.201700054>
119. Repper J, Carter T. A review of the literature on peer support in mental health services. *J Ment Health* 2011;**20**:392–411. <https://doi.org/10.3109/09638237.2011.583947>
120. Gillard S, Foster R, Gibson S, Goldsmith L, Marks J, White S. Describing a principles-based approach to developing and evaluating peer worker roles as peer support moves into mainstream mental health services. *Ment Heal Soc Incl* 2017;**21**:133–43. <https://doi.org/10.1108/MHSI-03-2017-0016>
121. Lloyd-Evans B, Mayo-Wilson E, Harrison B, Istead H, Brown E, Pilling S, et al. A systematic review and meta-analysis of randomised controlled trials of peer support for people with severe mental illness. *BMC Psychiatry* 2014;**14**:39. <https://doi.org/10.1186/1471-244X-14-39>
122. Pitt V, Lowe D, Hill S, Pictor M, Hetrick SE, Ryan R, Berends L. Consumer-providers of care for adult clients of statutory mental health services. *Cochrane Database Syst Rev* 2013;**3**:CD004807. <https://doi.org/10.1002/14651858.CD004807.pub2>
123. Johnson S, Lamb D, Marston L, Osborn D, Mason O, Henderson C, et al. Peer-supported self-management for people discharged from a mental health crisis team: a randomised controlled trial. *Lancet* 2018;**392**:409–18. [https://doi.org/10.1016/S0140-6736\(18\)31470-3](https://doi.org/10.1016/S0140-6736(18)31470-3)
124. Fortuna KL, Brooks JM, Umucu E, Walker R, Chow PI. Peer support: a human factor to enhance engagement in digital health behavior change interventions. *J Technol Behav Sci* 2019;**4**:152–61. <https://doi.org/10.1007/s41347-019-00105-x>
125. Yadav P, Kr Yadav U, Verma S. Software testing: approach to identify software bugs. *Int J Res Rev Eng Sci Technol* 2012;**1**:26–30.
126. Ritchie J, Lewis J. *Qualitative Research Practice: A Guide for Social Science Students and Researchers*. London: SAGE Publications Ltd; 2003.
127. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. *BMC Med Res Methodol* 2013;**13**:117. <https://doi.org/10.1186/1471-2288-13-117>
128. NHS Digital. *Approved Cryptographic Algorithms: Good Practice Guideline*. London: NHS Digital; 2016.
129. International Organization for Standardization. *ISO/IEC 25010:2011. Systems and Software Engineering – Systems and Software Quality Requirements and Evaluation (SQuARE) – System and Software Quality Models*. Geneva: International Organization for Standardization; 2017.
130. European Parliament and Council of the European Union. *General Data Protection Regulation*. 2016.
131. Gumley A, Bradstreet S, Ainsworth J, Allan S, Alvarez-Jimenez M, Beattie L, et al. Early signs monitoring to prevent relapse in psychosis and promote well-being, engagement, and recovery: protocol for a feasibility cluster randomized controlled trial harnessing mobile phone technology blended with peer support. *JMIR Res Protoc* 2020;**9**:e15058. <https://doi.org/10.2196/15058>
132. Campbell MK, Piaggio G, Elbourne DR, Altman DG, CONSORT Group. Consort 2010 statement: extension to cluster randomised trials. *BMJ* 2012;**345**:e5661. <https://doi.org/10.1136/bmj.e5661>



## REFERENCES

133. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA, PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *Pilot Feasibility Stud* 2016;**2**:64. <https://doi.org/10.1186/s40814-016-0105-8>
134. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA* 2013;**310**:2191–4. <https://doi.org/10.1001/jama.2013.281053>
135. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, *et al.* [Better reporting of interventions: Template for Intervention Description and Replication (TIDieR) checklist and guide.] *Gesundheitswesen* 2016;**78**:175–88. <https://doi.org/10.1055/s-0041-111066>
136. Solomon P. Peer support/peer provided services underlying processes, benefits, and critical ingredients. *Psychiatr Rehabil J* 2004;**27**:392–401. <https://doi.org/10.2975/27.2004.392.401>
137. George LC, O'Hagan M, Bradstreet S, Burge M. The Emerging Field of Peer Support within Mental Health Services. In Smith M, Jury A, editors. *Workforce Development Theory and Practice in the Mental Health Sector*. Hershey, PA: IGI Global; 2016. pp. 222–50.
138. Scottish Recovery Network. *Experts by Experience: Values Framework for Peer Working*. Glasgow: Scottish Recovery Network; 2012.
139. Palmier-Claus JE, Ainsworth J, Machin M, Barrowclough C, Dunn G, Barkus E, *et al.* The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. *BMC Psychiatry* 2012;**12**:172. <https://doi.org/10.1186/1471-244X-12-172>
140. Palmier-Claus JE, Rogers A, Ainsworth J, Machin M, Barrowclough C, Laverty L, *et al.* Integrating mobile-phone based assessment for psychosis. *BMC Psychiatry* 2013;**13**:34. <https://doi.org/10.1186/1471-244X-13-34>
141. Ainsworth J, Palmier-Claus JE, Machin M, Barrowclough C, Dunn G, Rogers A, *et al.* A comparison of two delivery modalities of a mobile phone-based assessment for serious mental illness: native smartphone application vs text-messaging only implementations. *J Med Internet Res* 2013;**15**:e60. <https://doi.org/10.2196/jmir.2328>
142. Lewis SW, Ainsworth J, Sanders C, Stockton-Powdrell C, Machin M, Whelan P, *et al.* Smartphone-enhanced symptom management in psychosis: an open, randomized controlled trial. *J Med Internet Res* 2020;**22**:e17019.
143. Stoyanov SR, Hides L, Kavanagh DJ, Wilson H. Development and validation of the user version of the Mobile Application Rating Scale (uMARS). *JMIR Mhealth Uhealth* 2016;**4**:e72. <https://doi.org/10.2196/mhealth.5849>
144. Great Britain. *The Medical Devices Regulations 2002*. London: The Stationery Office; 2002.
145. International Organization for Standardization. *Clinical Investigation of Medical Devices for Human Subjects – Good Clinical Practice*. Geneva: International Organization for Standardization; 2011.
146. World Health Organization. *Handbook for Good Clinical Research Practice (GCP): Guidance for Implementation*. Geneva: World Health Organization; 2002.
147. Goodwin I, Holmes G, Cochrane R, Mason O. The ability of adult mental health services to meet clients' attachment needs: the development and implementation of the service attachment questionnaire. *Psychol Psychother* 2003;**76**:145–61. <https://doi.org/10.1348/147608303765951186>
148. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. *Schizophr Res* 2000;**42**:241–7. [https://doi.org/10.1016/S0920-9964\(99\)00130-9](https://doi.org/10.1016/S0920-9964(99)00130-9)

149. Great Britain. *Mental Health Act 1983*. London: The Stationery Office; 1983.
150. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull* 1987;**13**:261–76. <https://doi.org/10.1093/schbul/13.2.261>
151. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. *Acta Psychiatr Scand* 2000;**101**:323–9. <https://doi.org/10.1034/j.1600-0447.2000.101004323.x>
152. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. *Schizophr Res* 1990;**3**:247–51. [https://doi.org/10.1016/0920-9964\(90\)90005-R](https://doi.org/10.1016/0920-9964(90)90005-R)
153. Sobell LC, Sobell MB. Alcohol Timeline Followback (TFLB). In Rush J, editor. *Handbook of Psychiatric Measures*. Washington, DC: American Psychiatric Association; 2000. pp. 477–9.
154. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983;**67**:361–70. <https://doi.org/10.1111/j.1600-0447.1983.tb09716.x>
155. Birchwood M, Jackson C, Brunet K, Holden J, Barton K. Personal beliefs about illness questionnaire-revised (PBIQ-R): reliability and validation in a first episode sample. *Br J Clin Psychol* 2012;**51**:448–58. <https://doi.org/10.1111/j.2044-8260.2012.02040.x>
156. Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. *Health Econ* 2018;**27**:7–22. <https://doi.org/10.1002/hec.3564>
157. Richardson J, Sinha K, Iezzi A, Khan MA. Modelling utility weights for the Assessment of Quality of Life (AQoL)-8D. *Qual Life Res* 2014;**23**:2395–404. <https://doi.org/10.1007/s11136-014-0686-8>
158. Hoefman RJ, van Exel NJ, Looren de Jong S, Redekop WK, Brouwer WB. A new test of the construct validity of the CarerQol instrument: measuring the impact of informal care giving. *Qual Life Res* 2011;**20**:875–87. <https://doi.org/10.1007/s11136-010-9829-8>
159. Neil ST, Kilbride M, Pitt L, Nothard S, Welford M, Sellwood W, et al. The questionnaire about the process of recovery (QPR): a measurement tool developed in collaboration with service users. *Psychosis* 2009;**1**:145–55. <https://doi.org/10.1080/17522430902913450>
160. Schwarzer R, Jerusalem M. Generalized Self-efficacy Scale. In Weinman J, Wright S, Johnston M, editors. *Measures in Health Psychology: A User's Portfolio*. Windsor: NFER-Nelson; 1995. pp. 35–7.
161. Berry K, Wearden A. Attachment styles, interpersonal relationships and psychotic phenomena in a non-clinical student sample. *Pers Individ Dif* 2006;**41**:707–18. <https://doi.org/10.1016/j.paid.2006.03.009>
162. Chambless DL, Blake KD. Construct validity of the perceived criticism measure. *Behav Ther* 2009;**40**:155–63. <https://doi.org/10.1016/j.beth.2008.05.005>
163. van Wijngaarden B, Schene AH, Koeter M, Vázquez-Barquero JL, Knudsen HC, Lasalvia A, McCrone P. Caregiving in schizophrenia: development, internal consistency and reliability of the Involvement Evaluation Questionnaire – European Version. EPSILON Study 4. European Psychiatric Services: inputs linked to outcome domains and needs. *Br J Psychiatry Suppl* 2000;**39**:s21–7. <https://doi.org/10.1192/bjp.177.39.s21>
164. Tait L, Birchwood M, Trower P. A new scale (SES) to measure engagement with community mental health services. *J Ment Health* 2002;**11**:191–8. <https://doi.org/10.1080/09638230020023570-2>

165. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, *et al.* Process evaluation of complex interventions: Medical Research Council guidance. *BMJ* 2015;**350**:h1258. <https://doi.org/10.1136/bmj.h1258>
166. Allan S, McLeod H, Bradstreet S, Beedie S, Moir B, Gleeson J, *et al.* Understanding implementation of a digital self-monitoring intervention for relapse prevention in psychosis: protocol for a mixed method process evaluation. *JMIR Res Protoc* 2019;**8**:e15634. <https://doi.org/10.2196/15634>
167. University of Aberdeen. *Statistical Analysis Plans*. URL: [www.abdn.ac.uk/hsru/what-we-do/trials-unit/statistical-analysis-plans-611.php](http://www.abdn.ac.uk/hsru/what-we-do/trials-unit/statistical-analysis-plans-611.php) (accessed 13 September 2019).
168. Zou G. A modified Poisson regression approach to prospective studies with binary data. *Am J Epidemiol* 2004;**159**:702–6. <https://doi.org/10.1093/aje/kwh090>
169. Brazier J, Connell J, Papaioannou D, Mukuria C, Mulhern B, Peasgood T, *et al.* A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. *Health Technol Assess* 2014;**18**(34). <https://doi.org/10.3310/hta18340>
170. Bucci S, Barrowclough C, Ainsworth J, Machin M, Morris R, Berry K, *et al.* Actissist: proof-of-concept trial of a theory-driven digital intervention for psychosis. *Schizophr Bull* 2018;**44**:1070–80. <https://doi.org/10.1093/schbul/sby032>
171. Torous J, Woodyatt J, Keshavan M, Tully LM. A new hope for early psychosis care: the evolving landscape of digital care tools. *Br J Psychiatry* 2019;**214**:269–72. <https://doi.org/10.1192/bjp.2019.8>
172. Greenhalgh T, Wherton J, Papoutsis C, Lynch J, Hughes G, A'Court C, *et al.* Beyond adoption: a new framework for theorizing and evaluating nonadoption, abandonment, and challenges to the scale-up, spread, and sustainability of health and care technologies. *J Med Internet Res* 2017;**19**:e367. <https://doi.org/10.2196/jmir.8775>
173. Department of Health and Social Care. *A Framework for Mental Health Research*. London: Department of Health and Social Care; 2017.
174. Christie HL, Martin JL, Connor J, Tange HJ, Verhey FRJ, de Vugt ME, Orrell M. eHealth interventions to support caregivers of people with dementia may be proven effective, but are they implementation-ready? *Internet Interv* 2019;**18**:100260. <https://doi.org/10.1016/j.invent.2019.100260>
175. Torous J, Firth J. Bridging the dichotomy of actual versus aspirational digital health. *World Psychiatry* 2018;**17**:108–9. <https://doi.org/10.1002/wps.20464>
176. Arnold C, Villagonzalo KA, Meyer D, Farhall J, Foley F, Kyrios M, Thomas N. Predicting engagement with an online psychosocial intervention for psychosis: exploring individual- and intervention-level predictors. *Internet Interv* 2019;**18**:100266. <https://doi.org/10.1016/j.invent.2019.100266>
177. Greenhalgh T, Snow R, Ryan S, Rees S, Salisbury H. Six 'biases' against patients and carers in evidence-based medicine. *BMC Med* 2015;**13**:200. <https://doi.org/10.1186/s12916-015-0437-x>
178. Faulkner A. *Randomised Controlled Trials: The Straitjacket of Mental Health Research?* London: McPin Foundation; 2015.
179. Gray-Burrows KA, Willis TA, Foy R, Rathfelder M, Bland P, Chin A, *et al.* Role of patient and public involvement in implementation research: a consensus study. *BMJ Qual Saf* 2018;**27**:858–64. <https://doi.org/10.1136/bmjqs-2017-006954>

180. Turner S, D'Lima D, Hudson E, Morris S, Sheringham J, Swart N, Fulop NJ. Evidence use in decision-making on introducing innovations: a systematic scoping review with stakeholder feedback. *Implement Sci* 2017;**12**:145. <https://doi.org/10.1186/s13012-017-0669-6>
181. Brocklehurst PR, Williams L, Burton C, Goodwin T, Rycroft-Malone J. Implementation and trial evidence: a plea for fore-thought. *Br Dent J* 2017;**222**:331–5. <https://doi.org/10.1038/sj.bdj.2017.213>
182. Braithwaite J, Churruca K, Long JC, Ellis LA, Herkes J. When complexity science meets implementation science: a theoretical and empirical analysis of systems change. *BMC Med* 2018;**16**:63. <https://doi.org/10.1186/s12916-018-1057-z>
183. Moore GF, Evans RE. What theory, for whom and in which context? Reflections on the application of theory in the development and evaluation of complex population health interventions. *SSM Popul Health* 2017;**3**:132–5. <https://doi.org/10.1016/j.ssmph.2016.12.005>
184. Sutcliffe K, Thomas J, Stokes G, Hinds K, Bangpan M. Intervention component analysis (ICA): a pragmatic approach for identifying the critical features of complex interventions. *Syst Rev* 2015;**4**:140. <https://doi.org/10.1186/s13643-015-0126-z>
185. Hardy A, Wojdecka A, West J, Matthews E, Golby C, Ward T, *et al.* How inclusive, user-centered design research can improve psychological therapies for psychosis: development of SlowMo. *JMIR Ment Health* 2018;**5**:e11222. <https://doi.org/10.2196/11222>
186. Huerta-Ramos E, Escobar-Villegas MS, Rubinstein K, Unoka ZS, Grasa E, Hospedales M, *et al.* measuring users' receptivity toward an integral intervention model based on mHealth Solutions for Patients With Treatment-Resistant Schizophrenia (m-RESIST): a qualitative study. *JMIR Mhealth Uhealth* 2016;**4**:e112. <https://doi.org/10.2196/mhealth.5716>
187. Lobban F, Appleton V, Appelbe D, Barraclough J, Bowland J, Fisher NR, *et al.* IMPLementation of A Relatives' Toolkit (IMPART study): an iterative case study to identify key factors impacting on the implementation of a web-based supported self-management intervention for relatives of people with psychosis or bipolar experiences in a National Health Service: a study protocol. *Implement Sci* 2017;**12**:152. <https://doi.org/10.1186/s13012-017-0687-4>
188. Bonell C, Fletcher A, Morton M, Lorenc T, Moore L. Realist randomised controlled trials: a new approach to evaluating complex public health interventions. *Soc Sci Med* 2012;**75**:2299–306. <https://doi.org/10.1016/j.socscimed.2012.08.032>
189. Greenhalgh T. What have the social sciences ever done for equity in health policy and health systems? *Int J Equity Health* 2018;**17**:1–3. <https://doi.org/10.1186/s12939-018-0842-9>
190. May CR, Cummings A, Girling M, Bracher M, Mair FS, May CM, *et al.* Using normalization process theory in feasibility studies and process evaluations of complex healthcare interventions: a systematic review. *Implement Sci* 2018;**13**:80. <https://doi.org/10.1186/s13012-018-0758-1>
191. May CR, Mair F, Finch T, MacFarlane A, Dowrick C, Treweek S, *et al.* Development of a theory of implementation and integration: normalization process theory. *Implement Sci* 2009;**4**:29. <https://doi.org/10.1186/1748-5908-4-29>
192. Davidoff F, Dixon-Woods M, Leviton L, Michie S. Demystifying theory and its use in improvement. *BMJ Qual Saf* 2015;**24**:228–38. <https://doi.org/10.1136/bmjqs-2014-003627>
193. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care* 2007;**19**:349–57. <https://doi.org/10.1093/intqhc/mzm042>

## REFERENCES

194. Braun V, Clarke V. Novel insights into patients' life-worlds: the value of qualitative research. *Lancet Psychiatry* 2019;**6**:720–1. [https://doi.org/10.1016/S2215-0366\(19\)30296-2](https://doi.org/10.1016/S2215-0366(19)30296-2)
195. Krueger RA, Casey MA. *Focus Groups: A Practical Guide for Applied Research*. 4th edn. London: SAGE Publications Ltd; 2008.
196. Bertolino A. *Software Testing Research: Achievements, Challenges, Dreams*. Future of Software Engineering (FOSE '07), Minneapolis, MN; 2007. pp. 85–103. <https://doi.org/10.1109/FOSE.2007.25>
197. Bucholtz M. The politics of transcription. *J Pragmat* 2000;**32**:1439–65. [https://doi.org/10.1016/S0378-2166\(99\)00094-6](https://doi.org/10.1016/S0378-2166(99)00094-6)
198. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol* 2006;**3**:77–101. <https://doi.org/10.1191/1478088706qp063oa>
199. Doyle S. Member checking with older women: a framework for negotiating meaning. *Health Care Women Int* 2007;**28**:888–908. <https://doi.org/10.1080/07399330701615325>
200. Smith JA. Beyond the divide between cognition and discourse: using interpretative phenomenological analysis in health psychology. *Psychol Heal* 1996;**11**:261–71. <https://doi.org/10.1080/08870449608400256>
201. Smith JA, Flowers P, Larkin M. *Interpretative Phenomenological Analysis: Theory, Method and Research*. London: SAGE; 2009.
202. Smith JA, Osborn M. Interpretative Phenomenological Analysis. In Smith JA, editor. *Qualitative Psychology: A Practical Guide to Research Methods*. London: SAGE Publications Ltd; 2003. pp. 53–80.
203. Murray E, Treweek S, Pope C, MacFarlane A, Ballini L, Dowrick C, *et al*. Normalisation process theory: a framework for developing, evaluating and implementing complex interventions. *BMC Med* 2010;**8**:63. <https://doi.org/10.1186/1741-7015-8-63>
204. Greer B, Robotham D, Simblett S, Curtis H, Griffiths H, Wykes T. Digital exclusion among mental health service users: qualitative investigation. *J Med Internet Res* 2019;**21**:e11696. <https://doi.org/10.2196/11696>
205. Berry N, Bucci S, Lobban F. Use of the internet and mobile phones for self-management of severe mental health problems: qualitative study of staff views. *JMIR Ment Health* 2017;**4**:e52. <https://doi.org/10.2196/mental.8311>
206. May CR, Johnson M, Finch T. Implementation, context and complexity. *Implement Sci* 2016;**11**:141. <https://doi.org/10.1186/s13012-016-0506-3>
207. Farrelly S, Lester H, Rose D, Birchwood M, Marshall M, Waheed W, *et al*. Barriers to shared decision making in mental health care: qualitative study of the Joint Crisis Plan for psychosis. *Health Expect* 2016;**19**:448–58. <https://doi.org/10.1111/hex.12368>
208. Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. *BMC Health Serv Res* 2017;**17**:88. <https://doi.org/10.1186/s12913-017-2031-8>
209. Vilardaga R, Rizo J, Kientz JA, McDonell MG, Ries RK, Sobel K. User experience evaluation of a smoking cessation app in people with serious mental illness. *Nicotine Tob Res* 2016;**18**:1032–8. <https://doi.org/10.1093/ntr/ntv256>
210. Ben-Zeev D, Kaiser SM, Brenner CJ, Begale M, Duffecy J, Mohr DC. Development and usability testing of FOCUS: a smartphone system for self-management of schizophrenia. *Psychiatr Rehabil J* 2013;**36**:289–96. <https://doi.org/10.1037/prj0000019>

211. Kumar D, Tully LM, Iosif AM, Zaksorn LN, Nye KE, Zia A, Niendam TA. A mobile health platform for clinical monitoring in early psychosis: implementation in community-based outpatient early psychosis care. *JMIR Ment Health* 2018;**5**:e15. <https://doi.org/10.2196/mental.8551>
212. Suka M, Yamauchi T, Yanagisawa H. Comparing responses to differently framed and formatted persuasive messages to encourage help-seeking for depression in Japanese adults: a cross-sectional study with 2-month follow-up. *BMJ Open* 2018;**8**:e020823. <https://doi.org/10.1136/bmjopen-2017-020823>
213. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? *Schizophr Res* 2005;**79**:231–8. <https://doi.org/10.1016/j.schres.2005.04.008>
214. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. *Br J Psychiatry Suppl* 1993;**163**:39–44. <https://doi.org/10.1192/S0007125000292581>
215. Eysenbach G. The law of attrition. *J Med Internet Res* 2005;**7**:e11. <https://doi.org/10.2196/jmir.7.1.e11>
216. Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. *Biometrics* 1997;**53**:983–97. <https://doi.org/10.2307/2533558>
217. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, *et al*. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;**20**:1727–36. <https://doi.org/10.1007/s11136-011-9903-x>
218. Brouwer WB, van Exel NJ, van Gorp B, Redekop WK. The CarerQol instrument: a new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations. *Qual Life Res* 2006;**15**:1005–21. <https://doi.org/10.1007/s11136-005-5994-6>
219. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, *et al*. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. *BMJ* 2013;**346**:1–6. <https://doi.org/10.1136/bmj.f1049>
220. National Institute for Health and Care Excellence. *Guide to the Methods of Technology Appraisal* 2013. London: National Institute for Health and Care Excellence; 2013.
221. Department of Health. *Pharmaceutical Benefits Advisory Committee. Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee (Version 5.0)*. Canberra, ACT: Department of Health; 2016.
222. Campbell and Cochrane Economics Methods Group, Evidence for Policy and Practice Information and Coordinating Centre. *CCEMG- EPPI Centre Cost Converter*. CCEMG-EPPI; 2019. URL: <https://eppi.ioe.ac.uk/costconversion/default.aspx> (accessed 9 September 2019).
223. Tate DF, Finkelstein EA, Khavjou O, Gustafson A. Cost effectiveness of internet interventions: review and recommendations. *Ann Behav Med* 2009;**38**:40–5. <https://doi.org/10.1007/s12160-009-9131-6>
224. Johns B, Baltussen R, Hutubessy R. Programme costs in the economic evaluation of health interventions. *Cost Eff Resour Alloc* 2003;**1**:1. <https://doi.org/10.1186/1478-7547-1-1>
225. Donker T, Blankers M, Hedman E, Ljótsson B, Petrie K, Christensen H. Economic evaluations of Internet interventions for mental health: a systematic review. *Psychol Med* 2015;**45**:3357–76. <https://doi.org/10.1017/S0033291715001427>

## REFERENCES

226. Australian Bureau of Statistics. *Australian Demographic Statistics, Dec 2018*. Canberra, ACT: Australian Bureau of Statistics; 2019.
227. Office for National Statistics. *Overview of the UK Population: July 2017*. Newport: Office for National Statistics; 2017.
228. Simeone JC, Ward AJ, Rotella P, Collins J, Windisch R. An evaluation of variation in published estimates of schizophrenia prevalence from 1990–2013: a systematic literature review. *BMC Psychiatry* 2015;**15**:1–14. <https://doi.org/10.1186/s12888-015-0578-7>
229. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. *Lancet* 2012;**379**:2063–71. [https://doi.org/10.1016/S0140-6736\(12\)60239-6](https://doi.org/10.1016/S0140-6736(12)60239-6)
230. Oppong R, Coast J, Hood K, Nuttall J, Smith RD, Butler CC, GRACE-01 Study Team. Resource use and costs of treating acute cough/lower respiratory tract infections in 13 European countries: results and challenges. *Eur J Health Econ* 2011;**12**:319–29. <https://doi.org/10.1007/s10198-010-0239-1>
231. Rivero-Arias O, Gray A. The multinational nature of cost-effectiveness analyses alongside multinational clinical trials. *Value Health* 2010;**13**:34–41. <https://doi.org/10.1111/j.1524-4733.2009.00582.x>
232. Oppong R, Jowett S, Roberts TE. Economic evaluation alongside multinational studies: a systematic review of empirical studies. *PLOS ONE* 2015;**10**:e0131949. <https://doi.org/10.1371/journal.pone.0131949>
233. NHS Improvement. *Reference Costs 2017/18: Highlights, Analysis and Introduction to the Data*. 2018. URL: <https://webarchive.nationalarchives.gov.uk/20200501111106/https://improvement.nhs.uk/resources/reference-costs/> (accessed 17 February 2021).
234. Curtis LA, Burns A. *Unit Costs of Health and Social Care 2018*. Canterbury: Personal Social Services Research Unit, University of Kent; 2018.
235. Joint Formulary Committee. *British National Formulary* 72 ed. London: BMJ Group and Pharmaceutical Press; 2017.
236. Australian Government, Department of Health. *2017 MBS File Downloads*. URL: [www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Downloads-2017-PDF](http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Downloads-2017-PDF) (accessed 18 February 2021).
237. Department of Health, Australian Government. *Pharmaceutical Benefits Scheme (PBS)*. URL: <https://pbs.gov.au/pbs/home;jsessionid=1rhrjqs83awc412dygpt5trt0o> (accessed 16 September 2019).
238. Independent Hospital Pricing Authority. *National Hospital Cost Data Collection Report, Public Sector, Round 21 (Financial Year 2016–17)*. URL: [www.ihpa.gov.au/sites/default/files/publications/national\\_hospital\\_cost\\_data\\_collection\\_australian\\_public\\_hospitals\\_cost\\_report\\_round\\_21\\_2016-17.pdf](http://www.ihpa.gov.au/sites/default/files/publications/national_hospital_cost_data_collection_australian_public_hospitals_cost_report_round_21_2016-17.pdf) (accessed 18 February 2021).
239. Australian Institute for Health and Welfare. *Mental Health Services in Australia*. URL: [www.aihw.gov.au/reports/mental-health-services/mental-health-services-in-australia/report-contents/expenditure-on-mental-health-related-services/specialised-mental-health-services-expenditure](http://www.aihw.gov.au/reports/mental-health-services/mental-health-services-in-australia/report-contents/expenditure-on-mental-health-related-services/specialised-mental-health-services-expenditure) (accessed 18 February 2021).
240. State of Victoria. *Department of Health and Human Services Policy and Funding Guidelines 2015. Volume 2: Health Operations 2015–16. Chapter 2: Pricing and Funding Arrangements for Victoria's Health System*. URL: [www.dhhs.vic.gov.au/policy-and-funding-guidelines-health-services](http://www.dhhs.vic.gov.au/policy-and-funding-guidelines-health-services) (accessed 18 February 2021).

241. Bedfordshire Police, Cambridgeshire Constabulary and Hertfordshire Constabulary (Strategic Alliance). *2017/2018 Fees and Charges Handbook*. 2017. URL: [www.herts.police.uk/assets/Information-and-services/About-us/AboutUs-FeesChargesHandbook-201718.pdf](http://www.herts.police.uk/assets/Information-and-services/About-us/AboutUs-FeesChargesHandbook-201718.pdf) (accessed 17 February 2021).
242. Productivity Commission. *Report on Government Services*. Melbourne, VIC: Productivity Commission; 2019. URL: [www.pc.gov.au/research/ongoing/report-on-government-services](http://www.pc.gov.au/research/ongoing/report-on-government-services) (accessed 9 September 2019).
243. Scottish Government. *Costs of the Criminal Justice System in Scotland Dataset 2018*. Edinburgh: Scottish Government; 2018.
244. Australian Bureau of Statistics. *4513.0 – Criminal Courts, Australia, 2017–18*. Canberra, ACT: Australian Bureau of Statistics; 2019. URL: [www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/4513.0Main+Features12017-18?OpenDocument=](http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/4513.0Main+Features12017-18?OpenDocument=) (accessed 9 September 2019).
245. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. *Pharmacoeconomics* 1993;4:353–65. <https://doi.org/10.2165/00019053-199304050-00006>
246. National Institute for Health and Care Excellence. *Position Statement on Use of the EQ-5D-5L Valuation Set for England (Updated November 2018)*. 2018. URL: [www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l](http://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l) (accessed 3 September 2019).
247. Hernández-Alava M, Pudney S. eq5dmap: a command for mapping between EQ-5D-3L and EQ-5D-5L. *Stata J* 2018;18:395–415. <https://doi.org/10.1177/1536867X1801800207>
248. Hoefman RJ, van Exel J, Brouwer WBF. Measuring care-related quality of life of caregivers for use in economic evaluations: CarerQol tariffs for Australia, Germany, Sweden, UK, and US. *Pharmacoeconomics* 2017;35:469–78. <https://doi.org/10.1007/s40273-016-0477-x>
249. Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. *Pharmacoeconomics* 2014;32:1157–70. <https://doi.org/10.1007/s40273-014-0193-3>
250. Rubin D. *Multiple Imputation for Nonresponse in Surveys*. New York, NY: Wiley and Sons; 2004.
251. Ferguson CJ. An effect size primer: a guide for clinicians and researchers. *Prof Psychol Res Pract* 2009;40:532–8. <https://doi.org/10.1037/a0015808>
252. Jordhøy MS, Fayers PM, Ahlner-Elmqvist M, Kaasa S. Lack of concealment may lead to selection bias in cluster randomized trials of palliative care. *Palliat Med* 2002;16:43–9. <https://doi.org/10.1191/0269216302pm523oa>
253. Togerson DJ, Togerson CJ. *Designing Randomised Controlled Trials in Health, Education and Social Sciences. An Introduction*. New York, NY: Palgrave Macmillan; 2008. [https://doi.org/10.1057/9780230583993\\_9](https://doi.org/10.1057/9780230583993_9)
254. Giraudeau B, Ravaud P. Preventing bias in cluster randomised trials. *PLOS Med* 2009;6:e1000065. <https://doi.org/10.1371/journal.pmed.1000065>
255. Kelders SM, Kok RN, Ossebaard HC, Van Gemert-Pijnen JE. Persuasive system design does matter: a systematic review of adherence to web-based interventions. *J Med Internet Res* 2012;14:e152. <https://doi.org/10.2196/jmir.2104>
256. Perski O, Blandford A, West R, Michie S. Conceptualising engagement with digital behaviour change interventions: a systematic review using principles from critical interpretive synthesis. *Transl Behav Med* 2017;7:254–67. <https://doi.org/10.1007/s13142-016-0453-1>



257. Bucci S, Morris R, Berry K, Berry N, Haddock G, Barrowclough C, *et al.* Early psychosis service user views on digital technology: qualitative analysis. *JMIR Ment Health* 2018;**5**:e10091. <https://doi.org/10.2196/10091>
258. Eisner E, Drake RJ, Berry N, Barrowclough C, Emsley R, Machin M, *et al.* Development, usability and long-term acceptability of ExPRESS, a smartphone app to monitor basic symptoms and early signs of psychosis relapse. *JMIR MHealth UHealth* 2019;**7**:e11568. <https://doi.org/10.2196/11568>
259. Aref-Adib G, O'Hanlon P, Fullarton K, Morant N, Sommerlad A, Johnson S, Osborn D. A qualitative study of online mental health information seeking behaviour by those with psychosis. *BMC Psychiatry* 2016;**16**:232. <https://doi.org/10.1186/s12888-016-0952-0>
260. Allan S, Bradstreet S, McLeod H, Farhall J, Gleeson J, Clark A, *et al.* Monitoring early signs of psychosis relapse using a mobile app: developing a hypothetical implementation framework of expectations for staff, carers and service users using qualitative methods. *J Med Internet Res* 2019;**21**:e14366. <https://doi.org/10.2196/14366>
261. Gleeson JF, Alvarez-Jimenez M, Cotton SM, Parker AG, Hetrick S. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. *Schizophr Res* 2010;**119**:79–88. <https://doi.org/10.1016/j.schres.2010.02.1073>
262. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. *Mol Psychiatry* 2013;**18**:53–66. <https://doi.org/10.1038/mp.2011.143>
263. Sim J. Should treatment effects be estimated in pilot and feasibility studies? *Pilot Feasibility Stud* 2019;**5**:1–7. <https://doi.org/10.1186/s40814-019-0493-7>
264. Eldridge SM, Costelloe CE, Kahan BC, Lancaster GA, Kerry SM. How big should the pilot study for my cluster randomised trial be? *Stat Methods Med Res* 2015;**25**:1039–56. <https://doi.org/10.1177/0962280215588242>
265. Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. *Stat Methods Med Res* 2016;**25**:1057–73. <https://doi.org/10.1177/0962280215588241>
266. Honary M, Fisher NR, McNaney R, Lobban F. A web-based intervention for relatives of people experiencing psychosis or bipolar disorder: design study using a user-centered approach. *JMIR Ment Health* 2018;**5**:e11473. <https://doi.org/10.2196/11473>
267. Lobban F, Robinson H, Appelbe D, Barraclough J, Bedson E, Collinge L, *et al.* Protocol for an online randomised controlled trial to evaluate the clinical and cost-effectiveness of a peer-supported self-management intervention for relatives of people with psychosis or bipolar disorder: Relatives Education And Coping Toolkit (REACT). *BMJ Open* 2017;**7**:e016965. <https://doi.org/10.1136/bmjopen-2017-016965>
268. Lederman R, Gleeson J, Wadley G, D'alfonso S, Rice S, Santesteban-Echarri O, *et al.* Support for carers of young people with mental illness. *ACM Trans Comput Interact* 2019;**26**:1–33. <https://doi.org/10.1145/3301421>
269. Keetharuth AD, Brazier J, Connell J, Bjorner JB, Carlton J, Taylor Buck E, *et al.* Recovering Quality of Life (ReQoL): a new generic self-reported outcome measure for use with people experiencing mental health difficulties. *Br J Psychiatry* 2018;**212**:42–9. <https://doi.org/10.1192/bjp.2017.10>

270. Ben-Zeev D, Brian R, Wang R, Wang W, Campbell AT, Aung MSH, *et al.* CrossCheck: integrating self-report, behavioral sensing, and smartphone use to identify digital indicators of psychotic relapse. *Psychiatr Rehabil J* 2017;**40**:266–75. <https://doi.org/10.1037/prj0000243>
271. Buck B, Scherer E, Brian R, Wang R, Wang W, Campbell A, *et al.* Relationships between smartphone social behavior and relapse in schizophrenia: a preliminary report. *Schizophr Res* 2019;**208**:167–72. <https://doi.org/10.1016/j.schres.2019.03.014>
272. Fraccaro P, Beukenhorst A, Sperrin M, Harper S, Palmier-Claus J, Lewis S, *et al.* Digital biomarkers from geolocation data in bipolar disorder and schizophrenia: a systematic review. *J Am Med Inform Assoc* 2019;**26**:1412–20. <https://doi.org/10.1093/jamia/ocz043>
273. Kimhy D, Delespaul P, Corcoran C, Ahn H, Yale S, Malaspina D. Computerized experience sampling method (ESMc): assessing feasibility and validity among individuals with schizophrenia. *J Psychiatr Res* 2006;**40**:221–30. <https://doi.org/10.1016/j.jpsychires.2005.09.007>
274. Myin-Germeyns I, Krabbendam L, Delespaul PAEG, Van Os J. Do life events have their effect on psychosis by influencing the emotional reactivity to daily life stress? *Psychol Med* 2003;**33**:327–33. <https://doi.org/10.1017/S0033291702006785>
275. Wykes T, Schueller S. Why reviewing apps is not enough: Transparency for Trust (T4T) principles of responsible health app marketplaces. *J Med Internet Res* 2019;**21**:e12390. <https://doi.org/10.2196/12390>
276. Scherer EA, Ben-Zeev D, Li Z, Kane JM. Analyzing mHealth engagement: joint models for intensively collected user engagement data. *JMIR Mhealth Uhealth* 2017;**5**:e1. <https://doi.org/10.2196/mhealth.6474>
277. Murray JM, French DP, Patterson CC, Kee F, Gough A, Tang J, Hunter RF. Predicting outcomes from engagement with specific components of an internet-based physical activity intervention with financial incentives: process analysis of a cluster randomized controlled trial. *J Med Internet Res* 2019;**21**:e11394. <https://doi.org/10.2196/11394>
278. Torous J, Nicholas J, Larsen ME, Firth J, Christensen H. Clinical review of user engagement with mental health smartphone apps: evidence, theory and improvements. *Evid Based Ment Health* 2018;**21**:116–19. <https://doi.org/10.1136/eb-2018-102891>
279. Curtis LA, Burns A. *Unit Costs of Health and Social Care 2015*. Canterbury: Personal Social Services Research Unit, University of Kent; 2015.
280. Curtis LA, Burns A. *Unit Costs of Health and Social Care 2017*. Canterbury: Personal Social Services Research Unit, University of Kent; 2017.
281. Information Services Division (NHS National Services Scotland). *Scottish Health Service Costs: Year Ended 31 March 2017*. 2018. URL: <https://beta.isdscotland.org/find-publications-and-data/healthcare-resources/finance/scottish-health-service-costs/20-november-2018/> (accessed 17 February 2021).
282. Office for National Statistics. *Average Hourly Pay*. GOV.UK; 2018. URL: [www.ethnicity-facts-figures.service.gov.uk/work-pay-and-benefits/pay-and-income/average-hourly-pay/latest](http://www.ethnicity-facts-figures.service.gov.uk/work-pay-and-benefits/pay-and-income/average-hourly-pay/latest) (accessed 9 September 2019).
283. Australian Government. *Report on Government Services 2019 – Chapter 11 Ambulance Services*. URL: [www.pc.gov.au/research/ongoing/report-on-government-services/2019/health/ambulance-services](http://www.pc.gov.au/research/ongoing/report-on-government-services/2019/health/ambulance-services) (accessed 18 February 2021).

## REFERENCES

284. Australian Government Fair Work Ombudsman. *Minimum Wages*. URL: [www.fairwork.gov.au/how-we-will-help/templates-and-guides/fact-sheets/minimum-workplace-entitlements/minimum-wages](http://www.fairwork.gov.au/how-we-will-help/templates-and-guides/fact-sheets/minimum-workplace-entitlements/minimum-wages) (accessed 18 February 2021).
285. Australian Bureau of Statistics. *Characteristics of Employment, Australia, August 2018*. URL: [www.abs.gov.au/statistics/labour/earnings-and-work-hours/characteristics-employment-australia/latest-release](http://www.abs.gov.au/statistics/labour/earnings-and-work-hours/characteristics-employment-australia/latest-release) (accessed 18 February 2021).

# Appendix 1 Novel or adapted measures

## Feasibility

### All service users

1) Do you use health and wellbeing Apps?

0	Not sure	If yes please specify:
1	Yes	
2	No	

2) Roughly how often do you use health and wellbeing Apps?

0	Not sure
1	Not at all
2	Rarely
3	Sometimes
4	Often

3) In the last three months how often have you sought help in relation to your early warning signs?

0	Not sure
1	Not at all
2	Rarely
3	Sometimes
4	Often

4) In the last three months how often has your family member or a carer sought help on your behalf in relation to your early warning signs?

0	Not sure
1	Not at all
2	Rarely
3	Sometimes
4	Often

5) How often has this resulted in a change in your clinical care e.g. appointment brought forward, changes in medication, referral to crisis team?

0	Not sure
1	Not at all
2	Rarely
3	Sometimes
4	Often

### Service users in the EMPOWER arm

1. Roughly how often do you use the App?

- 1 Not at all - If 'not at all' then please skip the rest of this questionnaire
- 2 Once a month
- 3 A few times a month
- 4 Weekly
- 5 Daily

2. Roughly how often do you share information from the App (e.g. charts) with your keyworker?

- 0 Not sure
- 1 Not at all
- 2 Rarely
- 3 Sometimes
- 4 Often

3. Roughly how often do you share information from the App (e.g. charts) with your family member/carer?

- 0 Not sure
- 1 Not at all
- 2 Rarely
- 3 Sometimes
- 4 Often

4. Roughly how often have you accessed charts on EMPOWER?

- 0 Not sure
- 1 Not at all
- 2 Rarely
- 3 Sometimes
- 4 Often

## uMARS

Adapted from the Mobile App Rating Scale user version (uMARS<sup>145</sup>) and used by service users in the EMPOWER arm.

1. Is the app interesting to use?
  - 1 Not interesting at all
  - 2 Mostly uninteresting
  - 3 OK, neither interesting nor uninteresting;
  - 4 Moderately interesting; would engage user for some time
  - 5 Very interesting, would engage user in repeat use
  
2. How easy is it to learn how to use the app; how clear are the menu labels, icons and instructions?
  - 1 No/limited instructions; menu labels, icons are confusing; complicated
  - 2 Takes a lot of time or effort
  - 3 Takes some time or effort
  - 4 Easy to learn (or has clear instructions)
  - 5 Able to use app immediately; intuitive; simple (no instructions needed)
  
3. Does moving between screens make sense; does app have all necessary links between screens?
  - 1 No logical connection between screens at all /navigation is difficult
  - 2 Understandable after a lot of time/effort
  - 3 Understandable after some time/effort
  - 4 Easy to understand/navigate
  - 5 Perfectly logical, easy, clear and intuitive screen flow throughout, and/or has shortcuts
  
4. Is app content (including messages) correct, well written, and relevant to the goal/topic of the app?
  - 1 Irrelevant/inappropriate/incoherent/incorrect
  - 2 Poor. Barely relevant/appropriate/coherent/may be incorrect
  - 3 Moderately relevant/appropriate/coherent/and appears correct

- 4 Relevant/appropriate/coherent/correct
- 5 Highly relevant, appropriate, coherent, and correct
5. Does the information within the app (including messages) seem to come from a credible source?
  - 1 Suspicious source
  - 2 Lacks credibility
  - 3 Not suspicious but legitimacy of source is unclear
  - 4 Possibly comes from a legitimate source
  - 5 Definitely comes from a legitimate/specialised source
6. Would you recommend the EMPOWER app to people who might benefit from it?
  - 1 [Not at all] I would not recommend this app to anyone
  - 2 There are very few people I would recommend this app to
  - 3 [Maybe] There are several people I would recommend this app to
  - 4 There are many people I would recommend this app to
  - 5 Definitely I would recommend this app to everyone
7. What is your overall star rating of the app?
  - \* One of the worst apps I've used
  - \*\*
  - \*\*\* Average
  - \*\*\*\*
  - \*\*\*\*\* One of the best apps I've used
  - NA This is the first App I've used so I can't fully judge

8. This app has increased my awareness of the importance of monitoring my mental health and wellbeing

Strongly disagree Strongly agree

1 2 3 4 5

9. This app has increased my knowledge/understanding of my mental health and wellbeing

Strongly disagree Strongly agree

1 2 3 4 5

10. The app has changed my attitudes toward improving my mental health and wellbeing

Strongly disagree Strongly agree

1 2 3 4 5

11. The app has increased my intentions/motivation to support my mental health and wellbeing

Strongly disagree Strongly agree

1 2 3 4 5

12. This app would encourage me to seek further help for my mental health and wellbeing (if I needed it)

Strongly disagree Strongly agree

1 2 3 4 5

13. Further comments about the EMPOWER App



Carers

1) In the last three/six months how often has [person cared for] discussed their early warning signs with you?

0	Not sure
1	Not at all
2	Rarely
3	Sometimes
4	Often

2) In the last three/six months how often times has [person cared for] sought help in relation to their early warning signs?

0	Not sure
1	Not at all
2	Rarely
3	Sometimes
4	Often

3) In the last three/six months how often have you sought help on their behalf in relation to early warning signs?

0	Not sure
1	Not at all
2	Rarely
3	Sometimes
4	Often

4) In the last three/six months how often has this resulted in a change in clinical management, e.g. appointment brought forward, changes in medication, referral to crisis team.

0	Not sure
1	Not at all
2	Rarely
3	Sometimes
4	Often

5) Has there been a relapse or readmission in the last three/six months?

0	Not sure
1	Not at all
2	Rarely
3	Sometimes
4	Often

## Care coordinators

- 1) In the last three/six months how often has [person in the study] discussed their early warning signs with you?
- 2) In the last three/six months how often times has [person in the study] sought help in relation to their early warning signs?
- 3) 3. In the last three/six months how often has their family member or a carer sought help on their behalf in relation to early warning signs?
- 4) In the last three/six months how often has this resulted in a change in clinical management, e.g. appointment brought forward, changes in medication, referral to crisis team.
- 5) Has there been a relapse or readmission in the last three/six months?

0	Not sure
1	Not at all
2	Rarely
3	Sometimes
4	Often
0	Not sure
1	Not at all
2	Rarely
3	Sometimes
4	Often
0	Not sure
1	Not at all
2	Rarely
3	Sometimes
4	Often
0	Not sure
1	Not at all
2	Rarely
3	Sometimes
4	Often
0	Not sure
1	Not at all
2	Rarely
3	Sometimes
4	Often

## Mechanisms

### Criticism and Warmth Measure

Adapted from the Perceived Criticism Measure (PCM)<sup>160</sup> and used with service users and carers.

How critical do you think you are of [person]?

Not at all									Very critical indeed
1	2	3	4	5	6	7	8	9	10

How critical do you think [person] is of you?

Not at all									Very critical indeed
1	2	3	4	5	6	7	8	9	10

How warm are you towards [person]?

Not at all									Very warm indeed
1	2	3	4	5	6	7	8	9	10

How warm is [person] towards you?

Not at all									Very warm indeed
1	2	3	4	5	6	7	8	9	10

How supported do you feel by [person]?

Not at all									Very supported indeed
1	2	3	4	5	6	7	8	9	10

## Appendix 2 Work package 3 semistructured interview

Interpretative Phenomenological Analysis of Study participants' experiences in testing the EMPOWER App and its potential impact on self-management in their recovery

Prior to undertaking interviews check that room and seating arrangements are comfortable; giving participant and interviewer equal access to the door and ensure that Digital Recorder is fully charged and working.

Take some time to settle the participant down before starting the interview. For example: "This interview has been designed to help us understand your experiences of using the EMPOWER App. We would like to understand what your experience was, how you found using the App and how it makes sense to you in your recovery. It is important that you understand that there are no right or wrong answers."

"To help us understand your experiences fully, I'll be recording this interview today using this Digital Recorder" [invite participant to try out recorder and test it for themselves] "We use this recorder to transcribe our conversation today. After transcribing the interview the recording will be destroyed. Any information contained in the interview that identifies you or anyone else will be concealed or anonymized."

"Do you have any questions before we get started?"

- How did you get involved in participating in the EMPOWER App testing?
- What were your general experiences in using the App?
  - Enquire about clarity of instructions
  - Ask for examples of experiences offered
  - Probe both positive and negative experiences

"Now I'd like to talk about some more specific aspects of the App"

- How did you experience the questions that were asked in the App?
  - Ask for examples of experiences offered
  - Probe both positive and negative experiences
- How did you experience the messages generated by the App.
  - Ask for examples of experiences offered
  - Probe both positive and negative experiences
- How did you experience the Charts Facility in the App?
  - Ask for examples of experiences offered
  - Probe both positive and negative experiences
- Did you receive any help in using the App?
  - What sort of help?
  - Practical help for technical difficulties?
  - Support from friends or family?

- Have you told others about the App?
  - How did they respond?
  - Family/friends/caretakers/health professionals/online?
- Did you have any worries about using the App?
  - Can you describe these?
  - Probe for examples
  - Did it cause you to worry about confidentiality?
  - What about “symptoms” or experiences?
  - What about relapse?

“Now I’d like to think about the App in relation to recovery”

- How would the App be useful in terms of your recovery in the future?
  - How would you use it?
  - How would you use it as a tool for self-management?
  - How would you share experiences and data?
  - How would you use it in your relationships with others?
    - What about family / friends?
    - What about services?

“Thank you very much – before we finish is there anything else you’d like to add?”

“Is there anything you’d expected me to ask but didn’t get raised?”

## Appendix 3 Additional baseline tables

TABLE 30 Carer baseline characteristics

Characteristic	EMPOWER (N = 42)	TAU (N = 31)	Total (N = 73)
Gender, n (%)			
Male	2 (29)	3 (30)	5 (29)
Female	5 (71)	7 (70)	12 (71)
Age (years), n: mean (SD)	7: 56 (14)	9: 58 (9)	16: 57 (11)
Years of education, n: mean (SD)	5: 16.20 (3.03)	8: 15.00 (4.87)	13: 15.46 (4.16)
UK ethnicity, n (%)	5 (71)	8 (80)	13 (76)
Scottish	5 (100)	6 (75)	11 (85)
Other British	-	1 (13)	1 (8)
UK unknown	-	1 (13)	1 (8)
Australian ethnicity, n (%)	2 (29)	2 (20)	4 (24)
Born in Australia	2 (100)	2 (100)	4 (100)

TABLE 31 Care co-ordinator baseline characteristics

Characteristic	EMPOWER (N = 42)	TAU (N = 31)	Total (N = 73)
Gender, n (%)			
Male	6 (27)	3 (12)	9 (19)
Female	16 (73)	19 (76)	35 (74)
Missing	-	3 (12)	3 (6)
Time with team (years), n: mean (SD)	13: 3.49 (4.52)	12: 6.57 (5.81)	25: 4.97 (5.30)
Years since qualified, n: mean (SD)	13: 7.22 (5.39)	12: 15.10 (9.57)	25: 11.01 (8.52)



## Appendix 4 General feasibility tables



TABLE 32 Service user general feasibility

	EMPOWER				TAU			
	Baseline	3 months	6 months	12 months	Baseline	3 months	6 months	12 months
Have you used any well-being apps?, <i>n</i> (%)								
Not sure	1 (2)	3 (7)	1 (2)		1 (3)	2 (6)	1 (3)	
Yes	4 (10)	23 (55)	19 (45)	20 (48)	5 (16)	7 (23)	5 (16)	4 (13)
No	37 (88)	6 (14)	10 (24)	10 (24)	24 (77)	19 (61)	20 (65)	24 (77)
Missing		10 (24)	12 (29)	12 (29)	1 (3)	3 (10)	5 (16)	3 (10)
How often have you used wellbeing apps?, <i>n</i> : mean (SD)	36: 1.25 (0.77)	26: 3.42 (1.14)	27: 3.11 (1.22)	27: 2.93 (1.33)	28: 1.29 (0.66)	24: 1.63 (1.10)	22: 1.41 (0.96)	25: 1.24 (0.66)
How often have you sought help with EWS?, <i>n</i> : mean (SD)	36: 2.19 (1.12)	26: 1.96 (1.00)	27: 2.04 (1.16)	27: 1.85 (1.06)	28: 2.39 (1.20)	24: 1.75 (1.15)	22: 2.14 (1.13)	25: 1.76 (1.05)
How often has your carer sought help for EWS?, <i>n</i> : mean (SD)	35: 1.80 (1.02)	26: 1.69 (1.05)	27: 1.48 (0.94)	27: 1.33 (0.73)	28: 1.46 (0.79)	24: 1.54 (0.88)	22: 1.45 (0.86)	25: 1.52 (0.87)
How often has this changed clinical management, <i>n</i> : mean (SD)	36: 2.42 (1.02)	26: 1.85 (1.01)	27: 1.96 (1.16)	27: 1.52 (0.94)	28: 2.25 (1.21)	24: 1.79 (1.14)	22: 1.95 (1.09)	25: 1.64 (1.11)

All questions relate to the last 3 months.

Frequency questions are answered on a scale from 1 (not at all) to 4 (often).

TABLE 33 Carer general feasibility

	EMPOWER, n: mean (SD)				TAU, n: mean (SD)			
	Baseline	3 months	6 months	12 months	Baseline	3 months	6 months	12 months
How often has service user discussed EWS with you?	6: 3.17 (0.75)	5: 2.40 (1.14)	5: 2.40 (0.55)	4: 3.25 (0.96)	10: 2.90 (0.99)	6: 2.67 (1.03)	5: 2.40 (0.55)	4: 2.25 (1.26)
How often have they sought help with EWS?	6: 3.17 (1.17)	5: 2.80 (1.10)	5: 2.00 (0.71)	4: 2.00 (1.41)	10: 2.60 (0.97)	6: 2.33 (1.21)	5: 2.80 (1.30)	4: 2.00 (1.41)
How often have you sought help for their EWS?	6: 2.33 (1.03)	5: 2.20 (1.30)	5: 2.00 (1.00)	4: 1.75 (1.50)	10: 1.70 (0.82)	6: 1.50 (0.55)	5: 1.40 (0.55)	4: 1.75 (1.50)
Has this changed clinical management	6: 2.00 (1.10)	5: 2.00 (1.00)	5: 1.60 (0.89)	4: 1.50 (1.00)	10: 1.90 (0.88)	6: 2.00 (1.10)	5: 2.20 (1.30)	4: 1.50 (1.00)
All questions relate to the last 3 months. Frequency questions are answered on a scale from 1 (not at all) to 4 (often).								

TABLE 34 Care co-ordinator general feasibility

	EMPOWER, n: mean (SD)				TAU, n: mean (SD)			
	Baseline	3 months	6 months	12 months	Baseline	3 months	6 months	12 months
How often has service user discussed EWS with you?	39: 2.97 (1.01)	30: 2.83 (0.79)	22: 2.91 (0.92)	13: 2.85 (0.99)	25: 3.32 (0.85)	21: 3.05 (0.67)	13: 2.54 (0.97)	10: 2.40 (0.70)
How often have they sought help with EWS?	39: 2.36 (1.16)	30: 2.13 (1.04)	22: 2.27 (1.16)	13: 2.69 (1.03)	24: 2.50 (1.35)	22: 2.32 (1.29)	13: 2.31 (0.95)	11: 2.45 (0.93)
How often has carer sought help for service user for EWS?	39: 1.85 (1.11)	30: 1.50 (0.86)	22: 1.32 (0.65)	13: 1.38 (0.65)	25: 1.76 (1.05)	22: 1.64 (1.00)	13: 1.31 (0.75)	11: 1.73 (1.10)
Has this changed clinical management	39: 2.21 (1.22)	30: 2.03 (1.03)	22: 1.82 (0.91)	13: 1.85 (0.99)	25: 2.28 (1.17)	21: 2.33 (1.11)	13: 1.77 (0.93)	11: 1.91 (1.04)
All questions relate to the last 3 months. Frequency questions are answered on a scale from 1 (not at all) to 4 (often).								



# Appendix 5 Describing engagement with the EMPOWER app

## Exploratory user engagement

Engagement with digital interventions can be conceptualised in multiple ways, including subjective experiences of how using an intervention makes a participant feel, as well as purely behavioural measures of actual intervention usage.<sup>256</sup> However, Kelders *et al.*<sup>255</sup> propose delineating user engagement into actual usage (i.e. how much participants use an intervention) and intended usage (i.e. how much participants must use an intervention to obtain a maximum benefit of some kind). Previous digital research in schizophrenia<sup>273,274</sup> used an EMA response rate of 33% for data to be considered reliable, while acknowledging that the criteria for determining EMA response rate feasibility vary in the literature.<sup>100</sup> Using the terminology developed by Kelders *et al.*,<sup>255</sup> intended usage would be the period during which users complete at least 33% of daily prompts because this would result in data that are of maximum reliability for detecting clinical change.

The proportion of users still using an app in its intended manner after 2 weeks has been suggested as a suitable metric for assessing intervention engagement.<sup>275</sup> However, this metric was developed for apps that are delivered remotely and is therefore less suitable for EMPOWER, given that it is a blended intervention. Additionally, participant usage of digital interventions for psychosis is higher in interventions that involve a high level of human contact.<sup>117</sup> Furthermore, trying to develop an accurate estimation of intended usage over time is especially challenging in a feasibility trial. Therefore, it was decided to explore when participants stopped inputting data at least 3 days per week (meeting 33% intended usage criteria) for 4 sequential weeks.

## Methods

Survival analysis methods are recommended for understanding attrition in digital interventions.<sup>215</sup> Attrition represents the amount of time to some sort of relevant event occurring, in this case 4 sequential weeks of not meeting the intended adherence criterion of completing 33% of daily prompts. In survival analysis, an event can be fully observed for some participants, for example participants who stop using the app for 4 weeks in a row. However, some participants might have used the app continuously during the observation period. In this case, it is known that these participants did not have an event during the observation period, but it is unknown if their usage would have dropped off had we observed them for longer. In survival analysis, participants such as these are said to be 'censored' for the purposes of analysis. Therefore, all participants who did not have an event during the observation period ( $n = 14$ , 42.4%; see below) were censored for the purposes of this analysis. Usage data were obtained from our secure server after the end of the trial.

Only data from participants who had completed a full baseline were eligible for this engagement analysis ( $n = 33$ ). If participants had restarted using the app for any reason, only their final usage period was used in this analysis as long as they had completed a full baseline. Fourteen participants (42.4%) were still using the app at their final follow-up assessment, so their usage period was cut to the week during which that follow-up assessment fell. The analysis was completed using the `survfit` function in the survival package in R, with bootstrapping performed using the `bootkm` function from the `hmisc` package in R.

## Results and discussion

Overall, the median survival for not missing 4 sequential weeks of intended usage was 32 weeks, with bootstrapped 95% CI 14 weeks; the upper limit returned an infinite value probably because of the skewed data. The large CIs can be seen in the Kaplan–Meier curve of time to 4 weeks' app use of < 33% (see *Figure 7*). In other words, for 50% of participants who had completed a baseline it took 33 weeks until they missed 4 sequential weeks of intended intervention usage. The width of the CIs suggests that some degree of uncertainty is appropriate in interpreting the result from this test. To summarise, the time to 50% of participants having 4 sequential weeks of no longer meeting the intended adherence criterion is hard to predict within this sample (especially in terms of an upper limit) but it is likely not to fall below 14 weeks.

Levels of participant engagement with interventions may change over time and may have implications for understanding what successful engagement would look like.<sup>276</sup> Therefore, it is important to report actual usage in addition to intended usage.<sup>255</sup> Five participants (15.1%) who had an event still continued to use the intervention afterwards for short periods, with a few cases of participants then re-meeting the 33% criteria, which suggests that recovery to intended usage may be possible following a 4-week period of discontinuation. Descriptive statistics of usage for these participants are provided in *Table 35*.

There is debate about whether future intervention studies should measure levels of engagement, with a view to making recommendations for retaining groups of participants who are at the highest risk of non-usage<sup>277</sup> or trying to understand what optimal engagement would look like from the end view of users,<sup>256</sup> rather than assuming that increased usage is good in some way. Although participants may need to respond to a certain number of prompts for the data to be valid for clinical use,<sup>274</sup> they may have their own views on optimal usage. To that end, actual raw usage (in weeks and the mean days across the observation period) is reported for all participants in *Table 36*. Please note that these usage levels are the actual usage in weeks (as reported from the direct server data) and do not reflect the usage period being cut to the week number during the follow-up assessment. One exception to this is participant 80503, who restarted the intervention; their final assessment was during week 1 of their usage period. Following a conversation among team members, the decision was made not to censor the participant at this point but to use their entire usage period in the analysis. These data may reflect user preference and so are being shared here in the interests of transparency.

## Limitations

There are key limitations to these analyses. In taking such a data-driven approach we have not considered any predictors, including levels of negative symptoms, that have been shown to be linked to lower engagement with digital interventions,<sup>278</sup> or the level of engagement with peer support workers,

TABLE 35 Recovery to intended engagement level following an event

Participant	Weeks using post event	Mean days per week
10302	4	1.25
40202	3	3
40301	4	3
60801	2	2
80601	1	1

TABLE 36 App engagement of participants achieving a baseline

Participant	Actual weeks used	Mean days per week	Percentage use
10301	6	5.00	71.42
10302	25	1.44	20.57
10501	17	3.35	47.90
10701	13	2.69	38.46
40103	49	5.75	82.21
40105	45	6.24	89.21
40201	42	3.28	46.94
40202	21	3.09	44.22
40301	15	1.80	25.71
40402	48	6.66	95.24
40601	43	5.60	80.07
40701	37	4.35	62.16
40702	43	4.53	64.78
40703	45	5.88	84.13
40704	50	6.46	92.29
60104	42	3.23	46.26
60109	30	3.86	55.24
60201	44	6.43	91.88
60202	39	5.17	73.99
60203	44	5.93	84.74
60206	11	4.63	66.23
60208	37	6.29	89.96
60210	40	5.47	78.21
60403	7	2.57	36.73
60801	12	2.41	34.52
80307	42	3.35	47.96
80402	34	5.00	71.43
80503	6	3.83	54.76
80601	14	2.07	29.59
80606	21	3.38	48.30
80803	45	6.02	86.03
81103	37	6.78	96.91
81901	37	5.45	77.99
Mean (SD)	31.5 (14.5)	4.5 (1.6)	64.1 (22.5)
Median (IQR)	37.0 (16.0–43.5)	4.6 (3.3–5.9)	66.2 (46.6–84.4)
Range	44.0	5.3	76.3

IQR, interquartile range.

which may increase engagement.<sup>117</sup> Cox proportional hazards models that include theoretically justified predictors may be helpful. Additionally, only participants who completed a baseline have been considered for analysis; six participants were excluded for this reason. Furthermore, these findings may reflect engagement with a research trial rather than engagement with EMPOWER as a blended intervention in itself in a non-research context. Importantly, these are all behavioural measures of engagement and do not consider subjective user experiences or the broader context of intervention usage.

## Appendix 6 Additional relapse outcome table

TABLE 37 Relapse characteristics at all time points

Relapse characteristics	EMPOWER, n (%)			TAU, n (%)		
	3 months	6 months	12 months	3 months	6 months	12 months
Return of or exacerbation of psychotic symptoms						
Yes	10 (24)	6 (14)	9 (21)	10 (32)	5 (16)	11 (35)
No	27 (64)	27 (64)	23 (55)	20 (65)	24 (77)	17 (55)
Missing	5 (12)	9 (21)	10 (24)	1 (3)	2 (6)	3 (10)
Duration of at least 1 week						
Yes	5 (12)	5 (12)	7 (17)	8 (26)	4 (13)	11 (35)
No	32 (76)	28 (67)	25 (60)	22 (71)	25 (81)	17 (55)
Missing	5 (12)	9 (21)	10 (24)	1 (3)	2 (6)	3 (10)
Reduction in functioning						
Yes	7 (17)	7 (17)	7 (17)	14 (45)	7 (23)	8 (26)
No	30 (71)	26 (62)	25 (60)	16 (52)	22 (71)	20 (65)
Missing	5 (12)	9 (21)	10 (24)	1 (3)	2 (6)	3 (10)
Increased risk						
Yes	1 (2)	0 (0)	2 (5)	7 (23)	1 (3)	8 (26)
No	36 (86)	33 (79)	30 (71)	23 (74)	28 (90)	20 (65)
Missing	5 (12)	9 (21)	10 (24)	1 (3)	2 (6)	3 (10)
Change in clinical management						
Yes	7 (17)	7 (17)	6 (14)	12 (39)	4 (13)	10 (32)
No	30 (71)	26 (62)	26 (62)	18 (58)	25 (81)	18 (58)
Missing	5 (12)	9 (21)	10 (24)	1 (3)	2 (6)	3 (10)
Hospital admission						
Yes	2 (5)	0 (0)	0 (0)	3 (10)	1 (3)	5 (16)
No	35 (83)	33 (79)	32 (76)	27 (87)	28 (90)	23 (74)
Missing	5 (12)	9 (21)	10 (24)	1 (3)	2 (6)	3 (10)
Mental Health Act used						
Yes	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	4 (13)
No	37 (88)	33 (79)	32 (76)	29 (94)	29 (94)	24 (77)
Missing	5 (12)	9 (21)	10 (24)	1 (3)	2 (6)	3 (10)
Type of relapse						
Type I	0 (0)	2 (5)	2 (5)	1 (3)	0 (0)	3 (10)
Type II	1 (2)	0 (0)	2 (5)	7 (23)	2 (6)	5 (16)
Type III	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)
No relapse	36 (86)	31 (74)	28 (67)	22 (71)	27 (87)	19 (61)
Missing	5 (12)	9 (21)	10 (24)	1 (3)	2 (6)	3 (10)





## Appendix 7 Clinical assessment calibration and reliability

Research assistant training and calibration in the EMPOWER trial was governed by a standard operating procedure designed to ensure that raters were well prepared for their role and provided with regular feedback on their rating fidelity throughout the trial. Oversight of the training, calibration and monitoring process was led by Hamish McLeod (UK), with additional input from John Farhall and John Gleeson (Australia) as required.

Reliability assessment of symptom and functioning measures occurred in two phases. First, all research assistants were calibrated to PANSS, CDSS and PSP scale measures by completing a structured training programme. Feedback on ratings was anchored to a set of training recordings and videos, with reference ratings provided by an expert rater and then checked for consensus agreement with at least three other raters. The majority of these training cases were conducted between April and May 2018, and research assistants did not progress to independently assessing study participants until they had been consistently rating recorded cases with no scoring deviations of 2 points or more from the reference rating. Up to the point of calibration being established for any rater, the scores they returned on assessed trial patients were adjusted to consensus scores if a deviation of  $\geq 2$  points was observed during co-rating checks, and the electronic record for that service user was adjusted.

Once raters had been calibrated and were providing consistently accurate ratings, the standard operating procedure moved into the reliability phase and no further adjustment of recorded scores occurred. In this phase, if a rater showed a deviation of more than 2 points on any item, they received feedback and additional supervision, but the recorded score was unchanged. The majority of data from this phase of reliability recording were acquired between June 2018 and May 2019. Nine separate cases were recorded and rated during this period, with input from at least one of the trial principal investigators (Table 38).

Data from the reliability phase were used to minimise rater drift and to ensure that research assistants were gaining regular feedback on their rating judgements. These data were analysed in two main ways. First, the rate at which ratings showed a deviation of 2 points or more was used to estimate how much the reported scale *total scores* may have been affected by unreliable rating. The results suggest that all three of the assessed scales were rated reliably for most items, a pattern that suggests that the training and calibration phase of rater training worked effectively. However, the data do suggest that rater disagreement affected a greater proportion of items on the PSP scale than on the CDSS and PANSS (Table 39).

TABLE 38 Sequence of reliability co-ratings post calibration

	June 2018	July 2018	August 2018	August 2018	October 2018	December 2018	January 2019	February 2019	May 2019
Service user	70801	50302	71507	60403	40201	40103	80397	51003	71507
Number of raters	8	8	6	8	4	6	4	3	5

TABLE 39 Post-calibration item-level rater reliability

Measure	Frequency of score deviations of $\geq 2$ points	Percentage of overall pool of scale items
<b>PANSS</b>		
ED4 tension	6	2.22
P6 somatic concern	5	1.85
P3 unusual thought content	3	1.11
D1 stereotyped thinking	3	1.11
D2 poor attention	3	1.11
D5 difficulty in abstract thinking	3	1.11
E1 poor impulse control	3	1.11
P2 hallucinatory behaviour	2	0.74
N2 blunted affect	2	0.74
N3 emotional withdrawal	2	0.74
D8 disturbance of volition	2	0.74
ED2 depression	2	0.74
P1 delusions	1	0.37
P4 suspiciousness/persecution	1	0.37
N4 passive/apathetic social withdrawal	1	0.37
N6 poor rapport	1	0.37
N7 active social avoidance	1	0.37
D4 conceptual disorganisation	1	0.37
D6 mannerisms and posturing	1	0.37
D7 lack of judgement and insight	1	0.37
E2 excitement	1	0.37
ED3 guilt feelings	1	0.37
<b>CDSS</b>		
CDSS4 guilty ideas of reference	1	1.23
CDSS7 early wakening	2	2.47
<b>PSP scale</b>		
PSP scale A – socially useful activity	2	5.56
PSP scale C – self-care	2	5.56
PSP scale B – social relationships	1	2.78

## Appendix 8 Intervention costs

TABLE 40 Breakdown of intervention costs

Resource	Unit	Amount	Unit cost (£)	Cost (£)	Cost type	Unit cost source and notes	Perspective		
							Health-care payer	Health-care sector	Societal
<b>R&amp;D</b>									
App development	Per app development	1	101,493	101,493	Sunk cost	Final grant application; year 1 software developer costs, 3 posts: £33,332 + £38,616 + £29,545	✓	✓	✓
Content development (staff cost)	Per app development	1	4552	4552	Sunk cost	University of Glasgow salary; 3 weeks' salary each band 6 and band 7. Band 6 2016, £35,296/52 × 3 = £2036; band 7 2016, £43,617/5 × 3 = £2516; total £4552	✓	✓	✓
Medical device registration	Per app	1	23,674	23,674	Sunk cost	Trial team; MHRA costs £3200 plus £13,424 Trial manager's time and £7050 Manchester time preparing application	✓	✓	✓
<b>Ongoing maintenance</b>									
App hosting	Per year	1	1667	1667	Fixed	Final grant application; 3-year trial period for servers to host EMPOWER app; £5000/3 years = £1667 for 1 year	✓	✓	✓
App maintenance – staffing	Per year	1	12,947	12,947	Fixed	Final grant application; year 2 and 3 software engineer, 1 post: £20,611 + £5282 = £25,893	✓	✓	✓
<b>Intervention delivery</b>									
<i>Capital costs</i>									
Phones	Per device	42	109.52	4600	Variable	Australia: 8 project phones AU\$2454 (or £1380)  UK: 28 project phones + 2 repairs £3220  Total £4600	✗	✓	✓

Resource	Unit	Amount	Unit cost (£)	Cost (£)	Cost type	Unit cost source and notes	Perspective		
							Health-care payer	Health-care sector	Societal
<i>Consumables</i>									
Internet	Per device per year	42	69.30	2910.63	Variable	Australia: total cost over 12 months AU\$810 (or £455.63)  UK: total cost over 12 months £2455  Total £2910.63	x	✓	✓
<i>Labour costs</i>									
Training CMHS staff	Per workshop	5	833	4165	Variable	Australia:  1 senior clinical psychologist: AU\$108 (including 30% on-costs) × 3 hours = AU\$324  6 care co-ordinators: AU\$46 (average wage of psychologist, nurse, social worker, occupational therapist; including 30% on-costs) × 3 hours × 6 = AU\$828  1 research assistant: AU\$56 (including 30% on-costs) × 3 hours = AU\$168  1 peer support worker: AU\$56 (including 30% on-costs) × 3 hours = AU\$168  Total per workshop AU\$1488 (or £833)	✓	✓	✓
Monitoring training of research assistants in reviewing CHIP information	Per training	2	367	34	Variable	Australia:  1 senior clinical psychologist: AU\$108 (including 30% on-costs) × 4 hours = AU\$432  1 research assistant: AU\$56 (including 30% on-costs) × 4 hours = AU\$224  Total AU\$656 (or £367)	✓	✓	✓

continued

TABLE 40 Breakdown of intervention costs (continued)

Resource	Unit	Amount	Unit cost (£)	Cost (£)	Cost type	Unit cost source and notes	Perspective		
							Health-care payer	Health-care sector	Societal
Peer support workers' engagement with service user	Per service user	42	1039	43,633	Variable	<p>Australia: peer support worker (FTE 0.4)  <math>AU\\$86,205 \times 0.4 = AU\\$34,482</math> (or £19,303)</p> <p>UK: peer support worker band 3 £24,330</p> <p>Total <math>£43,633/42 = £1039</math> per service user</p>	✓	✓	✓
Time spent using the app	Per service user	42	67	2814	Variable	<p>In Australia, the average hourly wage in 2018 was AU\$39.10</p> <p>25% of \$39.10 = \$9.775</p> <p>2 minutes <math>\times</math> 365 days = 730 minutes (12 hours) during the 12-month period</p> <p>12 hours <math>\times</math> AU\$9.775 = AU\$119 (or £67)</p>	✗	✗	✓
Routine monitoring <sup>a</sup>	Per service user	42	1003	42,117	Variable	<p>Australia:</p> <p>1 research assistant (FTE 0.05) =  <math>AU\\$69,081 \times 0.05 = AU\\$3454</math>            (2 hours per week)</p> <p>1 project co-ordinator (FTE 0.16) =  <math>AU\\$77,242 \times 0.16 = AU\\$12,359</math>            (6 hours per week)</p> <p>Total AU\$15,813 (or £8897)</p> <p>UK:</p> <p>Research nurse band 6 = £33,220</p> <p>Total <math>£42,117/42 = £1003</math> per service user</p>	✓	✓	✓

Resource	Unit	Amount	Unit cost (£)	Cost (£)	Cost type	Unit cost source and notes	Perspective		
							Health-care payer	Health-care sector	Societal
Ongoing supervision of CMHS staff	Per supervision session	9	201.33	1812	Variable	Australia:  1 senior clinical psychologist: AU\$108 (including 30% on-costs) × 1 hour = AU\$108  3 care co-ordinators: AU\$46 (average wage of psychologist, nurse, social worker, occupational therapist; including 30% on-costs) × 1 hour × 3 = AU\$138  1 research assistant: AU\$56 (including 30% on-costs) × 1 hour = \$56  1 peer support worker: AU\$56 (including 30% on-costs) × 1 hour = AU\$56  Per session = AU\$358 × 9 sessions = AU\$3222 (or £1812)	✓	✓	✓
<b>Total costs (£)</b>									
R&D							3.27	3.27	3.27
Ongoing maintenance							0.37	0.37	0.37
Intervention delivery							92,461	99,972	102,786
Total							92,465	99,976	102,790
Cost per service user <sup>b</sup>							2202	2380	2447
a By a research mental health nurse in Glasgow and a research assistant in Melbourne. b Total costs divided by 42 service users enrolled in the EMPOWER intervention arm.									





## Appendix 9 Unit costs

TABLE 41 UK unit costs

Service	Location	Sector	Cost in Great British pounds (£)	Source
<b>Health professional costs</b>				
GP	Clinic	Public	28	<i>Unit Costs of Health and Social Care 2018</i> clinic excluding qualification and direct care staff 9.22 minutes @ £3 per minute <sup>234</sup>
	Phone	Public	14.90	<i>Unit Costs of Health and Social Care 2018</i> GP telephone triage <sup>234</sup>
Psychiatrist	Clinic	Public	391	PSSRU 2015 plus uplift <sup>279</sup>
Psychologist	Clinic	Public	96	PSSRU 2015 plus uplift <sup>279</sup>
Counsellor	Clinic	Public	25	PSSRU 2018 counsellor band 6 <sup>91</sup>
Primary care nurse	Clinic	Public	9.30	PSSRU 2018 GP nurse (excluding qualifications)
Mental health nurse	Clinic	Public	79	<i>NHS Reference Costs 2017/18</i> Other specialist nursing adult face to face <sup>233</sup>
Drug and alcohol worker	Clinic	Public	118	<i>NHS Reference Costs 2017/18</i> DAS alcohol services adults community contacts <sup>233</sup>
Case manager/social worker	Clinic	Public	61	<i>NHS Reference Costs 2017/18</i> social worker adult services <sup>233</sup>
Speech therapist	Clinic	Public	99	<i>NHS Reference Costs 2017/18</i> Speech therapist A13A1 adult one to one <sup>233</sup>
Occupational therapist	Clinic	Public	81	<i>NHS Reference Costs 2017/18</i> Occupational therapist A06A1 adult one to one
Dentist	Clinic	Public	21.60	<i>Unit Costs of Health and Social Care 2018</i> NHS dental charge band 1 <sup>234</sup>
Physiotherapist	Clinic	Public	57	<i>NHS Reference Costs 2017/18</i> physiotherapist A08A1 adult one to one <sup>233</sup>
Optician	Clinic	Public	31.88	PSSRU 2016/17 with uplift <sup>280</sup>
Podiatrist	Clinic	Public	44.48	PSSRU 2016/17 with uplift <sup>280</sup>
Dietitian	Clinic	Public	77.04	PSSRU 2016/17 with uplift <sup>280</sup>
Support worker	Clinic	Public	23	<i>NHS Reference Costs 2017/18</i> Mental health cluster 12 ongoing or recurrent psychosis <sup>233</sup>
Other professional	Clinic	Public	125	<i>NHS Reference Costs 2017/18</i> 'Total outpatient attendances', average outpatient attendance excluding costs for professions above <sup>233</sup>
<b>Other health-care costs</b>				
Ambulance		Public	120	<i>Unit Costs of Health and Social Care 2018</i> Ambulance service average of all attendances <sup>234</sup>
Emergency room		Public	160	<i>NHS Reference Costs 2017/18</i> overall average A&E attendance <sup>233</sup>

continued

TABLE 41 UK unit costs (continued)

Service	Location	Sector	Cost in Great British pounds (£)	Source
Day treatment		Public	134	PSSRU 2017/18 outpatient service average of all attendances <sup>234</sup>
Inpatient mental health		Public	410	PSSRU 2017/18 Mental health cluster – bed-day <sup>234</sup>
Inpatient: general		Public	337	NHS Reference Costs 2017/18 non elective bed-day <sup>233</sup>
<b>Diagnostic test</b>				
Blood test		Public	14.80	ISD 2017/18 lab costs R130X plus nurse visit (above) <sup>281</sup>
CT scan		Public	90	NHS reference costs 2017/18 RD20A <sup>233</sup>
X-ray		Public	61	ISD 2017/18 R120X Other radiology <sup>281</sup>
MRI		Public	141	NHS Reference Costs 2017/18 MRI scan of one area RD01A <sup>233</sup>
Ultrasound		Public	54	NHS Reference Costs 2017/18 Ultrasound scan duration less than 20 minutes <sup>233</sup>
Urine test		Public	10.18	ISD 2017/18 R130X clinical chemistry plus one nurse visit (above) <sup>281</sup>
ECG		Public	108	NHS Reference Costs 2017/18 Simple echo 19 years and over <sup>233</sup>
Endoscopy		Public	227	NHS Reference Costs 2017/18 average of all 'Wireless capsule endoscopy' <sup>233</sup>
Blood pressure		Public	9.30	PSSRU 2017/18 Nurse visit as above <sup>234</sup>
Biopsy		Public	228	NHS Reference Costs 2017/18 average of all 'Biopsy ...' <sup>233</sup>
Heart rate monitor		Public	18.60	PSSRU 2017/18 Assume two nurse visits, one to attach and one to remove the monitor <sup>234</sup>
<b>Productivity costs</b>				
Minimum hourly wage			7.50	UK 2017 minimum wage ≥ 25 years <sup>282</sup>
National average hourly rate			14.04	Office for National Statistics <sup>282</sup>
National average hourly rate plus on-costs			17.55	Adding 25% on-costs to national average hourly rate
Unpaid work			3.51	25% of national average hourly rate
<b>Justice costs</b>				
Contact with police			268.40	Statement and interview <sup>241</sup>
Criminal court			441	Sheriff court, judge alone <sup>243</sup>
PSSRU, Personal Social Services Research Unit.				

TABLE 42 Australian unit costs

Services	Location	Sector	Cost in Australian dollars (AU\$)	Cost in Great British pounds (£)	Source
<i>Health professional costs</i>					
GP	Clinic	Public	44.20	21.46	MBS item number 3, 23, 36, 44, 2700, 2701, 2712, 2713, 2715, 2717, 2721, 2725 <sup>236</sup>
Psychiatrist	Clinic	Public	159.39	77.37	MBS item number 291, 293, 296, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 319 <sup>236</sup>
Psychologist	Clinic	Public	105.39	51.16	MBS item number 10968, 80000, 80010, 80100, 80110, 81355 <sup>236</sup>
	Clinic	Private	372.16	180.66	NHDC Round 21 Tier 2 – non-admitted service events, item 4029 (psychology) <sup>238</sup>
Counsellor	Clinic	Public	71.12	34.52	Average of GP, psychologist, social worker, mental health worker <sup>236</sup>
	Phone	Public	71.12	34.52	Average of GP, psychologist, social worker, mental health worker <sup>236</sup>
Primary care nurse	Clinic	Public	30.32	14.72	MBS item number 82200, 82205, 82210, 82215 <sup>236</sup>
Mental health nurse	Clinic	Public	30.72	14.91	MBS item number 81325, 10956, 82200, 82205, 82210, 82215 <sup>236</sup>
Drug and alcohol worker	Clinic	Public	170.91	82.97	NHDC Round 21 Tier 2 – non-admitted service events, item 4030 (alcohol and other drugs) <sup>238</sup>
Case manager/ social worker	Clinic	Public	77.04	37.40	MBS item number 80150, 80160 <sup>236</sup>
	Home	Public	95.74	46.48	MBS item number 80155, 80165 <sup>236</sup>
	Phone	Public	77.04	37.40	MBS item number 80150, 80160 <sup>236</sup>
Speech therapist	Clinic	Public	57.54	27.93	MBS item number 10970, 81360 <sup>236</sup>
	Phone	Public	57.54	27.93	MBS item number 10970, 81360 <sup>236</sup>
Occupational therapist	Clinic	Public	141.45	68.67	MBS item number 10985, 80125, 80130, 80135, 80140, 80145, 81330 <sup>236</sup>
	Phone	Public	101.75	49.39	MBS item number 80130, 80140 <sup>236</sup>
Dietitian	Clinic	Public	53.44	25.94	MBS item number 10954, 81320 <sup>236</sup>
Mental health service provider/ mental health worker	Clinic	Public	57.85	28.08	MBS item number 10956, 81325 <sup>236</sup>

continued

TABLE 42 Australian unit costs (continued)

Services	Location	Sector	Cost in Australian dollars (AU\$)	Cost in Great British pounds (£)	Source
Physiotherapy	Clinic	Public	53.35	25.90	MBS item number 10960, 81335 <sup>236</sup>
	Clinic	Private	156.75	76.09	NHCDC Round 21 Tier 2 – non-admitted service events, item 4009 (physiotherapy) <sup>238</sup>
Podiatry	Clinic	Public	53.09	25.77	MBS item number 10962, 81340 <sup>236</sup>
Chiropractor	Clinic	Public	52.96	25.71	MBS item number 10964, 81345 <sup>236</sup>
Osteopathy	Clinic	Public	53.73	26.08	MBS item number 10966 <sup>236</sup>
Dentist	Clinic	Public	70.42	34.18	MBS item number 75800 <sup>236</sup>
	Clinic	Private	396.56	192.50	NHCDC Round 21 Tier 2 – non-admitted service events, 1004 (dental) <sup>238</sup>
Ophthalmologist	Clinic	Public	62.43	30.31	MBS item number 106 <sup>236</sup>
	Clinic	Private	62.43	30.31	MBS item number 106 <sup>236</sup>
Optometrist	Clinic	Public	29.50	14.32	MBS item number 10905, 10907 <sup>236</sup>
Massage therapist	Clinic	Public	24.80	12.04	www.payscale.com (accessed 16 September 2019)
Endocrinologist	Clinic	Public	78.77	38.24	MBS item number 104, 105, 110, 132, 133 <sup>236</sup>
Specialist	Clinic	Public	115.60	56.12	Average of all specialist
<b>Other health-care costs</b>					
Ambulance			927.56	450.27	Report on Government Services 2019 <sup>283</sup>
Emergency room			532.81	258.65	Non-admitted emergency department. NHCDC Round 21, sheet 15. Emergency department by jurisdiction <sup>238</sup>
Day treatment			309.00	150.00	Independent Hospital Pricing Authority <sup>238</sup>
Inpatient acute psychiatric unit			1206.00	585.44	Australian Institute of Health and Welfare Expenditure on mental health services (exp. 19) <sup>239</sup>
Inpatient general			2338.33	1135.11	NHCDC Round 19 to 21 admitted acute overnight and same day, actual, by jurisdiction <sup>238</sup>
<b>On site at an organisation</b>					
PARC			480.78	233.39	Victorian health policy and funding guidelines 2015–16, part 2: pricing and funding arrangements <sup>240</sup>
Community care unit			389.60	189.13	Victorian health policy and funding guidelines 2015–20, part 2: pricing and funding arrangements <sup>240</sup>

TABLE 42 Australian unit costs (continued)

Services	Location	Sector	Cost in Australian dollars (AU\$)	Cost in Great British pounds (£)	Source
<b>Diagnostic test</b>					
ECG			80.45	39.05	MBS item number 11700, 11702, 11712, 55113, 55116, 55117 <sup>236</sup>
Ultrasound			113.55	55.12	MBS group I1: ultrasound <sup>236</sup>
Blood test			16.69	8.10	MBS group P1: haematology <sup>236</sup>
Urine test			21.41	10.39	MBS group P1: haematology <sup>236</sup>
X-ray			52.70	25.58	MBS group: I3 <sup>236</sup>
MRI			391.59	190.09	MBS group: I5 <sup>236</sup>
CT scan			324.41	157.48	MBS group: I2 <sup>236</sup>
Mammography			73.46	35.66	MBS item number 59300, 59301, 59303, 59304, 59306, 59309, 59312, 59314, 59315, 59318, 59319 <sup>236</sup>
Spirometry			21.75	10.56	MBS item number 11506 <sup>236</sup>
<b>Productivity costs</b>					
Minimum hourly wage			18.69	9.07	Australian Government Fair Work Commission <sup>284</sup>
National average hourly rate			30.69	6.82	Australian Bureau of Statistics, Characteristics of Employment, Australia, August 2018 <sup>285</sup>
National average hourly rate plus on-costs			38.36	8.52	Adding 25% to national average hourly rate
Unpaid work			7.67	1.70	25% of national average hourly rate
<b>Justice costs</b>					
Contact with police			459.00	222.82	Australian Government Productivity Commission, Report on Government Services 2017 <sup>242</sup>
Criminal court			1469.77	713.48	Australian Bureau of Statistics, Criminal Courts, Australia, 2016–17 <sup>244</sup>
CT, computed tomography; MRI, magnetic resonance imaging; NHCDC, National Hospital Cost Data Collection; PARC, Prevention And Recovery Care.					



# Appendix 10 Resource use outcomes



TABLE 43 Service user resource use

Resource type	3 months				6 months				12 months			
	EMPOWER (n = 42)		TAU (n = 31)		EMPOWER (n = 42)		TAU (n = 31)		EMPOWER (n = 42)		TAU (n = 31)	
	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)
<i>Direct health care</i>												
GP visits	21 (50.0)	2.57 (1.60)	19 (61.3)	2.63 (2.77)	18 (42.9)	1.94 (0.998)	18 (58.1)	2.72 (1.71)	16 (38.1)	2.38 (1.31)	19 (61.3)	5.63 (6.53)
Psychiatrist	21 (50.0)	1.55 (0.800)	26 (83.9)	2.31 (2.35)	16 (38.1)	1.94 (1.34)	21 (67.7)	1.55 (1.14)	22 (52.4)	2.18 (1.26)	23 (74.2)	3.0 (2.65)
Psychologist	4 (9.5)	2.0 (1.15)	5 (16.1)	2.4 (1.52)	3 (7.1)	1.67 (0.577)	2 (6.5)	2.5 (0.707)	3 (7.1)	3.33 (2.08)	3 (9.7)	7.67 (10.7)
Counsellor	2 (4.8)	3.0 (0)	1 (3.2)	1.0 (NA)	1 (2.4)	9.0 (NA)	0	NA	0	NA	1 (3.2)	4.0 (NA)
Care nurse	4 (9.5)	2.25 (1.26)	1 (3.2)	1.0 (NA)	5 (11.9)	3.8 (5.72)	3 (9.7)	1.33 (0.577)	2 (4.8)	1.5 (0.707)	4 (12.9)	1.75 (0.957)
Mental health nurse	21 (50.0)	5 (2.43)	16 (51.6)	4.75 (3.59)	21(50.0)	4.57 (3.49)	16 (51.6)	5.63 (4.92)	19	6.47 (4.96)	14 (45.2)	6.14 (5.65)
Alcohol worker	1 (2.4)	3.0 (NA)	1 (3.2)	2.0 (NA)	1 (2.4)	3.0 (NA)	2 (6.4)	2.5 (0.707)	1 (2.4)	4.0 (NA)	2 (6.4)	3.0 (1.41)
Case manager	9 (21.4)	4.0 (2.40)	12 (38.7)	3.27 (3.35)	11 (26.2)	3.91 (3.11)	10 (32.3)	3.1 (3.03)	12 (28.6)	6.08 (6.30)	12 (38.7)	3.0 (3.13)
Speech therapist	1 (2.4)	1 (NA)	1 (3.2)	6 (NA)	0	NA	0	NA	0	NA	0	NA
Occupational therapist	5 (11.9)	2.0 (0.707)	7 (22.6)	3.86 (2.61)	3 (7.1)	2.0 (1.0)	1 (3.2)	3.5 (3.54)	2 (4.8)	4.0 (2.83)	3 (9.7)	3.67 (2.08)
Other health professionals <sup>a</sup>	4 (9.5)	1.0 (0)	9 (29.0)	1.11 (0.333)	3 (7.1)	1.67 (0.577)	5 (16.1)	1.2 (0.447)	1 (2.4)	1.0 (NA)	7 (22.6)	1.43 (0.535)
Ambulance	2 (4.8)	1.5 (0.707)	2 (6.4)	1.0 (0)	1 (2.4)	1 (NA)	0	NA	2 (4.8)	2.0 (0)	3 (9.7)	2.0 (1.0)
Emergency room	3 (7.1)	1.33 (0.577)	6 (19.4)	1.67 (0.816)	2 (4.8)	1.0 (0)	3 (9.7)	2.33 (1.53)	2 (4.8)	1.5 (0.707)	7 (22.6)	1.43 (0.787)
Day treatment (outpatient)	3 (7.1)	1.0 (0)	4 (12.9)	1.75 (1.5)	5 (11.9)	1.4 (0.894)	4 (12.9)	1.75 (0.5)	1 (2.4)	1 (NA)	6 (19.4)	2.0 (1.10)
Inpatient: mental health units number of stays	0	NA	4 (12.9)	1.25 (0.5)	1 (2.4)	1.0 (NA)	1 (3.2)	1.0 (NA)	0	NA	3 (9.7)	1.33 (0.577)
Inpatient: non-mental health units number of stays	2 (4.8)	1.0 (0)	3 (9.7)	1.33 (0.577)	2 (4.8)	1.5 (0.707)	1 (3.2)	2.0 (NA)	2 (4.8)	1.0 (0)	2 (6.4)	1.5 (0.707)

Resource type	3 months				6 months				12 months			
	EMPOWER (n = 42)		TAU (n = 31)		EMPOWER (n = 42)		TAU (n = 31)		EMPOWER (n = 42)		TAU (n = 31)	
	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)
Inpatient – mental health units, <sup>b</sup> length of stay (days)	0	NA	4 (12.9)	14.0 (12.12)	1 (2.4)	14.0 (NA)	1 (3.2)	20.0 (NA)	0	NA	3 (9.7)	28.8 (26.4)
Inpatient – non-mental health units, length of stay (days)	2 (4.8)	7.5 (9.19)	3 (9.7)	4.75 (6.24)	2 (4.8)	11.0 (14.7)	1 (3.2)	4.5 (2.12)	2 (4.8)	14.5 (19.1)	2 (6.4)	12.0 (1.73)
Non-hospital on-site stay	1 (2.4)	1.0 (NA)	2 (6.4)	1.0 (0)	3 (7.1)	1.0 (0)	2 (6.4)	1.0 (0)	3 (7.1)	1.0 (0)	2 (6.4)	1.5 (0.707)
Non-hospital on-site length of stay (nights/days)	1 (2.4)	90.0 (NA)	2 (6.4)	87.0 (4.24)	3 (7.1)	86.0 (3.46)	2 (6.4)	87.0 (4.24)	3 (7.1)	69.3 (35.8)	2 (6.4)	88.0 (3.46)
Diagnostic tests	15 (35.7)	1.2 (0.561)	17 (54.8)	2.18 (2.70)	9 (21.4)	1.22 (0.441)	16 (51.6)	2.06 (1.61)	12 (28.6)	1.58 (0.793)	16 (51.6)	1.63 (1.02)
Mental health (hours searching internet for information)	19 (45.2)	10.96 (16.9)	9 (29.0)	3.43 (2.53)	23 (54.8)	15.0 (26.9)	12 (28.6)	7.01 (12.3)	18 (42.9)	27.0 (50.9)	9 (29.0)	23.3 (25.0)
Formal online therapy (hours)	0	NA	0	NA	0	NA	0	NA	0	NA	0	NA
Smartphone self-help app (hours) – excludes EMPOWER	4 (9.5)	4.64 (2.46)	2 (6.5)	2.25 (1.06)	7 (16.7)	19.6 (17.9)	2 (6.5)	20.3 (26.5)	6 (14.3)	54.0 (49.8)	2 (6.5)	65.0 (18.4)
Self-help materials (books, etc.) (hours)	1 (2.4)	26	0	NA	3 (7.1)	33.5 (26.3)	3 (9.7)	7.67 (6.83)	4 (9.5)	52.0 (48.5)	2 (6.5)	9.03 (12.7)
Gym attendance (hours)	3 (7.1)	47.7 (15.0)	2 (6.5)	71.5 (9.19)	3 (7.1)	30.3 (7.51)	2 (6.5)	52.8 (72.5)	2 (4.8)	32.0 (28.3)	3 (9.7)	61.5 (82.7)
Other mental health resources <sup>c</sup>	0	NA	1 (3.2)	1.0 (NA)	1 (2.4)	1.0 (NA)	0	NA	0	NA	1 (3.2)	1.0 (NA)
Medication (mental health)	29 (69.0)	1.62 (0.820)	28 (90.3)	1.79 (0.787)	27 (64.3)	1.78 (0.847)	27 (87.1)	2.19 (0.786)	26 (61.9)	2.12 (0.816)	26 (83.9)	1.92 (0.796)

continued

TABLE 43 Service user resource use (continued)

Resource type	3 months				6 months				12 months			
	EMPOWER (n = 42)		TAU (n = 31)		EMPOWER (n = 42)		TAU (n = 31)		EMPOWER (n = 42)		TAU (n = 31)	
	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)
<b>Criminal justice services</b>												
Contact with criminal justice services (yes/no)	4 (9.5)		0		3 (7.1)		0		3 (7.1)		2 (6.5)	
Contacts with the police	2 (4.8)	1.5 (0.707)	0	NA	3 (7.1)	3.0 (0)	0	NA	3 (7.1)	2.33 (1.15)	2 (6.5)	1.0 (0)
Nights spent in police cell or prison	0	NA	0	NA	0	NA	0	NA	0	NA	0	NA
Number of psychiatric assessments while in custody	0	NA	0	NA	0	NA	0	NA	0	NA	0	NA
Number of court appearances (criminal)	2 (4.8)	1.0 (0)	0	NA	1 (2.4)	2.0 (0)	0	NA	1 (2.4)	1.0 (NA)	0	NA
Number of court appearances (civil)	0	NA	0	NA	0	NA	0	NA	0	NA	0	NA
<b>Benefits</b>												
Receiving unemployment income support (yes/no)	5 (11.9)		1 (3.2)		3 (7.1)		1 (3.2)		3 (7.1)		1 (3.2)	
Receiving sickness/disability benefit (yes/no)	9 (21.4)		7 (22.6)		10 (23.8)		7 (22.6)		6 (14.3)		7 (22.6)	
Receiving housing benefit (yes/no)	4 (9.5)		1 (3.2)		3 (7.1)		1 (3.2)		1 (2.4)		2 (6.5)	
Receiving other benefits (yes/no) <sup>d</sup>	17 (40.5)		16 (51.6)		16 (38.1)		15 (48.4)		17 (40.5)		14 (45.2)	

Resource type	3 months		6 months		12 months							
	EMPOWER (n = 42)		TAU (n = 31)		EMPOWER (n = 42)		TAU (n = 31)					
	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)				
<b>Employment status</b>												
School/studying	1 (2.4)		0		3 (7.1)		1 (3.2)		1 (2.4)		2 (6.5)	
Employed	6 (14.3)		8 (25.8)		4 (9.5)		5 (16.1)		3 (7.1)		4 (12.9)	
Self-employed	0		0		0		0		0		0	
Housewife/ househusband	0		0		0		0		0		0	
Unemployed	19 (45.2)		13 (41.9)		18 (42.9)		16 (51.6)		19 (45.2)		15 (48.4)	
Unpaid work	3 (7.1)		3 (9.7)		3 (7.1)		1 (3.2)		2 (4.8)		3 (9.7)	
Retired/pre- pension plan	1 (2.4)		4 (12.9)		2 (4.8)		3 (9.7)		3 (7.1)		3 (9.7)	
Other	0		0		0		0		0		0	
Manager	0		0		0		0		0		0	
Profession	0		0		0		0		0		0	
Associate professional	0		0		1 (2.4)		0		1 (2.4)		0	
Clerical worker	0		1 (3.2)		0		1 (3.2)		0		1 (3.2)	
Services and sales workers	1 (2.4)		2 (6.4)		1 (2.4)		0		0		0	
Skilled labourer	0		1 (3.2)		0		1 (3.2)		0		0	
Plant and machine assemblers	0		1 (3.2)		0		1 (3.2)		0		2 (6.4)	
Elementary occupations	1 (2.4)		1 (3.2)		1 (2.4)		0		1 (2.4)		0	

continued

TABLE 43 Service user resource use (continued)

Resource type	3 months				6 months				12 months			
	EMPOWER (n = 42)		TAU (n = 31)		EMPOWER (n = 42)		TAU (n = 31)		EMPOWER (n = 42)		TAU (n = 31)	
	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)
Other <sup>e</sup>	4 (9.5)		2 (6.4)		2 (4.8)		2 (6.4)		1 (2.4)		1 (3.2)	
Number of paid hours per week	6 (14.3)	16.4 (14.8)	8 (25.8)	24.8 (22.9)	5 (11.9)	25.8 (11.1)	5 (16.1)	26.0 (13.5)	3 (7.1)	26.3 (15.9)	4 (12.9)	22.5 (15.5)
Number of days per week worked	6 (14.3)	2.04 (1.62)	8 (25.8)	3.25 (2.12)	5 (11.9)	3.6 (1.82)	5 (16.1)	4.0 (1.87)	3 (7.1)	4.33 (2.08)	4 (12.9)	3.75 (2.22)
Number of missed work days as a result of sickness	2 (4.8)	19.0 (15.6)	6 (19.4)	25.3 (34.7)	3 (7.1)	14.0 (14.4)	3 (9.7)	21.3 (30.1)	1 (2.4)	1.0 (NA)	1 (3.2)	30.0 (NA)
Monthly gross personal income (£)	4 (9.5)	£1085 (£653)	1 (3.2)	£850 (NA)	3 (7.1)	£1267 (£651)	0	NA	1 (2.4)	£900 (NA)	0	NA
Monthly gross personal income (AU\$)	2 (4.8)	\$125 (\$106)	6 (19.4)	\$1399 (£885)	2 (4.8)	\$1100 (\$1273)	2 (6.4)	\$2000 (\$1414)	2 (4.8)	\$1776 (\$2438)	4 (12.9)	\$2068 (\$1309)
At work but bothered by physical or mental problems (yes/no)	2 (4.8)		6 (19.4)		4 (9.5)		4 (12.9)		3 (7.1)		2 (6.4)	
At work but bothered by physical or mental problems (days)	2 (4.8)	18.5 (9.19)	7 (22.6)	37.1 (40.4)	4 (9.5)	5.0 (4.83)	3 (9.7)	36.0 (42.5)	2 (4.8)	17.0 (4.24)	1 (3.2)	84.0 (NA)
How much of normal work capacity achieved on days bothered by health problems (scale 0–10, where 0 is none and 10 is full capacity)	2 (4.8)	9.0 (1.41)	6 (19.4)	7.0 (1.90)	4 (9.5)	8.75 (2.5)	4	6.0 (2.58)	3 (7.1)	9.3 (1.15)	2 (6.4)	8.5 (2.12)

Resource type	3 months				6 months				12 months			
	EMPOWER (n = 42)		TAU (n = 31)		EMPOWER (n = 42)		TAU (n = 31)		EMPOWER (n = 42)		TAU (n = 31)	
	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)
Reduce unpaid work because of physical/mental health reasons (days)	6 (14.3)	27.2 (32.3)	3 (9.7)	52.0 (42.6)	1 (2.4)	20.0 (NA)	2 (6.4)	17.0 (18.4)	2 (4.8)	55.0 (49.5)	1 (3.2)	3 (NA)
Reduce unpaid work because of physical/mental health reasons (average hours per day missed)	6 (14.3)	2.58 (1.36)	3 (9.7)	9.67 (12.5)	1 (2.4)	110.0 (NA)	1 (3.2)	25.0 (NA)	2 (4.8)	2.5 (0.707)	1 (3.2)	6.0 (NA)
<b>Informal care</b>												
Extra help with child care because of health problems (hours)	1 (2.4)	168.0 (NA)	1 (3.2)	5.0 (NA)	1 (2.4)	210.0 (NA)	0	NA	2 (4.8)	197.0 (264.5)	2 (6.4)	63.0 (46.7)
Extra help with household activities because of health problems (hours)	13 (31.0)	123.7 (170.3)	10 (32.3)	28.1 (29.3)	10 (23.8)	77.6 (94.2)	11 (35.5)	40.9 (98.4)	9 (21.4)	38.9 (11.7)	9 (29.0)	26.9 (15.0)
Extra help with shopping, transport, etc. because of health problems (hours)	14 (33.3)	62.2 (153.2)	10 (32.3)	11.1 (11.7)	8 (19.0)	38.7 (29.6)	5 (16.1)	8.6 (12.1)	9 (21.4)	55.3 (106.1)	8 (25.8)	15.1 (10.1)

continued

TABLE 43 Service user resource use (continued)

Resource type	3 months				6 months				12 months			
	EMPOWER (n = 42)		TAU (n = 31)		EMPOWER (n = 42)		TAU (n = 31)		EMPOWER (n = 42)		TAU (n = 31)	
	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)
Extra help with personal care because of health problems (hours)	1 (2.4)	144.0 (NA)	3 (9.7)	6.0 (4.0)	2 (4.8)	3.0 (1.41)	1 (3.2)	1.0 (NA)	1 (2.4)	30.0 (NA)	1 (3.2)	1.0 (NA)
Other extra help because of health problems (hours) <sup>f</sup>	1 (2.4)	288.0 (NA)	0	NA	1 (2.4)	2.0 (NA)	0	NA	0	NA	0	NA
Friends/relatives took time off work because of mental/physical health (hours)	1 (2.4)	48.0 (NA)	1 (3.2)	76.0 (NA)	2 (4.8)	65.5 (64.3)	2 (6.4)	18.0 (24.0)	3 (7.1)	268.3 (331.1)	0	NA

NA, not applicable.

a 'Other health professional' visits comprised clozapine clinic, dentist, dietitian, endocrinologist, ophthalmologist, optician, peer support worker, physiotherapist, podiatrist, psychoanalyst, RAMH and support worker.

b Terms used to describe inpatient mental units were 'acute psychiatric', 'inpatient psychiatric hospital', 'mental health facility', 'psychiatric' and 'acute psychiatric'.

c 'Other mental health resources' comprised 'Facebook group chats regarding chronic fatigue', 'leaflets x3' and 'filling out forms for voluntary organisations'.

d 'Other benefits' comprised, for the UK, Child Benefit, Child Tax Credit, Council Tax, Disability Living Allowance, Employment Support Allowance, Pension Credit, Personal Independence Payment, Income Support, Mobility, Jobseekers' Allowance, Universal Credit, State Pension and Seniors Card; and for Australia, Family Tax Benefit and Youth Alliance.

e 'Other' reported occupations comprised business development manager, care assistant, charge nurse, chef, garden labourer, home carer, peer community worker, peer support worker, peer recovery worker, retail worker, staff nurse and teaching.

f Other categories of extra help comprised 'medication prompts' and 'reading forms, letter'.

TABLE 44 Carer resource use

Resource type	3 months				6 months				12 months			
	EMPOWER (n = 42)		TAU (n = 31)		EMPOWER (n = 42)		TAU (n = 31)		EMPOWER (n = 42)		TAU (n = 31)	
	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)	n (%)	Mean visits (SD)
<b>Direct health care</b>												
GP visits	2 (40)	1 (0)	5 (83.33)	1.2 (0.45)	4 (80)	1.67 (0.58)	6 (100)	2 (1)	3 (75)	1.5 (0.71)	3 (75)	1.67 (0.58)
Psychiatrist	0		1 (16.67)	1	0		2 (33.33)	2	0		0	
Psychologist	0		0		0		0		0		1 (25)	Not stated
Counsellor	0		0		2 (40.0)	1						
Care nurse	1 (20)		1 (16.67)	1	1 (20)	2	1 (16.67)	1			2 (50)	1 (0)
Mental health nurse	1 (20)		0		0		0		0		0	
Alcohol worker	1 (20)		0		0		0		0		0	
Case manager	0		0		1 (20)	2	0		0		0	
Speech therapist	0		0		0		0		0		0	
Occupational therapist	0		0		0		0		0		0	
Physiotherapist	0		0		0		0		0		0	
Other health professional	2	2.5 (0.71)	3	1.67 (0.58)	2	1.5 (0.71)	0		1	1		
Admitted to hospital (mental health)	0		0		0		0		0		0	
Admitted to hospital (not mental health)	0		0		0		2		0		1	
<b>Medication</b>												
General medication (not specific to mental health)	1 (20)	4 (4.24)	5 (83.3)	3.8 (1.1)	3 (60)	3.33 (4.04)	4 (66.67)	3.5 (0.58)	1 (25)	7	4 (100)	2.75 (1.26)





## Appendix 11 Work package 6 public engagement

We held three knowledge exchange events, one each in Coventry, Edinburgh and Glasgow, during August and September 2019. These events were titled 'Digital mental health: what's happening now? EMPOWER and beyond' and each featured presenters and group discussions on the EMPOWER intervention.

A combined total of 225 delegates registered for these knowledge exchange events and, from those, 144 were able to attend and take part in discussions and feedback sessions. These delegates came from a variety of backgrounds and included academics, service users, carers and service providers.

After the EMPOWER team had presented a breakdown of how the intervention had been conceived, developed and then tested in the feasibility trial, we asked delegates to form discussion groups of about eight people and to share and write down their views on two separate flipchart sheets. One flipchart sheet was titled 'EMPOWER now?' to gauge their views on what they had heard during the presentations. The second was titled 'EMPOWER future?' and we asked delegates to tell us their thoughts and ideas on how EMPOWER might develop going forward.

After all of the events had concluded, we gathered all of the responses and used thematic analysis<sup>198</sup> to construct themes to synthesise delegate perspectives.

### 'EMPOWER now?' feedback

Figure 15 illustrates the themes garnered from the 'EMPOWER now?' feedback (themes are not placed in any order of importance or priority). A summary of the main points raised by delegates in each theme follows.

#### *User-clinician interaction*

There was considerable discussion around how EMPOWER would aid the monitoring of EWS for both users and their clinicians and could similarly be a useful source of additional information for clinicians to better understand service users. Delegates saw the app's potential for opening up shared dialogue between app users and care teams in a way that would help the user feel more 'heard'. They felt that it would offer the opportunity for people to feed back their experiences between appointments with their team, with increased options for how to communicate that feedback and better reflect on them together.

#### *Inclusion/accessibility*

Questions arose about whether or not service users would have access to a smartphone capable of hosting the EMPOWER app, and this was followed by discussion about how EMPOWER might not be




FIGURE 15 The 'EMPOWER now?' themes.

accessible for those users with poor literacy skills, non-English speakers, 'low-functioning' service users, people with learning disabilities and people with cultural barriers. There was also a suggestion that a 'very explicit introduction/guide' would need to be developed to ensure that all users understood how to fully use the app. The app was also seen as a means to 'break down barriers' and would offer 'high engagement' among some users, in particular among young people.

### **Personalisation**

A factor seen as central to the EMPOWER app's success from the service user perspective was the app's capacity to be personalised to individual needs and preferences. This led to discussions around making the app 'individualistic', 'person centred' and 'recovery focused', as well as having the capacity to incorporate 'flexibility', with one delegate suggesting being able to add in and accommodate 'life events' as they arise. There was positive feedback on how EMPOWER allows some personalisation of its 'questions' and that its approach is 'not a one size fits all'.

### **Benefits**

Comments on the benefits of using the EMPOWER app ranged from potentially increasing 'self-awareness' and being able to 'see your pattern' when logging data, to the app 'supporting a positive recovery style', 'normalising "ebb and flow" of wellness' and 'boosting coping strategies and signposting to them'. The opportunity to improve app users' insight and understanding of EWS, triggers, moods, experiences and 'acceptance of their diagnosis' was also mentioned.

### **Peer support**

The peer support aspect of EMPOWER was viewed positively by delegates across all events. Peer support workers of EMPOWER were described as being able to 'help balance potential fear or paranoia' around the app as well as being 'very important regarding hope and stigma'. Peer support workers were viewed as a central 'human element' of EMPOWER and there was much discussion about how peer support would work in current NHS practice.

### **General positives**

This theme encompasses a collection of non-specific but positive comments delegates made on the flipchart sheets. Overall, the comments showed that a number of delegates felt positively about the EMPOWER intervention and told us that they viewed it as a 'positive initiative' with 'great potential'. In terms of the development of EMPOWER to its current stage, delegates offered the following insights: 'Reassured that it is not a substitute for relationships'; 'initially thought it would be a standalone app. Positive to know it is supported via mental health services and peer support'; 'Good consideration of adverse events'.

## **'EMPOWER future?' feedback**

Themes we derived from 'EMPOWER future?' feedback are shown in *Figure 16*.

After we thematically analysed the suggestions and views written on the flipcharts, we derived two main themes: 'development of EMPOWER app' and 'NHS implementing EMPOWER'.

### **Development of the EMPOWER app themes**

There were five subthemes, which are described below.

#### **App format: ideas**

Delegates were keen to discuss how improving the appearance of the EMPOWER app would make it easier to use as well as giving it a 'more polished and modern-looking design'. They talked about whether the app could be made 'available on a website' to get around the issue of users needing a smartphone to use the app in its current form and to offer users more control over the content and




FIGURE 16 The 'EMPOWER future?' themes.

when to respond to prompts to enter data. They also speculated about the self-management potential among users, which one delegate theorised could bring feelings of 'treatment optimism'. Other discussions around reducing the demands the app places on the user also occurred with insights into offering users more control over when they used the app and including a 'pause' button to allow users to take a break and return later as suited them. The opportunity for users to use the app in conjunction with other users was also mentioned, with the idea of users feeling less isolated and more 'connected to others' being central to that discussion. Finally, there were contributions on how to make the app more dynamic to give users more options to interact with it in ways that suited the app user as opposed to those set by the app itself.

### User impact and accessibility: ideas

The vast majority of delegates' comments on this theme underlined the perceived importance of making the app feel as personalised as possible. Delegates felt that personalisation should be ongoing throughout the app's research development. They also suggested that app users collaborating with their care team might increase the app's capacity to be personalised to the user's preferences, in the hope of optimising its person-centred feel, especially in terms of language and prompt use.

### Peer support

There was unanimous agreement across the discussion groups both that peer support is central to the effectiveness of the EMPOWER app and that every effort should be made to ensure this is a core factor of the intervention that must be retained going forward in its development.

## Monitoring

On the whole, the comments on the subject of an app utilising both active (e.g. question responses) and passive (i.e. automatically collected) data were positive. That said, delegates were quick to underline the importance of ensuring that any app with monitoring capabilities is 'optional' for users and not something that would ever be mandatory or 'forced' on them. The idea that factors such as sleep, steps, time on social media and behaviour changes could be captured in real time was something delegates felt could be beneficial. Being able to identify patterns, better predict outcomes and receiving alerts about when it might be time to take 'preventative action' were all aspects that appealed to delegates. Fitbits (Fitbit, Inc., San Francisco, CA, USA) were mentioned as additional technology that could be incorporated to expand the EMPOWER app's capacity to collect useful data from the user in a non-invasive way.

## Future app development

Delegates discussed where the EMPOWER app could go next, in terms of both its next stage of development and its scope going forward and its capacity to engage with future app users by incorporating forms of media into its format. Both Skype (Microsoft Corporation, Redmond, WA, USA) and FaceTime (Apple Inc., Cupertino, CA, USA) were mentioned as apps that delegates wanted to see added to EMPOWER as ways for people to chat with their care or support teams over live video. Giving app users more flexibility by offering them access to other self-help apps within the EMPOWER app was another suggestion. There was some discussion about how the app might benefit inpatients in psychiatric wards if they used it as part of their discharge plan with their inpatient team. There were also ideas about expanding the app to offer access to things people might want to engage with more, 'the app progressing with you', in tandem with their recovery, and resources such as films, articles, music and a platform for creative writing were seen as positive additions.

## Concerns

'Who owns the data?' was a concern commonly expressed by delegates and this led to broader discussions (noted elsewhere) about privacy, confidentiality and data protection. The app's smartphone platform was seen as a barrier to those with certain disabilities, as was the use of the English language to those users in the UK who might not speak or read English fluently. There was some more discussion about whether people would feel obliged to use the app as part of a care package and that this was something to be avoided. In addition to this, and as some delegates were quick to point out, not everyone likes using mobile phones, and also the current 'slide-scale' way of answering questions on the EMPOWER app might not suit everyone. There was also a perceived risk that answering time-limited questions on the app might feel like an unwelcome pressure to some users. Further conversations were around whether adverts would become part of the app to help with costs and, if so, if there would be ways to ensure that these did not have a negative impact on 'vulnerable patients'. Delegates also made it clear that if EMPOWER were to be implemented into the NHS it would need to have proven efficacy as 'a real tool'. Finally, some discussion took place around EMPOWER and apps and technology more generally as a 'threat to workforce', as concerns were shared about not seeing the value of human roles as 'tasks (are) replaced by technology'.

## *NHS implementing EMPOWER themes*

Our second theme, 'NHS implementing EMPOWER', had four subthemes. The suggestions gathered from delegates around those themes are described in the following sections.

### Effects on clinicians

Delegates had some concerns that the app would not be a viable option for those clinicians who work with 'critical need' service users, and they saw it as a way to stay more connected to GPs about service users' needs. Interestingly, it was pointed out that 'staff need to stay well too' and that EMPOWER was an app that mental health staff might want to use to maintain their own well-being.

### **Implementation demands**

There were concerns about the lack of peer support workers currently working in NHS mental health services. It was seen as desirable that both a recognition of the value of peer support workers and a financial commitment to funding such posts would have to take place for the EMPOWER intervention to be implemented in its current form. The importance of investing in training staff well so that they feel comfortable using the app with their service users was also highlighted to 'help with enthusiasm'. Depending on the level of data being disclosed and shared, this might also enhance clinicians' understanding of the contexts within which certain types of app responses take place. It was pointed out that 'outpatient appointments, Care Programme Approach reviews and clinical reviews' could be available to both service users and clinicians via the app and that if there was the potential to offer this information in a variety of formats it could increase shared understanding of the information and improve overall transparency.

### **Cost and data security**

Points were raised about financial sustainability of the app within the NHS. Concerns around whether the NHS would be responsible for supplying the smartphones that host the EMPOWER app were expressed and also whether this would mean that the NHS would be expected to pay for software or data costs. Issues around the safety of storing data on mobile phones were raised often and, similarly, worries around data protection and confidentiality featured in the feedback.

### **Potential for broader implementation**

Delegates had a wide variety of ideas in relation to the potential for EMPOWER to be implemented more broadly across the NHS. There was discussion around integrating it into current NHS systems and linking it with GPs, particularly as a resource for 'medication changes and renewals'. The potential implementation of EMPOWER into the NHS was seen more broadly as a helpful way to 'increase awareness and use across different populations' and as a 'part of prescribing' and 'watchful waiting'. Practical considerations such as how EMPOWER data could be linked to electronic clinical records were also mentioned. Overall, delegates were positive about EMPOWER being implemented into the NHS. The fact that the EMPOWER algorithm has been approved as a medical device by the MHRA led to a feeling that users and clinicians would view EMPOWER with a 'reassurance of something that has an authority behind it'.







EME  
HSDR  
**HTA**  
PGfAR  
PHR

Part of the NIHR Journals Library  
[www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

*This report presents independent research funded by the National Institute for Health and Care Research (NIHR).  
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the  
Department of Health and Social Care*

***Published by the NIHR Journals Library***